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Abstract 
This thesis explores the role of the circulating gut hormone oxyntomodulin in the regulation of 
food intake, energy expenditure and body-weight. Oxyntomodulin is a peptide hormone post- 
prandially secreted from endocrine L-cells in the small intestine. Administration of 
oxyntomodulin reduces short-term food intake in rats and normal-weight human volunteers. 
Repeated administration of oxyntomodulin over seven days results in a reduction in body- 
weight and adipose tissue in rodents. I therefore hypothesised that oxyntomodulin may be an 
effective weight loss therapy in man. 
I investigated the effects of oxyntomodulin on energy homeostasis in rodents using an 
automated metabolic cage system. I demonstrated that oxyntomodulin resulted in negative 
energy balance by reducing food intake and increasing energy expenditure. These two actions 
may be mediated by stimulation of the thyroid axis at the level of the hypothalamus and 
pituitary and / or by an increase in a-melanocortin release in the hypothalamus. 
I proceeded to perform the first studies of the effect of oxyntomodulin administration on energy 
homeostasis in overweight and obese humans and demonstrated that oxyntomodulin is effective 
when administered subcutaneously. Four-week administration of oxyntomodulin to volunteers 
in a randomised double-blinded placebo-controlled parallel-group protocol resulted in a 
reduction of food intake, a significant loss of body-weight and altered levels of adipose 
hormones consistent with a loss of adipose tissue. 
I then performed a double-blinded placebo-controlled cross-over study to specifically examine 
the effect of oxyntomodulin on energy expenditure in overweight and obese humans. This study 
demonstrated that oxyntornodulin increased energy expenditure in addition to reducing food 
intake, suggesting a possible mechanism of weight loss during oxyntomodulin administration in 
humans. 
My thesis suggests that oxyntomodulin plays an important role in the control of appetite and 
body-weight homeostasis. The effect is preserved in obese humans, making oxyntomodulin an 
attractive target in the development of anti-obesity agents. 
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1.1 Energy Homeostasis 
Homeostasis is the term used to describe the process by which an organism regulates its internal 
environment to maintain a stable, constant condition, despite a variable external environment 
(Cannon, 2006). Energy homeostasis results from the balance between the energy intake 
obtained from food and drink and the energy expended to maintain essential biological 
processes and carry out physical activity (Schwartz et al., 2000). If in the long-term energy 
intake exceeds energy expenditure the excess energy is stored, predominantly as adipose tissue. 
Conversely, if energy expenditure exceeds energy intake, energy stores are consumed in order 
to sustain life. 
In most adults, adiposity and body-weight are remarkably constant despite huge variations in 
daily food intake and energy expended. A complex physiological system composed of both 
afferent signals and efferent effectors exists to balance energy intake and energy expenditure. 
This system consists of multiple pathways which incorporate significant redundancy in order to 
maintain the drive to eat. Our knowledge of these physiological systems controlling energy 
homeostasis has increased dramatically over the last decade. In the circulation there are both 
hormones which act acutely to initiate or terminate a meal and hormones which reflect longer- 
term body adiposity and energy balance. These signals are integrated by peripheral nerves and 
brain centres, such as the hypothalamus and brainstem. The integrated signals regulate central 
neuropeptide release which in turn modulates feeding behaviour and energy expenditure. 
Obesity is the result of an interaction between environmental factors and genes which optimise 
energy conservation and that were favoured for millions of years of relative famine (Ravussin 
and Bogardus, 2000; Weinsier et al., 1998). Evolutionary pressure has resulted in a drive to 
overeat when highly palatable food is available. The disparity between the environment in 
which these systems evolved and the currently availability of food and low requirement for 
physical activity promotes the common forms of obesity. Understanding of the physiological 
systems regulating energy homeostasis is fundamental to establishing effective therapies for this 
worldwide heath crisis. 
1.2 Obesity 
The World Health Organisation has classified obesity as an epidemic (World Health 
Organization, 2000). The number of deaths per year attributable to obesity is approximately 
thirty thousand in the UK (2001) and three hundred thousand in the USA (2001; Allison et al., 
1999), where obesity is predicted to imminently overtake smoking as the main preventable 
cause of morbidity and early mortality (Mokdad et al., 2004). Currently over 65% of adults in 
the USA are overweight or obese, with 30% of the population actually obese (2001; Hedley et 
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al., 2004). Obesity emerged as a major public heath problem in Western populations, but is 
rapidly spreading to countries undergoing nutritional transition (from relative famine patterns), 
and is becoming the primary global nutritional problem (Mendez et al., 2005). Excess body- 
weight is now the sixth most important risk factor contributing to the worldwide burden of 
disease (Ezzati et al., 2002). 
Obesity is categorised by body-mass index (BMI), which is calculated by weight (kg) divided 
by height (in) squared. The WHO classification of BMI is shown below: 
BMI (k gIM2) WHO Classification 
< 18.5 Underweight 
18.5-24.9 Healthy 
25-29.9 Overweight 
30-39.9 Obese 
ý: 40 Morbid obese 
1.2.1 Obesity-related disorders 
The risk of conditions such as type 2 diabetes, hypertension, stroke, cardiovascular disease, 
respiratory problems, gallbladder disease, osteoarthritis and sleep apnoea, as well cancer of the 
colon, prostate, endometrium, kidney, gall bladder, oesophagus and post-menopausal breast 
cancer, are substantially increased in overweight and obese people (Kopelman, 2000). Many of 
the co-morbidities of obesity are reflected in the 'metabolic' syndrome which has recently been 
reclassified using the criteria of increased waist circumference (normal range dependent on 
ethnicity) in addition to abnormalities in two out of the four of triglycerides, HDL cholesterol, 
fasting blood glucose and blood pressure (International Diabetes Federation, 2005). 
1.2.2 The Aetiology of Obesity 
Individuals have a complex neuroendocrine system which acts to maintain body-weight over 
time. Although there are temporal fluctuations in energy intake and energy expenditure, body 
energy stores remain fairly constant. Despite this fine control of energy balance, populations are 
becoming progressively more overweight and obese. A weight gain of 0.5-1.0 kg over a year 
amounts to an excess of only 3500-7000 kcal, requiring an error in the homeostatic mechanism 
of less than 0.5% average daily calorie intake (Haslam and Jarnes, 2005). 
Genes are strongly implicated in the inter-individual variability in human obesity, underlying 
both individual differences in susceptibility and the pathways by which excess weight gain 
occurs. Genetic factors have been shown to influence the development and magnitude of weight 
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gain using twin and adoption studies (Bouchard et al., 1990) and it may be that silent genes now 
play an important permissive role in the current obesigenic environment (Weinsier et al., 1998; 
Ravussin and Bogardus, 2000). Rare single-trait conditions, such as mutations in the genes 
regulating leptin metabolism, have been described in patients with severe obesity (Montague et 
al., 1997; Clement et al., 1998; Strobel et al., 1998) and melanocortin receptor mutations may 
explain up to 6% of early-onset obesity in childhood (Lubrano-Berthelier et al., 2003a; 
Lubrano-Berthelier et al., 2003b; Farooqi et al., 2000). However, common obesity is a 
polygenic condition which reflects multiple genetic influences on energy expenditure, food 
intake and adipose tissue. 
Concern over the potential UK public heath problem of obesity was first highlighted in the 
1980's (Royal College of Physicians, 1983). This recent population trend to develop obesity 
cannot therefore be explained by genetic factors alone. The high energy-density of the western 
diet may predispose to excessive energy intake. A typical fast food menu has an extremely high 
average energy density (1100 KJ/100g), which is higher than the average UK diet (670 
KJ/100g) or a traditional African diet (450 KJ/100g) (Prentice and Jebb, 2003). Humans have 
been proposed to have a poor ability to recognise high energy-density foods and fail to down- 
regulate food quantity appropriately (Prentice and Jebb, 2003). Indeed, a recent study has 
reported that fast food consumption has strong positive associations with weight gain and 
insulin resistance (Pereira et al., 2005). The understanding of the role of energy intake in obesity 
is confounded by significant under-reporting of food intake in obesity (Poppitt et al., 1998; 
Lichtman et al., 1992). However, there is evidence that dietary macronutrient composition may 
influence overall energy intake by exerting differential effects on satiety. Fat has a weak 
satiating capacity compared with protein and experimental volunteers readily overeat when 
presented with high fat food (Lawton et al., 1993). High fat intake has been linked to greater 
weight and adiposity (Astrup, 2001) and low-fat, high carbohydrate intervention diets have 
consistently demonstrated significant weight loss in overweight subjects (Astrup et al., 2002). 
Although high carbohydrate diets are associated with low fat content, and are therefore usually 
thought of as beneficial, the glycaemic index (Foster-Powell et al., 2002) of the carbohydrates 
ingested may be important. There is evidence that high glycaemic index foods, which produce 
high levels of glucose and insulin post-ingestion, may induce obesity (Bell and Sears, 2003), 
and sugar-sweetened drinks have been linked to excess weight gain in children (Ludwig et al., 
2001). Food choices tend to be based on the criteria of taste, convenience and cost and the 
aggressive marketing strategies of the food industry (Poston and Foreyt, 1999). Thus, the easy 
availability of high-energy density highly-palatable foods may promote obesity in our current 
environment. 
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Reduced activity is also strongly implicated as a cause of obesity. In most developed countries 
there is evidence that the obesity epidemic has emerged whilst energy intakes have declined 
(Reilly and McDowell, 2003; Prentice and Jebb, 1995). However, this may represent under- 
reporting of food consumption and recent evidence of secular trends and obesity rates in 36 
countries suggest that changes in dietary and activity patterns are both important factors (Popkin 
and Gordon-Larsen, 2004). Many individuals have reduced their activity in response to the 
increased mechanisation of daily tasks and trends in leisure activity (Prentice and Jebb, 1995). A 
sedentary life-style has been associated with an increased risk of obesity in a number of studies 
(Reilly and McDowell, 2003; Prentice and Jebb, 1995; Rissanen et al., 1991) and in one 
prospective study, low physical activity was estimated to explain 77% of weight gain at one 
year (Hunter and Byrne, 2005). Although research has linked obesity with a sedentary lifestyle, 
reliable direct measures of physical activity are only just emerging (Brage et al., 2005). These 
new methods of measuring free-living energy expenditure provide the opportunity to further 
investigate the role of physical activity in obesity. 
The development of obesity may be considered as a response to a lifestyle which contrasts with 
the environment in which our species evolved (Eaton et al., 1988). This effect of the 
environment is apparent in genetically-similar populations, such as Native American Indians, 
Aborigines and Samoans, which have migrated to different environments (Poston and Foreyt, 
1999). In these cases, those exposed to the Western life-style of energy dense diets and reduced 
physical activity gain weight and develop obesity. These environmental factors interact with 
social factors; in poorer populations obesity is associated with higher economic status, whereas 
more westernised populations obesity is more prevalent in those of lower economic status who 
have less capacity to avoid the obesigenic environment (Poston and Foreyt, 1999). Changes in 
the environment in which we live may therefore be crucial in the fight against obesity. 
1.2.3 Current Strategies for the Treatment of Obesity 
Obesity has been estimated to decrease life-expectancy by an average of seven years (Peeters et 
at., 2003). A moderate amount of weight loss can have a large impact on the morbidity and 
mortality associated with excessive weight-gain. One meta-analysis has demonstrated that 
patients with obesity-related co-morbidities who lost 10% or less body-weight significantly 
improved glycaemic control and lipids and reduced blood pressure, as well as increasing 
lifespan (Goldstein, 1992). The estimated benefits of 10% weight loss include a fall of 
approximately 10 mmHg in systolic and diastolic blood pressure in hypertensive patients; a fall 
of up to 50% in fasting glucose in newly diagnosed diabetics; and a 40-60% fall in the incidence 
of diabetes, accompanied by a 20% fall in all-cause mortality, in people at high risk of diabetes 
(Haslam et al., 2006). Furthermore, for patients with established diabetes, weight loss is 
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associated with a significant reduction in all-cause, diabetic- and cardiovascular-associated 
mortality (Williamson et al., 2000). 
According to one US national survey (Williamson et al., 1992), about 40% of women and 25% 
of men are trying to lose weight at any one time. However, most weight loss attempts consist of 
6 months of loss followed by gradual regain to baseline (Jeffery et al., 2004) Despite campaigns 
to promote a healthy diet and an active lifestyle, the obesity epidemic continues to escalate. The 
metabolic syndrome develops insidiously without overt symptoms, which may explain the lack 
of motivation for change observed in many obese individuals. When lifestyle advice proves 
insufficient to result in weight loss, medical and surgical therapy should be considered. 
1.2.3.1 Medical Treatment 
Orlistat inhibits the action of intestinal and pancreatic lipases and impairs the digestion of 
dietary triglycerides (Hadvary et al., 1988), which reduces dietary fat absorption by 
approximately 30% (Zhi et al., 1994). The National Institute for Clinical Excellence (NICE) has 
recommended the use of orlistat in patients who achieve 2.5 kg weight loss over a month in 
response to lifestyle modifications and have a body-mass index of >30 kg/M2 (or >28 k gIM2 
with risk factors for obesity-related co-morbidity). A meta-analysis of twenty-two clinical trials 
demonstrated that, compared to controls, volunteers experienced a 2.75 kg weight loss in 
response to orlistat combined with dietary treatment at I year (Li et al., 2005). The XENDOS 
study demonstrated that treatment with orlistat can reduce the progression to diabetes in patients 
with impaired glucose tolerance (Torgerson et al., 2004). The side-effects of orlistat are mainly 
gastrointestinal (diarrhoea, flatulence, abdominal pain and dyspepsia) and are exacerbated by 
the consumption of high fat foods. Orlistat can also lead to vitamin D, E or P-carotene 
deficiency (Sjostrorn et al., 1998; Davidson et al., 1999). 
Sibutramine, a derivative of the amphetamine precursor P-phenethylamine, blocks central pre- 
synaptic nerve terminal re-uptake of noradrenaline, serotonin and dopamine (Li et al., 2005) and 
acts as an appetite suppressant. NICE has recommended the use of sibutramine in patients with 
a body-mass index of >30 k g/M2 (or >27 kg/m2 with additional risk factors). A meta-analysis of 
twenty-nine clinical trials suggested that obese patients treated with sibutramine and diet lose an 
additional 4.45 kg compared to controls (Li et al., 2005). However, sibutramine can cause small, 
but clinically significant increases in blood pressure and pulse rate (Li et al., 2005) which can 
negate the normally beneficial effects of weight loss on cardiovascular parameters (James et al., 
2000). It is therefore recommended that treatment is stopped if blood pressure reaches 145/90 
mmHg or increases by 10 mmHg, or if pulse rate increases by 10 beats per minute. 
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Rimonabant is a cannabinoid I receptor antagonist which is first-in-class to be licensed as an 
anti-obesity treatment. The first published trial (RIO-Europe) demonstrated that treatment with 
rimonabant for one year reduced body-weight and waist circumference, whilst improving 
metabolic risk factors for diabetes and cardiovascular disease (Van Gaal et al., 2005). Another 
one year study (RIO-Lipids), designed to investigate the effect of rimonabant in dyslipidaernic 
obese volunteers, found that rimonabant reduced body-weight, abdominal adiposity and 
improved features of the metabolic syndrome (Despres et al., 2005). A further study of over 
3000 obese patients, indicated that treatment with high-dose rimonabant (20mg) in combination 
with diet resulted in a 6.3 kg weight loss compared with 1.6 kg in the control group (Pi-Sunyer 
et al., 2006). A recent Cochrane review of rimonabant as a treatment for obesity suggested that 
rimonabant (20mg) and diet produced an additional 4.9 kg weight loss over one year. However, 
this does was associated with significant side-effects, especially of nervous system, psychiatric 
and gastrointestinal origin, resulting in attrition rates of 40% (Curioni and Andre, 2006). In 
Europe, the European Agency for the Evaluation of Medicinal Products (EMEA) approved 
rimonabant in June 2006 for the treatment of overweight and obese patients with associated risk 
factors. 
1.2.3.2 Surgical Treatment 
Available pharmacological agents have limited efficacy, cause significant side-effects, and are 
restricted to one or two years of therapy (Li et al., 2005). The only obesity treatment in clinical 
use which has shown significant long-term weight loss is gastrointestinal bypass surgery 
(Mitchell et al., 2001; Frandsen et al., 1998). However, because of its complications, surgical 
procedures are restricted to patients with morbid obesity (BMI >40 k g/M2). 
In one series of patients, bariatric surgery produced a considerable average weight loss of 29.5 
kg fifteen years post-operatively (Mitchell et al., 2001). In another study, subjects who 
underwent bypass surgery had maintained a 14.5% loss of body-weight a decade after the 
operation (Sjostrom et al., 2004). In this study, appetite and food intake decreased and physical 
activity increased in the treated group, accompanied by a lower 10-year incidence rate of 
diabetes and hypertriglyceridaemia, when compared with the control group. 
Bariatric surgery was initially thought to result in weight loss by inducing malabsorption of 
nutrients. However, although malabsorption does occur in the short-term, weight loss is 
secondary to a permanent loss of appetite (Atkinson and Brent, 1982; Sjostrorn et al., 2004). 
This appetite loss may occur because of beneficial changes in the circulating profile of 
gastrointestinal hormones. In patients who have undergone bypass surgery, baseline plasma 
ghrelin levels are reduced by 77% and the usual pre-meal peaks of ghrelin are absent 
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(Cummings et al., 2002b), whereas both PYY and oxyntomodulin are significantly elevated 
(Sarson et al., 1981; Naslund et al., 1997). Therefore, therapies based on these hormones may be 
effective in the long-term, without the need for surgical intervention. 
1.3 The Hypothalamus 
The hypothalamus occupies the ventral half of the diencephalon on either side of the third 
ventricle and lies above the pituitary gland. The mammalian hypothalamus consists of more 
than forty distinct nuclei and areas, and many of the nuclei can be further divided into subnuclei 
(Figure 1.0) (Berthoud, 2002). Functionally, the hypothalamus is divided into three longitudinal 
zones, the periventricular, medial and lateral zones (Crosby and Woodburne, 1949) and rostro- 
caudally into four regions, preoptic, anterior, tuberal and marnmillary (Le Gros Clark, 1938). 
The hypothalamus has been shown to regulate multiple homeostatic systems including 
reproduction, thirst, temperature and aggressive or defensive behaviour. For over fifty years, it 
has been accepted that the hypothalamus is also essential for the regulation of appetite and 
energy balance. An early 'dual centre' model incorporating lateral hypothalamic 'feeding 
centres' and ventromedial hypothalamic 'satiety centres' hypothesised that these two nuclei 
worked in a reciprocal fashion to maintain energy homeostasis (Stellar, 1994; Hetherington and 
Ranson, 1983). This model was based on several studies which demonstrated that lesions of the 
lateral hypothalamus (LHA) decreased food intake and eventually led to starvation and death, 
whereas lesions of several of the mediobasal hypothalamic nuclei resulted in obesity, decreased 
activity and neuroendocrine abnormalities. Destruction of the arcuate nucleus (ARC) with 
systemic monosodium glutamate also results in obesity and hyperphagia (Olney, 1969), whilst 
lesions of the ventromedial nucleus (VMN) produce increased body-weight and central 
hypogonadism (Debons et al., 1977). Similarly, lesions in the paraventricular nucleus (PVN) 
also led to hyperphagia and weight gain. Thus, a few morphologically well-defined regions of 
the hypothalamus appear to play a major role in the regulation of body-weight. However, rather 
than a simple two-centre hypothesis with feeding and satiety centres, recent models are based on 
hypothalamic neural networks which send signals of energy balance using specific 
neuropeptides. 
1.3.1 The Arcuate Nudeus 
The ARC, called the infundibular nucleus in man, is thought to play a pivotal role in the 
integration of signals regulating appetite. Schwartz et aL proposed a model of appetite 
regulation in which ARC neurones act as the primary hypothalamic site of action of circulating 
hormones such as insulin and leptin (Schwartz et al., 2000). The ARC lies in close proximity to 
the median eminence, which has a relatively permeable blood-brain barrier 
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Figure 1.0: a three-dimensional view of the hypothalamic nuclei (right 
hemisphere). Anterior Hypothalamic Area (AHA); Arcuate nucleus (ARC); 
Anteroventral area of third ventricle (AV3V); Capsula Interna (CI); Dorsal 
parvocellular subnucleus of paraventricular nucleus (DP PVN); Dorsomedial 
nucleus (DMN); Fornix (F); Lateral hypothalamic area (LHA); Lateral 
magnocellular nucleus of paraventricular nucleus (LM PVN); Lateral preoptic 
area (LPOA); Median eminence (ME); Medial parvocellular paraventricular 
nucleus (MP PVN); Medial preoptic area (MPO); Optic tract (OT); 
Suprachiasmatic nucleus (SCh); Supraoptic nucleus (SON); Substantia 
inomminata (SI); Subthalamic nucleus (ST); Ventromedial nucleus (VMN); 
Ventral parvocellular subnucleus of paraventricular nucleus (VP PVN). 
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medial )w lateral 
(Broadwell and Brightman, 1976), and thus is accessible to peripheral signals of energy balance. 
Furthermore, nutrients and hormones are also able to gain access to the ARC neurones by 
diffusion across the ependyma from the cerebrospinal fluid in the third ventricle (Elmquist et al., 
1998b). Other important neural inputs to the ARC include those from the medial amygdala and 
several brainstern sites including the nucleus of the solitary tract (NTS) (Ricardo and Koh, 
1978). Thus, the ARC is in a position to receive information from circulating nutrients and 
humoral signals, vagal input from the gastrointestinal tract and information about the rewarding 
or emotional aspects of food. 
There are two primary populations of neurones within the ARC which integrate signals of 
nutritional status to influence energy homeostasis (Cone et al., 2001) (Figure 1.1). A 
subpopulation of neurones in the medial ARC co-express the orexigenic peptides neuropeptide 
Y (NPY) and agouti related peptide (AgRP) (Broberger et al., 1998b; Hahn et al., 1998). These 
neurones project primarily to the ipsilateral PVN, but also to the LHA (Bai et al., 1985; 
Broberger et al., 1998b), dorsomedial hypothalamus (DMH) (Kalra et al., 1999) and directly to 
other neurones within the ARC. More laterally lie a second subpopulation which inhibit food 
intake via the expression of cocaine and amphetamine-regulated transcript (CART) and pro- 
opiornelanocortin (POMC) which is processed to alpha-melanocyte stimulating hormone (a- 
NISH) (Elias et al., 1998a; Kristensen et al., 1998). These neurones project to the PVN (Cowley 
et al., 1999; Fekete et al., 2000; Elmquist et al., 1998b) and to other hypothalamic nuclei such as 
the LHA, DMH and perifornical area (Elias et al., 1998b; Elmquist et al., 1998b; Kalra et al., 
1999) (Figure 1.2). Some ARC NPY neurones release GABA locally to inhibit the adjacent 
POW neurones (Roseberry et al., 2004). Other efferent projections of ARC neurones extend to 
many extra-hypothalamic targets such as the stria terminalis, midline thalamic nuclei, the 
ventral and dorsal raphe nuclei, the periaqueductal gray and lateral parabrachial nucleus 
(Broberger et al., 1998b; Broberger and Hokfelt, 2001). ARC neurones have access to endocrine 
effectors in the hypothalamus, to cognitive, reward and emotion related areas of the forebrain, 
and to motor and autonomic areas of the brainstern and spinal cord either directly or via their 
connections (e. g. through the LHA) (Berthoud, 2004). 
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Figure 1.1: the arcuate nucleus of the hypothalamus (ARC). Peripheral signals of 
energy balance cross the blood-brain barrier at the level of the median eminence. 
These signals are integrated in the ARC by two neuropeptide populations, one 
subpopulation release the orexigenic neuropeptides neuropeptide Y (NPY) and 
agouti-related peptide (AgRP) and a second subpopulation release the anorectic 
neuropeptides cocaine and amphetamine-regulated transcript (CART) and alpha- 
melanocyte stimulating hormone (ct-MSH). These neurones project to other areas, 
including the paraventricular nucleus (PVN) in order to regulate energy balance. 
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Energy Balance 
Figure 1.2: a schematic diagram in coronal section showing the connections with 
the arcuate nucleus of the hypothalamic nuclei involved in feeding (right 
hemisphere). Arcuate nucleus (ARC), Ventromedial nucleus (VMH), Dorsomedial 
nucleus (DMH), Paraventricular nucleus (PVN), Perifornical nucleus (PFA), 
Lateral hypothalamic nucleus (LHA), Median eminence (ME), Corticotrophin 
releasing hormone (CRH), Thyrotropin-releasing hormone (TRH), Melanin- 
concentrating hormone (MCH), Brain derived neurotrophic factor (BDNF), 
Neuropeptide Y (NPY), Agouti-related peptide (AgRP), Alpha melanocyte 
stimulating hormone ((xMSH), Cocaine and amphetamine-regulated transcript 
(CART). 
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1.3.2 The Paraventricular Nucleus 
The PVN integrates neuropeptide signals via projections it receives from a number of sites in 
the brain, including the ARC, brainstem, cortex and limbic areas (Sawchenko and Swanson, 
1983; Simerly, 1995). The PVN is highly sensitive to administration of many orexigenic and 
anorectic signals implicated in feeding, e. g. cholecystokinin (CCK) (Hamamura et al., 1991), 
NPY (Lambert et al., 1995), ghrelin (Lawrence et al., 2002), orexin-A (Edwards et al., 1999; 
Shirasaka et al., 2001), leptin (Elmquist et al., 1997; Van DiJk et al., 1996) and GLP-I (Van 
DiJk et al., 1996). Administration of melanocortin agonists directly into the PVN results in 
potent inhibition of food intake (Giraudo et al., 1998; Kim et al., 2000a) and inhibits the 
orexigenic effect of NPY administration (Wirth et al., 2001), whereas, the administration of a 
melanocortin antagonist to the PVN results in a potent increase in food intake (Giraudo et al., 
1998). Electrophysiological studies in the PVN have shown neurones expressing NPY / AgRP 
attenuate inhibitory GABA-ergic signalling, whilst POMC neurones potentiate GABA-ergic 
signalling (Cowley et al., 1999). 
Recent work suggests that neuropeptides involved in appetite regulation in the PVN may signal 
via a common pathway involving AMP-activated protein kinase (AMPK). AMPK is a 
heterodimer consisting of catalytic cc-subunits and regulatory P and y subunits. Multiple 
anorexic factors including leptin, insulin and MT-II (a melanocortin agonist) suppress cc2AMPK 
activity in the ARC and PVN, whereas the cc2AMPK activity is stimulated by orexigenic factors 
such as AgRP and ghrelin (Andersson et al., 2004; Minokoshi et al., 2004). A 
pharmacologically-induced increase in the level of AMPK in the PVN increases food intake 
(Andersson et al., 2004). cc2AMPK activity may be regulated by the melanocortin-4 receptor, as 
peripheral signals of energy status are unable to modulate cc2AMPK activity in MC4R knockout 
mice (Minokoshi et al., 2004). 
Many neuropeptides that modulate appetite also influence endocrine function, for example 
thyroid function, and hence energy expenditure. The PVN plays a major role in the integration 
of these functions. Magnocellular neuron projections to the posterior pituitary are responsible 
for the secretion of oxytocin and vasopressin. Parvocellular secretory neurones produce 
thyrotropin-releasing hormone (TRH) and corticotrophin-releasing hormone (CRH) which 
control the release of thyroid hormones and glucocorticoids respectively. NPY / AgRP and 
melanocortin projections from the ARC terminate on TRH neurones in the PVN (Legradi and 
Lechan, 1999; Fekete et al., 2000). NPY / AgRP projections have an inhibitory effect on the 
pro-TRH gene expression in the PVN (Fekete et al., 2002), whereas cc-MSH projections have a 
stimulatory effect and prevent the fasting-induced inhibition of TRH (Fekete et al., 2000). NPY 
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projections from the ARC influence CRH expression and release and this in turn may modulate 
energy homeostasis (Sarkar and Lechan, 2003). 
1.3.3 The Dorsomedial Hypothalamus 
There is some evidence for a role of the DMH in the modulation of energy intake, as lesions in 
the DMH result in hyperphagia and obesity, though less dramatically than VMN lesioning 
(Bernardis and Bellinger, 1996). Injection of orexigenic peptides, such as galanin and GABA, 
into the DMH increase food intake (Kelly et al., 1979; Kyrkouli et al., 1990) and central NPY 
injection induces neuronal activation in the DMH (Yokosuka et al., 1998). The DMH receives 
AgRP / NPY releasing neurones from the ARC (Kalra et al., 1999), but also contains NPY- 
expressing cell bodies. Alpha-MSH immunoreactive fibres lie in close proximity to these NPY- 
expressing cells and DMH administration of melanocortin agonists have been demonstrated to 
reduce local NPY expression and suckling-induced hyperphagia in rats (Chen et al., 2004b). 
1.3.4 The Lateral Hypothalamic / Perifornical Area 
The LHA / perifornical area is also involved in downstream control of energy homeostasis. 
Indeed, the perifornical area has been found to be more sensitive to NPY-elicited feeding than 
the PVN (Stanley et al., 1993). The LHA / perifornical area contains neurones expressing 
melanin-concentrating hormone (MCH) (Marsh et al., 2002), which project very broadly 
through the CNS (Bittencourt et al., 1992; Bittencourt and Elias, 1998). The receptor for MCH 
is also distributed through areas of the cortex, reward areas and brainstern (Kokkotou et al., 
2001; Saito et al., 2001). Fasting increases MCH mRNA, and repeated intracerebroventricular 
(ICV) administration of MCH increases food intake (Qu et al., 1996) and results in mild obesity 
in rats (Marsh et al., 2002). Conversely, MCH-1 receptor antagonists reduce feeding and result 
in a sustained reduction in body-weight if administered repeatedly (Borowsky et al., 2002). 
Transgenic mice over-expressing precursor MCH are hyperphagic and develop central obesity 
(Marsh et al., 2002), whereas mice with a disruption of the MCH gene are hypophagic, lean and 
have increased energy expenditure, despite reduced anorectic signals such as ARC POMC 
expression and circulating leptin (Marsh et al., 2002; Shimada et al., 1998). Mice which lack 
both MCH and leptin have an attenuation in weight gain and adiposity compared to mice 
lacking leptin alone (Segal-Lieberman et al., 2003). This suggests that MCH may be a 
downstream mediatory of the effects of leptin and POMC on feeding. 
The LHA / Perifornical area also contain neurones which express pre-pro-orexin and release the 
products orexin A and B (or hypocretin I and 2). The orexin-immunoreactive cells are distinct 
from those which produce MCH (Sakurai et al., 1998; De Lccca et al., 1998). Orcxin neurones 
project widely throughout the brain, including to the PVN, ARC, NTS and dorsal motor nucleus 
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of the vagus (Peyron et al., 1998; De Lecea et al., 1998). Orexin may not be primarily a 
regulator of feeding as, although orexin-A administration increases daytime feeding (Haynes et 
al., 1999), it does not change overall food intake or bodyweight (Haynes et al., 1999; Yamanaka 
et al., 1999). Orexin-A injected into the PVN has been found to increase non-feeding activity in 
rodents and it may be a central mediator of non-exercise activity thermogenesis (Kiwaki et al., 
2004). Orexin neurones project to areas associated with arousal and attention as well as feeding, 
and orexin-knockout mice have narcolepsy (Chemelli et al., 1999). In circumstances of 
starvation, the orexin neuropeptides may mediate an arousal / activity response in order to 
initiate food-seeking behaviour. 
NPY, AgRP and oc-MSH terminals are abundant in the LHA and are in contact with MCH and 
orexin expressing cells (Broberger et al., 1998a; Horvath et al., 1999; Elias et al., 1998b). 
Central orexin neurones also express NPY (Campbell et al., 2003) and leptin receptors (Horvath 
et al., 1999) and are thus able to integrate adiposity signals. Further integration of peripheral 
signals is provided by the large number of glucose-sensing neurones in the LHA (Bernardis and 
Bellinger, 1996) and orexin expression is increased by hypoglycaernia (Cai et al., 1999). 
Glucose signalling also occurs in other hypothalamic nuclei such as the VMH (Dunn-Meynell et 
al., 1997) and in the ARC; where glucose-sensing neurones express NPY (Muroya et al., 1999). 
The mechanism by which the MCH and orexin neurones exert their effects on energy 
homeostasis has not been fully elucidated. However, it is clear that the LHA has vast efferent 
projections including those to other hypothalamic nuclei, the hippocampal formation, amygdala, 
basal ganglia and thalamus, the midbrain and pons, the brainstern and spinal cord and it receives 
afferent inputs from many cortical, limbic and brainstern regions (Saper, 2000; Rempel-Clower 
and Barbas, 1998; Simerly, 1995). 
1.3.5 The Ventromedial Hypothalamus 
The VMH receives projections from ARC NPY, AgRP and a-MSH immunoreactive neurones 
and in turn, VMH neurones project to other hypothalamic nuclei (e. g. DMH) and to brainstem 
regions. The expression of NPY is altered in the VMH of obese mice (Guan et al., 1998) and 
MC4R expression is up-regulated in the VMH of diet-induced obese rats (Huang ct al., 2003). 
Brain derived neurotrophic factor (BDNF) is highly expressed within the VMN and is regulated 
by food deprivation and administration of melanocortin agonists (Xu et al., 2003). Mice with 
reduced BDNF receptor expression or reduced BDNF signalling have significantly increased 
food intake and body weight (Rios ct al., 2001; Xu et al., 2003). Therefore, VMH BDNF 
neurones may act as an additional downstream pathway through which the melanocortin system 
regulates appetite and body-weight. 
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1.4 Hypothalamic Neuropeptides 
A concept of energy homeostasis has developed in which discrete neuronal pathways are 
integrated into a complex neural network in which orexigenic and anorexigenic 
neurotransmitters are released from specific neurones to influence energy balance. Often 
orexigenic neuronal pathways also inhibit energy expenditure, so can be considered anabolic 
pathways. Conversely, anorectic neuronal systems often promote energy expenditure and can be 
considered catabolic pathways. Over the last decade, there has been a dramatic increase in the 
number of neuropeptides that have been found to be important in the CNS control of food intake 
(Table 1.0). 
Table 1.0: neuropeptides and gut hormones that influence appetite and energy 
expenditure. 
Orexigenic Activity I Anorexigenic Activity 
Agouti-related peptide 
Endocannabinoids 
Galanin 
Ghrelin 
Growth hormone-releasing hormone 
Melanin-concentrating hormone 
Neuropeptide Y 
Noradrenaline 
Opioid peptides 
Orexin-A 
1.4.1 Neuropeptide Y 
Alpha-melanocyte-stimulating hormone 
Amylin 
Bombesin 
Cholecystokinin 
Cocaine and amphetamine-regulated transcript 
Corticotrophin-releasing hormone 
Glucagon 
Glucagon-like peptide I 
Insulin 
Leptin 
Oxyntomodulin 
Pancreatic polypeptide 
Peptide YY 
Thyrotropin-releasing hormone 
Serotonin 
Somatostatin 
NPY is one of the most abundant neurotransmitters in the brain (Allen et al., 1983), but the 
ARC is the major hypothalamic site of NPY expression (Morris, 1989). Hypothalamic levels of 
NPY reflect the body's nutritional status, with levels of NPY mRNA and NPY release rising 
with fasting and falling after refeeding (KaIra et al., 1991; Sanacora et al., 1990; Swart et al., 
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2002). NPY is the most potent orexigen known and repeated third ventricle or PVN injection of 
NPY causes marked hyperphagia and obesity (Stanley et al., 1986; Zarjevski et al., 1993). 
Central administration of NPY also reduces energy expenditure by inhibition of the thyroid axis 
(Fekete et al., 2002), brown fat thermogenesis (Billington et al., 1991) and suppression of 
sympathetic nerve activity (Egawa et al., 1991). 
Despite the potent orexigenic action of NPY, mice deficient in NPY have normal body weight 
and adiposity (Thorsell and Heilig, 2002), with the only demonstrable abnormality of energy 
homeostasis being a reduction in fast-induced feeding (Bannon et al., 2000). This absence of a 
lean phenotype may be due to the presence of compensatory mechanisms or alternative 
orexigenic pathways, such as those which signal via AgRP (Marsh et al., 1999). Adult mice 
which undergo rapid ablation of the NPY / AgRP neurones develop profound, life-threatening 
anorexia (Luquet et al., 2005; Gropp et al., 2005). However, mice which experience neuronal 
ablation during the neonatal period (Luquet et al., 2005) have only mild effects on energy 
balance, demonstrating that the timing of neuronal ablation is vital. In humans, recent evidence 
suggests that polymorphisms of the NPY gene may be involved in the development of obesity at 
a younger age (van Rossum et al., 2006). 
NPY is part of the PP-fold family of peptides, including peptide YY (PYY) and pancreatic 
polypeptide (PP). This family bind to seven transmembrane domain G-protein coupled 
receptors, designated YI-Y6 (Larhammar, 1996). YI-Y5 receptors have been demonstrated in 
rat brain, but Y6, identified in mice, is absent in rats and inactive in primates (Inui, 1999). NPY 
is thought to stimulate feeding predominantly via the YI and Y5 receptors (Marsh et al., 1998; 
Kanatani et al., 2000; Wieland et al., 1998; Kanatani et al., 1996). 
1.4.2 The Melanocortin System 
The melanocortin system is comprised of the peptide products of POMC cleavage, including 
adrenocorticotrophin (ACTM and NISH, their receptors, and the endogenous melanocortin 
antagonists, agouti and AgRP. Levels of POMC expression reflect energy status and are reduced 
in fasted animals and increased by refeeding or the exogenous administration of leptin 
(Schwartz et al., 1997; Swart et al., 2002). Human PONIC mutations or abnormal POMC 
processing result in early-onset obesity, adrenal insufficiency and red hair (Krude et al., 1998). 
The loss of a single copy of the POMC gene in mice is sufficient to render them susceptible to 
diet-induce obesity (Challis et al., 2004). 
Five melanocortin receptors have been identified (MCI-MCSR), but only the melanocortin 3 
(MOR) and 4 (MC4R) receptors are particularly implicated in energy homeostasis. These 
34 
receptors are widely expressed in hypothalamic nuclei including the ARC, VMH and PVN 
(Harrold et al., 1999; MountJoy et al., 1994). Lack of the MC4R leads to hyperphagia and 
obesity in rodents (Huszar et al., 1997; Fan et al., 1997) and abnormalities of these receptors can 
be found in 1-6% of severe early-onset human obesity (Farooqi et al., 2000; Lubrano-Berthelier 
et al., 2003a; Lubrano-Berthelier et al., 2003b). Polymorphism of the MC4R has also been 
implicated in polygenic late-onset obesity in man (Argyropoulos et al., 2002). The MC3 
receptor may be important, as MOR null mice are obese and develop increased adipose tissue 
when fed on high fat chow. MOR mutations have been found in human subjects with morbid 
obesity (Mencarelli et al., 2004). 
The main endogenous ligand for the MOR / MC4R is oc-MSH, which is expressed by cells in 
the lateral part of the ARC (Watson and Akil, 1979). ICV administration of a-MSH inhibits 
feeding and reduces body weight in rodents by agonising these receptors (Benoit et al., 2000; 
Barsh, 1999; Rossi et al., 1998). In addition to its effects on feeding, a-MSH also stimulates the 
thyroid axis (Kim et al., 2000b) and increases energy expenditure (as measured by oxygen 
consumption) (Hwa et al., 2001; Pierroz et al., 2002), sympathetic nerve activity and the 
temperature of brown adipose tissue (Yasuda et al., 2004). In human studies, six-week nasal 
administration of NISH / ACTH (4-10), a fragment of POMC, results in a significant reduction 
of body-weight and adiposity in normal-weight volunteers. However, nasal administration of 
this, core fragment has no effect on body-weight in overweight volunteers (Hallschmid et al., 
2006), casting doubt on the efficacy of a melanocortin agonist as a treatment for obesity. 
Two endogenous antagonists of melanocortin receptors have been described: Agouti and AgRP. 
The agouti protein is a competitive antagonist of cc-MSH at MCIR and MC4R receptors (Lu et 
al., 1994). Agouti expression is normally restricted to the hair follicle, where its antagonistic 
effect on the peripheral MCIR results in a yellow coat. However, the agouti mouse ectopically 
expresses the agouti protein within the CNS, thereby antagonising the actions of a-MSH at the 
hypothalamic MC4R resulting in hyperphagia and obesity (Fan et al., 1997). Unlike agouti, 
AgRP is normally expressed in the CNS, primarily in the medial part of the ARC (Shutter et al., 
1997). AgRP is partially homologous to agouti peptide and is a potent selective antagonist at the 
MOR and MC4R (Ollmarm et al., 1997) (Figure 1.1). AgRP expression increases during 
fasting, remaining elevated for significantly longer than NPY (Swart et al., 2002). Central 
administration of AgRP or the c-terminal fragment AgRP (83-132) increases food intake by 
antagonism of a-MSH (Rossi et al., 1998). This hyperphagia has been reported to persist for up 
to a week following a single injection (Hagan et al., 2000; Rossi et al., 1998), resulting in a 
greater cumulative effect on food intake than NPY, and probably involves more diverse 
signalling pathways than the melanocortin pathway alone (Hagan et al., 2000; Hagan et al., 
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2001; Zheng et al., 2002). Independent of its effects on food intake, AgRP may increase body- 
weight via decreased energy expenditure. Central AgRP administration has been found to 
suppress TRH, reduce oxygen consumption and decrease the ability of brown adipose tissue to 
expend energy (Small et al., 2001; Small et al., 2003). 
Transgenic mice with ubiquitous over-expression of AgRP are obese, but as AgRP is inactive at 
the MC1R, they show no alteration in coat colour (Ollmann et al., 1997). Conversely, the 
reduction of hypothalamic AgRP RNA by RNA interference results in lower body weight, 
partly due to an increase of energy expenditure (Makimura et al., 2002). The role of AgRP in 
human obesity is not well-defined, although a polymorphism of the human AgRP gene has been 
reported to be associated with lower body weight and fat mass (Marks et al., 2004). 
1.4.3 Cocaine And Amphetamine-regulated Transcript 
CART is the third most abundant transcript within the hypothalamus and is expressed in the 
ARC (almost exclusively with POMC) (Elias et al., 1998a; Kristensen et al., 1998), LHA and 
PVN (Couceyro et al., 1997). Food deprived animals show a pronounced reduction in CART 
mRNA within the ARC nucleus, whereas peripheral administration of leptin to leptin-deficient 
ob/ob mice results in a stimulation of CART mRNA expression (Kristensen et al., 1998). CART 
(1-102) or CART (82-103) injected into the third ventricle inhibits both the normal and NPY- 
stimulated feeding response, but may result in abnormal behavioural responses at high dose 
(Kristensen et al., 1998; Lambert et al., 1998). Conversely, ICV injection of antiserum to CART 
peptide (1-102) or CART peptide fragment (82-103) increases feeding in rats, suggesting it is 
part of the physiological control of energy homeostasis (Kristensen et al., 1998; Lambert et al., 
1998). Interestingly, intranuclear injection of CART (55-102) into the ARC or VMN increases 
food intake (Abbott et al., 2001). Thus, there may be more than one population of CART- 
expressing neurones which exhibit different roles in feeding behaviour. 
1.5 The Brainstem Pathways 
Extensive reciprocal connections exist between the hypothalamus and the brainstem, 
particularly the NTS (van der et al., 1984; Ricardo and Koh, 1978; Ter Horst et al., 1989). The 
NTS is in close anatomical proximity to the area postrema, a circumventricular organ with a 
relatively permeable blood-brain barrier (Ellacott and Cone, 2004). Like the ARC, it is in an 
ideal position to respond to peripheral circulating signals, but in addition also receives vagal 
afferents from the gastrointestinal tract and afferent input from the glossopharngeal nerves 
(Kalia and Sullivan, 1982; Sawchenko, 1983). It has been proposed that the hypothalamus is 
primarily responsible for responding to metabolic state and the brainstern is responsible for meal 
initiation and termination (Grill and Kaplan, 2002). Recent work suggests that the gastric 
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hormone ghrelin and the gut hormone GLP-1 may mediate their effects on food intake 
predominantly via the brainstern (Williams et al., 2003; Grill et al., 2004; Faulconbridge et al., 
2003; Takahashi, 2003). 
The NTS contains NPY and melanocortin neuronal circuits. The NTS has a high density of NPY 
binding sites (Harfstrand et al., 1986) including YI (Glass et al., 2002) and Y5 receptors 
(Dumont et al., 1998). Extracellular NPY levels within the NTS fluctuate with feeding 
(Yoshihara et al., 1996) and NPY neurones from this region project forward to the PVN 
(Sawchenko et al., 1985). There is also evidence for a separate brainstern melanocortin system 
in the NTS (Kawai et al., 1984). POMC-derived peptides are synthesised in the NTS of the rat 
(Bronstein et al., 1992; Fodor et al., 1996; Kawai et al., 1984) and caudal medulla in humans 
(Grauerholz et al., 1998), and these POMC neurones are activated by feeding and by peripheral 
CCK administration (Fan et al., 2004). The MC4R is present in the NTS (MountJoy et al., 1994) 
and food intake is reduced by the administration of a MC3/4 receptor agonist to the fourth 
ventricle or dorsal motor nucleus of the vagus nerve, whereas MC3/4 receptor antagonists 
increase intake (Williams et al., 2000). 
1.6 The Hypothalamic-Pituitary-Thyroid (HPT) Axis 
The PVN contains TRII-expressing neurones which have an important role in the regulation of 
energy homeostasis through their hypophysiotropic actions on anterior pituitary thyrotrophs to 
regulate circulating levels of thyroid hormones and via direct effects on the CNS (Lechan and 
Fekete, 2006). Hypophysiotropic TRH neurones are located in the parvocellular subdivision of 
the PVN and receive direct projections from a-MSH / CART neurones (Fekete et al., 2000) and 
NPY / AgRP neurones (Legradi and Lechan, 1999) in the ARC. These ARC neurones are able 
to influence TRH gene expression (Fekete et al., 2000; Fekete et al., 2002) and thus influence 
the HPT axis in response to prevailing metabolic state (Lechan and Fekete, 2004). Other regions 
of the brain may also serve as metabolic sensors for hypophysiotropic TRH neurones including 
the DMH, which has direct projections to the PVN (Lechan and Fekete, 2006). 
Axons from hypophysiotropic TRH neurones in the PVN project to the median eminence, 
allowing access of TRH to the fenestrated capillaries of the portal system for transport to the 
anterior pituitary where TRH regulates the release of thyroid-stimulating hormone (TSM. TSH 
then stimulates the release of the thyroid hormones, thyroxine (T4) and 3,3,5 tri-iodothyronine 
(T3), from the thyroid gland into the peripheral circulation. The HPT axis demonstrates negative 
feedback, in that thyroid hormones inhibit hypophysiotropic TRH neurones and anterior 
pituitary thyrotrophs in order to maintain a 'normal' set-point for circulating levels of plasma 
thyroid hormone (Lechan and Fekete, 2006). 
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The thyroid hormones are iodinated derivatives of tyrosine which play a critical role in 
differentiation, growth and metabolism. Under normal conditions T4 is the main product of the 
thyroid gland, although a small amount of T3 and inactive reverse T3 (r T3) are secreted. T3 is the 
biologically active hormone which is derived from the metabolism of T4 in peripheral tissues by 
deiodinase activity (Bianco and Larsen, 2005). Circulating thyroid hormones bind reversibly to 
plasma proteins, and it is'only the free hormone is able to enter cells to bind to the nuclear 
receptor. The nuclear receptors mediate most of the physiological functions of the thyroid 
hormones and have much greater affinity for T3 (Yen, 2005). Thyroid hormones are required for 
the normal function of nearly all tissues and are particularly important in the regulation of 
obligatory (basal homeostatic function) and adaptive (thermogenesis) energy expenditure (Silva, 
1995). The basal metabolic rate can be reduced by up to 30 % in the absence of thyroid 
hormone, whereas hyperthyroidism increases metabolic rate (Silva, 1995). The effect of thyroid 
hormone on metabolic rate may partially occur via an action on uncoupling proteins (Gong et 
al., 1997; Queiroz et al., 2004; Ribeiro et al., 2001), which function by short-circuiting the 
proton gradient across the inner mitochondrial membrane, uncoupling fuel oxidation from the 
synthesis of ATP to generate heat (Jezek, 2002). Thyroid hormones may also influence activity- 
related energy expenditure, as an infusion of T3 has been shown to increase spontaneous 
physical activity in rodents (Levine et al., 2003). 
1.7 Peripheral Signals of Adiposity 
Over fifty years ago, the existence of a humoral signal from fat was proposed as a controller of 
body-weight homeostasis (KENNEDY, 1953). Coleman et aL performed surgical cross- 
circulation experiments in the late 1960's which demonstrated that the hyperphagic, obese oblob 
mouse was lacking a circulating satiety factor, whilst the dbldb mouse was resistant to the 
effects of this circulating factor (Coleman, 1973; Coleman and Hummel, 1969). It was not until 
1994 that the gene implicated in the obese phenotype of the oblob mouse and the hormone it 
encodes were discovered (Campfield et al., 1995; Zhang et al., 1994). The hormone was named 
leptin, from the Greek 'leptos' meaning thin. 
1.7.1 Leptin 
Leptin has multiple functions including influences on energy homeostasis, neuroendocrine 
function (Chehab et al., 1996; Ahima et al., 1996) and immune function (Lord et al., 1998). 
Leptin is a product of the ob gene expressed predominantly by adipocytes in white adipose 
tissue (Zhang et al., 1994) and also at lower levels, in gastric epithelium (Bado et al., 1998) and 
placenta (Masuzaki et al., 1997). Circulating leptin levels reflect both energy stores, and to an 
extent short-term energy balance. Plasma leptin levels are highly correlated with adipose tissue 
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mass (Maffei et al., 1995), but short-term restriction of food intake (over a period of days) 
results in a suppression of leptin levels which can be reversed by refeeding (Frederich et al., 
1995; Maffei et al., 1995) or administration of insulin (Saladin et al., 1995). 
Leptin signals the availability of fat stores to the brain by crossing the blood-brain barrier via a 
saturable process (Banks et al., 1996). Exogenous leptin replacement decreases fast-induced 
hyperphagia (Ahima et al., 1996), and chronic peripheral administration of leptin to wild-type 
rodents results in reduced food intake, loss of body weight and fat mass (Halaas et al., 1995). 
The effect of leptin on body-weight may partly mediated by an effect on energy expenditure 
(Pelleymounter et al., 1995; Halaas et al., 1995). A replacement dose of leptin is able to reverse 
the starvation induced changes of the neuroendocrine axes in both rodents (Ahima et al., 1996) 
and man (Chan et al., 2003). 
The long-form of the leptin receptor, Ob-Rb, is expressed widely within the hypothalamus but is 
found particularly in the ARC, VMH, DMH, LHA and medial preoptic area (MPOA) (Fei et al., 
1997; Elinquist et al., 1998a). Ob-Rb mRNA is also expressed in appetite-modulating pathways 
of the brainstem (Mercer et al., 1998). Peripheral leptin administration alters neuronal activity in 
these hypothalamic and brainstem regions (Elmquist et al., 1997; Hosoi et al., 2002). In the 
ARC, Ob-Rb mRNA is specifically expressed by NPY / AgRP (Mercer et al., 1996) and POMC 
/ CART neurones (Cheung et al., 1997). The orexigenic NPY / AgRP neurones are inhibited by 
leptin, and therefore activated in conditions of low circulating leptin (Schwartz et al., 1996; 
Stephens et al., 1995; Elias et al., 1999; Hahn et al., 1998). Conversely, leptin activates 
anorexigenic POMC / CART neurones (Cowley et al., 2001; Thornton et al., 1997; Schwartz et 
al., 1997). Whilst Ob-Rb mRNA is expressed in many hypothalamic nuclei, the actions of leptin 
may differ between these regions. Using viral-mediated gene expression, chronic leptin over- 
expression in the ARC, PVN and VMH result in reduced food intake and increased energy 
expenditure. However, leptin over-expression in the MPOA reduces body-weight by increasing 
energy expenditure alone (Bagnasco et al., 2002). 
The absence of leptin has profound effects on body-weight. Lack of circulating leptin, due to a 
mutation in the ob gene, leads to hyperphagia, obesity, neuroendocrine and immune disturbance 
in the ob/ob mouse, which can be normalised by leptin administration (Campfield et al., 1995; 
Halaas et al., 1995; Pelleymounter et al., 1995). Similarly, human leptin deficiency results in 
severe obesity and hypogonadism (Montague et al., 1997; Strobel et al., 1998) which can be 
ameliorated with recombinant leptin therapy in both children (Farooqi et al., 1999) and adults 
(Licinio et al., 2004). Defective leptin signalling also alters body-weight and endocrine function. 
A point mutation in the intracellular portion of the Ob-Rb receptor prevents signalling and 
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results in obesity in the db/db mouse (Chen et al., 1996; Lee et al., 1996). Mutations within the 
human leptin receptor result in early-onset morbid obesity (though less severe than that seen 
with leptin deficiency) and a failure to undergo puberty (Clement et al., 1998). 
Although a small subset of obese human subjects have a relative leptin deficiency, the majority 
of obese animals and humans have a proportionally high circulating leptin (Considine et al., 
1996; Maffei et al., 1995). This suggests resistance to leptin's actions and indeed, recombinant 
leptin administered subcutaneously to obese human subjects has only a modest effect on body- 
weight (Fogteloo et al., 2003; Heymsfield et al., 1999). Leptin resistance appears to be the result 
of a combination of factors, including reduced transport across the blood-brain barrier 
(Schwartz et al., 2000; Van Heek et al., 1997; Banks et al., 1999) and reduced leptin signalling 
in the leptin-sensitive hypothalamic neurones (Sahu, 2002; El Haschimi et al., 2000). Although 
leptin deficiency has profound effects on body weight, the effect of high leptin levels seen in 
obesity and the therapeutic administration of leptin are much less potent at restoring body 
weight. Thus, leptin's primary role may be as a hormone of starvation rather than one of plenty. 
1.7.2 Insulin 
Insulin is the major regulator of peripheral glucose homeostasis and was one of the first 
adiposity signals to be described (Schwartz et al., 1992a). Like, leptin, insulin levels are 
positively correlated with long-term energy balance (Woods et al., 1974). Circulating insulin 
levels are dependent on peripheral insulin sensitivity which is related to both total body fat and 
fat distribution, with visceral fat being a key determinant (Porte, Jr. et al., 2002). However, 
unlike leptin, insulin secretion increases rapidly after a meal (Polonsky et al., 1988). 
Insulin penetrates the blood-brain baff ier via a saturable, receptor-mediated process, at levels 
which are proportional to circulating insulin (Baura et al., 1993) and acts in the brain as an 
anorexigenic signal. An infusion of insulin, into the lateral cerebral ventricles in primates 
(Woods et al., 1979) or third ventricle in rodents (Ikeda et al., 1986), results in a dose-dependent 
decrease in food intake and body weight. Injections of insulin directly into the hypothalamic 
PVN also decrease food intake and rate of weight gain in rats (Menendez and Atrens, 1991). 
Conversely, antibodies to insulin injected into the VMH of rats stimulate food intake and rate of 
weight gain (Strubbe and Mein, 1977; McGowan et al., 1992). Thus, the VMH and PVN seem 
to play an important part in the ability of centrally administered insulin to reduce food intake. 
Studies of peripheral insulin administration are complicated by resultant hypoglycaernia, which 
in itself potently stimulates food intake. However, hyperinsulinaemic, euglycaemic clamp 
studies have demonstrated an anorectic effect of circulating insulin in both rodents and baboons 
(Woods et al., 1984; Nicolaidis and Rowland, 1976). 
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Insulin signals via receptors with intrinsic tyrosine kinase activity. These receptors are widely 
distributed in the brain, particularly in hypothalamic nuclei involved in food intake (ARC, 
DMH, PVN, suprachiasmatic and periventricular regions) (Marks et al., 1990; Corp et al., 
1986). Male mice with neuron-specific deletion of the insulin receptor in the CNS are obese and 
dyslipidaemic with increased peripheral levels of insulin (Bruning et al., 2000). Reduction of 
insulin receptor proteins in the ARC by administration of an antisense RNA directed against the 
insulin receptor precursor protein results in hyperphagia and increased fat mass (Obici et al., 
2002). 
The anorectic effect of insulin is mediated by the NPY and melanocortin systems. Central 
administration of insulin during food deprivation in rats prevents the fasting-induced increase in 
hypothalamic levels of NPY mRNA in the ARC and PVN (Schwartz et al., 1992b). NPY 
expression is increased in insulin-deficient, streptozocin-induced diabetic rats, but reduced to 
control levels by insulin replacement (White et al., 1990; Williams et al., 1989)). Insulin 
receptors have been found on POMC neurons in the ARC (Benoit et al., 2002) and third 
ventricle administration of insulin to fasted rats increases POMC mRNA expression. The 
anorectic effects of insulin are blocked by a melanocortin antagonist (Benoit et al., 2002). 
Furthermore, POMC mRNA is reduced by 80% in rats with untreated diabetes, and this can be 
attenuated by peripheral insulin treatment which partially reduces the hyperglycaernia (Sipols et 
al., 1995). 
1.7.3 Adiponectin 
Adiponectin is a complement-like protein secreted from adipose tissue which circulates at high 
levels (Scherer et al., 1995; Berg et al., 2002). In contrast to leptin and insulin, adiponectin is 
reduced in obesity and increased in response to weight loss (Hu et al., 1996; Arita et al., 1999; 
Hotta et al., 2001). A reduction in adiponectin is associated with insulin resistance, 
dyslipidaernia and atherosclerosis (Maeda et al., 2002; Kubota et al., 2002; Hotta et al., 2001). 
Treatment with adiponectin can reduce body weight gain, increase insulin sensitivity and 
decrease lipid levels in rodents (Berg et al., 2001; Qi et al., 2004; Yamauchi et al., 2001). 
Adiponectin may exert its actions on body-weight centrally and its receptors have been detected 
in the brain, including the hypothalamus (Qi et al., 2004). Peripheral administration of 
adiponectin to rodents has been shown to attenuate body weight gain by increasing energy 
expenditure (measured by oxygen consumption) without reducing food intake (Fruebis et al., 
2001; Berg et al., 2001; Yamauchi et al., 2001). This effect on energy expenditure may be 
mediated by the hypothalamus, since adiponectin activates neurones in the PVN (Qi et al., 
2004). It is perhaps counterintuitive for a factor which increases energy expenditure to increase 
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following weight loss; however, reduced adiponectin could perhaps contribute to the 
pathogenesis of obesity. 
1.8 Peripheral Signals From The Gastrointestinal Tract 
Peripheral signals from adipose tissue, pancreas and the gastrointestinal tract interact in order to 
signal nutrient availability (Figure 1.3). The only known peripheral circulating orexigenic signal 
is a hormone from the stomach named ghrelin. However, several peptide hormones from the 
gastrointestinal tract act as satiety signals, including cholecystokinin (CCK), peptide tyrosine- 
tyrosine (PYY), pancreatic polypeptide (PP) and the proglucagon-derived products, glucagon- 
like peptide 1 and oxyntomodulin. 
1.8.1 Ghrelin 
Ghrelin is the endogenous agonist of the growth hormone secretagogue receptor type Ia (GHS- 
RI a) and is a potent orexigenic factor. It is produced and released primarily by the gastric X/A- 
like cells within the oxyntic glands of the fundal mucosa and to a lesser extent from duodenum, 
ileum, caecurn and colon (Date et al., 2000a; Sakata et al., 2002). Ghrelin is a 28 amino acid 
peptide with an acyl side chain, n-octanoic acid, which is essential for its actions on appetite and 
for binding to the GHS-R la (Kojima et al., 1999). Ghrelin also stimulates growth hormone 
(GH) release via this receptor in the hypothalamus (Date et al., 2000b; Tschop et al., 2000; 
Wren et al., 2000; Kojima et al., 1999). However, the orexigenic action of ghrelin is observed in 
GH-deficient mice and is therefore independent of its effects on GH (Shintani et al., 2001; 
Tschop et al., 2000). 
In humans on a fixed feeding schedule, circulating ghrelin levels are high during a period of 
fasting, fall after eating (Cummings et al., 2001; Tschop et al., 2001; Ariyasu et al., 2001) and 
are thought to be regulated by both calorie intake and circulating nutritional signals (Sakata et 
al., 2002; Tschop et al., 2000). Ghrelin levels decrease in response to the ingestion of food or 
glucose, but not following water, suggesting gastric distension is not a regulator (Tschop et al., 
2000). However, the type of macronutrient ingested appears to be crucial, as the suppression 
observed following fat intake is of shorter duration than that observed following carbohydrate 
consumption (Sanchez et al., 2004). 
An increase in circulating ghrelin levels may occur as a consequence of the entrained 
anticipation of food or it may physiologically initiate feeding. Administration of ghrelin, either 
centrally or peripherally, increases food intake and body-weight in rodents (Tschop et al., 2000; 
Wren et al., 2001b). Furthermore, central infusion of anti-ghrelin antibodies in rodents inhibits 
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Figure 1.3: energy homeostasis is controlled by peripheral signals from adipose 
tissue, pancreas and the gastrointestinal tract. Peripheral signals from the gut 
include peptide tyrosine-tyrosine (PYY), oxyntomodulin (OXM), ghrelin, 
pancreatic polypeptide (PP), glucagon-like peptide 1 (GLP-1) and cholecystokinin 
(CCK). These gut-derived peptide and adiposity signals influence central circuits 
in the hypothalamus and brainstem in order to produce a negative or positive 
energy balance. Thus, the drive to eat and energy expenditure are adjusted so that 
over time body weight remains stable. 
Adapted from Wynne et al. J Endocrinol 2005 Feb; 184(2): 291-318 
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the normal feeding response after a period of fasting, suggesting ghrelin is an endogenous 
regulator of food intake (Nakazato et al., 2001). Intravenous administration of ghrelin increases 
short-term food intake by 28% human volunteers, without effecting gastric emptying (Wren et 
al., 2001a), and rising pre-prandial ghrelin levels correlate with hunger scores in humans 
initiating meals spontaneously (Cummings et al., 2004). The severe hyperphagia seen in Prader- 
Willi syndrome is associated with elevated ghrelin levels (Cummings et al., 2002a), and the fall 
in plasma ghrelin concentration after bariatric surgery, which occurs despite weight loss, is 
thought to be partly responsible for the suppression of appetite and weight loss seen after these 
operations (Cummings et al., 2002b). However, one study has failed to show a correlation 
between ghrelin levels and the spontaneous initiation of a meal in humans (Callahan et al., 
2004), and an alteration of feeding schedule in sheep has been shown to modify the timing of 
ghrelin peaks (Sugino et al., 2002). Thus ghrelin secretion may be a conditioned response which 
occurs to prepare metabolism for an influx of calories. 
Circulating ghrelin levels correlate with long-term energy stores. Anorexic individuals have 
high circulating ghrelin which falls to normal levels after weight gain (Otto et al., 2001). 
Conversely obese subjects have a suppression of plasma ghrelin levels which normalise after 
diet-induced weight loss (Hansen et al., 2002; Cummings et al., 2002b). Unlike lean individuals, 
obese subjects may not experience the same rapid post-prandial drop in ghrelin levels (English 
et al., 2002), which could result in increased food intake and contribute to obesity. The 
involvement of ghrelin gene polymorphisms in the pathogenesis of obesity remains 
controversial (Hinney et al., 2002; Wang et al., 2004). However, there are reports of 
polymorphisms associated with early-onset obesity (Korbonits et al., 2002; Miraglia et al., 
2004) and other polymorphisms have been found to be protective against fat accumulation 
(Ukkola et al., 2002). 
The orexigenic action of ghrelin is likely to be mediated in part via the ARC. Peripheral ghrelin 
administration activates ARC NPY neurones (Wang et al., 2002), and ghrelin fails to increase 
food intake following ablation of the ARC (Tamura et al., 2002) or in knock-out mice lacking 
both NPY and AgRP signaling (Chen et al., 2004a). However, the brainstern is also an 
important mediator of ghrelin's actions. GHS-R are found on the vagus nerve (Date et al., 2002) 
and administration of ghrelin activates neurones in the NTS and area postrema (Lawrence et al., 
2002; Nakazato et al., 2001). Vagotomy abolishes ghrelin-stimulated feeding in animal models 
(Date et al., 2002; Williams et al., 2003) and ghrelin does not stimulate appetite in humans 
following surgical procedures involving vagotomy (Le Roux et al., 2005b). 
Whilst ghrelin has potent actions on food intake in animals and man, both ghrelin null mice and 
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mice lacking the GHS-R Ia have normal appetite and body composition on standard diet (Sun et 
al., 2004; Chen et al., 2004a). However, one study of a ghrelin antagonist has demonstrated a 
significant reduction of food intake and body-weight in mice (Asakawa et al., 2003a). Therefore 
it remains controversial whether ghrelin blockade could be an effective therapy for obesity. 
1.8.2 Cholecystokinin 
CCK is primarily produced by mucosal endocrine I cells in the upper small intestine (Polak et 
al., 1975), although it is widely distributed in the gastrointestinal tract (Larsson and Rehfeld, 
1978). CCK circulates in multiple bioactive forms, including CCK-58, CCK-33, and CCK-8 
(Reeve, Jr. et al., 1994). CCK is rapidly released locally and into the circulation in response to 
nutrients, and remains elevated for up to 5 hours (Liddle et al., 1985). CCK is also found within 
the brain where it functions as a neurotransmitter involved in diverse processes such as reward 
behaviour, memory and anxiety, as well as satiety (Crawley and Corwin, 1994). CCK has an 
important role in digestion, as it stimulates the release of enzymes from the pancreas and 
gallbladder, increases intestinal motility and inhibits gastric emptying (Liddle et al., 1985; 
Moran and Schwartz, 1994). 
CCK was the first gut hormone shown to inhibit food intake following exogenous peripheral 
administration in rodents (Gibbs et al., 1973) and has since been shown to inhibit food intake in 
man (Kissileff et al., 1981). Although CCK exerts its effect on food intake rapidly, its duration 
of action is brief. It has a half-life of only 1-2 minutes in vivo, and it is not effective at reducing 
meal size if the peptide is administered more than 15 minutes before a meal (Gibbs et al., 1973). 
In animals, chronic pre-prandial administration of CCK does reduce food intake, but is seen to 
increase meal frequency, with no resultant effect on body weight (West et al., 1984; West et al., 
1987). A continuous infusion of CCK becomes ineffective after the first 24 hours (Crawley and 
Beinfeld, 1983). However, the OLETF rat which lacks CCKA receptors (but not the CCKA 
receptor knockout mouse) is hyperphagic and obese (Moran et al., 1998; Schwartz et al., 1999). 
Similarly, chronic administration of both CCK antibodies and CCKA antagonists results in 
weight gain in rodent models, although without a significant increase in food intake 
(McLaughlin et al., 1985; Meereis-Schwanke et al., 1998). The long-term effect of CCK on 
body weight may partially result from an interaction with signals of adiposity such as leptin, 
which enhance the satiating effect of CCK (Matson et al., 2000). The evidence for a role of 
CCK in long-term body-weight regulation, and hence as a potential therapy for obesity, remains 
contradictory. 
Circulating CCK sends satiety signals via activation of vagal fibres (Moran et al., 1997; 
Schwartz and Moran, 1994). The action of CCK on the vagal nerve may partly be a paracrine or 
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neuroendocrine effect, as there is evidence that locally released CCK may activate vagal fibres 
without a significant increase in plasma CCK level (Reidelberger and Solomon, 1986). The 
vagal nerve projects to the NTS, which in turn relays information to the hypothalamus 
(Schwartz et al., 2000). Peripheral CCK may also act directly on the CNS by crossing the blood- 
brain barr ier (Reidelberger et al., 2003). Evidence from the CCKA receptor knock-out (OLETF) 
rat suggests that CCK acts on the DMH to suppress NPY levels (Bi et al., 2001). This is 
supported by data which demonstrates that administration of CCK directly into the DMH 
significantly inhibits food intake (Blevins et al., 2000). 
1.8.3 Peptide Tyrosine-Tyrosine 
PYY is a 36 amino acid peptide which derives its name from its amino acid structure: 
containing tyrosine residues at both the C and N termini. PYY belongs to the same family as 
NPY and PP which all exhibit a characteristic U-shaped fold in their tertiary structure (Glover et 
al., 1983). The highest tissue concentrations of PYY are found in the rectum, followed by the 
colon and ileum (Adrian et al., 1985a). PYY release from the gastrointestinal tract occurs in 
proportion to calorie intake, with levels rising to a plateau 1-2 h after a meat and remaining 
elevated for up to 6 hours (Adrian et al., 1985a). There is a greater rise in levels after isocaloric 
intake of fat, compared with protein or carbohydrate (Lin and Chey, 2003). PYY is synthesized 
and secreted into the circulation in two forms: PYY(1-36) and the truncated form PYY(3-36) 
(Grandt et al., 1994). The latter, thought to be the biologically active satiety signal, is the 
product of the cleavage of N-terminal Tyr-Pro residues from PYY(I-36) by Dipeptidyl 
Peptidase 4 (DPP-4) (Mentlein et al., 1993). Removal of the two N-terminal amino acids of 
PYY (1-36) to produce PYY (3-36) confers a change in peptide conformation which 
significantly increases its affinity for the Y2 receptor (Keire et al., 2000). 
Peripheral administration of PYY has actions on both digestion and appetite. Administration of 
PYY causes a delay in gastric emptying, a delay in secretions from the pancreas and stomach, 
and increases the absorption of fluid and electrolytes from the ileum after a meal (Adrian et al., 
1985b; Allen et al., 1984; Hoentjen et al., 2001). Although there was some initial contention 
regarding the effects of PYY (3-36) on appetite (Boggiano et al., 2005; Tschop et al., 2004), a 
number of groups have demonstrated that peripheral administration of PYY (3-36) inhibits food 
intake and reduce weight gain in several animal species (Halatchev et al., 2004; Chelikani et al., 
2004; Pittner et al., 2004; Sileno et al., 2006; Koegler et al., 2005; Batterharn et al., 2002; 
Challis et al., 2003). The minimization of environmental stress, which in itself can result in a 
decrease in food intake, is vital in order to observe the anorectic effect of PYY (3-36) 
(Halatchev et al., 2004). In addition, the precise dosing regimen and subsequent plasma levels of 
46 
PYY (3-36) are also important factors in determining the anorectic response (Chelikani et al., 
2004). 
Current evidence suggests the anorectic effect of PYY(3-36) is mediated by the Y2 receptor 
(Batterharn et al., 2002; Abbott et al., 2005b), a putative presynaptic autoreceptor that is thought 
to mediate negative feedback of NPY onto NPY-expressing neurons. There is evidence that this 
receptor is important in energy homeostasis, as a centrally administered Y2 agonist has been 
found to suppress food intake in rodents (Leibowitz and Alexander, 1991) and mice with 
deletion of the Y2 receptor have increased food intake, adiposity and body-weight (Naveilhan et 
al., 1999). PYY alters signalling in both the NPY and melanocortin neurotransmitter systems 
(Challis et al., 2003; Challis et al., 2004; Halatchev et al., 2004; Acuna-Goycolea and van den 
Pol, 2005) and Y2 receptors are highly expresses on NPY neurones in the ARC (Broberger et 
al., 1997). Acute stress has been shown to activate the NPY system (Conrad and McEwen, 
2000; Makino et al., 2000), which may render the system insensitive to the inhibitory effect of 
PYY (3-36), resulting in masking of the anorectic effect of the peptide. The vagal-brainstem 
pathway may also play a role in signalling the anorectic effect of PYY as Y2 receptors are 
present on the vagal nerve, and the efficacy of PYY (3-36) is attenuated in vagotomised rats 
(Koda et al., 2005). In contrast to peripheral PYY (3-36), centrally-administered PYY (1-36) 
and PYY (3-36) increase food intake. PYY injection into the third, lateral or fourth cerebral 
ventricles (Clark et al., 1987; Corp et al., 2001) or the PVN (Stanley et al., 1985) potently 
stimulates food intake in rodents. However, this effect is reduced in both YI and Y5 receptor 
knockout mice (Kanatani et al., 2000). Therefore, whilst circulating PYY (3-36) may access the 
higher affinity ARC Y2 receptors (Batterham et al., 2002), the central feeding effects of PYY 
(1-36) and PYY (3-36) may be mediated by the lower affinity YI and Y5 receptors. 
PYY (3-36) is effective at reducing food intake in humans. Batterham et aL have demonstrated 
that intravenous administration of PYY (3-36) reduces food intake by 30% and also decreases 
subjective hunger ratings in normal-weight human subjects, without an alteration in gastric 
emptying (Batterham et at., 2002; Batterham et al., 2003a). Interestingly this effect was 
observed for up to 12 hours after the PYY (3-36) infusion was terminated and long after 
circulating PYY levels have returned to normal (Batterham et al., 2002). A further study has 
recently observed a dose-dependent reduction in appetite and spontaneous food intake in 
response to PYY (3-36) administration in normal-weight volunteers, although nausea occurred 
at higher doses (Degen et al., 2005). 
Importantly, for any potential anti-obesity therapy, obese subjects have been found to be equally 
responsive to the short-term anorectic effects of PYY (3-36) (Batterham et al., 2003a). Levels of 
guhrelin were reduced during administration of PYY (3-36) in lean and obese subjects, an effect 
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which may contribute its anorectic action (Batterharn et al., 2003a). 
PYY levels are elevated in conditions associated with loss of appetite such as pancreatitis, 
tropical sprue, acute gastroenteritis (Adrian et al., 1986) and cardiac cachexia associated with 
primary pulmonary hypertension (Le Roux et al., 2005a). Elevated PYY levels are also thought 
to contribute to the anorexia observed following jejuno-ileal bypass surgery (Holst et al., 1979) 
and vertical banded gastroplasty (Alvarez et al., 2002). Conversely, PYY levels have been 
found to be suppressed in obese patients (Batterham et al., 2003a; Le Roux et al., 2006) and a 
deficiency of post-prandial release has been observed (Le Roux et al., 2006). This has led to the 
hypothesis that obese humans have a relative TYY deficiency' that contributes to reduced 
satiety and hence overeating (Le Roux et al., 2006). Emerging evidence suggests that 
polymorphisms of the PYY gene can be linked with human obesity (Ahituv et al., 2005). 
The therapeutic potential of PYY as an anti-obesity treatment remains controversial. There is 
limited data regarding the effect of repeated doses of PYY (3-36) on body-weight in humans. A 
pharmaceutical company has recently reported preliminary data investigating the effect of short- 
term repeated intranasal administration of PYY (3-36) on food intake and body-weight in obese 
subjects (Nastech Pharmaceutical Company Inc., 2004). Volunteers who received PYY (3-36) 
had a dose-frequency-dependent reduction in daily energy intake. Subjects who received three- 
times daily dosing lost on average 0.6 kg over the six-day study period. Further peer-reviewed 
studies are needed to investigate the ability of PYY to reduce body-weight in obese human 
volunteers. 
1.8.4 Pancreatic Polypeptide 
PP is produced by cells at the periphery of the islets of the endocrine pancreas and to a lesser 
extent in the exocrine pancreas, colon and rectum (Larsson et al., 1975). It is a member of the 
PP-fold family and shows highest affinity for the Y4 and Y5 receptors (Larhammar, 1996). The 
release of PP occurs in proportion to the number of calories ingested and levels remain elevated 
for up to 6 hours post-prandially (Adrian et al., 1976). The levels of PP have been found to 
reflect long-term energy stores with lower levels in obese subjects (Glaser et al., 1988; 
Lassmann et al., 1980) and higher levels in anorexic subjects (Fujimoto et al., 1997; Uhe et al., 
1992). However, some studies have found no difference between lean and obese subjects 
(Wisen et al., 1992), or between obese subjects before and after weight loss (Meryn et al., 
1986). 
Peripheral administration of PP reduces food intake and increases energy expenditure (as 
measured by oxygen consumption) in rodents (Asakawa et al., 2003b). Repeated administration 
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has been found to ameliorate insulin resistance and dyslipidaernia and reduce body-weight gain 
in rodent models of obesity (Malaisse-Lagae et al., 1977; Asakawa et al., 2003b). Transgenic 
mice which over-express PP also have a lean phenotype with reduced food intake (Ueno et al., 
1999). However, it has been suggested that obese rodents are less sensitive to the effects of PP 
than normal weight rodents (McLaughlin and Baile, 1981). 
Normal weight human volunteers given an infusion of PP have decreased appetite and ingest 
25% less calories over the 24 hours following infusion (Batterharn et al., 2003b). Patients with 
Prader-Willi Syndrome patients have a blunted basal and post-prandial PP responses which may 
contribute to their hyperphagia and obesity (Zipf et al., 1981; Zipf et al., 1983) and a twice-daily 
'replacement' of PP by infusion results in a 12% reduction in the food intake of these patients 
during the therapy (Berntson et al., 1993). However, its efficacy in non-syndromic obesity 
remains to be investigated. 
Circulating PP may exert its anorectic effect on brainstern regions by crossing the relatively 
permeable blood-brain barrier at the area postrema (Whitcomb et al., 1990). This effect may 
occur via the Y5 receptor, as there is no anorectic effect of peripherally administered PP in Y5 
receptor knockout mice. However, the anorectic effect is not reduced by Y5 receptor antisense 
oligonucleotides (Katsuura et al., 2002). Following the peripheral administration of PP, the 
expression of hypothalamic NPY and orexin mRNA is significantly reduced and gastric 
emptying is delayed (Asakawa et al., 2003b). Like PYY (3-36), PP also reduces gastric ghrelin 
mRNA expression, and this may be its mechanism of action in the treatment of hyperphagia 
secondary to Prader-Willi Syndrome (Asakawa et al., 2003b). In contrast to its peripheral 
effects, central administration of PP increases food intake (Clark et al., 1984). The mechanism 
of this orexigenic effect following central injection is unclear, but may represent the action of 
PP on different receptor subtypes. 
1.8.5 Proglucagon-derived Products 
1.8.5.1 The Proglucagon Gene 
The structure of the mammalian proglucagon gene was discovered in 1983 (Bell et al., 1983) 
and the processing of the pre-prohormone, pre-proglucagon, to its constituent peptides was first 
established in 1986 (MqJsov et al., 1986). The proglucagon gene product undergoes tissue- 
specific post-translational processing in the intestine, pancreas and central nervous system 
(Tang-Christensen et al., 2001; Drucker, 2005) (Figure 1.4). In the islet a-cells, proglucagon is 
cleaved by prohormone convertase 2 into the 29-amino acid glucagon and a larger unprocessed 
polypeptide designated 'major proglucagon fragment'i (Patzelt and Schiltz, 1984). In the 
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Figure 1A a diagrammatic representation of the tissue-specific processing of 
proglucagon in the pancreas and intestine / brain. The numbers refer to the amino 
acid position starting at the N-terminal amino acid. Differences between the amino 
acid numbers in proglucagon and the constituent peptides reflect processing and 
removal of spacer amino acids between the peptides. Intestinal and brain 
processing yields glicentin, GRPP, oxyntomodulin, GLP-1 and GLP-2 as the main 
end-products. Pancreatic processing yields glucagon, GRPP and MPGF. GLP: 
glucagon-like peptide; GRPP: glicentin-related pancreatic polypeptide; IP: 
intervening peptide; OXM: oxyntomodulin; MPGF: major proglucagon fragment; 
PC: prohormone convertase. 
Proglucagon 
30 64 69 107 126 158 
GRPP Glucagon GLP-1 111" 111 GL III 111 0.11 Ia. 
Intestine / brain (PC1; ' 
69 78 107 126 158 
Glicentin GLP-1 
60-80% 
3033 69 
1 oxm 
20-40% 20-40% 
Pancreas (PC2) 
3033 61 72 158 
Glucagon MPGF 
60-80% 
3033 61 72 107 126 158 
Glucagon LP-1 (1-36) GLP-2 
20-40% 20-40% 
Adapted from Tang-Christensen et al. Int J Obes 2001 25: SuppI 5, S42-S47 
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Figure 1.5: the amino acid sequences of the proglucagon-derived peptides and 
exendin-4. The key to the amino acid codes is given in Appendix A. GLP: 
glucagon-like peptide; OXM: oxyntomodulin; IP: intervening peptide. 
I Gluca H-S-Q-G-T-F-Y-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-V-Q-W-L-M-N-T 
H-A-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-V-K-G-R 
GL H-A-D-G-S-F-S-D-E-M-N-T-1-L-D-N-L-A-A-R-D-F-I-N-W-L-I-Q-T-K- I I-T-D 
H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E-W-L-K-N-G- 
G-P-S-S-G-A-P-P-P-S 
R-S-L-Q-D-T-E-E-K-S-R-S-F-S-A-S-A-A-D-P-L-S-D-P-D-Q-M-N-E- 
D-K-R-H-S-Q-G-T-F-Y-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-V-Q-W-L- 
-N-T-K-R-N-K-N-N-1-A 
H-S-Q-G-T-F-Y-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-V-Q-W-L-M-N-T- 
K-R-N-K-N-N-1-A 
II K-R-N-K-N-N-1-A 
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enteroendocrine L-cells of the small intestine and in the NTS, proglucagon is cleaved by 
prohormone convertase I into glicentin (enteroglucagon), oxyntomodulin, glucagon-like peptide 
I (GLP-1) and glucagon-like peptide 2 (GLP-2). The amino acid sequences of the proglucagon- 
derived products are shown in Figure 1.5. 
1.8.5.2 Glucagon 
Glucagon is a 29 amino acid peptide released from the a-cells of the islets of Langerhans. The 
primary function of glucagon is to regulate hepatic glucose production. Glucagon opposes the 
actions of insulin at the hepatocytes to regulate gluconeogenesis: the de novo generation of 
glucose. Circulating levels of glucagon are low in the post-prandial state and increase with 
fasting. Glucagon action is mediated by a specific G-protein coupled receptor (Jelinek et al., 
1993), which shares 42% homology with the receptor for GLP-l. High affinity glucagon 
binding sites have been identified in liver, kidney, intestinal smooth muscle, brain, adipose 
tissue and islet P-cells (Moens et al., 1996). The metabolic derangement which occurs in type 2 
diabetes is due to a failure of post-prandial glucagon suppression and elevated circulating 
glucagon, together with insulin deficiency and / or insulin resistance (Unger and Orci, 1975). 
The administration of glucagon receptor antagonists attenuates glucagon-stimulated hepatic 
glucose production in short-term studies of non-diabetic volunteers (Petersen and Sullivan, 
2001) and may provide a strategy for the treatment of diabetes. Interestingly, two newly 
licensed anti-diabetic drugs pramlintide (analogue of amylin: a product of the P-cell co-secreted 
with insulin) and exenatide (exendin4) both exert their actions partly through inhibition of 
glucagon secretion (Schmitz et al., 2004). 
1.8.5.3 Glucagon-like Peptide 1 
GLP-I is a 30 amino acid peptide product of proglucagon which contains two helical regions at 
amino acid positions 7- 14 and 18 - 29 (Thornton and Gorenstein, 1994). Two equipotent 
bioactive forms of GLP-I are released from the L-cells of the intestine following nutrient 
ingestion: GLP-I (7-37) and GLP-I (7-36) amide (Herrmann et al., 1995; Orskov et al., 1993). 
GLP-I physiologically stimulates glucose-dependent insulin secretion and inhibits glucagon 
secretion, gastric emptying and food intake (Drucker, 2001). GLP-I is one of the most 
important incretin hormones (Kreymarm et al., 1987) and has been found to potentiate all steps 
of insulin biosynthesis (MacDonald et al., 2002). GLP-I is also a signal of energy homeostasis. 
Circulating GLP-I levels are inversely correlated with body-mass (Holst et al., 1983; Naslund et 
al., 1999; Ranganath et al., 1996; Verdich et al., 2001b) and GLP-I inhibits food intake when 
administered centrally (Turton et al., 1996) or peripherally (Tang-Christensen et al., 2001) to 
rodents. Furthermore, repeated daily injections of GLP-I into the cerebral ventricles over a six- 
day period reduces body-weight in rats (Meeran et al., 1999). The anorectic effect of GLP-I 
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probably occurs via hypothalamic and brainstem centres, as well as via delayed gastric 
emptying (Yamamoto et al., 2003; Turton et al., 1996; Flint et al., 1998). The anorectic effects 
of GLP-I are abolished following vagotomy or transaction of the brainstem-hypothalamic 
pathway in rodents, suggesting the vagal-brainstern pathway is vital for the anorectic action of 
GLP-I in the brain (Abbott et al., 2005a). GLP-I administered intravenously or into the cerebral 
ventricles increases energy expenditure (measured by whole-body oxygen consumption and 
core temperature) in anaesthetised rodents, an effect which may also be mediated by the 
brainstern and sympathetic system (Osaka et al., 2005). However, this effect of centrally 
administered GLP-I on energy expenditure has not been demonstrated in obese rodents (Hwa et 
al., 1998). 
Endogenous central proglucagon-expressing neuronal circuits may play a role in energy 
homeostasis. A small group of leptin-responsive neurones expressing proglucagon products are 
present in the NTS (Larsen et al., 1997; Tang-Christensen et al., 2001). This population of 
neurones is thought to provide a pathway between the brainstern and hypothalamus, with GLP-I 
immunoreactive fibres present in the PVN and DMH, and to a lesser extent the ARC (Larsen et 
al., 1997; Merchenthaler et al., 1999). Central administration of GLP-I, either into the third or 
forth ventricle, potently reduces fasting and NPY-induced food intake (Turton et al., 1996) and 
blockade of endogenous GLP-I, with the GLP-I receptor antagonist, exendin (9-39), increases 
food intake (Turton et al., 1996). 
GLP-I signals through the GLP-I receptor, a seven-membrane spanning domain, G-protein 
coupled receptor which stimulates adenylate cyclase and intracellular calcium (Thorens, 1992; 
Gromada et al., 1995). GLP-I receptors are expressed in the hypothalamus and brainstern 
(Shimizu et al., 1987; Uttenthal et al., 1992; Goke et al., 1995a), pituitary gland (Goke et al., 
1995b; Alvarez et al., 1996), lung (Richter et al., 1990), pancreatic islets (Thorens, 1992), 
stomach (Schmidtler et al., 1994; Schepp et al., 1994), heart (Wei and Mojsov, 1995), intestine 
and kidney (Bullock et al., 1996). Fasting and refeeding modulate GLP-I receptor expression in 
the hypothalamus and brainstern (Zhou et al., 2003), with expression being lower in fed than 
fasted rats. GLP-I receptor knockout mice exhibit fasting hyperglycaernia and reduce glucose- 
stimulated insulin secretion, but demonstrate no alteration in feeding behaviour or body-weight 
(Scrocchi et al., 1996), demonstrating GLP-I's primary role as a regulator of glucose 
homeostasis. Although the existence of a second GLP-I receptor is being actively pursued, only 
a single receptor has been isolated to date. 
Human studies have demonstrated that GLP-I administration improves blood glucose levels in 
poorly controlled type 2 diabetes during both a short-term intravenous infiision (Nauck et al., 
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1993), and after a six-week subcutaneous infusion (Zander et al., 2002). In the latter study, 
body-weight was reduced by 1.6 kg over the six-week study period (Zander et al., 2002). The 
effect of GLP-I on body-weight is due to a reduction in food intake. One meta-analysis has 
demonstrated that administration of GLP-I decreases food intake in both lean and obese human 
volunteers in a dose-dependent manner (Verdich et al., 2001 a). However, the anorectic effect is 
small when infusions achieve normal post-prandial circulating levels (Flint et al., 2001; Verdich 
et al., 2001b). 
The effect of GLP-I on energy expenditure in humans remains controversial. Higher fasting 
plasma concentrations of endogenous GLP-I are associated with higher resting energy 
expenditure in both men and women over a range of body-weights (Pannacciulli et al., 2006). 
However, the effect of GLP-I on resting energy expenditure is not clear, as a four-hour infusion 
of GLP-I conversely reduced resting energy expenditure (measured by a ventilated hood 
system) in both normal-weight and obese volunteers (Flint et al., 2000; Flint et al., 2001). 
Another study has demonstrated a positive effect of GLP-I infusion on energy expenditure in 
healthy volunteers, but suggested that this effect was entirely secondary to the stimulation of 
insulin release (Shalev et al., 1997). 
Some evidence suggests GLP-1 secretion is reduced in obese subjects (Holst et al., 1983; 
Naslund et al., 1999; Ranganath et al., 1996) and weight loss normalises the levels (Verdich et 
al., 2001b). Reduced secretion of GLP-1 could therefore contribute to the pathogenesis of 
obesity and replacement may restore satiety. Indeed, obese subjects, given subcutaneous GLP-1 
prior to each meal, reduce their calorie intake by 15% and lose 0.5kg in weight over 5 days 
(Naslund et al., 2004). Although GLP-1 may be a useful treatment for type 2 diabetes, it has 
been reported to cause hypoglycaernia in non-diabetic subjects (Edwards et al., 1998) which 
could limit its usefulness as an obesity therapy. Dose-limiting side-effects of nausea and 
vomiting determine the maximum tolerated dose in human subjects. 
GLP-I is rapidly broken down by the enzymes DPP-4 and neutral endopeptidase, and is 
removed by renal clearance, resulting in a short half-life of one to two minutes in the circulation 
(Orskov et al., 1993; Deacon et al., 1995). Therefore, the development of GLP-1-based 
therapeutic approaches has focussed on degradation-resistant, longer-acting GLP-I receptor 
agonists with a longer duration of action in vivo. Resistant albumin-bound GLP-I (e. g. 
liraglutide), exendin-4 (Exenatide), and inhibitors of the enzyme DPP-4 (e. g. vildagliptin) are all 
currently in development for the treatment of diabetes (see review (Holst, 2004)). 
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1.8.5.4 Exendin-4 
Exendin4 is a naturally occurring 39 amino acid GLP-I receptor agonist originally isolated 
from the venom of the Heloderma suspectum lizard (Eng et al., 1992). It is a potent long-acting 
agonist at the mammalian GLP-I receptor (Schepp et al., 1994; Goke et al., 1993; Thorens et al., 
1993). The efficacy of exendin-4 (Exenatide) for the treatment of type 2 diabetes has recently 
been examined in phase III clinical trials. Exendin-4 significantly reduced HbAlc in poorly- 
controlled diabetics treated with metformin, a sulphonylurea, or metformin plus a sulphonylurea 
(Buse et al., 2004; DeFronzo et al., 2005; Kendall et al., 2005). Exendin-4 therapy was also 
associated with prevention of weight gain or modest weight loss over the 30-week treatment 
period. Open-label extension studies in patients continuing treatment demonstrated a weight loss 
of 4.4 kg at 82 weeks (Blonde et al., 2006). However, similar to GLP-I, nausea was the 
principal dose-limiting side-effect. 
1.8.5.5 Glucagon-like Peptide 2 
GLP-2 is a 33 amino acid peptide product of proglucagon which is structurally related to 
glucagon and GLP-1. Like GLP-1, GLP-2 is secreted from intestinal L-cells in a nutrient- 
dependent manner and is susceptible to degradation by DPP4 (Drucker, 2005). However, the 
actions of GLP-2 are mediated by a separate GLP-2 receptor (Munroe et al., 1999). The actions 
of GLP-2 include inhibition of gastrointestinal motility and gastric acid secretion, stimulation of 
nutrient absorption, reduction of intestinal epithelial permeability and alterations in small bowel 
mucosal growth in response to nutrient availability (Drucker et al., 1996). A degradation 
resistant GLP-2 analogue, teduglutide, is being evaluated in phase III clinical trials for the 
treatment of short-bowel syndrome (Jeppesen et al., 2005). Although central administration of 
GLP-2 has been found to inhibit food intake in rodents (Tang-Christensen et al., 2001), GLP-2 
does not act as a satiety factor in normal human subjects (Schmidt et al., 2003) 
1.8.5.6 Glicentin 
Glicentin is a 69 amino acid peptide that contains the sequence of glucagon together with N- 
terminal and C-terminal extensions. Glicentin reduces pancreatic (Kirkegaard et al., 1982), 
gastric (Anini et al., 2000) and ileal secretion (Hirotani et al., 2000) and alters gastric motility in 
rodents (Pellissier et al., 2004). A separate receptor for glicentin has not yet been identified. 
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1.8.5.7 Oxyntomodulin 
Oxyntomodulin is a 37 amino acid peptide that that contains the sequence of glucagon with an 
octapeptide C-terminal extension (intervening peptide 1) (Bataille et al., 1981). Oxyntomodulin 
was first isolated from porcine jejuno-ileal cells in the early 1980's (Bataille et al., 1982). Prior 
to its isolation, oxyntomodulin was known as 'bioactive enteroglucagon'; enteroglucagon being 
the term applied to the region of proglucagon comprising of oxyntomodulin and glicentin. 
Oxyntomodulin contributes to approximately 50% of all endogenous plasma 'oxyntomodulin- 
like immunoreactivity' (OLI), the remaining component being glicentin (Kervran et al., 1987). 
Significant amounts of oxyntomodulin have been found in human distal intestine (Baldissera et 
al., 1988). In rodents, the gastrointestinal tissue concentration of oxyntomodulin gradually 
increases from the duodenum to ileum, thereafter decreasing in caecurn and colon (Kervran et 
al., 1987). Oxyntomodulin is released from the intestinal L-cells 5-10 min after meal ingestion 
in proportion to calorie intake (Ghatei et al., 1983; Le Quellec et al., 1992), peaking at around 
30 minutes (Anini et al., 1999). Circulating levels of OLI demonstrate a diurnal variation, 
independent of food intake, with levels highest in the evening and lowest in the early morning 
(Le Quellec et al., 1992). Oxyntomodulin has a short half-life in circulation, reported to be 12 ± 
I minute in humans (Schjoldager et al., 1988) and 6.4 ± 0.5 minutes in the rat (Kervran et al., 
1990). It is removed by renal clearance and is a likely substrate for the enzyme DPP-4 
(Boonacker and Van Noorden, 2003; Zhu et al., 2003). 
The administration of oxyntomodulin acutely reduces food intake in rodents, without altering 
behavioural patterns (Dakin et al., 2001; Dakin et al., 2004). Dark-phase and fast-induced 
feeding are decreased following an injection of oxyntomodulin into the peritoneum or after 
administration into the cerebral ventricles, PVN or ARC (Dakin et al., 2001; Dakin et al., 2004). 
Peripheral oxyntomodulin activates c-fos (an early gene marker of neuronal activation) in the 
ARC (Dakin et al., 2004; Horvath, 2005), PVN, area postrema and NTS (Horvath, 2005; Baggio 
et al., 2004b) and the anorectic effect of peripheral oxyntomodulin may be mediated by an 
increase in hypothalamic a-MSH (Dakin et al., 2004). Peripheral administration of 
oxyntomodulin has also been found to reduce circulating ghrelin in rodents (Dakin et al., 2004) 
and humans (Cohen et al., 2003) which may contribute further to its anorectic action. Repeated 
administration of oxyntomodulin over seven days reduces body-weight gain and adiposity when 
given intraperitoneally (Dakin et al., 2004) or into the cerebral ventricles of male Wistar rats 
(Dakin et al., 2002). Interestingly, oxyntomodulin-treated animals lose more weight than 
animals eating the same amount which suggests that oxyntomodulin may influence body-weight 
by increasing energy expenditure (Dakin et al., 2002). 
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As yet, the existence of a unique oxyntomodulin receptor has not been clearly demonstrated. It 
has been suggested that oxyntomodulin exerts its anorectic effect by signalling through the 
GLP-I receptor, as it is ineffective in GLP-I receptor deficient mice (Baggio et al., 2004b) and 
administration of the GLP-I antagonist, exendin (9-39), into the cerebral ventricles inhibits the 
anorectic actions of both GLP-1 and oxyntomodulin (Dakin et al., 2001; Turton et al., 1996). 
However, there is evidence of biological differences between oxyntomodulin and GLP-I, which 
suggest that oxyntomodulin may signal via a separate unidentified receptor that is also 
antagonized by exendin (9-39). The effect of peripherally administered oxyntomodulin is 
blocked by exendin (9-39) administered directly into the ARC, whereas the effect of peripheral 
GLP-I is retained, regardless of the antagonism of hypothalamic receptors in this region (Dakin 
et al., 2004); furthermore, GLP-I and oxyntomodulin both potently inhibit food intake at 
equimolar doses in rats (Dakin et al., 2001), despite the affinity of oxyntomodulin for the GLP-I 
receptor being two orders of magnitude lower than that of GLP-I itself (Dakin et al., 2001; 
Fehmann et al., 1994). In support of an alternative receptor, a recent study suggests that 
oxyntomodulin elevates murine heart rate via a GLP-I receptor-independent mechanism 
(Sowden et al., 2006). The differential effects of GLP-I and oxyntomodulin may therefore be 
due to the presence of separate receptors. Alternatively, differences in peptide breakdown, tissue 
penetration, or context-dependent alterations in receptor signalling (such as the receptor- 
activity-modifying proteins which regulate the affinity of calcitonin receptors (Born et al., 
2002)) may result in the observed differences between these two proglucagon products. 
The effect of oxyntomodulin on food intake and body-weight in rodents led to the investigation 
of its appetite-suppressant properties in humans. Our laboratory performed the first clinical 
study, which demonstrated that an intravenous administration of oxyntomodulin reduced energy 
intake at a single study meal by 19 ± 6% in normal-weight volunteers, an effect which persisted 
up to twelve hours post-infusion (Cohen et al., 2003). Anorexia also occurs in human conditions 
associated with high oxyntomodulin levels, such as tropical sprue (Besterman et al., 1979) and 
jejuno-ileal bypass surgery (Holst et al., 1979; Sarson et al., 1981). Thus, oxyntomodulin may 
regulate energy homeostasis in humans. However, the ability of oxyntomodulin to modulate 
food intake and body-weight in the obese, and therefore its potential as an anti-obesity therapy 
remains unknown. The role of oxyntomodulin in the control of energy homeostasis forms the 
topic of this thesis. 
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1.9 Hypothesis And Aims Of Thesis 
Hypothesis: Oxyntomodulin is a gut hormone which regulates energy homeostasis in 
rodents and man. 
Aims: The programme of research presented in this thesis has the following aims to 
test this hypothesis: 
1. To investigate the effect of oxyntomodulin on food intake, energy expenditure and body- 
weight in rodents 
2. To investigate the effect of the subcutaneous administration of oxyntomodulin on food 
intake and body weight in healthy overweight and obese human volunteers. 
3. To investigate the effect of the subcutaneous administration of oxyntomodulin on energy 
expenditure in healthy overweight and obese human volunteers. 
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Chapter 2 
The Effect Of Oxyntomodulin On 
Energy Homeostasis In Rodents 
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2.1 Introduction 
Peripheral signals of appetite from the gastrointestinal tract acutely regulate food intake. These 
signals have also been shown to control longer-term body-weight homeostasis. For example, 
rodent studies have demonstrated that repeated administration of ghrelin increases body-weight 
gain and adiposity (Wren et al., 2001b; Tschop et al., 2000). Whereas chronic administration of 
PYY (3-36) (Vrang et al., 2006; Batterham et al., 2002; Pittner et al., 2004), GLP-I receptor 
agonists (Rodriquez de et al., 2000; Mack et al., 2006) and oxyntomodulin (Dakin et al., 2004) 
result in a reduction in body-weight gain and adiposity. 
The weight loss which occurs following repeated intraperitoneal oxyntomodulin injection is 
postulated to be due to an increase in energy expenditure, as well as a decrease in energy intake, 
as oxyntomodulin-treated rats have lower adiposity and body-weight than rats eating the same 
amount (Dakin et al., 2004). However, this effect of oxyntomodulin on energy expenditure has 
not been confirmed by direct measurement. It is important to characterise the mechanism of 
action by which oxyntomodulin reduces body-weight in rodents in order to elucidate its possible 
role as an anti-obesity therapy in humans. 
The central satiety action of oxyntomodulin is thought to occur via the hypothalamus and 
brainstem. Peripheral administration of oxyntomodulin has been shown to induce c-fos (a 
marker of neuronal activation) in the ARC (Dakin et al., 2004; Horvath, 2005), PVN, area 
postrema and NTS (Horvath, 2005; Baggio et al., 2004b). Within the hypothalamus it is possible 
that the anorectic effect may be mediated by an increase in release of a-MSH (Dakin et al., 
2004) or by a decrease in release of the orexigenic NPY / AgRP neuropeptides. It has been 
hypothesised that a positive effect of oxyntomodulin on energy expenditure in rodents may 
occur by stimulating TRH release in the hypothalamus, preventing the normal suppression 
observed in plasma TSH during fasting (Dakin et al., 2002). 
A 24 chamber open-circuit Oxymax Comprehensive Lab Animal Monitoring System was used 
for the investigation of energy homeostasis in rodents. This is an automated cage system that 
allows simultaneous measurement of food intake, activity and metabolic parameters of energy 
expenditure at regular intervals with minimal disturbance to the experimental animal. The 
volume of oxygen (V02) and carbon dioxide (VC02) measured in expired air, can be used to 
calculate respiratory quotient (RQ) or respiratory exchange ratio (RER): defined as the ratio of 
VC02 produced to V02 consumed. The RER gives an indication of the type of fuel metabolised 
by an organism to provide energy: the value for carbohydrate is approximately 1.0, while that 
for protein is 0.8 and fat is 0.7. Synchronously recorded measurements of V02 and RER can be 
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used to derive measurements of total energy expenditure using indirect calorimetry formulae 
(Elia and Livesey, 1992; Cunningham, 1990; Brockway, 1987): 
TEE= 1.32*VO2*(1.23*RER+3.81) 
Total energy expenditure consists of resting energy expenditure, incorporating both basal 
metabolic rate and the thermic effect of food, and activity-related energy expenditure 
(Castaneda et al., 2005). The thermic effect of food is a short-term increase in energy 
expenditure in response to feeding (Castaneda et al., 2005), whilst food restriction is associated 
with a fall in energy expenditure which helps to limit nutritional requirements during periods of 
starvation (Larsen et al., 2001; Vinter et al., 1988; Forsum et al., 1981; Severinsen and Munch, 
1999; Even and Nicolaidis, 1993). In animals, basal metabolic rate can be further divided into 
obligatory energy expenditure (required to maintain normal cellular functions) and adaptive 
thermogenesis (Girardier, 1977; Castaneda et al., 2005). Adaptive thermogenesis is facultative 
heat production; oxygen consumption increases markedly in rodents after cold exposure at 4'C 
due in part to the release of heat from skeletal muscle secondary to shivering and also to the 
stimulation of heat production by non-shivering thermogenesis in brown adipose tissue (BAT) 
(DAVIS et al., 1960). The brain controls adaptive thermogenesis through the sympathetic 
nervous system, which densely innervates BAT and skeletal muscle (Nnodirn and Lever, 1988), 
and via the hypothalamo-pituitary-thyroid axis (Silva, 1995). In BAT, a specialised uncoupling 
protein (UCP-1) allows protons to leak back across the inner mitochondrial membrane to 
produce heat Qezek, 2002). UCP-I expression and activity is regulated by the sympathetic 
nervous system, and signalling via the P3-adrenergic receptor has been implicated in UCP-I 
activation (Yoshida et al., 1998). Humans express UCP-I in BAT and babies have detectable 
BAT in the interscapular region. However, BAT is very sparse in adult humans and therefore 
non-shivering thermogenesis may be primarily a physiological process in animal models of 
energy expenditure Qezek, 2002). 
2.2 Hypothesis And Aims 
Oxyntomodulin has been found to act as a satiety signal when administered peripherally to both 
rodents and humans (Cohen et al., 2003; Dakin et al., 2004). A dose of 50 nmol/kg 
oxyntomodulin administered twice-daily by intraperitoneal injection has been shown to reduce 
body-weight gain and adiposity over a seven day period (Dakin et al., 2004). 
Hypothesis: I hypothesise that repeated administration of oxyntomodulin to rodents will 
decrease food intake and increase energy expenditure, resulting in a significant reduction of 
body-weight gain. 
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Aims: 
1. Characterise the effect of the peripheral and central administration of oxyntomodulin on 
food intake, activity and energy expenditure using metabolic cages. 
2. Investigate the effect of oxyntomodulin on the release of hypothalamic a-MSH, NPY, 
CART, AgRP, and TRH using a static incubation explant system. 
3. investigate the effect of oxyntomodulin on TSH release from pituitary explants using a 
static incubation system. 
2.3 The Effect Of Peripheral And Central Administration Of Oxyntomodulin On 
Energy Homeostasis In Rodents 
2.3.1 Materials and Methods 
2.3.1.1 Materials 
Oxyntomodulin was synthesised by Bachem (St. Helens, UK), divided into aliquots on the first 
day of the experiment and freeze-dried, to ensure that its structure and bioactivity were 
preserved. Freeze-dried peptide was reconstituted in sterile 0.9% saline. Chemicals were 
purchased from Merck Eurolab (Leicestershire, UK) unless otherwise stated. 
2.3.1.2 Rodent Models 
Groups of twenty-four adult male C5713L/6 mice (20-30g) or twenty-four adult male Wistar rats 
(200-250g) (Charles River, UK) were used for in vivo rodent studies. These strains were chosen 
as they are predisposed to diet-induced obesity and are therefore a good rodent model of human 
obesity (Newby et al., 1990; Moraes et al., 2003). Rodents were handled and received sham 
injections of saline on at least two occasions prior to the study days in order to acclimatise the 
animals to the injection procedure. Rodents were maintained at 241C with a 12: 12hr light-dark 
cycle (light period 0700-1900). Food (ground RMI chow) and water were freely available 
unless a period of fasting was required during the study. All animal procedures undertaken were 
approved by the British Home Office Animals (Scientific Procedures) Act 1986 (Project 
License PPL 70/6402). 
2.3.1.3 Metabolic Cages 
A 24 chamber open-circuit Oxymax Comprehensive Lab Animal Monitoring System 
(Columbus Instruments, Columbus, OH, USA) was used for the investigation of energy 
homeostasis. Rodents were acclimatized to the metabolic cages for 48 hours prior to each study, 
unless otherwise stated. Rodents were individually housed in plexiglass chambers, through 
which air was passed at a flow rate of 2.5 litres/minute and 0.6 litres/minute for rat and mouse 
cages respectively. Exhaust air from each air-tight chamber was sampled for one minute at 30 
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minute intervals. Sample air was sequentially passed through 02 and C02 sensors (Columbus 
Instruments) for determination Of 02 and C02 Content. The sensors were calibrated daily by use 
of a standard span gas. For each animal, 02 consumption and C02 production values were 
normalised with respect to body weight and corrected to an effective mass value. These values 
were used to calculate respiratory exchange ratio (RER) and energy expenditure. The 
ambulatory activity of each rodent was assessed simultaneously using the optical beam 
technique (Opto M3, Columbus Instruments, Columbus, OH, USA). Consecutive photo-beam 
breaks across the horizontal axis were scored as an ambulatory movement (XAMB) and single 
photo-beam breaks across the vertical axis were scored as ambulatory movement (ZTOT). 
Cumulative activity counts were recorded over each 30 minute interval. Food intake was 
measured using ground RMI diet placed in food hoppers attached to each individual cage. The 
side-feeders rested on balances directly linked to a computer which measured food intake every 
30 minutes. 
2.3.1.4 Surgical Cannulation Of The Third ventricle 
Surgical implantation of an indwelling cannula allows central administration of peptide directly 
to the brain. Prior to surgery, adult male Wistar rats were anaesthetised with an IP injection of 
xylazine (20 mglkg) (Rompun, Bayer UK Ltd., Bury St. Edmonds, UK) and ketamine (60 
mg/kg) (Ketalar, Parke-Davis, Pontypool, UK) and placed on a Kopf stereotaxic frame (Harvard 
Apparatus, Edenbridge, Kent, UK), with the incisor bar set 3.0 mm below the inter-aural plane. 
The rats' skulls were exposed and three stainless steel screws were fixed to the skull. Animals 
had a permanent stainless steel 22-gauge unilateral guide cannula (Plastics One, Roanoke, VA, 
USA) stereotactically implanted into the third cerebral ventricle (Edwards et al., 1999) [0.8 mm 
posterior to bregma, on the mid-sagittal line, 6.5 mm below the outer surface of the skull 
(Paxinos et al., 1985)]. Each cannula was then anchored to the screws by the application of 
dental cement to the exposed surface. After surgery, a dummy stylet was inserted into each 
cannula to prevent blockage. Following a 7-day recovery period, the correct placement of the 
cannulae was verified by an injection of the dipsogenic peptide, angiotensin II (150 ng / animal 
in 5 [it saline) into the third ventricle. Animals not demonstrating a robust and sustained 
drinking response were excluded from the study (<10%). Animals were handled daily following 
recovery from surgery until the completion of the studies. 
2.3.1.5 Subcutaneous Implantation Of Atzet Osmotic Minipumpse 
Alzet osmotic minipumpe (Durect Corporation, Cupertino, CA, USA) are an established 
method of chronic peptide delivery and have previously been used for the administration of 
appetite-regulating peptides, including PYY (Pittner et al., 2004; Wang et al., 2006) and ghrelin 
(Tschop et al., 2000; Thompson et al., 2004). These implantable pumps have the advantage of 
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continuous administration without the need for connectors or frequent handing. Prior to 
implantation, the peptide is injected into a flexible central reservoir within the pump. This 
reservoir is separated by an impermeable membrane from an outer chamber with high salt 
concentration. Once implanted into the animal, fluid enters via a semi-permeable cellulose outer 
membrane due to the high osmotic pressure of the salt. This mechanically compresses the 
central reservoir and results in delivery of the treatment at a fixed rate (dependent on outer 
membrane permeability) via a stainless steel flow moderator. The pumps utilised in the 
experiments were model 2001 (length 300mm, circumference 0.7mm, weight 1.1g, release rate 
I pl / hour) and models 1003D and 1007D (length 150 mm, circumference 0.6 mm, weight 0.4g, 
release rate I [tl / hour and 0.5pl / hour respectively). On the morning of surgery, pumps were 
loaded with either oxyntomodulin reconstituted in 100pM acetic acid (pH 3.6) or placebo 
vehicle (acetic acid alone). The acidification of oxyntomodulin in solution had previously been 
found to improve the stability of the peptide when tested in vitro (personal communication, Mr 
James Minnion, Department of Metabolic Medicine, Imperial College London). Osmotic pumps 
were implanted subcutaneously below the scapulae in mice anaesthetised with inhaled 
isoflurane. Intra-operative antibiotic (Enrofloxacin 5mg/kg intramuscularly) was administered. 
The incision was closed with two surgical staples which were removed a maximum of fourteen 
days post-surgery. 
2.3.1.6 Preliminary Dose-Finding Study Of The Intraperitoneal Administration 
Of Oxyntomodulin To Rodents 
Twenty-four male C57BL/6 mice and twenty-four male Wistar rats were randomised to three 
groups (n=8) by body-weight. The groups were allocated metabolic cages by stratified 
randomisation ensuring that there was an even distribution of position. Thus, an equal number 
of animals from each group were placed in the top and bottom cages and in each rack of eight 
cages. Each group was fasted overnight and then received a single intraperitoneal injection of 
either saline, low dose or high dose oxyntomodulin in the early light-phase (0900-1000h). The 
doses of oxyntomodulin in each experiment administered to mice and rats were as follows: 
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Experiment Species Dose (nmol/kg) 
A Mice 2700 
5400 
B Mice 400 
1400 
C Rats 400 
1400 
D Rats 100 
400 
These doses were chosen based on previous data using the same batch of peptide administered 
to animals in open cages. Initially, the highest effective dose was used and this dose was 
progressively decreased if it was found to reliably reduce food intake in the metabolic cage 
environment. Following the intraperitoneal injection, animals were returned to the metabolic 
cages and allowed ad libitum access to food. Measurements of food intake were then 
automatically taken every 30 minutes over a twenty-four hour period. 
2.3.1.7 The Effect Of Repeated Intraperitoneal Administration Of 
Oxyntomodulin On Body-Weight In Mice 
Twenty-four male C57BL/6 mice were randomised to two groups (n=12) by body-weight, so 
that at the start of the experiment the body-weights were matched. The groups were allocated 
cages by stratified randomisation within the metabolic cage system ensuring that there was an 
even distribution of position. Each group received twice-daily intraperitoneal injection of either 
saline or 1400 nmol/kg oxyntomodulin in the early light-phase (0900-1 000h) and just prior to 
the dark-phase (1800-1900h) over a ten day period. This dose of oxyntomodulin was based on 
the lowest effective anorectic dose from the previous dose-finding study. During the study 
period the animals were allowed ad libitum access to food and water. Body-weight 
measurements were taken twice a day just prior to the injection. Food intake was recorded at 
intervals of 30 minutes over twelve hours following the final dark-phase intraperitoneal 
injection. 
2.3.1.8 The Effect Of Intracerebroventricular Administration Of Oxyntomodulin 
On Food Intake And Energy Expenditure In Rats 
Following a 7-day post-surgery recovery period, 24 rats with cannulae in the third cerebral 
ventricle were randomised by body-weight in two groups. The groups were allocated cages by 
65 
stratified randomisation ensuring that there was an even distribution of position. All animals 
were allowed to acclimatise to the metabolic cages for 24 hours. Each group was then fasted 
overnight before receiving intracerebroventricular (ICV) administered oxyntomodulin (3nmol) 
or saline in the early light-phase (0900-1000h). This dose was used as it has previously been 
shown to robustly reduce food intake when administered into the third ventricle (Dakin et al., 
2001). Oxyntomodulin was reconstituted in 0.9% saline and either peptide or saline was injected 
in a volume of 5 pl. Substances were administered via a stainless steel injector, projecting 0.5 
mm below the tip of the carmula. This was connected, via a polyethylene tube (inner diameter 
0.5 mm, outer diameter 1.0 mm), to a Hamilton Syringe (Reno, Nevada, USA) in a syringe 
pump (Harvard Apparatus, Edenbridge, Kent, UK), set to deliver the 5 ýtl ICV solution over I 
minute. The injector was kept in position for a further 30 seconds to ensure adequate diffusion. 
All injections were performed on conscious, freely-moving rats. Following injection, the rats 
were returned to their home cages in the metabolic cage system and recordings of food intake, 
activity, and metabolic parameters were made at 30 minute intervals during ad libitum feeding. 
The experiment was terminated 21 hours after the injection. 
2.3.1.9 The Effect Of Continuous Subcutaneous Administration Of 
Oxyntomodulin On Body-Weight, Food Intake And Energy Expenditure 
In Mice 
Twenty-four male C5713L/6 mice were randomised by body-weight into three groups (n=8) to 
receive placebo, 1000 pmol/kg/min oxyntomodulin or 2000 pmol/kg/min oxyntomodulin by 
continuous subcutaneous infusion. The highest dose of 2000 pmol/kg/min was chosen as it 
approximated to the dose of 1400 nmol/kg administered twice-daily by an intraperitoneal route 
(Study 2.3.1.7). On day I of the study, all mice were anaesthetised and seven-day Alzet osmotic 
pumps'ý' (model 2001) were inserted. After recovery, the mice were placed in the metabolic 
cages and daily recordings of food intake, activity, and metabolic parameters were made at 30 
minute intervals during ad libitum feeding. The experiment was terminated on day six. The 
animals from the 2000 pmol/kg/min pump group were dissected post-mortem in order to 
recover the osmotic pumps. The remaining contents of the pump were removed for analysis 
using High Performance Liquid Chromatography (HPLC). 
In a second study, 24 male C5713L/6 mice were randomised by body-weight into three group 
(n=8) to received placebo, 300 pmol/kg/min or 600 pmol/kg/min oxyntomodulin by continuous 
subcutaneous infusion. This lower dose was given in order to investigate the minimal dose 
which would decrease body-weight gain. Seven-day Alzet osmotic pumpse (model 2001) were 
inserted and recordings were made in the metabolic cages as above. Six days post-surgery, two 
mice from the group receiving 300 pmol/kg/min oxyntomodulin and two mice from the group 
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receiving 600 pmol/kg/min were culled, the osmotic pumps were recovered post-mortem and 
the remaining contents of the pump underwent analysis by HPLC. After seven days, the 
remaining mice were moved to open cages and body-weights were recorded daily in order to 
investigate body-weight recovery after the osmotic pump administration had ceased. 
2.3.1.10 The Effect Of Fasting And Acute Injection Of Exendin 9-39 On The Effect 
Of Continuous Subcutaneous Administration Of Oxyntomodulin 
Twenty-four male C5713L/6 mice were randomised by body-weight into two groups (n=12) 
which received either placebo or 600 pmol/kg/min oxyntomodulin by continuous subcutaneous 
infusion. This dose was chosen as the lowest reliable dose from the earlier study (Section 
2.3.1.9). On day I of the study, all mice were anaesthetised and a three-day Alzet osmotic 
pumpe (model 1003D) was inserted. After recovery, the mice were placed in the metabolic 
cages. Two days post-surgery, fasting blocks were placed in the food hoppers prior to the onset 
of the dark-phase to prevent feeding overnight. This fasting period was performed in order to 
investigate the effect of continuous oxyntomodulin administration during a period in which 
feeding was prevented. Mice were allowed ad libitum access to food from the onset of the light- 
phase. Just prior to the dark-phase on day 3, an intraperitoneal injection of 3000 nmol/kg 
exendin 9-39, a GLP-1 receptor antagonist, was administered to six of the placebo group and six 
of the treatment group. This study was performed in order to investigate the effect of receptor 
blockage on the actions of oxyntomodulin, using a dose based on data from previous open cage 
feeding studies in mice (personal communication, Dr Maralyn Druce, Department of Metabolic 
Medicine, Imperial College London). The remaining animals received an intraperitoneal 
injection of saline as a control. Recordings of food intake, activity and metabolic parameters 
were made at 30 minute intervals throughout the study periods. 
2.3.1.11 The Sensitivity Of Mice To Exogenously Administered Oxyntomodulin 
Following Continuous Subcutaneous Oxyntomodulin Administration 
Twenty-four male C57BL/6 mice were randomised into two group (n=12) which received either 
placebo or 600 pmol/kg/min oxyntomodulin by continuous subcutaneous infusion. On day I of 
the study, all mice were anaesthetised and a seven-day Alzet osmotic pump" (model 1007D) 
was inserted. After recovery, the mice were placed in the metabolic cages and allowed to 
recover overnight. Recordings of food intake, activity and metabolic parameters were made at 
30 minute intervals throughout the study. Two days post-surgery, fasting blocks were placed in 
the cages prior to the onset of the dark-phase to prevent feeding overnight. Mice were allowed 
ad libitum access to food from the onset of the light-phase. Five days post-surgery, an 
intraperitoneal injection of oxyntomodulin (1400 nmol/kg) was administered to six animals 
from the placebo group and six animals from the treatment group just prior to the dark-phase. 
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The remaining animals received a saline injection as control. This study was intended to 
investigate the responsiveness of mice to oxyntomodulin following a period of continuous 
administration of the peptide. 
2.3.1.12 High Performance Liquid Chromatography 
High Performance Liquid Chromatography (HPLQ can be used to separate components of a 
mixture based on chemical interactions between the analytes and column. Separation by 
reverse-phase HPLC is based on the hydrophobicity of the molecule, using a column (stationary 
phase) which consists of a neutral silica matrix substituted with Cs or Cis moieties and a polar 
aqueous solution (mobile phase). Once loaded onto the column, peptides are held in place by 
weak intermolecular Van der Waals interactions. A gradient of the polar solvent is used to elute 
the peptides. The retention time is longer for molecules that are predominantly non-polar in 
nature and polar molecules to elute more readily. 
Reverse phase chromatography was carried out on a JASCO High Pressure Liquid 
Chromatography system with the UVNis detector set at 214nm connected to a high resolution 
reversephase Gemini 5 micronC-18 110A column (Phenomenex, CA, USA). Samples fromthe 
Alzet osmotic minipumpsO were diluted (using distilled water containing 0.05% trifluroacetic 
acid) to a final concentration of 10 nmol oxyntomodulin in 100 [il. The 100 [d volume was 
fractionated by reverse phase HPLC, using a column eluted with a 2-100% gradient of 
acetonitrile / 0.05% trifluroacetic acid (v/v) over a total period of 105 minutes. Data collection 
and analysis was performed using Chrompass Software (version 1.7.403.1). Individual fractions 
collected at a rate of I ml / minute were dried in a Savant vacuum centrifuge and reconstituted in 
assay buffer. The peak observed by HPLC was then confirmed as having oxyntomodulin-like 
immunoreactivity using a total glucagon radioirnmunoassay (Appendix B). 
2.3.1.13 Static Incubation Of Hypothalamic Explants 
To investigate the effect of oxyntomodulin on release of hypothalamic a-MSH, NPY, CART, 
AgRP, and TRH a static incubation system was used (Stanley et al., 1999). Male Wistar rats 
were killed by decapitation (between 09: 00 and 10: 00 hours) and the whole brain was 
immediately removed and mounted ventral surface uppermost. The mounted brain was then 
placed in a cooled (2-4"C), oxygenated, chamber of artificial cerebrospinal fluid (aCSF- 20 mM 
NaHC03.126 mM NaCl, 0.09 mM Na2HP04.2H20,6 mM KCI, 1.4 mM CaC12.21-120,0.09 mM 
MgS04.71-120,5 mM D-glucose, 0.18 mg/ml ascorbic acid and 100 ýtg/ml aprotinin) within a 
vibrating microtome (Motorised Advance Vibroslice, model MA752, Campden Instruments, 
Loughborough, UK). A 1.7 mm slice was taken from the basal hypothalamus blocked lateral to 
the Circle of Willis, which encompassed the MPO, PVN, DMH, VMH, LHA, and ARC. The 
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hypothalami were initially incubated in a water bath at 25'C in tubes containing I ml aCSF, 
saturated with 95% 02 and 5% C02. When all hypothalamic explants had been placed in the 
incubation tubes, a two hour equilibration period was commenced: the water bath temperature 
was increased to 37'C and the aCSF was changed at the start of the period and after I hour. 
Following equilibration, each explant was incubated for a further 45 min in 600 [d aCSF (basal 
period) before being challenged with a 45 minute test period of oxyntomodulin (100 nM dose: 
representing a concentration approximately ten times the IC50 of oxyntomodulin's activity for 
the GLP-I receptor) or with either of the positive controls, GLP-I (100 nM) or exendin-4 (100 
nM). The viability of the tissue was confirmed by a final 45 minute period of potassium 
stimulation in which the explants were exposed to aCSF containing 56 MM KCI (replacing the 
sodium salts with potassium to retain isotonicity). At the end of each experimental period, the 
aCSF was removed and stored at -201C until measurement of ct-MSH, CART, NPY, AgRP, and 
TRH by radioimmunoassay. A separate dose-response experiment using the same protocol was 
performed to investigate the release of TRH from hypothalamic explants exposed to 
oxyntomodulin, GLP-I or exendin-4 at concentrations of 10 nM, 100 nM and 1000 nM. Viable 
explants (>80%) were defined as hypothalami which released a greater amount of neuropeptide 
following potassium stimulation. Nonviable explants were excluded from data analysis. 
2.3.1.14 Static Incubation Of Anterior Pituitary Segments 
The direct effect of oxyntomodulin on TSH release from the pituitary was determined using ex 
vivo anterior pituitary segments. This method was a modification of that previously described 
(Buckingham and Hodges, 1977). Male Wistar rats were killed by decapitation (between 09: 00 
and 10: 00 hours) and anterior pituitary glands were immediately harvested and divided into four 
pieces of approximately equal size. The segments were randomly placed (one segment per well) 
in the wells of a 48-well tissue culture plate (Nunc International, Denmark) and incubated in 500 
[LI of aCSF. The anterior pituitary quadrants were maintained for two hours at 37'C in a 
humidified environment saturated with 95%02and 5%C02, with the aCSF changed at one and 
two hours. The segments were then incubated for a further four hours in either aCSF alone 
(control), oxyntomodulin (100 nM) or in either of the positive controls GLP-1 (100 nM) or 
exendin-4 (100 nM). At the end of this period, the aCSF was removed and stored at -201C until 
measurement of TSH by radioimmunoassay. A separate dose-response experiment using the 
same protocol was performed to investigate the release of TSH from pituitary explants exposed 
to oxyntomodulin, GLP- I or exendin4 at concentrations of 10 nM, 100 nM and 1000 nM. 
2.3.1.15 Statistical Analysis 
Combined data is shown as mean ± standard error of the mean. In vivo data was analysed using 
a non-parametric two-sample Wilcoxon rank-sum (Mann-Whitney) test comparing the placebo 
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group with the treatment group. For interval data obtained from experiments of the continuous 
administration of peptide, parameters were also analysed using a Generalised Estimating 
Equation (GEE) to compare the effect of placebo and oxyntomodulin over the entire study 
period. This stringent method was used in order to account for high expected within-group 
correlation when peptide or placebo was administered at a constant rate. Ex vivo data from 
pituitary and hypothalamic single-dose static incubation experiments were analysed using a 
paired Mest comparing the basal and test period for each hypothalamic explant. Multiple data 
sets from dose-response experiments of hypothalamic and pituitary explants were analysed 
using a non-parametric Kruskal-Wallis statistic with post-hoc Dunn's Multiple Comparison 
Test. Statistical analysis was performed using Stata 9 (StataCorp, Texas, USA) and Prism 
Version 4.0. A p< 0.05 was considered to be statistically significant. Statistical advice was 
provided by Mr Joseph Eliahoo at the Statistical Advisory Service, Imperial College London. 
2.3.2 Results 
2.3.2.1 Preliminary Dose-Finding Study Of Intraperitoneal Administration Of 
Oxyntomodulin To Rodents 
Experiment A: The interval food intake in the mice receiving treatment was significantly 
reduced 0.5 hours post-injection by the 5400 nmol/kg oxyntomodulin dose (saline 0.30 ± 0.07 g 
versus oxyntomodulin 0.00 ± 0.00 g, p=0.0078) (Figure 2. OA). This resulted in a significant 
reduction in cumulative food intake between 0.5-2.5 hours post-injection (0.5 hours, p=0.0024; 
1 hour, p=0.0047; 1.5 hours, p=0.009; 2 hours, p=0.0234; 2.5 hours, p=0.0208) (Figure 2. OB). 
Food intake was also significantly reduced 0.5-1 hour post-injection by the 2700 nmol/kg 
oxyntomodulin dose (0.5 hours: saline 0.30 ± 0.07 g versus oxyntomodulin 0.08 ± 0.06 g, p- 
0.0 10 1 and I hour: saline 0.22 ± 0.08 g versus oxyntomodulin 0.00 ± 0.00g, p=0.0 106) (Figure 
2. OA). This resulted in a significant reduction in cumulative food intake I hour post-injection 
(p=0.0047) (Figure 2. OB). 
Experiment B: The interval food intake in the mice receiving 1400 nmol/kg oxyntomodulin was 
decreased 0.5-1 hours post-injection (saline 0.34 ± 0.08 g versus oxyntomodulin 0.11 ± 0.07 g, 
p=0.0421) and I hour post-injection (saline 0.32 ± 0.13 g versus oxyntomodulin 0.19 ± 0.08 g, 
p=0.0438) (Figure 2.1A). This resulted in a significant reduction in cumulative food intake 
between 0.5-2.5 hours post-injection (0.5 hours, p=0.0237; I hour, p=0.0487; 1.5 hours, 
p=0.0356; 2 hours, p=0.0356; 2.5 hours, p=0.0460) (Figure 2.1B). Food intake was not 
significantly reduced by the 400 nmol/kg oxyntomodulin dose, although there was a trend 
towards a reduction at 0.5 hours (saline 0.34 ± 0.08g versus oxyntomodulin 0.14 1 0.07g, 
p=0.0792). 
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Experiment C The interval food intake in the rats receiving oxyntomodulin was significantly 
reduced 0.5 hours post-injection by the 1400 nmol/kg oxyntomodulin dose (saline 6.47 ± 0.37g 
versus oxyntomodulin 1.89 ± 0.74g, p=0.0026) (Figure 2.2A). This resulted in a significant 
reduction in cumulative food intake 0.5 hours post-injection (p=0.0026) (Figure 2.2B). Food 
intake was significantly reduced 0.5 hours post-injection by the 400 nmol/kg oxyntomodulin 
dose (saline 6.47 ± 0.37g versus oxyntomodulin 2.17 ± 0.08g, p=0.0026) (Figure 2.2A). This 
resulted in a significant reduction in cumulative food intake between 0.5-3 hours (0.5 hours, 
p=0.0026; I hour, p=0.0455; 1.5 hours, p=0.0321; 2 hours, p=0.0321; 2.5 hours, p=0.0455; 3 
hours, p=0.0455) (Figure 2.213). 
Experiment D: In this experiment, oxyntomodulin administered intraperitoneally at a dose of 
400 nmol/kg or 100 nmol/kg did not significantly reduce food intake post-injection, in 
comparison to the control group (p>0.05 for all time-points) (data not shown). 
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Figure 2.0: the effect of 2700 nmol/kg (n=8) and 5400 nmol/kg (n=8) 
oxyntomodulin administered by intraperitoneal injection (t--O) on (A) interval and 
(B) cumulative food intake in male C57BL/6 mice. The solid bar below the x axis 
represents the dark-phase and the open bar represents the light-phase. The dotted 
lines represent standard error of the mean. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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Figure 2.1: the effect of 400 nmol/kg (n=8) and 1400 nmol/kg (n=8) oxyntomodulin 
administered by intraperitoneal injection (t--O) on (A) interval and (B) cumulative 
food intake in male C57BL/6 mice. The solid bar below the x axis represents the 
dark-phase and the open bar represents the light-phase. The dotted lines represent 
standard error of the mean. Statistical significance shown graphically refers to 
p<0.05 (Mann-Whitney test). 
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Figure 2.2: the effect of 400 nmol/kg (n=8) and 1400 nmol/kg (n=8) oxyntomodulin 
administered by intraperitoneal injection (t--O) on (A) interval and (B) cumulative 
food intake in male Wistar rats. The solid bar below the x axis represents the dark- 
phase and the open bar represents the light-phase. The dotted lines represent 
standard error of the mean. Statistical significance shown graphically refers to 
p<0.05 (Mann-Whitney test). 
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2.3.2.2 The Effect Of Repeated Intraperitoneal Administration Of 
Oxyntomodulin On Body-Weight In Mice 
At the start of the experiment the control group weighed 24.7 ± 0.3 g and the oxyntomodulin 
treatment group weighted 24.6 ± 0.3 g. Twice daily intra-peritoneal injections of oxyntomodulin 
(1400 nmol/kg) did not result in a change in body-weight in the treatment group when compared 
to the control group at any time-point during the ten day study period (p>0.05, Figure 2.3). The 
final body-weight of the control group was 24.8 ± 0.3g and the final weight of the treatment 
group was 25.1 ± 0.2g. Food intake was measured at 30 minute intervals following the final 
intraperitoneal injection on day 10. The final dark-phase intraperitoneal injection of 
oxyntomodulin did not significantly alter food intake (p>0.05, Figure 2.4A). The cumulative 
twelve-hour food intake in the control group was 3.48 ± 0.1 g and in the treatment group was 
3.28 ± 0.1 g (Figure 2.4B). 
2.3.2.3 The Effect Of Centrally Administered Oxyntomodulin On Food Intake 
And Energy Expenditure In Rats 
A single injection of oxyntomodulin (3nmol) into the third ventricle significantly reduced food 
intake 1- 2 hours post-injection, in comparison to the saline treated group (p<0.05) (Figure 
2.5A). This had a significant effect on cumulative food intake from 1.5 -6 hours post-injection 
when compared to control (p<0.05) (Figure 2.513). After two hours of ad libitum feeding the 
control group had ingested 7.66 ± 0.90 g whereas the oxyntomodulin treated group had only 
ingested 1.41 ± 0.63 g (p=0.0003), and after six hours the control group had ingested 9.42 ± 
1.09 g, whereas the treated group had ingested only 6.12 ± 1.55 g of food (p=0.0488). The 
anorectic effect of oxyntomodulin was no longer present at the end of the study (22 hours post- 
injection) when the control group had ingested 26.66 ± 2.74 g and the oxyntomodulin group had 
ingested 26.93 ± 2.92g (p=0.8182). 
Respiratory exchange ratio was 0.71 ± 0.01 in the control group and 0.72 ± 0.01 in the 
oxyntomodulin-injected group following the overnight fast. The RER increased toward a value 
of 1.0 over the course of the ad libitum feeding study period in both groups. However, RER 
remained significantly reduced in the oxyntomodulin-injected group from 0.5 - 4.5 hours when 
compared with the control group (p<0.05) (Figure 2.6A). The RER was measured as 0.90± 0.01 
in the control group and 0.75 ± 0.02 in the treatment group two hours post-injection (p=0.0002). 
Energy expenditure in the early light-phase, after the overnight fast was 7291 ± 417 kcal/kg/hr 
in the control group and 7124 ± 342 kcal/kg/hr in the oxyntomodulin-injected group (Figure 
2.6B). The central administration of oxyntomodulin significantly increased energy expenditure 
from 0.5-1 hours post-injection. The value in the treatment group increased at 0.5 hours post- 
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injection to 8299 ± 491 kcal/kglhr, compared to 6563 ± 388 kcal/kg/hr in the control group 
(p=0.0179). At I hour post-injection energy expenditure was 8985 ± 340 kcal/kg/hr in the 
treatment group, compared to 6672 ± 554 kcal/kg/hr in the control group (p=0.0032) (Figure 
2.6B). As expected, in both groups energy expenditure was increased during the dark-phase 
relative to the light-phase, with average levels being 9407 ± 109 kcal/kg/hr in the control group 
(p<0.0001) and 9307 ± 82 kcal/kg/hr in the treatment group (p=0.0001). 
There was an increase in activity in the group which had received oxyntomodulin, which only 
reached significance at 5 hours (p=0.0325) for the XAMB parameter (Figure 2.7A) and at 4.5 - 
5 hours for the ZTOT parameter (p=0.0176 and 0.0225 respectively, Figure 2.8A). However, a 
trend toward increased activity could be observed over earlier time-points. This effect on 
activity did not reach significance when expressed cumulatively, although at the end of the 
light-phase horizontal activity counts (XAMB) were measured as 1784 ± 180 in the control 
group and 2817 ± 872 in the treatment group and at the end of the subsequent dark-phase 
horizontal counts (XAMB) were measured at 6802 ± 876 in the control group and 8844 ± 1536 
in the treatment group (Figure 2.7B). A similar trend was observed in vertical activity counts 
(ZTOT), which were measured as 1788 ± 233 in the control group and 2954 ± 999 in the 
treatment group and at the end of the dark-phase vertical counts (ZTOT) were measured at 7284 
± 1130 in the control group and 9166 ± 1439 in the treatment group (Figure 2.813). 
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Figure 2.3: the effect on body-weight of twice daily 1400 nmol/kg oxyntomodulin 
(n=12 per group) administered by intraperitoneal injection in male C57BL/6 mice. 
Injections were commenced immediately after the randomisation period (day 0). 
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Figure 2.4: the effect of an injection of 1400 nmol/kg oxyntomodulin on dark-phase 
(A) interval and (B) cumulative food intake in male C57BL/6 mice following 
repeated administration of intraperitoneal oxyntomodulin over 10 days (n=12 per 
group). The solid bar below the x axis represents the dark-phase and the open bar 
represents the light-phase. The dotted lines represent standard error of the mean. 
A 
Injection -13- Saline I- OXM 
0 
(D = 
0 
Time (hours) 
B 
Injection Oxm 
Saline 
- 
Time (hours) 
78 
10 12 
10 12 
Figure 2.5: the effect on (A) interval and (B) cumulative food intake of 3 nmol 
oxyntomodulin administered by intracerebroventricular injection in male rats 
(n=12 per group). The solid bar below the x axis represents the dark-phase and the 
open bar represents the light-phase. The dotted lines represent standard error of 
the mean. Statistical significance shown graphically refers to p<0.05 (Mann- 
Whitney test). 
A 
ICV In jection 
-a-Saline 
4 OXM 
3 
2- 
T, 
I 
0123456 10 14 18 22 
Time (hours) 
I NW] 
B 
ICV Injection 
351 
-Ei-Saline 
-OXM 
25- 
20- 
15- 
101 
12356 10 1"4 1'8 22 
Time (hours) 
END 
79 
Figure 2.6: the effect on (A) respiratory exchange ratio and (B) energy expenditure 
of 3 nmol oxyntomodulin administered by intracerebroventricular injection in 
male rats (n=12 per group). The solid bar below the x axis represents the dark- 
phase and the open bar represents the light-phase. The dotted lines represent 
standard error of the mean. Statistical significance shown graphically refers to 
p<0.05 (Mann-Whitney test). 
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Figure 2.7: the effect on (A) interval and (B) cumulative XAMB of 3 nmol 
oxyntomodulin administered by intracerebroventricular injection in male rats 
(n=12 per group). The solid bar below the x axis represents the dark-phase and the 
open bar represents the light-phase. The dotted lines represent standard error of 
the mean. Statistical significance shown graphically refers to p<0.05 (Mann- 
Whitney test). 
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Figure 2.8: the effect on (A) interval and (B) cumulative ZTOT of 3 nmol 
oxyntomodulin administered by intracerebroventricular injection in male rats 
(n=12 per group). The solid bar below the x axis represents the dark-phase and the 
open bar represents the light-phase. The dotted lines represent standard error of 
the mean. Statistical significance shown graphically refers to p<0.05 (Mann- 
Whitney test). 
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2.3.2.4 The Effect Of Continuous Subcutaneous Administration Of 
Oxyntomodulin (1000 pmol/kglmin or 2000 pmol/kg/min) On Body- 
Weight, Food Intake And Energy Expenditure In Mice 
Continuous administration of oxyntomodulin via an Alzet osmotic minipumps containing 1000 
pmol/kg/min or 2000 pmol/kg/min of peptide resulted in a lower body-weight compared to 
control group (Figure 2.9). The difference in body-weight was significant up to day 6 in the 
1000 pmol/kg/min group and was significant on day 14 and day 6 in the 2000 pmol/kg/min 
group (p<0.05). At the end of the study the control group had gained 2.25 ± 0.53 g, whereas the 
change in body-weight for the group receiving 1000 pmol/kg/min was - 0.79 ± 0.7 g (p=0.0087) 
and for the group receiving 2000 pmol/kg/min was - 0.43 ± 0.90 g (p=0.0274). 
A continuous subcutaneous infusion of oxyntomodulin significantly reduced mean daily food 
intake in the mice (Figure 2.1 OA). The group receiving 1000 pmol/kg/min oxyntomodulin had a 
significantly reduced mean food intake on day I (control: 2.99 ± 0.15 g versus treatment: 1.80 ± 
0.07 g; p=0.0008), day 4 (control: 4.50 ± 0.68 g versus treatment: 2.91 ± 1.53 g; p=0.0238) and 
day 5 (control: '5.26 ± 0.26 g versus treatment: 4.02 ± 0.3 g; p=0.0045). The group receiving 
2000 pmol/kg/min oxyntomodulin had a significantly reduced mean food intake on day I 
(control: 2.99 ± 0.15 g versus treatment: 1.13 ± 0.19 g; p=0.0008) and day 2 (control: 4.86 ± 
0.42 g versus treatment: 2.71 ± 0.62 g; p=0.0209). Mean daily food intake was not significantly 
different from control in either group by the last day of the study period (control: 5.05 ± 0.24 g 
versus 1000 pmol/kg/min: 4.46 ± 0.63 g, p=0.248; versus 2000 pmol/kg/min: 4.39 ± 0.49 g, 
p=0.3177). The effect of oxyntomodulin on cumulative food intake during each 30 minute 
interval reached significance using a GEE analysis on day 5 (p=0.0121) in the group receiving 
1000 pmol/kg/min. The analysis of individual time-points using a non-parametric two-sample 
Wilcoxon rank-sum (Mann-Whitney) test comparing treatment group with control is shown 
graphically in the Supplementary Data (Appendix C, Figure C I). 
The RER was significantly reduced by continuous administration of oxyntomodulin. Analysis 
using a GEE demonstrated the difference between oxyntomodulin and control was significant 
on day I (p=0.0008), day 2 (p<0.0001), day 3 (p--0.0003) and day 4 (p=0.0072) in the group 
receiving 1000 pmol/kg/min. The group receiving 2000 pmol/kg/min had a significantly lower 
RER on day I (p<0.0001) and day 2 (p<0.0001). Both the 1000 pmol/kg/min and 2000 
pmol/kg/min groups demonstrated a significantly increased RER on day 6 (p=0.0079 and 
p=0.0002 respectively) relative to control, which occurred during the light-phase. The analysis 
of each time-point using a non-parametric two-sample Wilcoxon rank-sum (Mann-Whitney) test 
comparing treatment group with saline is shown graphically (Figure 2.11). 
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A continuous subcutaneous infusion of oxyntomodulin significantly reduced mean energy 
expenditure in the mice receiving 1000 pmol/kg/min oxyntomodulin on day 4 (control: 30954 ± 
1254 kcal/kg/hr versus treatment: 26816 ± 1004 kcal/kglhr; p=0.0274), day 5 (control: 31346 ± 
1254 kcal/kg/hr versus treatment: 26901 ± 888 kcal/kg/hr; p=0.0209) and day 6 (control: 30551 
± 1103 kcal/kg/hr versus treatment: 26605 ± 1041 kcal/kg/hr; p=0.046) of the study (Figure 
2.1013). There was no significant difference between the 2000 pmol/kg/min group and saline. 
The effect of oxyntomodulin on interval energy expenditure during each 30 minute period 
reached significance using a GEE analysis on day 4 (p=0.0054) and day 5 (p=0.0020) in the 
group receiving 1000 pmol/kg/min. The analysis of each time-point using a non-parametric two- 
sample Wilcoxon rank-sum (Mann-Whitney) test comparing treatment group with saline is 
shown graphically in the Supplementary Data (Appendix C, Figure C2). 
The infusion of 1000 pmol/kg/min oxyntomodulin resulted in a trend to increase daily vertical 
activity count (ZTOT) on day 3 and 4 (Figure 2.1213). This reached significance on day 3 when 
individual time-points were analysed by GEE (p=0.0499); at the end of the light-phase vertical 
activity counts were measured as 101 ± 26 in the control group and 607 ± 377 in the treatment 
group and at the end of the subsequent dark-phase counts were measured at 1905 ± 453 in the 
control group and 3912 ± 1126 in the treatment group. A similar trend to increase vertical 
activity was seen on day 4: at the end of the light-phase counts were measured as 136 ± 24 in 
the control group and 1464 ± 669 in the treatment group and at the end of the dark-phase counts 
were measured at 2787 ± 861 in the control group and 4756 ± 1424 in the treatment group, 
although this did not reach statistical significance (p=0.0842). The group receiving 1000 
pmol/kg/min oxyntomodulin had daily horizontal activity counts (XAMB) similar to the control 
group on days 1-5, and reduced activity counts on day 6 (p<0.05). The group receiving 2000 
pmol/kg/min oxyntomodulin demonstrated a reduction in daily horizontal activity counts on 
days 1-4 (p<0.05, Figure 2.12A) and a reduction in daily vertical activity counts on days 2-4 and 
day 6 (p<0.05, Figure 2.1213). The analysis of individual time-points using a non-parametric 
two-sample Wilcoxon rank-sum (Mann-Whitney) test comparing treatment group with saline is 
shown graphically for horizontal and vertical activity in the Supplementary Data (Appendix C, 
Figure C3 and C4 respectively). 
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Figure 2.9: the effect of continuous administration of oxyntomodulin (1000 
pmol/kg/min or 2000 pmol/kg/min) on body-weight in male mice (n=8 per group). 
Statistical significance shown graphically refers to p<0.05 (Mann-Whitney test). 
Oxyntomodulin resulted in a reduction in body-weight relative to the control 
group on day 1 (p=0.04 and p=0.0038), day 2 (p=0.0008 and p=0.0032), day 3 
(p=0.0027 and p=0.0153), day 4 (p=0.0023 and p=0.031), day 5 (p=0.0062 and 
p=0.0659) and day 6 (p=0.0087 and 0.0274) in the 1000 pmol/kg/min and 2000 
pmol/kg/min groups respectively. 
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Figure 2.10: the effect of continuous administration of oxyntomodulin (1000 
pmol/kg/min, n=8 or 2000 pmol/kg/min, n=8) on (A) average daily food intake and 
(B) average daily energy expenditure in male mice. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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Figure 2.11: the effect of continuous administration of oxyntomodulin (1000 
pmol/kg/min or 2000 pmol/kg/min) on respiratory exchange ratio (RER). 
Statistical values in the legend are analysed using a GEE and are given for the 
1000 pmol/kg/min group (n=8) and 2000 pmol/kg/min group (n=8) respectively. (A) 
Day I (p=0.0008 and p<0.0001), (B) Day 2 (p<0.0001 and p<0.0001), (C) Day 3 
(p=0.0003 and p=0.0934), (D) Day 4 (p=0.0072 and p=0.9037), (E) Day 5 (p=0.8076 
and p=0.5089) and (F) Day 6 (p=0.0079 and p=0.0002). The solid bar below the x 
axis represents the dark-phase and the open bar represents the light-phase. The 
dotted lines represent standard error of the mean. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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Figure 2.12: the effect of continuous administration of oxyntomodulin (1000 
pmol/kg/min, n=8 or 2000 pmol/kg/min, n=8) on (A) daily horizontal activity 
(XAMB) and (B) daily vertical activity (ZTOT). Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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2.3.2.5 The Effect Of Continuous Subcutaneous Administration Of 
Oxyntomodulin (300 pmol/kg/min or 600 pmol/kg/min) On Body-Weight, 
Food Intake And Energy Expenditure In Mice 
Implantation of Alzet osmotic minipumpso at a dose of 600 pmol/kg/min or 300 pmol/kg/min 
oxyntomodulin resulted in a lower body-weight compared to the control group (Figure 2.13). 
The difference in body-weight reached statistical significance on day I to day 6 at both 
oxyntomodulin doses (p<0.05). On day 6 of the study the change in body-weight for the control 
group was + 0.75 ± 0.34 g, whereas the change in body-weight for the group receiving 300 
pmol/kg/min was - 0.29 ± 0.32 g (p=0.0204) and for the group receiving 600 pmol/kg/min was 
-1.00 ± 0.81 g (p=0.0472). The volume available for administration in the pump was expected to 
expire on day 7 of the study. There was a trend for the body-weight to be lower in the group 
receiving 600 pmol/kg/min oxyntomodulin on day 7 (control: + 0.98 ± 0.28 g versus treatment: 
- 1.23 ± 1.06 g, p=0.0695) and day 8 (+ 1.2 ± 0.24 g versus - 0.33 ± 0.75 g, p=0.0609). 
However, on day 7 the body-weight of the group receiving 300 pmol/kglmin was no different 
from the control (control: + 0.98 ± 0.28 g versus treatment: + 0.48 ± 0.37 g, p=0.2377). After 
the end of the treatment period, the change in body-weight for both treatment groups increased 
back toward that of the control group. Seven days after the end of the expected treatment period 
(day 14) body-weight in the control group had increased from baseline by 2.75 ± 0.26 g. Body- 
weight had also increased from baseline in both treatment groups: by 2.44 ± 0.28 g in the group 
receiving 300 pmol/kg/min (p=0.556) and by 2.45 ± 0.39 g in the group receiving 600 
pmol/kg/min oxyntomodulin (p=0.6503). 
A continuous subcutaneous infusion of 300 or 600 pmol/kg/min oxyntomodulin significantly 
reduced mean daily food intake in the mice (Figure 2.14A). The group receiving 300 
pmol/kg/min oxyntomodulin reduced food intake on day I (control: 2.68 ± 0.19 g versus 
treatment: 1.71 ± 0.33 g; p=0.0427) when compared to control. The group receiving 600 
pmol/kglmin oxyntomodulin had a significantly reduced mean food intake on day I (control: 
2.68 ± 0.19 g versus treatment: 1.01 ± 0.32 g; p=0.0016), day 2 (control: 4.12 ± 0.29 g versus 
treatment: 3.16 ± 0.33 g; p=0.0459) and day 3 (control: 4.18 ± 0.32 g versus treatment: 3.01 J: 
0.32 g; p=0.0078). Mean daily food intake was not significantly different from control in either 
treatment group by day 7 (control: 4.92 ± 0.32 g versus 300 pmol/kglmin: 4.93 ± 0.36 g, 
p=0.5576; versus 600 pmol/kg/min: 4.34 ± 0.32 g, p=0.1871). The anorectic effect of 
oxyntomodulin on cumulative food intake during each 30 minute interval reached significance 
using a GEE analysis on day I in both the group receiving 300 pmol/kg/min (p=0.0166) and 600 
pmol/kg/min (p=0.0002), and showed a trend to reduce cumulative food intake on day 2 in both 
groups (p=0.0612 and p=0.0618 respectively). The analysis of individual time-points using a 
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Mann-Whitney test comparing treatment group with control is shown graphically in the 
Supplementary Data (Appendix C, C5). 
The RER was significantly reduced by continuous administration of 600 pmoVkg/min 
oxyntomodulin on day I (p=0.0007), day 2 (p=0.0490) and day 3 (p=0.0267) when compared to 
control by GEE analysis. There was a trend to reduce RER on day I (p=0.0555) and a 
significant reduction of RER on day 2 (p=0.0470) in animals treated with 300 pmol/kg/min 
oxyntomodulin. Both the 300 pmol/kg/min and 600 pmol/kg/min groups demonstrated a 
significant increase of RER on day 7 (p=0.0445 and p=0.0392 respectively). There was also a 
trend for the 300 pmol/kg/min oxyntomodulin group to increase RER on day 6 (p=0.0598). The 
analysis of each time-point using a Mann-Whitney test comparing the treatment group with 
saline is shown graphically (Figure 2.15). 
Treatment with oxyntomodulin by continuous subcutaneous infusion did not alter mean daily 
energy expenditure at either dose. The mean energy expenditure was not significantly different 
from control in either of the treatment groups at the start of the study (control: 34450 ± 1281 
kcal/kg/hr versus 300 pmol/kg/min: 32438 ± 794 kcal/kg/hr, p=0.1649; versus 600 
pmol/kg/min: 32146 ± 886 kcal/kg/hr, p=0.1722) or at the end of the seven day period (control: 
33788 ± 1469 kcal/kg/hr versus 300 pmol/kg/min: 32013 ± 1489 kcal/kg/hr, p=0.5582; versus 
600 pmol/kg/min: 32340 ± 1373 kcal/kg/hr, p=0.6056, Figure 2.14B). There were no significant 
effects of oxyntornodulin on interval energy expenditure on any of the study days when 
analysed using GEE (p>0.05) (data not shown). 
The infusion of 300 pmol/kg/min oxyntomodulin resulted in a reduction in daily horizontal 
activity counts (XAMB) on day I and day 3-6 (p<0.05, Figure 2.16A). Likewise, horizontal 
activity counts were reduced on days 1-6 in the group receiving 600 pmol/kg/min 
oxyntomodulin (p<0.05, Figure 2.16A). The group receiving 300 pmol/kg/min oxyntomodulin 
also demonstrated reduced daily vertical counts on day 3 and 4 (p<0.05, Figure 2.1613). The 
daily vertical activity counts were not significantly different from control in the group receiving 
600 pmol/kg/min. In contrast, there was a significant increase in vertical activity counts in this 
group on day 4 when individual time-points were analysed by GEE (p=0.0430); at the end of the 
light-phase, control: 312 ± 53 counts versus treatment: 1014 ± 381 counts; at the end of the 
dark-phase, control: 2102 ± 245 counts versus treatment: 3387 ± 806 counts. The analysis of 
individual time-points for horizontal and vertical activity using a Mann-Whitney test to compare 
the treatment group with saline is shown graphically in the Supplementary Data (Appendix C, 
Figures C6 and C7). 
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Figure 2.13: the effect of continuous administration of oxyntomodulin (300 
pmol/kg/min or 600 pmol/kg/min) on body-weight in male mice. Statistical 
significance shown graphically refers to p<0.05 (Mann-Whitnev test). 
Oxyntomodulin treatment resulted in a reduction of body-weight relative to the 
control group on day 1 (p=0.0025 and p=0.0007), day 2 (p=0.0108 and p=0.0032), 
day 3 (p=0.0127 and p=0.0062), day 4 (p=0.0128 and p=0.018), day 5 (p=0.0237 and 
p=0.0459) and day 6 (p=0.0204 and p=0.0472) in the 300 pmol/kg/min group (n=8) 
and 600 pmol/kg/min group (n=8) respectively. 
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Figure 2.14: the effect of continuous administration of oxyntomodulin (300 
pmol/kg/min, n=8 or 600 pmol/kg/min, n=8) on (A) average daily food intake and 
(B) energy expenditure. Statistical significance shown graphically refers to p<0.05 
(Mann-Whitney test). 
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Figure 2.15: the effect of continuous administration of oxyntomodulin (300 
pmol/kg/min or oxyntomodulin 600 pmol/kg/min) on respiratory exchange ratio 
(RIER). Statistical values in the legend are analysed using a GEE and are given for 
the 300 pmol/kg/min group (n=8) and 600 pmol/kg/min group (n=8) respectively. 
(A) Day 1 (p=0.0555 and p=0.0007), (B) Day 2 (p=0.0470 and p=0.0490), (C) Day 3 
(p=0.0925 and p=0.0267), (D) Day 4 (p=0.4885 and p=0.4797), (E) Day 5 (p=0.3560 
and p=0.0685), (F) Day 6 (p=0.0598 and p=0.9537) and (G) Day 7 (p=0.0445 and 
p=0.0392). The solid bar below the x axis represents the dark-phase and the open 
bar represents the light-phase. The dotted lines represent standard error of the 
mean. Statistical significance shown graphically refers to p<0.05 (Mann-Whitney 
test). 
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Figure 2.16: the effect of continuous administration of oxyntomodulin (300 
pmol/kg/min, n=8 or 600 pmol/kg/min, n=8) on (A) daily horizontal activity 
(XAMB) and (B) daily vertical activity (ZTOT). Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
A 
-B-Placebo 
OXM 300 
OXM 600 30000- 
25000- 
20000- 
15000- 
10000- ---- -- 
5000- 
0 
01234567 
Time (days) 
B 
700 
600 
500 
400 
300 
200 
N loo 
0 
-'3-Placebo 
-A--OXM 300 
w OXM 600 
94 
23457 
Time (days) 
2.3.2.6 The Effect Of Fasting On The Effect Of Continuous Subcutaneous 
Administration Of Oxyntomodulin 
Treatment with oxyntomodulin (600 pmol/kg/min) significantly decreased food intake during 
the light phase following an overnight fast. GEE analysis demonstrated the effect on food intake 
was significant for the interval data (Figure 2.17A, p=0.0003) and the cumulative data (Figure 
2.1713 p<0.0001) over the entire study period. At the end of the eight hour ad libitum feeding 
period the control group had eaten 1.60 ± 0.22 g compared to the oxyntomodulin-treated group 
who had consumed only 0.7 ± 0.13 g (p=0.0039, Figure 2.1713). 
During the overnight fast, RER was between 0.7 and 0.8 in both groups. The RER rapidly 
increased back toward 1.0 in the control group after refeeding, but remained significantly lower 
in the oxyntomodulin-treated group when analysed by GEE (p<0.0001, Figure 2.18A). A period 
of fasting overnight reduced energy expenditure in both the control and treatment groups. At the 
start of the dark-phase, energy expenditure was 38575 ± 1328 kcal/kg/hr falling to 24379 ± 
1610 kcal/kg/hr by the end of the dark phase in the control group (p=0.0023). Similarly, energy 
expenditure fell from 39912 ± 1385 kcal/kglhr to 19201 ± 1849 kcal/kg/hr in the treatment 
group (p<0.0001). At the end of the subsequent light phase, energy expenditure was 28235 ± 
1596 kcal/kg/hr in the control group and 27972 ± 914 kcal/kg/hr in the oxyntomodulin-treated 
group. Treatment with oxyntomodulin (600pmol/kg/min) did not alter energy expenditure from 
the levels of control when analysed by GEE (p=0.4256, Figure 2.1813). 
There was a decrease in horizontal activity counts during the overnight fast from a peak of 1738 
± 302 counts / interval at the start of the dark-phase to 433 ± 230 counts / interval prior to the 
start of the light-phase in the control group (p=0.0107). Horizontal counts also fell significantly 
from a peak of 2164 ± 247 counts / interval to 222 ± 101 counts / interval during the dark-phase 
fast in the treatment group (p<0.0001). There was no significant effect of treatment on interval 
(p=0.1021) or cumulative (p=0.2360) horizontal activity when analysed by GEE (Figure 2.19). 
The control group was observed to reduce their vertical activity count during the overnight fast 
from a peak of 813 ± 167 counts / interval at the start of the dark-phase to 53 ± 35 counts / 
interval prior to the start of the light-phase in the control group (p=0.00 10). Vertical counts also 
fell significantly from 1035 ± 166 counts / interval to 47 ± 25 counts / interval during the dark- 
phase fast in the treatment group (p<0.0001). There was no significant effect of treatment on 
interval (p=0.1894) or cumulative (p=0.3669) vertical activity when analysed by GEE (Figure 
2.20). 
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Figure 2.17: the effect of an overnight fast on (A) interval and (B) cumulative food 
intake in mice receiving 600 pmol/kg/min oxyntomodulin administered by 
continuous subcutaneous infusion (n=12 per group). The solid bar below the x axis 
represents the dark-phase and the open bar represents the light-phase. Statistical 
significance shown graphically refers to p<0.05 (Mann-Whitney test). 
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Figure 2.18: the effect of an overnight fast on (A) respiratory exchange ratio and 
(B) energy expenditure in mice receiving 600 pmol/kg/min oxyntomodulin 
administered by continuous subcutaneous infusion (n=12 per group). The solid bar 
below the x axis represents the dark-phase and the open bar represents the light- 
phase. Statistical significance shown graphically refers to p<0.05 (Mann-Whitney 
test). 
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Figure 2.19 the effect of an overnight fast on (A) interval and (B) cumulative 
horizontal activity (XAMB) in mice receiving 600 pmol/kg/min oxyntomodulin by 
continuous subcutaneous infusion (n=12 per group). The solid bar below the x axis 
represents the dark-phase and the open bar represents the light-phase. Statistical 
significance shown graphically refers to p<0.05 (Mann-Whitney test). 
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Figure 2.20: the effect of an overnight fast on (A) interval and (B) cumulative 
vertical activity (ZTOT) in mice receiving 600 pmol/kg/min oxyntomodulin by 
continuous subcutaneous infusion (n=12 per group). The solid bar below the x axis 
represents the dark-phase and the open bar represents the light-phase. Statistical 
significance shown graphically refers to p<0.05 (Mann-Whitney test). 
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2.3.2.7 The Effect Of Exendin (9-39) On The Anorectic Effect Of Continuous 
Subcutaneous Administration Of Oxyntomodulin 
The administration of oxyntomodulin (600 pmoVkg/min) by chronic subcutaneous infusion 
resulted in a reduction in cumulative food intake (2.45 ± 0.32 g) when compared to control 
(3.41 ± 0.38 g) at the end of the 14 hour study period (p=0.0328, Figure 2.21). An acute 
intraperitoneal injection of exendin (9-39) to mice implanted with placebo pumps resulted in a 
trend to reduce cumulative food intake (2.9 ± 0.44 g) compared to mice implanted with placebo 
pumps who received a saline injection (3.41 ± 0.38 g), although this did not reach significance 
when analysed by GEE (p=O. 1688). An acute intraperitoneal injection of exendin (9-39) to mice 
implanted with oxyntomodulin pumps resulted in a trend to increase cumulative food intake 
(2.84 ± 0.18) compared to mice implanted with oxyntomodulin pumps who received a saline 
injection (2.45 ± 0.32) (p=0.1474). 
2.3.2.8 The Sensitivity Of Mice To Exogenously Administered Oxyntomodulin 
Following Continuous Subcutaneous Oxyntomodulin Administration 
Implantation of Alzet osmotic minipumpst administering oxyntomodulin (600 pmol/kg/min) 
resulted in a lower body-weight over days 1-5 of the study when compared to the control group 
(p<0.05, Figure 2.22A). On day 5 of the study the control group had gained 0.36 ± 0.19 g, 
whereas the change in body-weight for the oxyntomodulin-treated group was - 2.08 ± 0.51 g 
(p<0.0001). A continuous subcutaneous infusion of oxyntomodulin significantly reduced mean 
daily food intake on day I (control: 2.91± 0.26 g versus treatment: 1.5 8± 0.17 g; P=0.00 15), day 
2 (control: 3.96 ± 0.22 g versus treatment: 3.16 ± 0.48 g; p=0.0047) and day 3 (control: 2.02 ± 
0.13 versus treatment: 1.03 ± 0.12 g; p<0.0001), but was not significantly different from the 
control group on day 4 (control: 4.46 ± 0.15 g versus 4.13 ± 0.44 g; p=0.0825) (Figure 2.22B). 
Two days after pump implantation surgery, the mice were subjected to an overnight fast. 
Treatment with oxyntomodulin (600 pmol/kg/min) significantly decreased cumulative food 
intake during the subsequent light phase (control: 2.02 ± 1.13 g versus treatment: 1.03 ± 0.12 g; 
p<0.0001) and RER remained significantly lower in the treatment group after refeeding 
(p=0.0028). Treatment with oxyntomodulin (600 pmol/kg/min) did not alter energy expenditure 
from the levels of control (p=0.8376) either during the fasting period or in the ad libitum 
feeding period (data not shown). There was no significant effect of treatment on interval 
(p=0.5654) or cumulative (p=0.5389) horizontal activity or interval (p=0.6155) or cumulative 
(p=0.9333) vertical activity over the entire study period when analysed by GEE (data not 
shown). However, vertical activity was increased in the early dark phase during the fast in the 
oxyntomodulin-treated group, an effect which reached significance at one hour and between 
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2.5-4.5 hours after the start of the fast when cumulative data was analysed (p<0.05), shown 
graphically in Supplementary Data (Appendix C, Figure C8). 
On day 5, an acute intraperitoneal injection of oxyntomodulin (1400 nmol/kg) to mice 
implanted with placebo pumps resulted in a significant reduction in cumulative food intake in 
comparison to the mice implanted with placebo pumps injected with saline (p<0.0001, Figure 
2.23). Mice implanted with oxyntomodulin pumps also demonstrated a significant reduction in 
cumulative food intake in response to oxyntomodulin administered intraperitoneally (p=0.0008, 
Figure 2.23). The anorectic effect of acute intraperitoneal oxyntomodulin remained significant 
for at least ten hours in both groups (placebo pump / saline injection: 3.04 ± 0.10 g versus 
placebo pump / oxyntomodulin injection: 2.27 ± 0.21 g; p=0.0061) (oxyntomodulin pump 
saline injection: 2.06 ± 0.42 g versus oxyntomodulin pump / oxyntomodulin injection: 1.62 
0.36 g; p=0.0163). By day 5 post-operatively, the cumulative food intake in the animals which 
received an intraperitoneal saline injection were not significantly different irrespective of 
whether they had a saline or oxyntomodulin pump implanted, although there was a slight trend 
for the oxyntomodulin pump animals to eat less (p=O. 1257, Figure 2.23). 
2.3.2.9 High Performance Liquid Chromatography (HPLC) Of Oxyntomodulin 
Used For Continuous Subcutaneous Administration 
HPLC was performed on the solution from six Alzet osmotic minipumpse taken post-mortern 
six days post-surgery and originally filled at a concentration which provided 2000 pmol/kg/min 
of oxyntomodulin. This solution demonstrated a single immunoreactive peak eluting at the same 
position (59 - 60 minutes) as a fresh oxyntomodulin solution prepared at the same concentration 
(Figure 2.24A). HPLC was also performed on the solution taken six days post-surgery from two 
Alzet Minipumps'O filled at an oxyntomodulin concentration of 3 00 pmol/kg/min and two pumps 
filled at a concentration of 600 pmol/kg/min. Similarly, these solutions demonstrated a single 
immunoreactive peak eluting at the same position as fresh oxyntomodulin solution prepared at 
the same concentration (Figure 2.2413). 
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Figure 2.21: the effect of an intraperitoneal injection of exendin (9-39) on 
cumulative food intake in mice receiving 600 pmol/kg/min oxyntomodulin by 
continuous subcutaneous infusion (n=6 per group). The solid bar below the x axis 
represents the dark-phase and the open bar represents the light-phase. The dotted 
lines represent standard error of the mean. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test) comparing CI with A. 
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Figure 2.22: the effect of continuous administration of oxyntomodulin (600 
pmol/kg/min) on (A) body-weight and (B) food intake in C57BL/6 male mice (n=12 
per group). A fast was administered overnight on day 2. Statistical significance 
shown graphically refers to p<0.05 (Mann-Whitney test). Oxyntomodulin 
administration resulted in a reduction in body-weight relative to the control group 
on day 1 (p=0.0348), day 2 (p=0.0003), day 3 (p<0.0001), day 4 (p<0.0001) and day 
5 (p<0.0001). The treatment group demonstrated reduced food intake on day I 
(p=0.0015), day 2 (p=0.0047) and day 3 (p<0.0001). 
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Figure 2.23: the effect of acute intraperitoneal injection of oxyntomodulin (1400 
nmol/kg) in mice receiving continuous administration of oxyntomodulin (600 
pmol/kg/min) or placebo (n=6 per group). The solid bar below the x axis represents 
the dark-phase and the open bar represents the light-phase. The dotted lines 
represent standard error of the mean. Statistical significance shown graphically 
refers to p<0.05 (Mann-Whitney test) comparing 0 with 13 (*), and comparing L 
with L (*). Oxyntomodulin injection resulted in a decrease in food intake in both 
groups. 
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Figure 2.24: High performance liquid chromatography of oxyntomodulin 
recovered from Alzet osmotic minipumps(V for a (A) 2000 pmol/kg/min and (B) 
600 or 300 pmol/kg/min dose. 
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2.3.2.10 Static Incubation of Hypothalamic Explants 
Incubation of hypothalamic explants with oxyntomodulin (100nM) showed a trend to increase 
a-MSH release (basal: 2.4 ± 0.2 fmol/explant versus peptide: 2.7 ± 0.2; n=18, p=0.1140). 
Whereas, incubation with the same concentration of GLP-I (basal: 2.3 ± 0.2 fmot/explant versus 
peptide: 2.7 ± 0.3; n=1 5, p=0.0347) and exendin-4 (basal: 2.7 ± 0.4 fmol/explant versus peptide: 
3.3 + 0.5; n=12, p=0.0073) significantly increased the release of a-MSH (Figure 2.25). 
The release of CART was not altered by incubation with 100 nM of oxyntomodulin (basal: 703 
± 79 fmol/explant versus peptide: 623 71 fmol/explant; n=20, p=0.3337), GLP-I (basal: 590 ± 
78 fmol/explant versus peptide: 568 71 fmol/explant; n=20, p=0.7369) or exendin4 (basal: 
824 ± 112 finol/explant versus peptide: 711 ± 106 finol/explant; n= 18, p=O. 1469). Similarly, the 
hypothalamic release of NPY was not significantly changed by incubation with 100 nM of 
oxyntomodulin (basal: 205 ± 31 fmol/explant versus peptide: 197 31 fmoVexplant; n--9, 
p=0.6643), GLP-I (basal: 106 ± 20 fmol/explant versus peptide: 125 26 fmol/explant; n=13, 
p=0.2665) or exendin-4 (basal: 188 -129 fmol/explant versus peptide: 181 ± 34 fmol/explant; 
n=14, p=0.7335). The release of AgRP was also unaltered by incubation with 100 nM of 
oxyntomodulin (basal: 423 ± 76 pg/explant versus peptide: 542 105 pg/explant; n=8, 
p=0.1486), GLP-I (basal: 425 ± 74 pg/explant versus peptide: 411 87 pg/explant; n=ll, 
p=0.8656) or exendin-4 (basal: 555 ± 154 pg/explant versus peptide: 649 ± 176 pg/explant; n=7, 
p=0.4545). 
Incubation of hypothalamic explants with oxyntomodulin (100 nM) significantly increased the 
release of TRH (basal: 23.7 ± 3.1 fmol/explant versus peptide: 33.0 ± 5.0; n=19, p=0.0325). 
Incubation with GLP-1 (100nM) did not change the release of TRH compared with the basal 
period (basal: 23.4 ± 3.4 fmol/explant versus peptide: 24.5 ± 3.4; n--19, p=0.5500). Incubation 
with exendin4 (I OOnM) increased TRH release (basal: 17.2 ± 2.7 fmol/explant versus peptide: 
23.4 ± 3.3; n=17, p=0.0293). I therefore proceeded to perform a dose-response study, which 
demonstrated a significant difference in TRH release following incubation with the peptides at 
varying doses (p=0.0031, Figure 2.26). Post-hoc testing indicated that the increase in TRH in 
response to a concentration of 10 nM oxyntomodulin did not reach significance (basal: 29.3 ± 
4.7 finol/explant versus peptide: 45.0 ± 10.4 fmol/explant, p>0.05). However, TRH release was 
significantly increased when incubated with concentrations of 100 nm oxyntomodulin (basal: 
20.4 ± 3.3 fmol/explant versus peptide: 76.5 ± 13.7 fmol/explant, p<0.01) and 1000 nM 
oxyntomodulin (basal: 18.9 ± 3.4 finol/explant versus peptide: 68.6 ± 7.3 finol/explant p<0.01). 
There was no significant difference in TRH release following incubation with GLP-I (p>0.05) 
or exendin-4 (p>0.05) at any concentration. 
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2.3.2.11 Static Incubation of Pituitary Quadrants 
Incubation of pituitary quadrants with oxyntomodulin (100 nM) significantly increased the 
direct release of TSH from the pituitary (aCSF: 18.6 ± 3.5 pg1explant versus oxyntomodulin: 
38.3 ± 5.1 pg/explant; n--19, p=0.0034). The release of TSH was not significantly changed by 
incubation with the same concentration of GLP-1 (aCSF: 18.6 ± 3.5 pg/explant versus GLP-l: 
24.1 ± 4.9 pg/explant; n=19, p=0.3714) or exendin-4 (aCSF: 18.6 ± 3.5 pg/explant versus 
exendin-4: 26.1 ± 2.6 pg/explant; n=19, p=0.0939). A subsequent dose-response study 
demonstrated a significant difference in TSH release following incubation with the peptides at 
varying doses (p<0.0001, Figure 2.27). Post-hoc testing indicated that the significance was due 
to the increase in release observed following incubation with oxyntomodulin at a dose of 10 riM 
(29.5 ± 4.1 pg/explant, p<0.05), 100 nM (37.1 ± 9.8 pg/explant, p<0.05) and 1000 nM (39.34 +_ 
10.2, p<0.0 1) when compared to incubation with aCSF (14.5 ± 2.2 pg/explant). There was also a 
significant increase in TSH following incubation with exendin-4, but only at the highest dose of 
1000 nM (aCSF: 18.6 ± 3.5 pg/explant versus exendin-4 39.8 ± 5.1, p<0.001). 
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Figure 2.25: the effect of incubation with 100 nM solution of oxyntomodulin, GLP- 
1 or exendin-4 on hypothalamic release of a-MSH. Significance shown graphically 
refers to comparison of the peptide-stimulated period with the basal period using a 
paired t test (*p<0.05, **p<0.01). 
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Figure 2.26: the release of TRH from hypothalamic explants in response to 
incubation with oxyntomodulin at a concentration of 10 nM (n=12), 100 nM (n=10) 
and 1000 nM (n=9), GLP-1 at a concentration of 10 nM (n=10), 100 nM (n=9) and 
1000 nM (n=8) or exendin-4 at a concentration of 10 nM (n=10), 100 nM (n=7) and 
1000 nM (n=9). Significance shown graphically refers to comparison of the peptide 
stimulated period with the basal period using a paired t test (**p<0.01). 
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Figure 2.27: the release of TSH from pituitary explants in response to incubation 
with aCSF (n=48), oxyntomodulin at a concentration of 10 nM (n=16), 100 nM 
(n=16) and 1000 nM (n=16), GLP-1 at a concentration of 10 nM (n=16), 100 nM 
(n=16) and 1000 nM (n=15) or exendin-4 at a concentration of 10 nM (n=14), 100 
nM (n=15) and 1000 nM (n=16). Significance shown graphically refers to 
comparison of the peptide-stimulated period with the basal period using a paired t 
test (*p<0.05, **p<0.01, ***p<0.005). 
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2.3.3 Discussion 
Oxyntomodulin is a satiety signal which decreases food intake when administered exogenously 
to rats (Dakin et al., 2004; Dakin et al., 2002) and humans (Cohen et al., 2003). Repeated 
intraperitoneal or central injections of oxyntomodulin over a seven day period has been shown 
to reduce body-weight gain in rats (Dakin et al., 2004; Dakin et al., 2002). 1 characterised the 
effects of peripheral and central administration of oxyntomodulin on food intake, activity and 
energy expenditure using metabolic cages. I then proceeded to investigate the effect of 
oxyntomodulin on the release of appetite-regulatory hypothalamic neuropeptides and pituitary 
TSH using a static incubation system. 
Oxyntomodulin administered intraperitoneally to rodents in the early light-phase acutely 
reduced food intake after an overnight fast (Section 2.3.2.1). In mice, 1400 nmol/kg, 2700 
nmol/kg and 5400 nmol/kg of oxyntomodulin were effective over a short period post-injection. 
In rats, the 1400 nmol/kg dose was also effective at reducing short-term food intake. The dose 
of 1400nmol/kg was deemed to be reliable in both species within the metabolic cage 
environment and was therefore administered in subsequent studies. Dakin et aL have reported 
an intraperitoneal dose of 30 nmol/kg oxyntomodulin decreased food intake and a twice daily 
dose of 50 nmol/kg oxyntomodulin successfully reduced body-weight gain in male Wistar rats 
over a seven day period in open cages (Dakin et al., 2004). It is possible that a higher dose of 
oxyntomodulin is needed to demonstrate an effect in the potentially more stressful environment 
of a metabolic cage system. Previous studies have demonstrated that stress can influence the 
effectiveness of the satiety signal PYY (3-36) (Halatchev et al., 2004; Abbott et al., 2005c) and 
Abbott et aL have demonstrated that transfer of a rat to a novel environment inhibits the 
anorectic response to peripherally administered oxyntomodulin (300nmol/kg) (Abbott et al., 
2005c). Alternatively, the difference in dose may have been secondary to a difference in 
composition of the oxyntomodulin peptide batch, as weight rather than amino acid content was 
used to calculate the dosages in the current experiments. The oxyntomodulin used in the current 
rodent experiments was subsequently confirmed as having 75.3% purity by weight using amino 
acid analysis (Alta Bioscience, University of Birmingham, UK). 
The in vivo dose-finding data demonstrated a short-lived anorectic effect of intraperitoneal 
oxyntomodulin administered to male C57BL/6 mice. Although this effect was of limited 
duration, there did not appear to be any compensatory increase in food intake over the 
remainder of the study period and this resulted in a non-significantly lower cumulative food 
intake over twenty-four hours (Section 2.3.2.1). 1 therefore hypothesised that chronic repeated 
dosing would result in a significant body-weight reduction in mice. However, body-weight was 
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not significantly different from the control group in rodents who received repeated twice-daily 
injection of 1400 nmol/kg oxyntomodulin within the metabolic cage environment (Section 
2.3.2.2). There are several reasons why the treatment group may not have reduced their body- 
weight relative to the controls. It may have been that the dose used was inadequate to inhibit 
feeding in freely fed animals, as the dose-ranging study was performed in rodents fasted 
overnight. An overnight fast would be expected to accentuate the effect of a satiety peptide on 
food intake, as fasted animals have increased food intake on re-feeding, compared to the small 
intake usually observed during the light-phase. This refeeding effect is secondary to a change in 
the background appetite-regulatory neuropeptide levels in the hypothalamus and this may 
subsequently permit a greater effect of peripheral oxyntomodulin on appetite signalling within 
the hypothalamus. For example, oxyntomodulin has been reported to increase levels of 
hypothalamic a-MSH (Dakin et al., 2004) and, as baseline levels of this anorectic neuropeptide 
are reduced by fasting (Schwartz et al., 1997; Swart et al., 2002), the effect of oxyntomodulin 
on a-MSH may have a greater influence on appetite-signalling in the fasted state. It is also 
possible that in this study following a period of satiety there was compensatory over-eating 
which negated the initial anorexia. Alternatively, the repeated injections may have caused the 
rodents sufficient stress to negate the effect of oxyntomodulin. Finally, the acute effect of 
oxyntomodulin may have been lost with repeated injection so that it was no longer effective, 
accounting for the lack of response seen when food intake data was recorded during the dark- 
phase at the end of the ten-day study period. An additional study in which food intake data was 
recorded daily at regular intervals within the metabolic cages would be needed to elucidate this 
further. However, I felt that in practice, twice-daily intra-peritoneal injection in rodents was not 
the optimum administration regime to characterise the chronic peripheral effects of 
oxyntomodulin, as this protocol failed to demonstrate any significant effect on the primary end- 
points of food intake and body-weight. 
The short-lived effect of oxyntomodulin demonstrated in the dose-finding study (Section 
2.3.2.1) is contributed to by its rapid clearance from the circulation. The circulating half-life of 
oxyntomodulin in plasma has been estimated at 12 ±I minutes in humans (Schjoldager et al., 
1988) and at 6.4 d: 0.5 minutes in the rat (Kervran et al., 1990). In order to better demonstrate 
the actions of oxyntomodulin in the metabolic cages, an alternative method of administration 
was required to avert this short-lived effect. One method of avoiding peripheral breakdown is to 
administer the peptide directly to the brain, at the site of action, thereby avoiding degradation 
within the circulation. I therefore proceeded to administer oxyntomodulin to the third ventricle 
via an indwelling cannula. 
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Administration of oxyritomodulin to the third ventricle resulted in a significant reduction in food 
intake and a concurrent increase in total energy expenditure (Section 2.3.2.3). These effects, if 
ongoing, would result in a negative energy balance and are a useful combination of actions for 
any potential anti-obesity therapy. The observed increase in energy expenditure may have been 
due to an increase in resting energy expenditure or / and activity-related energy expenditure. A 
specific measurement of resting energy expenditure was not performed in these studies. There 
was some indication that activity was increased by central administration of oxyntomodulin, 
however the method by which activity was measured in the cages may have not been sensitive 
enough to record the absolute magnitude of a change in activity, particularly if movements were 
small and therefore insufficient to break two consecutive beams in the horizontal axis. However, 
the activity measurements were sufficiently sensitive to capture the normal expected increase in 
night-time activity in the rodents. This nocturnal pattern was consistent with the increase in 
feeding and energy expenditure observed during the dark-phase. The proposed dual effect of 
centrally-administered oxyntomodulin is in agreement with previously published data which 
demonstrated a reduction in food intake and provided indirect evidence for an increase in energy 
expenditure, using parameters such as temperature measurement and pair-feeding data (Dakin et 
al., 2001; Dakin et al., 2002). This is the first direct demonstration of an increase in total energy 
expenditure after oxyntomodulin administration using whole body calorimetry. 
Peptides administered to the third ventricle diffuse to various hypothalamic nuclei due to their 
close anatomical proximity. Although this data gives an indication of the global role of 
oxyntomodulin within the hypothalamus, it does not necessarily represent the effect of 
circulating peripheral oxyntomodulin, which may have actions on specific hypothalamic 
neuropeptide circuits and other brain regions such as the brainstern (Baggio et al., 2004b; 
Horvath, 2005). This phenomenon is exemplified by PYY (3-36), which inhibits food intake 
following peripheral administration or administration directly into the ARC (Batterham and 
Bloom, 2003), but potently increases food intake after central administration into the third 
ventricle (Clark et al., 1987; Corp et al., 2001; Stanley et al., 1985). 1 therefore proceeded to 
characterise the effect of continuous peripheral administration of oxyntomodulin in the 
metabolic cage system to determine whether it was in agreement with the data obtained from 
central administration. 
Subcutaneous administration of peptide represents a feasible route of treatment for humans, 
whereas the intraperitoneal administration of oxyntomodulin is not transferable to clinical 
practice. A corollary for using subcutaneous oxyntomodulin for the treatment of human obesity 
is provided by the subcutaneous administration of GLP-I (Naslund et al., 2004) and the longer- 
acting analogue exenatide (exendin4) (Buse et al., 2004; Kendall et al., 2005; DeFronzo et al., 
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2005; Heine et al., 2005), which have demonstrated a small reduction in body-weight in diabetic 
patients following chronic therapy. Administration of oxyntomodulin via a subcutaneous route 
in rodents therefore warrants further investigation, as it is unknown whether it is effective 
subcutaneously. I therefore performed studies of continuous subcutaneous oxyntomodulin 
infusion using Alzet osmotic minipumpso. This method of administration had the advantage of 
avoiding any stress induced by repeated peripheral injections. These studies were performed in 
mouse models as the experiments required lower amounts of peptide relative to rat studies due 
to the much smaller body-weight of experimental mice. 
Continuous subcutaneous administration of oxyntomodulin using Alzet osmotic pumpse 
resulted in a reduction in body-weight gain (Section 2.3.2.4 and 2.3.2.5). Pumps administering 
oxyntomodulin in the dose range 300 pmol/kg/min to 2000 pmol/kglmin were implanted into 
male mice. This represented a daily dose of between 432 nmol/kg and 2880 nmol/kg over a 24 
hour period. The highest dose was chosen as it approximated to the dose of 1400 nmol/kg 
administered twice-daily (total 2800 nmoUkg/day) by an intra-peritoneal route in Section 
2.3.2.2. The administration of oxyntomodulin by continuous infusion was a far more effective 
means of reducing body-weight when compared to twice-daily intraperitoneal injection, despite 
the total daily dose being equivalent or lower. This suggests that the lack of an anorectic effect 
observed following chronic oxyntomodulin administration in the previous experiment (Section 
2.3.2.2) was not due to the dose being inadequate, but rather to the dosing regime. The change 
in body-weight for the group receiving 300 pmol/kg/min and 600 pmol/kg/min oxyntomodulin 
rapidly approached that of the control group during the second week when the pump was 
expected to have ceased administering peptide. This suggests that oxyntomodulin treatment had 
not rendered the animals chronically unwell and that repeated treatment is necessary to maintain 
an effective body-weight reduction. The dose of 300 pmol/kg/min oxyntomodulin had a 
significant effect on body-weight, but the change in body-weight was observed to return toward 
that of the control group prior to the end of the expected treatment period on day 7 (Figure 
2.13). This suggests that 600 pmol/kg/min may be the lowest chronically effective dose in mice. 
Importantly, the study demonstrates that subcutaneous administration of oxyntomodulin may 
effectively reduce body-weight in rodents, providing a possible practical means of 
administration to humans. 
The effect of continuous oxyntomodulin administration on food intake was progressively 
diminished over the course of the study period (Section 2.3.2.4 and 2.3.2.5). At all doses, the 
food intake of the treatment groups became similar to that of the control groups before the 
administration of peptide had ceased. However, this loss of effect was not secondary to 
degradation of oxyntomodulin within the osmotic pump, as separation by hydrophobicity using 
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HPLC confirmed intact peptide at the end of the study (Figure 2.24). The transient nature of 
oxyntomodulin's anorectic effect is likely to represent the development of counter-regulatory 
mechanisms in response to weight loss, which are present in order to prevent starvation. For 
example, as the animal loses body-weight, leptin levels will fall, signalling a negative energy 
balance and resulting in a drive to eat, thereby counteracting the effect of the oxyntomodulin 
infusion. However, ongoing treatment with oxyntomodulin appears to prevent the normal 
compensatory over-eating and weight regain, resulting in a stable, but lower, body-weight. This 
counter-regulatory phenomenon has also been seen with other weight-reducing agents. For 
example, chronic PYY infusion administered to rodents using osmotic minipumps results in a 
transient reduction of food intake accompanied by a sustained reduction of body-weight (Pittner 
et al., 2004; Wang et al., 2006). Similarly, a stable analogue of the anorectic peptide a-MSH 
administered into the peritoneum resulted in a return of food intake to the level of control after 
four days, with a plateau of body-weight below the level of control (Pierroz et al., 2002). 
The RER varies with the macronutrient composition of the fuel being utilised by the animal to 
generate energy. The reduction in RER observed in the oxyntomodulin treated animals 
represents the effect of negative energy balance on metabolism, so that these animals begin to 
utilise their fat stores causing RER to fall below 1.0. Toward the end of these continuous 
infusion studies, the animals have a similar energy intake to the control group and enter a phase 
of body-weight equilibrium (albeit at a lower set-point) and so their RER returns to the level of 
the control group. It was observed that, toward the end of continuous administration of 
oxyntomodulin, the RER of the treatment group increased above the level of the control group. 
In Section 2.3.2.4 the relative increase in RER on day 6 during continuous administration of 
oxyntomodulin at 1000 or 2000 pmol/kg/min (Figure 2.1 IF) is likely to be due to the non- 
significantly higher food intake observed during the light-phase (Appendix C, Figure CIF). 
However, in Section 2.3.2.5 a relative increase in RER was observed in the treatment group, 
receiving 300 or 600 pmol/kg/min, during the light-phase (Figure 2.15G) which was not 
associated with any change in feeding behaviour (Appendix C, Figure C5G). It cannot be 
excluded that treatment with oxyntomodulin directly switched metabolism towards 
carbohydrate utilisation in this circumstance. 
A period of starvation or negative energy balance would be expected to reduce energy 
expenditure and activity in order to preserve body-weight in rodents (Even and Nicolaidis, 
1993; Severinsen and Munch, 1999; Forsurn et al., 1981; Vinter et al., 1988; Larsen et al., 2001) 
(Section 2.3.2.6 and 2.3.2.8). It is therefore not surprising that some reduction in both 
parameters was observed during continuous subcutaneous oxyntomodulin treatment, as it did 
indeed induce negative energy balance. The fact that similar energy expenditure was observed 
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in the groups receiving 300 / 600 and 2000 pmol/kg/min was therefore notable. Likewise, the 
increase in activity observed transiently in the groups receiving 600 / 1000 pmol/kg/min was 
also interesting. A previous paper by Baggio et aL has compared the effect of oxyntomodulin 
administration with the long-acting GLP-I receptor agonist exendin-4 on the metabolic 
parameter V02 (as a marker of energy expenditure) (Baggio et al., 2004b). Central and 
peripheral administration of exendin-4 significantly reduced V02, whereas administration of 
oxyntomodulin administered by either route had no such effect. This may represent a 
differential effect on energy expenditure between oxyntomodulin and other proglucagon 
products. However, in this study the authors failed to demonstrate an anorectic effect of 
oxyntomodulin following peripheral administration and the anorectic effect of oxyntomodulin 
and exendin-4 were not equivalent when administered centrally - thus the variable effect on 
food intake would confound measurements of energy expenditure. A further experiment in the 
metabolic cages in which an additional control group was pair-fed to the group receiving 
oxyntomodulin would be required in order to determine whether the changes in energy 
expenditure and activity seen after oxyntomodulin administration were different from that 
expected from a similar degree of negative energy balance. Unfortunately, such a study is 
technically difficult in the metabolic cages under conditions which allow direct measurement of 
these parameters. 
I hypothesised that oxyntomodulin may prevent the compensatory reduction in energy 
expenditure and activity expected with negative energy balance, as suggested by the previous 
central administration study (Section 2.3.2.3). In order to remove any confounding effect of 
reduced food intake and body-weight loss, I proceeded to perform an acute fasted study (Section 
2.3.2.6) in which rodents receiving continuous subcutaneous oxyntomodulin (600 pmol/kg/min) 
were exposed to an overnight fast and measurements were taken prior to significant loss of 
body-weight. Energy expenditure and activity were reduced over the period of fasting as 
expected. However, there did not appear to be any protective effect of oxyntomodulin as these 
changes in parameters were observed in both groups. During the period of refeeding, animals 
treated with oxyntomodulin had significantly lower food intake and RER. However, despite this 
ongoing reduction in energy intake, the energy expenditure was similar to that of the control 
group, providing some indirect evidence that oxyntomodulin may result in a relative increase in 
energy expenditure when administered peripherally. This was corroborated by a repeat fasted 
study in which similar observations of food intake, RER and energy expenditure were made 
(Section 2.3.2.8). In these two studies there was no definitive evidence that this dose of 
subcutaneous oxyntomodulin increased activity, although there was a suggestion that vertical 
activity may be increased in the early dark-phase. 
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Exendin-4 is a 39 amino acid peptide isolated from the salivary gland of the Gila monster 
(Heloderma suspectum) (Eng et al., 1992) which is a potent long-acting agonist at the GLP-I 
receptor (Schepp et al., 1994; Goke et al., 1993; Thorens et al., 1993). A ftagment of exendin-4, 
exendin (9-39) has been reported to be a competitive antagonist (Raufffian et al., 1992; Baggio 
et al., 2004b) or an inverse agonist (Serre et al., 1998) at the GLP-l receptor and when co- 
administered blocks the actions of GLP-I (Schepp et al., 1994; Serre et al., 1998). However, it 
has also been reported to interfere with GLP-2 receptor signalling (Tang-Christensen et al., 
2000). Oxyntomodulin has been hypothesised to exert its anorectic effect via the GLP-I 
receptor, as it is ineffective when administered centrally or peripherally to GLP-I receptor 
deficient mice (Baggio et al., 2004b) and administration of the GLP-I antagonist, exendin (9- 
39), into the cerebral ventricles has been reported to inhibit the anorectic actions of both GLP-I 
and oxyntomodulin (Dakin et al., 2001; Turton et al., 1996). 1 therefore planned to investigate 
whether exendin (9-39) could block the feeding effect of oxyntomodulin administered by 
subcutaneous infusion, and if so, whether removing the confounding effect of negative energy 
balance by this method would reveal a positive effect of peripheral oxyntomodulin on energy 
expenditure and activity. 
Exendin (9-39) administered by acute intraperitoneal injection resulted in a tendency to decrease 
food intake when given alone and a tendency to increase food intake in animals receiving 
oxyntomodulin (600 pmol/kg/min) by continuous subcutaneous infusion (Section 2.3.2.7). Any 
acute study using the metabolic cages designed with four experimental groups is limited to six 
animals per group; these small numbers contribute to the lack of significance achieved in the 
study. However, some inferences can be made from the data. Firstly, the effect of exendin (9- 
39) did not return the food intake of the oxyntomodulin group completely back to the level of 
the control group. This may be due to inadequate dosing, as the dose given by communication 
was extrapolated from that needed to antagonise an acute oxyntomodulin injection rather than 
continuous administration. However, administration of a dose greater than 3000 nmol/kg would 
be difficult to prepare in the small volumes suitable for intra-peritoneal injection in mice. 
Secondly, the effect of exendin (9-39) administered alone tended to decrease food intake, 
whereas if it acted as a competitive antagonist of endogenous GLP-I / oxyntomodulin, or as an 
inverse agonist of a constitutively active GLP-I receptor, the injection would be expected to 
increase food intake. The more complex feeding response observed in this study may instead 
represent a weak partial agonist effect of exendin (9-39). These observations made exendin (9- 
39) a much less useful tool for differentiating the anorectic effect of oxyntomodulin from its 
effects on energy expenditure. I therefore decided not to pursue investigation of the effects of 
exendin (9-39) further. 
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Continuous subcutaneous administration of oxyntomodulin results in a transient reduction in 
food intake over several days. Animals which lost weight secondary to implantation of a pump 
administering oxyntomodulin, but demonstrated mean daily food intake at the same level as 
control, continued to demonstrate a short-term reduction in food intake in response to an 
exogenous intraperitoneal dose of oxyntomodulin (1400 nmol/kg) (Section 2.3.2.8). There was 
no evidence that the anorectic response to acute oxyntomodulin in animals receiving continuous 
subcutaneous oxyntomodulin was of a lower magnitude than that of animals which had not 
received continuous oxyntomodulin. This suggests that there was not significant receptor down- 
regulation with chronic treatment and therefore that ongoing treatment may result in continued 
weight-reduction. It further supports the hypothesis that the loss of anorectic effect is secondary 
to the induction of counter-regulatory mechanisms which prevent starvation, as it does not 
appear to be due to the development of resistance to oxyntomodulin treatment. However, it 
remains a possibility that the acute dose of oxyntomodulin chosen induced a maximal response 
which failed to differentiate the development of a more subtle resistance and that eventually 
with longer-term treatment body-weight would return to the level of the control animals - 
although there was no evidence of this over seven-day oxyntomodulin administration. 
The anorectic effect of oxyntomodulin is thought to occur via the hypothalamus, as peripheral 
administration of oxyntomodulin has been shown to activate early gene expression in the ARC 
and PVN (Dakin et al., 2004; Horvath, 2005; Baggio et al., 2004b). Ex vivo investigation of the 
release of appetite-regulatory neuropeptides in response to oxyntomodulin demonstrated a non- 
significant increase in release of a-MSH, the main product of the appetite-inhibitory POMC 
neurones (Section 2.3.2.10). This is in agreement with data published previously which 
demonstrated a significant increase in hypothalamic cc-MSH release in response to 
oxyntomodulin in a static incubation system (Dakin et al., 2004). In addition to its actions on 
feeding, central administration of a-MSH is known to increase oxygen consumption (Pierroz et 
al., 2002) and stimulate sympathetic nervous activity in brown adipose tissue (Yasuda et al., 
2004). Melanocortin cells in the ARC have projections which terminate on TRH-producing cell 
bodies in the PVN to induce release of hypothalamic TRH (Fekete et al., 2000; Fekete et al., 
2002; Kim et al., 2000b) and in vivo administration of a stable a-MSH analogue increases 
plasma TSH in fasted rats (Kim et al., 2000b). Thus, oxyntomodulin could both decrease food 
intake and increase energy expenditure via stimulation of a-MSH release in combination with 
secondary stimulation of the thyroid axis. 
Interestingly, there was a significant increase in a-MSH after incubation with an equimolar dose 
of GLP-1, and a greater increase in response to exendin-4. It has previously been demonstrated 
that the potency of these peptides to displace 1251[exendin-4] from the GLP-1 receptor is 
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exendin-4 = GLP-I > exendin (9-39) > oxyntomodulin and that c-AMP production is stimulated 
equally by GLP-I and exendin-4, but less potently by oxyntomodulin (Fehmann et al., 1994). 
This pattern of a-MSH release is consistent with the affinity of these peptides for the GLP-I 
receptor, perhaps in combination with the longer-lasting effect of exendin-4 in vivo because of 
its relative protection from degradation by the ubiquitous protease DPP-4 (Thum et al., 2002). 
In situ hybridisation has demonstrated significant GLP-IR mRNA in the ARC and PVN 
(Shughrue et al., 1996) and the presence of the receptor in the ARC has also been demonstrated 
by autoradiographic localisation (Uttenthal et al., 1992). However, it is not known whether these 
receptors are co-localised with POMC-expressing neurones. No alteration of NPY, AgRP or 
CART release was observed in response to incubation with the peptides, despite CART being 
co-released by 90% of POMC neurones within the ARC (Elias et al., 1998a). 
TRH release from the hypothalamus and TSH release from the pituitary were significantly 
increased by incubation with oxyntomodulin at increasing concentrations in a dose-dependent 
manner (Section 2.3.2.10 and 2.3.2.11). This infers a direct effect of oxyntomodulin on the 
thyroid axis both at the level of the hypothalamus and at the pituitary. This effect was not 
observed with GLP-l incubation and stimulation of TSH was only seen at the highest 
concentration with exendin4 incubation. The lack of effect of GLP-I (lOnM to 1000 nM) on 
TSH release from explants contrasts with previous published results of dispersed anterior 
pituitary cells which have been reported to release TSH in response to GLP-I (I OOnM) (Beak et 
al., 1996). Unlike the pattern observed with release of a-MSH, the stimulation of the 
hypothalamo-pituitary-thyroid axis was greater for oxyntomodulin, and was therefore not 
consistent with the affinity or activity of these peptides at the GLP-I receptor (Young et al., 
1999), despite evidence that the GLP-I receptor is present in both the hypothalamus and 
pituitary gland (Alvarez et al., 1996; Shimizu et al., 1987). The stimulation of hypothalamic 
TRH by oxyntomodulin provides another possible mechanism for its dual effect on feeding and 
energy expenditure. TRH has central effects which reduce food intake in fed, fasting and 
stressed animals, as well as having effects on the thyroid axis, thermogenesis, locomotor activity 
and autonomic regulation (Lechan and Fekete, 2006). 
It has been suggested that oxyntomodulin exerts its anorectic effects through the GLP-1 receptor 
(Baggio et al., 2004b). The differential stimulation of TRH release by oxyntomodulin, GLP-1 
and exendin-4 suggest that oxyntomodulin may mediate its effects on the UPT axis via an 
alternative mechanism. There is evidence that oxyntomodulin may signal via a receptor that has 
not yet been identified. GLP-1 and oxyntomodulin both potently inhibit food intake at 
equimolar doses in rats (Dakin et al., 2004) despite the affinity of oxyntomodulin for the GLP-I 
receptor being two orders of magnitude lower than GLP-I itself (Fehmann et al., 1994; Dakin et 
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al., 2001). As discussed above, a study by Baggio et aL suggests that GLP-I and oxyntomodulin 
differentially regulate food intake and energy expenditure in mice (Baggio et al., 2004b). Some 
studies have alluded to the possibility of a second GLP-I receptor, in adipocytes, hepatocytes 
and myocytes, distinct from the known cloned pancreatic GLP-I receptor (Valverde and 
Villanueva-Penacarrillo, 1996; Redondo et al., 2003). Other studies demonstrate a lack of an 
inhibitory effect of exendin (9-39) on GLP-I action in the liver and gastrointestinal tract 
(Nishizawa et al., 2000; Daniel et al., 2002). Thus, oxyntomodulin (and perhaps other GLP-I 
receptor agonists) may also act via an alternative receptor structurally similar to the GLP-I 
receptor. Currently, the only other receptor known to bind oxyntomodulin is the glucagon 
receptor. Although oxyntomodulin contains all 29 amino acid residues of glucagon, its receptor 
affinity is only 2% that of glucagon itself (Baggio et al., 2004b; Baldissera et al., 1988) and the 
anorectic effects of oxyntomodulin are intact in the glucagon receptor knockout mouse (Baggio 
et al., 2004b), indicating this receptor is not necessary for the feeding effects. 
To summarise, oxyntomodulin administered centrally resulted in an acute reduction in food 
intake and increase in total energy expenditure. Peripheral subcutaneous oxyntomodulin 
administered by continuous infusion was demonstrated to reduce body-weight gain compared 
with controls. This weight-reduction was secondary to a transient decrease in food intake and 
possibly a prevention of the reduction in energy expenditure expected during negative energy 
balance. The two actions of oxyntomodulin could be mediated by an increase in a-MSH and / or 
by primary or secondary stimulation of the thyroid axis. Counter-regulatory mechanisms are 
likely to prevent ongoing weight loss which would result in starvation; therefore treatment with 
oxyntomodulin resets body-weight at a lower homeostatic point. There was no evidence of the 
effect on oxyntomodulin on body-weight being attenuated over the course of the study period. 
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Chapter 3 
The Effect Of Oxyntomodulin On Food 
Intake And Body-weight In Humans 
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3.1 Introduction 
The prevalence of obesity is rapidly increasing worldwide; currently over 65% of adults in the 
USA are overweight (Hedley et al., 2004). Although even modest weight loss can reduce 
morbidity and mortality, existing medical interventions and public health campaigns to promote 
exercise and improve diet have failed to limit the obesity epidemic. Novel medical therapies are 
therefore urgently required. 
Our laboratory has previously reported that oxyntomodulin reduces food intake in rodents and 
by 19.3% in normal weight humans when administered intravenously (Cohen et al., 2003). 
Oxyntomodulin has been found to reduce white adipose tissue and lower body-weight after 
repeated intraperitoneal administration to rodents over seven days (Dakin et al., 2004). 1 have 
demonstrated a significant reduction in body-weight when oxyntomodulin is administered to 
rodents by continuous subcutaneous infusion (Chapter 2). Therefore, if oxyntomodulin results in 
appetite suppression in obese volunteers, repeated administration could potentially result in 
weight loss. 
The long-term use of oxyntomodulin as a weight loss therapy would require a safe and effective 
route of administration. Although the intravenous administration of oxyntomodulin has been 
shown to reduce food intake (Cohen et al., 2003), this method is impractical for repeated 
delivery of any drug treatment. Oral administration is the most acceptable mode of 
administration where possible, but the oral route is limited by an incomplete absorption and 
first-pass metabolism. In particular, peptides such as oxyntomodulin undergo significant first- 
pass metabolism, as peptidases present in the intestinal wall and liver breakdown orally- 
administered proteins (Holford, 2001). Subcutaneous administration avoids this first-pass 
metabolism and may allow adequate absorption without the need for modification of the 
hormonal structure. Indeed, diabetic patients have effectively self-administered subcutaneous 
insulin since the 1920's (Banting and Best, 1922). More recently growth hormone has been 
successfully administered by a subcutaneous route (Shimon, 2003; Soyka et al., 1970). 1 
therefore chose to administer oxyntomodulin subcutaneously to overweight and obese 
volunteers in order to investigate its effects on appetite and body-weight. 
3.2 Hypothesis And Aims 
A single intravenous infusion of oxyntomodulin decreased food intake in volunteers with a BMI 
in the normal range (Cohen et al., 2003). However, the ability of oxyntomodulin to inhibit food 
consumption in overweight and obese volunteers has not been investigated. This is vital, as 
obesity is known to confer resistance to some peripheral signals of appetite such as leptin (Sahu, 
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2003). Furthermore, the effect of repeated doses of oxyntomodulin to human volunteers is 
unknown. 
Hypothesis: 
I hypothesise that repeated subcutaneous administration of oxyntomodulin will reduce food 
intake and body-weight in healthy overweight and obese volunteers. 
Aims: 
1. To determine the plasma concentration of oxyntomodulin-like immunoreactivity 
achieved by subcutaneous oxyntomodulin administration. 
2. To investigate the effect of a subcutaneous injection of oxyntornodulin on appetite and 
food intake at a study meal. 
3. To determine the effects of four-week pre-prandial administration of subcutaneous 
oxyntomodulin on food intake, body-weight and adipose hormones in healthy 
overweight and obese volunteers. 
Three separate studies were performed in order to achieve these aims: 
Study 1-a small preliminary study investigating the efficacy of administering oxyntomodulin 
as a subcutaneous injection, in comparison to intravenous infusion, using food intake as the 
primary end-point. 
Study 2-a pilot study of eight overweight and obese volunteers investigating the effect of 
repeated doses of subcutaneous oxyntomodulin on food intake and body-weight. 
Study 3-a randomised-controlled parallel group study of 26 overweight and obese volunteers 
investigating the effect of four-week administration of subcutaneous oxyntomodulin on food 
intake, adipose hormones and body-weight. 
3.3 Materials And Methods 
3.3.1 Peptides And Chemicals 
Oxyntomodulin was synthesised by Bachem (St. Helens, UK), a commercial source of known 
high purity. Matrix-assisted laser desorption ionisation-time of flight mass spectroscopy 
(Kratos, Manchester, UK), kindly performed by Dr Kevin Murphy (Department of Metabolic 
Medicine, Imperial College London) was used to confirm the identity of the peptide. Saline was 
purchased from Bayer (Haywards Heath, UK). Haemacel was supplied by Beacon (Tunbridge 
Wells, UK). Oxyntomodulin was dissolved in 100 gL of 0.9% saline and aliquoted into sterile 
glass vials using an aseptic technique in a laminar flow cabinet, before being freeze-dried. Equal 
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volumes of 0.9% saline were aliquoted into identical glass vials and freeze-dried; these placebo 
vials enabled double-blinding of the study. 
Oxyntomodulin and saline vials were randomly selected to undergo microbiological testing 
(Department of Microbiology, Hammersmith Hospital, London, UK) and the Limulus 
Amoebocyte Lysate test for pyrogen (Associates of Cape Cod, Liverpool, UK). The vials were 
sterile on culture after seven days and the Limulus Amoebocyte Lysate test was within the safe 
range for human administration. Greater than ten times the human dose (per kg) of 
oxyntomodulin was administered to C57BL/6 mice for toxicology testing. No behavioural 
anomalies were noted in the mice post-injection and there were no abnormalities found on 
histological examination of murine stomach, small intestine, colon, spleen, pancreas, kidney, 
liver, lung or heart. 
3.3.2 Volunteers 
Healthy male and female volunteers, aged 18 to 55 years, with a stable BMI between 25 and 
40k g/m 2, were recruited through advertisement. All potential subjects were non-smokers with 
normal physical examination, full blood count, urea and electrolytes, liver function tests, plasma 
glucose and electrocardiograms. Volunteers were screened using a standard DEB questionnaire 
(Van Strien et al., 1986) and SCOFF questionnaire (Morgan et al., 1999) and excluded if they 
demonstrated abnormal eating behaviour. Volunteers who were on calorie-restricting diets or 
weight loss medications were also excluded. Food preferences were assessed using a nine-point 
hedonistic scale to ensure the study meal was acceptable. Women of child-bearing age were 
advised to use adequate contraception and provided urine samples to ensure they were not 
pregnant. All participants gave informed written consent and the study was performed in 
accordance with the Declaration of Helsinki. 
3.3.2.1 Study 1: Subcutaneous Efficacy Study 
Five healthy overweight and obese subjects (3 males, 2 females, mean body-mass index 28.9 ± 
0.7 k g/M2) were recruited by advertisement. Ethical approval for this initial efficacy study was 
obtained from Hammersmith, Queen Charlotte's & Chelsea and Acton Hospitals' Research 
Ethics Committee (reference 2003/6565). 
3.3.2.2 Study 2: Pilot Investigation Of Repeated Subcutaneous Oxyntomodulin 
Administration in Healthy Overweight and Obese Volunteers 
Eight healthy overweight and obese subjects (4 males, 4 females, mean body-mass index 32.1 ± 
1.1 kg/M2) were recruited by advertisement. At the time of entry to the trial, participants were 
given a subcutaneous injection of saline in order to assess whether they would find regular 
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injections acceptable. Ethical approval was obtained from Riverside Medical Ethics Committee 
(Reference 3397). 
3.3.2.3 Study 3: Four-Week Pre-Prandial Subcutaneous Administration Of 
Oxyntornodulin In Healthy Overweight And Obese Volunteers 
A power calculation was used in order to estimate the number of subjects required to complete 
this study in order to detect a significant effect of oxyntomodulin on participants' body-weight. 
Using a power calculator available on-line at 'http: //calculators. stat. ucla. edu/powcrcalc/', 
assuming a difference of 1.0 ± 0.2 kg to be clinically significant, using a significance level of 
p<0.05 and 90% power, it was calculated that at least 12 subjects were required in each group. I 
recruited a total of 31 healthy male and female volunteers through advertisement, in order to 
allow for any volunteer withdrawal from the study. The demographics of the final treatment and 
control groups are shown in Table 3.0. At the time of entry to the trial, participants were given a 
subcutaneous injection of saline in order to assess whether they would find regular injections 
acceptable. Ethical approval was obtained from Riverside Medical Ethics Committee (reference 
3397). 
3.3.3 Protocols 
3.3.3.1 Study 1: Subcutaneous Efficacy Study 
The study was a double-blinded, placebo-controlled protocol, designed to compare the 
subcutaneous and intravenous administration of oxyntomodulin. The volunteers received three 
separate treatments (Figure 3.0) in random order as allocated by an independent investigator. At 
each attendance participants received either 0.9% saline; oxyntomodulin as an intravenous 
infusion at 3.0 pmol/kg/min; or oxyntomodulin as a subcutaneous injection (100 or 150 nmol). 
Each attendance was separated by at least 72 hours. Pilot work had demonstrated that doses of 
up to 150 nmol of subcutaneous oxyntomodulin were safely tolerated in humans (Dr Alison 
Wren, Department of Metabolic Medicine, Imperial College London, personal communication). 
Subjects I and 2 received 100 nmol oxyntomodulin subcutaneously and subjects 3,4 and 5 
received 150 nmol oxyntomodulin subcutaneously. 
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Figure 3.0: study 1 protocol during the investigation of the effects of 
oxyntomodulin infusion or subcutaneous injection on appetite and food intake in 
overweight and obese humans. Protocol A, B and C show the combination of 
substances administered by subcutaneous and intravenous routes on each study 
day. The interventions were performed in random order, separated by at least 72 
hours. 
A 
B 
C 
intravenous 0.9 % saline infusion + 
Subcutaneous 0.9 % saline injection 
Intravenous 0.9 % saline infusion + 
Subcutaneous oxyntomodulin injection (100 or 150 nmol) 
Intravenous oxyntomodulin infusion (3pmol/kg/min) 
Subcutaneous 0.9 % saline injection 
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Volunteers maintained a similar diet for 48 hours before each infusion. They were asked to 
avoid alcohol and strenuous exercise for 24 hours prior to the study meal. The participants then 
fasted overnight and attended the Sir John McMichael Centre for the research study. 
Throughout the study day the volunteers were encouraged to relax by reading or watching films. 
Clocks and watches were removed in order to limit any potential effect of time on meal 
anticipation. Volunteers had a cannulae placed into the antecubital fossa of one arm for 
administration of the infusion and into the contralateral arm for blood sampling. The 
intravenous infusion was prepared by dissolving a freeze-dried vial in 0.9% saline containing 
5% Haemacel. Haemacel was used in the preparation in order to reduce any potential adsorption 
of oxyntomodulin to the administration syringe and tubing. The infusion was commenced at the 
time designate zero, and was continued for 105 minutes. The subcutaneous injection was 
prepared by adding 0.25 ml of saline to a freeze-dried vial and was administered 45 minutes 
after the start of the infusion. A study meal provided in excess was served 75 minutes after the 
start of the infusion. In order to avoid interruptions during the study meal, the infusion was not 
terminated until after feeding. The mass of food was measured before and after participants had 
fed ad libitum in order to calculate energy intake. The protocol is represented in Figure 3.1. 
Venous blood from each participant was sampled at -30,0,30,60,75,105 and 135 minutes 
from the arm contralateral to that receiving the infusion. The 10 ml blood samples were placed 
into lithium-heparin tubes (LIP Ltd., Cambridge, UK) containing 2000 kallikrein inhibitor units 
(0.2 ml) aprotinin (Trasylol, Bayer) and stored on ice. After refrigerated centrifugation, plasma 
was immediately separated and stored at -20'C prior to analysis. Each participant had 
continuous cardiac monitoring by electrocardiogram during the study as a safety measure. 
Subjects remained in the study room for four hours after the start of the infusion. After 
departure, they recorded their meals, snacks and drinks in diaries for a total of 24 hours. 
3.3.3.2 Study 2: Pilot Investigation Of Repeated Subcutaneous Oxyntomodulin 
Administration In Healthy Overweight and Obese Volunteers 
The study followed a double-blinded, placebo-controlled, parallel-group protocol designed to 
investigate the effect of repeated administration of subcutaneous oxyntomodulin on energy 
intake and body-weight (Figure 3.2). A subcutaneous dose of 200 nmol oxyntomodulin was 
chosen based on the plasma levels achieved by the doses in Study I and aiming for the 
subcutaneous injection to result in plasma OLI levels comparable to 907 ± 32 pmol/L level 
reported by the study of intravenous infusion in normal weight volunteers (Cohen et al., 2003). 
Volunteers were instructed to maintain their usual dietary and exercise regimens from the time 
of recruitment and were not placed on a calorie-restrictive diet. For one week prior to the study, 
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Figure 3.1: study 1 protocol for the study meals during investigation of the effects 
of oxyntomodulin infusion or subcutaneous injection on appetite and food intake in 
overweight and obese humans. Saline or oxyntomodulin were administered by 
intravenous infusion over a 105 minute period (blue bar). A subcutaneous injection 
of saline or oxyntomodulin was administered at t--45 minutes (red arrow). The 
study meal was served at t--75 minutes. Blood samples and visual analogue scales 
were taken at -30,0,30,60,75,105 and 135 minutes. 
Infusion Subcutaneous Study Infusion 
started injection meal stopped 
1 
14 Ftt 
-30 0 Is 30 45 60 75 90 105 120 135 
Time (minutes) 
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Figure 3.2: study 2 protocol during the pilot study investigating the effects of 
repeated administration of oxyntomodulin on food intake and body-weight in 
overweight and obese humans. A one week placebo 'run-in' period was followed by 
a four week period of saline or oxyntomodulin (200 nmol) injections. Energy intake 
was measured at an early morning study meal on day 1, day 2 and day 29. On day 
1 all subjects self-administered a saline injection, whereas on day 2 and day 29 
subjects were randomised to either saline or oxyntomodulin injections. 
Dietary and Exercise Study Meal 
Advice Day 1+2 
II 
Pre-prandial 
saline injections 
Study Meal 
Day 29 
Randomised to pre-prandial saline 
or 200 nmol OXM injections 
IL A 
4 weeks 
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all subjects self-administered saline by subcutaneous injection, three times daily, 30 minutes 
pre-prandially, into their abdominal subcutaneous tissue. This initial week was single-blinded, 
in that the investigators were aware that the volunteers were receiving saline, but the 
participants were not. Injections were prepared by the addition of 0.25 ml sterile water to vials 
containing freeze-dried powder and were self-administered using a 27 gauge needle. 
Following successful completion of this initial 'run-in' week, participants were allocated to the 
control or treatment group by an independent investigator using stratified randomisation for 
BMI, age and sex. Therefore, the control and treatment groups were matched for BMI (32.9 ± 
1.5 k g/m 2 and 31.2 1 1.6 k gIM2 respectively) and age (38.8 ± 3.9 years and 38.0 ± 3.8 years 
respectively), with two males and two females in both the treatment and the saline control 
group. 
During the four-week double-blinded study period, subjects self-administered subcutaneous 
saline or oxyntomodulin (200nmol), three times daily, 30 minutes pre-prandially. All volunteers 
were reviewed weekly to check their injection technique and monitor for side-effects and 
compliance. Pregnancy was excluded in females using a standard commercial urinary P-hCG 
test prior to the first injection and then at weekly intervals. Volunteers were asked to record any 
potential adverse events during the injection period and doctors were available to provide advice 
throughout the study. Protocol compliance was 98.2 ± 1.1% in the control group and 98.5 ± 
0.8% in the treatment group as estimated by counting returned empty vials. Compliance was 
also assessed by checking for cutaneous sites of injection and inspecting subjects' accumulated 
used needles. Subjects were weighed on each visit and three fasting weights recorded on three 
separate days at both the start and end of the study, using a calibrated electronic scale (Marsden, 
London UK) accurate to the nearest 100 g. Participants wore the same light-weight clothing and 
voided urine prior to each measurement. 
Energy intake was measured during an early morning study meal at 0930 hours (Figure 3.3) on 
two days at the start of the study and one day at the end of the study. On the day prior to each 
study meal, subjects refrained from alcohol and strenuous exercise and fasted overnight. 
Subjects self-administered their injection (designated time zero) and a meal consisting of 
breakfast cereal with milk was provided in excess 30 minutes later. Volunteers were requested 
to eat until they felt comfortably full. On day 1, all subjects administered a saline injection prior 
to the meal. On day 2 and day 29, the control group administered saline and the treatment group 
administered oxyntomodulin prior to the meal. 
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Figure 3.3: Study 2 study meal protocol during the pilot study investigating the 
effects of repeated administration of oxyntomodulin on energy intake in 
overweight and obese humans. On day 1 all subjects self-administered saline 
subcutaneously. On day 2 and 29 subjects were randomised to receive either saline 
or oxyntomodulin subcutaneously. The study meal was provided 30 minutes after 
the injection was administered. Blood samples were taken, and blood pressure and 
pulse were measured, at t-- -30,0,15,30,60,90,150,210,240 minutes. Visual 
analogue scores were recorded at t-- -30,0,30,60,90,150,210,240 minutes. 
Subcutaneous Study Study 
injection meal Ended 
I11 
-30 0 15 30 60 90 150 210 270 
Time (minutes) 
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On each study day, blood samples were collected at -30,0,15,30,60,90,150,210 and 240 
minutes to measure plasma oxyntomodulin-like immunoreactivity (OLI) levels. Blood samples 
(10ml) were taken from a carmula placed in the antecubital fossa and transferred to a 
lithium/heparin tube (LIP Ltd., Cambridge, UK) containing 2000 kallikrein inhibitor units (0.2 
ml) aprotinin (Trasylol, Bayer) and stored on ice. After centrifugation, plasma was immediately 
separated and stored at -20*C until analysis. Blood pressure and pulse were measured just prior 
to each blood sample. Volunteers completed visual analogue scales rating hunger, desire to eat, 
satiety, prospective food consumption, and nausea (Appendix D) at -30,0,30,60,90,150,210 
and 240 minutes. These scales consisted of aI 00mm line with text expressing the most positive 
and most negative ratings anchored at each end. In order to assess appetite the volunteers were 
asked 'How hungry do you feel? ', 'How pleasant would it be to eat? ', 'How full do you feel? ' 
and 'How much do you think you could eat? ' with higher values signifying more positive 
subjective ratings. 
3.3.3.3 Study 3: Four-Week Pre-Prandial Subcutaneous Administration Of 
Oxyntomodulin In Healthy Overweight And Obese Volunteers 
The study followed a randomised double-blinded, placebo-controlled, parallel-group protocol 
designed to investigate the effect of oxyntomodulin on body-weight, food intake and adipose 
hormones (Figure 3.4). Prior to commencing this study, I obtained ethical approval and safely 
administered 400 nmol of oxyntomodulin subcutaneously in two additional volunteers with no 
adverse effects (reference 2003/6565). Therefore, a subcutaneous dose of 400 nmol 
oxyntomodulin was chosen, based on the plasma levels achieved by the doses in Study 2 and 
aiming to achieve plasma OLI levels comparable to 907 ± 32 pmol/L level reported by the study 
of intravenous infusion in normal weight volunteers (Cohen et al., 2003). 
The participants completed the study protocol in the community and also attended the Charing 
Cross Hospital Clinical Trials Unit for assessment of energy intake. From recruitment, subjects 
were instructed to continue their current level of exercise and usual diet in a regimen of three 
meals a day, intended to examine the effect of oxyntomodulin without the addition of a calorie- 
restricted diet. For one week prior to the study, all subjects self-administered saline injections 
three times daily, 30 minutes pre-prandially, into their abdominal subcutaneous tissue in order 
to habituate to the injection procedure. During this initial week the protocol was single-blind, in 
that the investigators were aware that study participants were administering saline 
subcutaneously, but the volunteers were not. All subjects prepared their injections by the 
addition of 0.25ml sterile water to vials containing freeze-dried saline and self-administered 
injections using a 27 gauge needle. Subjects who failed to comply with the protocol during this 
week were removed from the study. 
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Figure 3.4: protocol for study 3 during the four-week administration of 
subcutaneous oxyntomodulin. The protocol commences with a1 week 'run-in' 
period, followed by four-week blinded self-administration of subcutaneous saline 
or oxyntomodulin injections. Participants administered saline during week 1 and 
were then randomised to administer either oxyntomodulin injections (400 nmol) or 
saline injections for the remaining four weeks. Energy intake was measured at a 
lunchtime study meal on day 1, day 2 and day 29. On day 1 all subjects self- 
administered a saline injection, whereas on day 2 and day 29 subjects were 
randomised to either saline or oxyntomodulin injections. 
Dietary and Exercise Study Meal 
Advice Day 1+2 
II 
Pre-prandial 
saline injections 
Study Meal 
Day 29 
Randomised to pre-prandial saline 
or 400 nmol OXM injections 
1 we 4 weeks 
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Volunteers were randomly allocated to the control or treatment group by an independent 
investigator. Participants were stratified using parameters of BMI and age; subsequent 
randomisation into the control or treatment group was performed by coin toss. The control and 
treatment groups were matched for BMI (32.8 ± 0.9 k g/M 2 and 33.7 ± 0.9 k g/M2 respectively) 
and age (35.0 ± 2.0 years and 32.5 ± 1.8 years respectively) and had similar mean height and 
weight measurements (Table 3.0). 
During the four-week study period, subjects self-administered saline or oxyntomodulin 
(400nmol), three times daily, 30 minutes pre-prandially. This protocol was performed in a 
double-blinded manner, in that neither the investigators nor the participants knew whether they 
were randomised to the control or treatment group. The vials of saline and oxyntomodulin were 
coded by an independent investigator and were indistinguishable from each other. At the start of 
each week during the study, a physician blinded to the identity of the substance allocated a one- 
week supply of designated coded vials to the subjects. An identical protocol for injection 
preparation and administration was used as in the previous run-in week. 
The subjects were reviewed weekly by the investigators to measure body-weight, check 
injection technique and monitor for side-effects and compliance. Protocol compliance was 94.4 
± 1.1% in the control group and 95.3 A: 1.2% in the treatment group, estimated by counting 
returned empty vials. Compliance was also confirmed by checking for cutaneous sites of 
injection and inspecting subjects' accumulated used needles. Volunteers were asked to record 
any possible adverse events during the injection period in a diary. Doctors were available to 
provide information and advice to the subjects at any time. 
The body-weight of the volunteers was measured on each visit and three fasting weights 
recorded on three separate days at both the start and end of the study, using a calibrated 
electronic scale accurate to the nearest 100g (Marsden, London, UK). Subjects wore the same 
light-weight clothing and voided urine prior to weight measurement. Pre-injection blood 
samples were taken at the start and end of the study to measure plasma levels of leptin and 
adiponectin. 
Energy intake was measured during a lunchtime meal on day 1, day 2 and day 29 of the study 
(Figure 3.5). On day 1, all subjects administered a subcutaneous saline injection prior to the 
study meal. On day 2 and day 29, the control group self-administered subcutaneous saline and 
the treatment group administered oxyntomodulin prior to the study meal. 
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Figure 3.5: Protocol for the study meals during the investigation of the effects of 
four-week administration of oxyntomodulin on food intake in overweight and 
obese humans. On day 1 all subjects self-administered saline subcutaneously. On 
day 2 and 29 subjects were randomised to receive either saline or oxyntomodulin 
(400 nmol) subcutaneously. Blood samples were taken, and cardiovascular 
parameters were measured, at -30,0,15,30,60,90,150,210 and 240 minutes. 
Visual analogue scales were measured at t=-30,0,30,60,90,150,210 and 240 
minutes. 
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On the day before each study meal, subjects refrained from alcohol and strenuous exercise, 
consumed an identical pre-fast meal, and then fasted overnight from 9pm. On arrival at the 
Clinical Trials Unit, subjects ingested a fixed 200kcal breakfast consisting of digestive biscuits 
and caffeine-free tea or coffee, and 210 minutes later self-administered their injection 
(designated time zero). A meal of known caloric content was provided in excess 30 minutes 
later. Subjects were placed in isolation and requested to eat until they felt comfortably full. Each 
individual received an identical study meal on each occasion. Depending on their taste 
preference this was either: chicken curry (171Kcal, 6g protein, 19g carbohydrate, 7.9g fat per 
I 00g), mushroom stroganoff (123 Kcal, 3.1 g protein, 17.9g carbohydrate, 4.3g fat per I 00g) or 
chicken tagliatelle (129 Kcal, 6.9g protein, 16.7g carbohydrate, 3.8g fat per 100g). The mass of 
food consumed was measured and used to calculate energy intake. 
Throughout the study meal day, participants were encouraged to relax by reading or watching 
films. Clocks were removed from the study room to limit any potential effect of meal 
anticipation on appetite sensation. Visual analogue scales, 100mm in length, were completed at 
baseline, and at 30,60 90,150,210 and 240 minutes. These scales consisted of a 100mm line 
with text expressing the most positive and most negative ratings anchored at each end 
(Appendix D). In order to assess appetite the volunteers were asked 'How hungry do you feel? ', 
'How pleasant would it be to eatT 'How full do you feelT and 'How much do you think you 
could eat? ' with higher values signifying more positive subjective ratings. 
Blood samples were taken at baseline, and at 15,30,60,90,150,210 and 240 minutes to screen 
for any acute effect of oxyntomodulin on other analytes (Table 3.2). Blood samples (10ml) were 
collected from an antecubital fossa carmula into lithium/heparin tubes (LIP Ltd., Cambridge, 
UK) containing 2000 kallikrein inhibitor units (0.2 ml) aprotinin (Trasylol, Bayer, UK) and 
stored on ice. After refrigerated centrifugation, plasma was immediately separated and stored at 
-20'C until analysis. Blood pressure and pulse were measured prior to blood sampling on each 
of the study meal days. 
3.3.4 Hormone, Lipid and Glucose Measurement 
Plasma OLI was measured using an established in-house radioimmunoassay (Appendix B). In 
study 3, in vivo antibody formation to subcutaneous synthetic oxyntomodulin in the subjects' 
plasma was assessed in the same OLI assay; 100 pl of each baseline sample from Day 29 was 
assayed with 100 Id label and 600 [tl assay buffer without the addition of in-house antibody 
preparation; any endogenous production of antibody by the participant would be measurable by 
binding to the OLI label. Commercially available assays were used to measure plasma leptin 
and adiponectin (Appendix B). Glucose, total cholesterol and HDL cholesterol were measured 
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by an Olympus AU640 Analyser (Melville, NY). Insulin, PYY and ghrelin-like 
immunoreactivity were measured using in-house radioirnmunoassays (Appendix B). In each 
study, all plasma samples were assayed in duplicate and within one assay to eliminate inter- 
assay variation. 
3.3.5 Gel Permeation Chromatography 
In study 3, plasma taken 30 and 90 minutes post-injection was analysed by gel permeation 
chromatography to assess for oxyntomodulin degradation into other molecular forms. 
Separation by size exclusion chromatography is based on the spherical diameter of the peptide. 
Sephadex gel is formed from dextran beads with pores of varying size; molecules larger than the 
largest pores do not enter the beads and pass through the gel bed in the liquid phase, eluting in 
the void volume. Molecules smaller than the smallest pore have access to the entire gel bed and 
elute in the column volume. Molecules of intermediate size enter the pores to a varying degree 
and elute at intermediate positions. As the elution volume may vary with column packing, the 
elution position is expressed in terms of K.,. The K., was calculated for each immunoreactive 
peak on column chromatography according to a modification of the equation K., = (V, -V. )Nt- 
V,, ) (Andrews, 1970), where: 
V,, = Void volume: the volume of mobile phase in the column not associated with the 
gel matrix and determined by the elution of dextran blue 
Vt = Total volume of the gel matrix and mobile phase in the column, determined by 
the elution of 1251-Na detected by gamma counter 
V. = Elution volume of the analyte, between V. and Vt, and determined by 
radioimmunoassay 
Plasma was fractionated with Sephadex G-50 Superfine on a 60 x 0.9 cm column (Amersham 
Pharmacia Biotech, Uppsala, Sweden). The column was prepared using pre-swollen Sephadex 
G-50 Superfine equilibrated overnight with column buffer (0.06 M phosphate buffer containing 
0.2 M NaCI and 0.3% (vol/vol) BSA). To determine the relative elution coefficient (K. J of 
OLI, dextran blue (molecular weight, 2000000; 30 mg/ml; K. V=O), horse heart cytochrome c 
(molecular weight, 12384; 30 mg/ml; K. V=0.26) and 
125 I-Na (30 Bq) (K., =I. O) were added to 
each sample extract (n=3), which were loaded as a volume of 0.7 ml. The column was eluted at 
a flow rate of 3.2 ml/h at 4'C and 0.8 ml fractions were collected. The OLI in these fractions 
was then measured by radioimmunoassay and an elution profile constructed. 
3.3.6 Statistical Analysis 
Combined data are presented as mean ± standard error of the mean. Energy intake data is 
presented both in absolute Kcal and as a percentage of each individual's baseline intake. The 
percentage data was included to avoid bias due to the large inter-individual variation in meal 
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consumption, as when mean absolute Kcal data is given for a group, the volunteers with higher 
energy intake are over-represented in the analysis. This manipulation is particularly important in 
parallel group studies where the effect of individual variation does not apply equally to both 
groups. Prism Version 4.0 was used for statistical calculations. Statistical advice was given by 
Dr David Stephens, Imperial College London. 
Study 1: Energy intake in the three groups was compared using a repeated measures non- 
parametric Friedman test, in order to compare saline, subcutaneous and intravenous 
oxyntomodulin. Post-hoe testing of the data was performed using Dunn's multiple comparison 
test. For these statistical tests p<0.05 was considered significant. Food diaries were analysed by 
an independent dietician using Dietplan software 4.0 (Forestfield Software Ltd., West Sussex, 
LJK). 
Study 2: Changes in body-weight were compared using a non-parametric Mann Whitney test 
for between-group analysis. Changes in energy intake and visual analogue scales were 
compared using a repeated measures non-parametric Friedman test for within-group analyses 
and Mann Whitney test for between-group analysis. Post-hoc testing of the data was performed 
using Dunn's multiple comparison test. For these statistical tests p<0.05 was considered 
significant. 
Study 3: The data collected for the primary endpoints of change in body-weight, energy intake 
and adipose hormones were normally distributed and therefore analysed using parametric 
analyses; paired t tests were used for within-group analyses and unpaired t tests for between- 
group analyses. Visual analogue scores and cardiovascular parameters were compared using an 
Analysis of Variance (ANOVA). For these statistical tests p<0.05 was considered significant. 
The integrated area under the curve for incremental plasma insulin was calculated using the 
trapezoid rule. The measured analytes insulin, glucose, cholesterol, high-density cholesterol, 
ghrelin and PYY were compared within each group using paired t tests, incorporating a 
Bonferonni correction in order to account for multiple statistical tests. 
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3.4 Results 
3.4.1 Study 1: Subcutaneous Efficacy Study 
3.4.1.1 Energy Intake 
The energy intake at the study meal was decreased after intravenous or subcutaneous 
administration of oxyntomodulin when compared with saline administration (data from 
100nmol dose (n=2) and 150nmol dose (n=3) combined). Energy intake after saline 
administration was 846 ± 175 Kcal; whilst energy intake during oxyntomodulin infusion was 
791 157 Kcal and following a subcutaneous injection of oxyntomodulin was only 521 ±I IS 
Kcal (p=0.0394). Post-hoc testing demonstrated that the difference between groups was due to a 
significant difference between energy intake following administration of subcutaneous 
oxyntomodulin and saline (p<0.05). When each individual's energy intake was expressed as a 
percentage of their energy intake on the day saline was administered, intake was 94.6 ± 10.3% 
during intravenous oxyntomodulin administration and 68.5 ± 12.1% after subcutaneous 
oxyntomodulin administration (p=0.0394) (Figure 3.6). Post-hoc testing demonstrated that the 
difference between groups was due to a significant difference between energy intake following 
administration of subcutaneous oxyntomodulin and saline (p<0.05). 
Energy intake recorded by food diary was non-significantly reduced in the 24 hour period 
following oxyntomodulin administration compared to saline administration. Energy intake in 
the 24 hour period after saline administration was 5280 ± 758 Kcal, after intravenous 
oxyntomodulin administration was 4578 ± 749 Kcal and following subcutaneous 
oxyntomodulin administration was 4508 ± 888 Kcal (p=0.1242). When expressed as a 
percentage of energy intake on the day saline was administered, intake was 82.6 ± 7.5 after 
intravenous administration and 85.3 ± 5.0 % after subcutaneous administration, although this 
did not reach significance (p=O. 1242). ' 
There were no adverse events reported during the study period or abnormalities on 
electrocardiogram recording during the study day. 
3.4.1.2 Oxyntomodulin-like Immunoreactivity 
The mean baseline plasma OLI was 82.9 :L5.4 pmol/L. On the study day when saline was 
administered, post-prandial OLI levels increased to 120.9 ± 21.2 pmol/L (t--135). After 
administration of 100 nmol subcutaneous oxyntomodulin plasma OLI levels peaked at 239.6 ± 
31.4 pmol/L (t--60), whereas after administration of 150 nmol subcutaneous oxyntomodulin, 
OLI levels peaked at 310.9 :L 172.2 pmol/L (t--60). At the termination of the intravenous 
oxyntomodulin infusion plasma OLI levels peaked at 569.2 ± 76.4 pmol/L (t-- 105) (Figure 3.7) 
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Figure 3.6: energy intake at the study meal following intravenous or subcutaneous 
oxyntomodulin. Volunteers received saline (n=5), intravenous (IV OXM, n=5) or 
subcutaneous oxyntomodulin (SC OXM, n=5). The intake for the volunteers who 
received subcutaneous oxyntomodulin represents combined data from the 100nmol 
injection (n=2) and the 150nmol injection (n=3). Post-hoc testing demonstrated a 
significant difference between the energy intake following saline and subcutaneous 
oxyntomodulin administration (*p<0.05). 
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Figure 3.7: plasma oxyntomodulin-like immunoreactivity (OLI) following 
intravenous or subcutaneous oxyntomodulin. Intravenous oxyntomodulin (0 IV 
OXM, n=5) was commenced at time zero. Subcutaneous oxyntomodulin (A 100 
nmol SC OXM, n=2 or '7 150 nmol SC OXM, n=3) was administered at 45 
minutes. 
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3.4.2 Study 2: Pilot Investigation Of Repeated Subcutaneous Oxyntomodulin 
Administration In Healthy Overweight and Obese Volunteers 
3.4.2.1 Body-weight 
Repeated pre-prandial subcutaneous injection of oxyntomodulin over a four week period 
resulted in a 2.2 ± 0.8% reduction in body-weight; this did not reach significance when 
compared to the 1.2 ± 1.0% reduction observed in the control group over the four-week study 
period (p=0.4206). When expressed as an absolute value, the treatment group had a 2.0± 0.7 kg 
reduction in body-weight, compared to a 1.2 J: 1.0 kg reduction in the control group (P=0.4206) 
(Figure 3.8). 
3.4.2.2 Energy Intake 
A subcutaneous injection of oxyntomodulin injection reduced energy intake. The energy intake 
of the control group increased on successive study days: day 1 (562 ± 80 Kcal), day 2 (664 ± 
107 Kcal) or day 29 (886 ± 149 Kcal) (p=0.0046). Post hoc testing demonstrated that the 
significance was due to a difference between day I and day 29 (p<0.05). On day 1, when the 
treatment group self-administered a saline injection, energy intake (800 ± 250 Kcal) was not 
statistically different to the control group (p=0.8571). Energy intake at the subsequent meals 
was expressed as a percentage of each individual's intake on day 1; this method was intended to 
avoid bias due to any inter-individual variation in meal consumption. The control group and the 
treatment group both consumed more on day 2 and day 29. However, this effect was reduced in 
the group self-administering oxyntomodulin. The anorectic effect of oxyntomodulin did not 
reach significance on day 2 when compared to control (saline 117 ±- 4.2% versus oxyntomodulin 
112.4 ± 9.1 %, p=0.3429), but was significant on day 29 (saline 156.4 d: 7.5% versus 
oxyntomodulin 103.5 ± 1.4%, p=0.0286) (Figure 3.9). 
Thirty minutes after injection of saline or oxyntomodulin, there were no significant differences 
in the pre-prandial visual analogue scales for appetite. The change from baseline values after 
saline injection (day 1) or oxyntomodulin injection (day 2 and day 29) were similar for scores of 
hunger (day 1: +4 ±4 mm; day 2: +7 ±8 mm; day 29: +3 ±2 mm; p=O. 83 2 1), desire to eat (day 
1: +1 ±3 mm; day 2: 0±3 mm; day 29: +1 ±3 mm; p=0.8591), satiety (day 1: -13 ±8 mm; day 
2: +3 ±3 mm; day 29: +1 ±4 mm; p=0.3717) and prospective food consumption (day 1: +4 ±5 
mm; day 2: 0±I mm; day 29: +1 ±3 mm; p=0.328 1). 
There was no difference in the subjective scores of nausea recorded by the treatment group 
immediately pre-prandially after oxyntomodulin administration on day 2 and 29, when 
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compared to saline administration on day I (day 1: -1 ±I mm; day 2: -2 ±I mm; day 29: 2±2 
mm; p=0.1210). Neither was there any difference in post-prandial assessment of subjective 
palatability of the food between the control group and treatment group (day 2: 53 ±5 mm and 
53 ±7 mm respectively, p=0.6458; day 29: 48 ±8 mm and 47 ±7 mm respectively, p=0.7546). 
One subject in the oxyntomodulin treated group failed to complete the study meal protocol. This 
subject was excluded from food intake and appetite analysis prior to un-blinding. Thus study 
meal data was analysed with n=4 for the control group and n=3 for the treatment group. 
3.4.2.3 Oxyntomodulin-like Immunoreactivity 
Following administration of subcutaneous oxyntomodulin, plasma OLI increased to a pre- 
prandial peak of 632.9 ± 166.6 pmol/L, 15 minutes post-injection (Figure 3.10). In comparison, 
on the days that subjects self-administered saline, the mean baseline OLI level was 69.8 ± 11.2 
pmol/L and peak post-prandial level of OLI was 99.8 ± 21.4 pmol/L, 30 minutes after the study 
meal. 
3.4.2.4 Adverse Events 
During the study there were no significant side-effects reported. However, volunteers reported 
short-lived minor discomfort at the injection site immediately after administration of saline or 
oxyntomodulin. There were no changes in blood pressure or pulse rate recorded on the study 
day (data not shown). 
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Figure 3.8: change in body weight over the four-week study period (pilot study) 
after self-administration of subcutaneous saline (13 n=4) or 200 nmol 
oxyntomodulin (A n=4). There was no significant difference in body-weight after 
oxyntomodulin administration when compared to the control group. 
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Figure 3.9: energy intake at the study meal (pilot study) 30 minutes after self- 
administration of subcutaneous saline (n=4) or oxyntomodulin (OXM, n=4). The 
data for day 2 and day 29 was expressed as a percentage of each individual's 
energy intake on day 1, when all subjects self-administered a saline injection. The 
energy intake after an oxyntomodulin injection on day 29 was reduced when 
compared to saline treatment (*p=0.0286). 
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Figure 3.10: plasma oxyntomodulin-like immunoreactivity levels (OLI) (pilot 
study) following self-administration of saline (13, n=4) or 200 nmol oxyntomodulin 
(A, n=4). The time of injection was designated 0 minutes and the study meal was 
consumed at 30 minutes. 
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3.4.3 Study 3: Four-Week Pre-Prandial Subcutaneous Administration Of 
Oxyntomodulin In Healthy Overweight And Obese Volunteers 
3.4.3.1 Participant Flow 
Eighty-nine subjects were assessed for eligibility to the study. Thirty-three healthy subjects 
were eligible according to the study criteria. Fifty-six subjects were excluded either because of 
abnormal eating behaviour or co-existing health problems. Thirty-one subjects agreed to enter 
the study. Two subjects were excluded in the week prior to randomisation because of non- 
compliance with the 'run-in' protocol of subcutaneous saline injections. Twenty-nine subjects 
were randomised into the study phase, 16 within the treatment group and 13 within the control 
group. One female subject, randomised to the treatment group, withdrew at two weeks. Another 
female subject, randomised to the control group, withdrew at three weeks. Both these subjects 
cited a dislike of self-administering injections as their reason for withdrawal. A male volunteer, 
subject MB, was removed from the treatment group by the investigators after day 2 because of 
severe nausea post-injection. Thus, twenty-six subjects completed the entire four weeks 
injection period, 14 within the treatment group and 12 within the control group (Figure 3.11). 
3.4.3.2 Effect Of Oxyntomodulin On Body-Weight 
Repeated pre-prandial subcutaneous injection of oxyntomodulin resulted in a 2.4 ± 0.4% 
reduction in body-weight, compared to a 0.5 ± 0.6% reduction in the control group (p=0.0129) 
over the four week study period. This represented a significant weight loss of 2.3 ± 0.4 kg in the 
treatment group compared with 0.5 ± 0.5 kg weight loss in the control group (p=0.0 106) (Figure 
3.12). After two weeks of injections, interim data demonstrated a significant weight loss of 1.1 
± 0.3 kg in the treatment group (p=0.0343), increasing to 1.4 ± 0.4 kg after three weeks 
(p=0.0331). There was thus, on average, an additional 0.45 kg weight loss per week in the 
oxyntornodulin group. 
Over the study period, there was a change in adipose hormones in the treatment group consistent 
with a reduction in adipose tissue (Figure 3.13). At the start of the study, the plasma leptin and 
adiponectin levels in the control and treatment groups were not significantly different. In the 
treatment group the plasma leptin levels were reduced from baseline (325 ± 50 ng/ml) by 79 ± 
35ng/ml (or 19.5 +- 6.2 %), this change was significant when compared to the control group 
(p=0.0 185) (Table 3.1). The plasma adiponectin levels were increased from baseline (83.6 ± 9.5 
Vg/ml) by 8.3 ±4.3 pg/ml (or 9.4 ± 4.9 %) in the treatment group, this change was also 
significant when compared to the control group (p=0.0068) (Table 3.1). 
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3.4.3.3 The Effect of Oxyntomodulin On Energy Intake And Appetite 
A subcutaneous injection of oxyntomodulin reduced energy intake during the study meal. The 
energy intake of the control group was not significantly different on day 1 (716 ± 108 Kcal), day 
2 (660 ± 99 Kcal) or day 29 (711 ± 87 Kcal) (Figure 3.14A). On day 1, when the treatment 
group self-administered a saline injection, energy intake was not statistically different to the 
control group (678 ± 45 Kcal, p=0.7319). However, subjects that self-administered 
oxyntomodulin had significantly lower energy intake on day 2 (508 ± 46 Kcal, p=0.0007) and 
day 29 (428 ± 61 Kcal, p=0.0023), when compared to their energy intake on day I (Figure 
3.1413). The energy intake data for each participant was also expressed as a percentage of each 
individual's intake on day 1; intending to avoid any bias which may arise from inter-individual 
variation in food consumption. Thus, on day 2, the control group consumed 92.6 ± 3.8 % of 
their energy intake on day 1, whereas the treatment group consumed only 75.3 ± 5.3 % 
(p=0.0194). On day 29, the control group consumed 107.0 ± 7.7 % of their day I intake and the 
treatment group consumed 65.3 ± 9.2% (p=0.0030). There was no significant difference 
between the amount consumed on day 2 and day 29 in the treatment group (p=0.1480) or the 
amount consumed on day 2 and 29 in the control group (p=0.0938) (Figure 3.15). 
Thirty minutes after an oxyntomodulin injection, there were no significant differences in the 
pre-prandial visual analogue scores for appetite (Figure 3.16). The change from baseline values 
after saline injection (day 1) or oxyntomodulin injection (day 2 and day 29) were similar for 
scores of hunger (day 1: +3 ±5 mm; day 2: +5A: 2 mm; day 29: +4 ±4 mm; p=0.9032), desire 
to eat (day 1: -3 ±7 mm; day 2: +3 ±2 mm; day 29: -1 ±5 mm; p=0.7113), satiety (day 1: +1 ± 
4 mm; day 2: +4± 4 mm; day 29: -1 ±4 mm; p=0.6446) and expected food consumption (day 1: 
0±3 mm; day 2: +5 ±2 mm; day 29: 6±4 mm; p=0.2123). The visual analogue scales did 
record a reduction in subjective appetite after the variable energy intake at the study meal 
(Figure 3.16). 
There was no significant difference in nausea scores after an injection of oxyntomodulin. The 
change from baseline values after saline injection (day 1) or oxyntomodulin injection (day 2 and 
day 29) were similar immediately prior to the study meal (day 1: +2 ±2 mm; day 2: +8 ±5 mm; 
day 29: 17 ±- 7 mm; p=O. 1065) or over the 240 minute study period (day 1: mean saline -6 ±2 
min. versus oxyntomodulin -3 ±2 mm, p=0.4378; day 2: mean saline -3 ±I mm versus 
oxyntomodulin -3 ±2 mm, p=0.8541; day 29: mean saline 0±I mm versus oxyntomodulin +3 
±2 mm, p=0.2857). 
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There was no significant difference in the post-prandial assessment of food palatability by the 
control group (day 2: 44 +- 6 mm, day 29: 48 ±8 mm, p=0.8968) and the treatment group (day 2: 
43 ±5 mm, day 29: 44: L 7 mm, p=0.7725). 
Only two subjects in each group failed to complete the study meal protocol. These subjects did 
not consume the same food type at each study meal. In the interest of accuracy, these subjects 
were excluded from energy intake and appetite analysis prior to un-blinding of the data. Thus, 
the study meal data was analysed with n--10 for the control group and n=12 for the treatment 
group. 
3.4.3.4 Plasma Levels Of Oxyntomodulin 
Following an injection of 400 nmol oxyntomodulin, plasma OLI increased to a peak of 991.7 
161.0 pmol/L at 30 minutes. This was greater than the pre-prandial peak of 632.9 J: 166.6 
pmol/L achieved in Study 2 following an injection of 200 nmol oxyntomodulin (Figure 3.17). In 
comparison, on the days that subjects administered saline, mean baseline level of OLI was 56.0 
± 8.3 pmol/L and peak post-prandial level of OLI was 83.5 ± 9.5 pmol/L at 240 minutes. 
Gel permeation chromatography (Murphy et al., 2000) demonstrated a single immunorcactive 
peak eluting at the same position as synthetic oxyntomodulin, in plasma samples taken 30 and 
90 minutes after an oxyntomodulin injection (Figure 3.18). Thus, separation by size exclusion 
chromatography indicated the measured OLI was indeed whole sequence synthetic 
oxyntomodulin. Assessment of in vivo antibody formation demonstrated no evidence of 
antibody formation to oxyntomodulin in the volunteers' plasma samples at the end of the four- 
week administration period. 
3.4.3.5 Hormone Levels, Lipids And Glucose 
The control and treatment group had similar baseline levels of insulin, glucose, cholesterol, high 
density lipoprotein, ghrelin and PYY (Table 3.0). 
Thirty minutes after subcutaneous administration of oxyntomodulin there was a significant 
increase in pre-prandial insulin levels, which was small compared to the effect of meal ingestion 
and insufficient to affect plasma glucose levels (Table 3.2). This pre-prandial stimulatory effect 
on insulin was present on both day 2 and day 29 (Figure 3.19). However, over the entire study 
period, the area under the curve for the incremental insulin level in the treatment group was 
non-significantly lower on day 2 (18.0: h 0.9 nmol. min/L, p=0.1378) and significantly lower on 
day 29 (14.9 ± 0.7 nmol. minAL, p=0.0398) over the four hour post-injection period, compared to 
the day saline was administered (day 1: 21.6 ± 1.1 nmol. min/L). The injqction of oxyntomodulin 
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did not significantly affect plasma levels of PYY or ghrelin 30 minutes after injection (Table 
3.2). 
Four-week oxyntomodulin treatment did not change pre-injection baseline values of insulin, 
glucose, cholesterol, high-density cholesterol, ghrelin or PYY, when compared to the control 
goup (Table 3.1). 
3.4.3.6 Cardiovascular Parameters 
Observations of pulse rate and blood pressure over the 240 minute study period were not 
significantly different after an injection of saline or oxyntomodulin (Figure 3.20). Compared to 
day I when the volunteers administered saline subcutaneously, there was no effect of 
oxyntomodulin administration on pulse rate (p=0.9815), systolic blood pressure (p=0.5150) or 
diastolic blood pressure (p=0.7772) in the treatment group. 
3.4.3.7 Adverse Events 
Short-lived minor discomfort at the site of injection was reported by 8/14 of the subjects in the 
treatment group and 5/12 of the control group. In total, 6.9% of all oxyntomodulin injections 
and 6.6% of all saline injections were reported to cause minor discomfort; thus, in this study 
discomfort did not appear related to the substance injected (p=0.7199). 
Oxyntomodulin injections were reported to be associated with transient mild nausea on 3.1 ± 
5.2% of occasions, compared to 0.2 ± 0.5% of all saline injections (p=0.0389). This data 
included subject EM, who experienced nausea associated with 13 of the first 47 injections. The 
dose subject EM self-administered was halved and the incidence of nausea decreased to two out 
of the remaining 37 injections. On day 29, EM had a peak OLI level of 868.4 pmol/L at 60 
minutes, compared to the mean peak for the group of 991.7 ± 161.0 pmol/L, despite 
administering half the dose of oxyntomodulin. A second subject MB was removed from the 
treatment group after day 2 and was not included in any analysis; after each of the initial three 
oxyntomodulin injections, subject MB had significant nausea which interfered with his daily 
activities. This subject's plasma OLI levels peaked at 2140 pmol/L, 15 minutes post-injection, 
and were significantly higher than the rest of the treatment group over the entire 4 hour study 
period (P<0.0001). Another subject regularly experienced nausea for two days mid-menstrual 
cycle and this data was included in the treatment group data in the interest of stringency. 
The incidence of all other reported adverse events was less than 2% and not significantly 
different between the treatment and control groups. 
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3.4.3.8 Follow-Up Data 
Two weeks after the end of the study phase, the treatment group had gained 1.1 ± 0.4kg. The 
control group gained 0.5 ± 0.2kg and were no different from their initial weight. The difference 
in weight loss between the control and treatment group was no longer significant two weeks 
after terminating self-injection (p=0.1339). One subject in the control group, and one in the 
treatment group were lost to follow-up after the end of the trial, therefore, the follow-up data 
was analysed with n=l I in the control group and n=13 in the treatment group. 
3.4.3.9 Intention To Treat Analysis 
An intention to treat analysis was performed for all volunteers randomised into the study phase 
within the treatment group (n=16) and placebo group (n=13). The last recorded weight for each 
of the discontinued subjects was used as their final weight. This analysis also demonstrated a 
significant reduction in body-weight following chronic oxyntomodulin administration. 
Oxyntomodulin administration resulted in a 2.0 ± 0.4 kg reduction in body-weight, compared to 
a 0.4 ± 0.5 kg reduction in the control group (p=0.0 199) over the four-week study period. 
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Figure 3.11: participant flow during the four-week pre-prandial subcutaneous 
administration of oxyntomodulin in healthy overweight and obese volunteers. 
89 people reviewed 
for entry to the study 
33 healthy people eligible 1 156 people ineligible due to 
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I healthy obese volunteen 
consented to enter the trial 
2 subjects non-compliant 
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16 subjects entered 14 il 13 subjects entered 
treatment group I, control group 
Subject MB discontinued I subject discontinued 
due to adverse effects and lost to follow-up 
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(12 for energy intake data) 
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at follow-up 
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Figure 3.12: change in body-weight during the four-week pre-prandial 
subcutaneous administration of oxyntomodulin in healthy overweight and obese 
volunteers. In the control group (n=12) there was a 0.5 ± 0.5 kg weight loss over the 
four-week study period. In the treatment group (n=14), a significant weight loss of 
1.1 ± 0.3 kg was observed after two weeks of injections (*p=0.0343). This loss 
increased to 1.4 ± 0.4 kg after three weeks of injections (*p=0.0331). A total weight 
loss of 2.3 ± 0.4 kg was observed by the end of the four week study period 
(**p=0.0106). 
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Figure 3.13: change in plasma leptin and adiponectin during the four-week pre- 
prandial subcutaneous administration of oxyntomodulin in healthy overweight and 
obese volunteers. In the treatment group (n=14), adiponectin levels were increased 
from baseline by 8.3 ±4.3 pg/ml (**p=0.0068, compared with control, n=12) and 
leptin levels were reduced from baseline by 79 ± 35ng/ml (*p=0.0185, compared 
with control, n=12). 
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Figure 3.14: energy intake (kcal) at the study meals during the four-week pre- 
prandial subcutaneous administration of oxyntomodulin in healthy overweight and 
obese volunteers. On day 1, all subjects administered saline. On day 2 and day 29, 
the control group (n=10) administered saline and the treatment group (n=12) 
administered oxyntomodulin. Graph (A) shows the energy intake (Kcals) for the 
control group (n=10). Graph (B) shows the energy intake (Kcals) for the treatment 
group (n=12) (****p=0.0007 and ***p=0.0023). 
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Figure 3.15: energy intake (%) during the four-week pre-prandial subcutaneous 
administration of oxyntomodulin in healthy overweight and obese volunteers. 
Energy intake is given for the control group (n=10) and treatment group (n=12) at 
the study meals on day 2 and day 29. Data is expressed as a percentage of each 
subject's energy intake on day 1, when all participants self-administered a saline 
injection. The treatment group had a significantly lower percentage energy intake 
after an injection of oxyntomodulin. On day 2 and day 29, this represented a 25 ±5 
% and a 35 ±9% reduction, respectively, when compared to the initial study meal. 
(*p=0.0194, ***p=0.0030, compared to the control group). 
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Figure 3.16: subjective measures of appetite during the four-week pre-prandial 
subcutaneous administration of oxyntomodulin in healthy overweight and obese 
volunteers. Appetite scores are shown after administration of saline (day 1: 13) or 
400nmol oxyntomodulin (day 2: L/ dotted line; day 29: V/ solid line) in the 
treatment group (n=12). Figures a-d show the change from baseline values of 
visual analogue scores for appetite. Subjects recorded their subjective assessment 
in response to a questionnaire asking (A) 'How Hungry do you feel? ', (B) 'How 
pleasant would it be to eat? ', (C) 'How full do you feel? ' and (D) How much do you 
think you can eat? '. The injection was administered at 0 minutes and the study 
meal was provided at 30 minutes. There was no significant difference in scores of 
appetite after an injection of oxyntomodulin or saline. 
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Figure 3.17: oxyntomodulin-like immu no reactivity (OLI) levels after self- 
administration of subcutaneous oxyntomodulin during the four-week study in 
healthy overweight and obese volunteers. OLI is shown for the treatment group on 
day 1, after self-administration of saline (day 1: [1, n=14) or 400 nmol 
oxyntomodulin (day 29: V, n=14). OLI is also shown for the pilot study after self- 
administration of 200 nmol oxyntomodulin (-L, n=4). The time of injection was 
designated 0 minutes and the study meal was consumed at 30 minutes. 
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Figure 3.18: sephadex G-50 column chromatography of plasma 30 and 90 minutes 
after subcutaneous oxyntomodulin injection. Plasma from three subjects (A, B and 
Q was fractionated 30 minutes after injection of 400nmol oxyntomodulin (A / 
solid line) and 90 minutes post-injection (L / dotted line). Separation by size 
exclusion chromatography indicated the measured OLI was whole sequence 
synthetic oxyntomodulin, as the samples eluted at a position corresponding to the 
standard (0 / solid line), K., =0.61. 
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Figure 3.19: plasma insulin levels during the four-week pre-prandial subcutaneous 
administration of oxyntomodulin in healthy overweight and obese volunteers. The 
graph shows insulin levels for the treatment group (n=14) after subcutaneous 
injection of saline (day 1: 13) or 400nmol oxyntomodulin (day 2: 'L / dotted line; 
day 29 V/ solid line). The time of injection was designated 0 minutes and the study 
meal was consumed at 30 minutes. After oxyntomodulin injection there was a 
small but significant rise in pre-prandial insulin (*****day 2,15 minutes p=0.0003, 
30 minutes p=0.0004; ***day 29,15 minutes p=0.005,30 minutes p=0.0008) when 
compared to saline injection. 
Injection Meal 
E6 
"- - 
- 
3 
1 
ay 
Day 2 
Day 29 
-30 0 15 30 
Time (minutes) 
160 
Figure 3.20: cardiovascular parameters during the four-week pre-prandial 
subcutaneous administration of oxyntomodulin in healthy overweight and obese 
volunteers. Pulse rate, systolic and diastolic blood pressure in the treatment group 
(n=14) after subcutaneous injection of saline (day 1: 13) or 400nmol oxyntomodulin 
(day 2: L/ dotted line; day 29 V/ solid line) are shown. The time of injection was 
designated 0 minutes and the study meal was consumed at 30 minutes. After 
oxyntomodulin injection there were no significant changes in cardiovascular 
parameters. 
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Table 3.0: the demographic and baseline plasma levels of the control and treatment 
groups prior to the start of the study period. An unpaired t test was used to compare 
values between the two groups. 
PARAMETER CONTROL GROUP 
(N=12) 
TREATMENT GROUP 
(N=14) 
p value 
BMI (k g/M2) 32.8 ± 0.9 33.7 ± 0.9 0.467 
Age (years) 35.0 ± 2.0 32.511.8 0.3573 
Height (metreoN 1.64 ± 0.03 1.67 ± 0.02 0.3453 
Weight (kg) 89.0 ± 4.7 94.6 ± 3.4 0.3300 
Sex II females: I male II females: 3 males - 
Leptin (ng/ml) 283 ± 24 325 50 0.4561 
Adiponectin (pg/ml) 111.4 ± 11.3 83.6 9.5 0.0707 
Insulin (pmol/L) 26.7 ± 8.5 34.5 4.7 0.4151 
Glucose (mmol/L) 4.61 ± 0.09 4.76 0.11 0.3430 
Cholesterol (mmol/L) 4.71 ± 0.26 4.66 ± 0.19 0.8820 
HDL (mmol/L) 1.07 ± 0.06 1.12 ± 0.09 0.6747 
Ghrelin (pmol/L 493 87 371 65 0.2627 
PYY (pmol/L) 11.8 1.6 12.2 2.1 0.8881 
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Table 3.1: the chronic response of pre-injection analytes after 4 weeks of self- 
administration of either saline (n=12) or oxyntomodulin (n=14). An unpaired t test is 
used to compare the change in the control group with the change in the treatment 
group. *p value reaches significance. 
ANALYSIS CONTROL GROUP TREATMENT GROUP p value 
(N=12) (N=14) 
Initial value A Initial value A 
Leptin 283 ± 24 +31 ± 25 325 50 -79 ± 35 0.0185* 
(ng/ml) 
Adiponectin 111.4± 11.3 -7.6± 3.0 83.6 9.5 +8.3 ±4.3 0.0068* 
(m/ml) 
Insulin 26.7 ± 8.5 -1.1 ± 5.4 34.5 4.7 -7.8 ± 4.4 0.3394 
(pmol/L) 
Glucose 4.61 ± 0.09 +0.21 0.09 4.76± 0.11 +0.12 0.08) 0.4111 
(mmol/L) 
Cholesterol 4.71 ± 0.26 -0.26 0.15 4.66 ± 0.19 -0.15 0.11 0.5154 
(mmol/L) 
HDL 1.07 ± 0.06 -0.01 0.03 1.12 ± 0.09 -0.02 0.03 0.8459 
(mmol/L) 
Ghrelin 493 =L 87 +47 ± 58 371 65 +35 ± 44 0.8586 
(pmol/L 
PYY 11.8 ± 1.6 -2.6 ± 1.5 12.2 2.1 -0.6 ± 1.6 0.3651 
(Pmon) I I I I 
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Table 3.2: the acute response of analytes to injection of saline or oxyntomodulin within 
the treatment group (n=14). A paired t test is used to compare the change from baseline 
30 minutes after an injection of oxyntomodulin, with the change on day 1 when the 
treatment group injected saline. *P value reaches significance. 
ANALYSIS TREATMENT GROUP (N=14) 
Day I (Saline) Day 2 (OXM) Day 29 (OXM) 
Initial A Initial A p value Initial p value 
value value value 
Insulin 34.5 -6.1 27.4 +32.6 0.0004* 26.7 +40.5 0.0008* 
(pmol/L) ±4.7 ± 3.2 ±3.6 ± 7.7 ±4.3 ± 10.1 
Glucose 4.79 -0.04 4.73 +0.07 0.3000 4.88 +0.02 0.6629 
(mmol/L) ± 0.09 ± 0.06 ± 0.10 ± 0.08 ± 0.09 ± 0.07 
Ghrelin 370 -5 375 -42 0.3429 405 -49 0.2327 
(pmol/L) ± 65 ± 23 ± 74 ± 35 ± 86 ± 22 
pYY 12.2 +1.1 15.2 -3.5 0.3377 12.1 -2.6 0.1637 
(pmol/L) 2.1 2.2 4.4 4.1 1.6 1.3 
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3.5 Discussion 
The preliminary study investigated the potential efficacy of treatment with subcutaneous 
oxyntomodulin and compared it to an intravenous infusion. Following the subcutaneous 
administration of oxyntomodulin, plasma OLI levels reached approximately half that of those 
achieved during intravenous infusion. Despite this, intravenous oxyntomodulin did not 
significantly change energy intake at the study meal, whereas subcutaneous oxyntomodulin had 
a significant anorectic effect at the study meal. Data collected during the 24 hours following 
administration of oxyntomodulin suggested that there may be an anorectic effect of both 
intravenous and subcutaneous oxyntomodulin, although this did not reach significance. It would 
be expected that higher levels of plasma oxyntomodulin would reduce food intake to a greater 
extent. However in this preliminary study, there was a lack of correlation between plasma OLI 
levels achieved by different routes of administration and the reduction in energy intake. This is 
likely to reflect the small number of participants combined with a non-specific intra-individual 
variation in energy intake at the study meal on different study days. 
Conservative interpretation of these finding suggested that subcutaneous oxyntomodulin could 
reduce food intake in overweight and obese volunteers. I therefore proceeded to undertake a 
pilot study in eight overweight volunteers to investigate the effect of repeated administration of 
oxyntomodulin on body-weight. A dose of 200 nmol was chosen in order to achieve plasma OLI 
levels more comparable to those previously quoted as effectively reducing food intake in normal 
weight subjects. I postulated that this larger dose would result in higher circulating levels and a 
greater anorectic effect, whilst plasma levels would still remain within known well-tolerated 
limits. 
A 200 nmol dose of subcutaneous oxyntomodulin was safely and effectively self-administered 
over four weeks within the community. Body-weight was reduced in the treatment group after 
four weeks. However, the magnitude of weight loss was not significantly greater than the weight 
loss observed in the control group (saline 1.2 ± 1.0 kg versus oxyntomodulin 2.0 ± 0.7 kg). The 
degree of weight loss observed in the control group was largely due to one subject. This subject 
was unexpectedly bereaved at the start of the study period, and proceeded to lose 3.4 kg in the 
first week post-randomisation and a total of 4.2 kg over the four-week study period. This 
volunteer was retained in the analysis in the interest of stringency. Although the change in body- 
weight was not statistically significant, the treatment group appeared to lose weight at a 
consistent rate of approximately 0.5 kg per week over the four-week study period. 
Energy intake at each study meal showed a tendency to increase over the course of the four- 
week study. This increase is likely to be a result of the participants becoming acclimatised to the 
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environmental conditions. It has been established that this habituation phenomenon is an 
important factor in the response to gut hormones in rodent models of appetite (Abbott et al., 
2005c; Tschop et al., 2004), and I observed a similar effect in a study of the orexigenic hormone 
ghrelin in patients with end-stage kidney disease (Wynne et al., 2005). In the pilot study, on day 
29, following weekly attendances at the research centre and two previous study meals, the 
energy intake in the control group increased considerably. In comparison, the participants' 
energy intake on day 29 after an injection of oxyntomodulin was significantly lower as a 
percentage of their baseline value. This suggests that subcutaneous oxyntomodulin may reduce 
food intake, an effect which is retained at the end of the four-week administration period. 
Energy intake at an early morning study meal was a primary endpoint in the pilot study. The 
timing of the study meal was designed in order to diminish the duration of time volunteers spent 
in the research centre. However, previous published studies have used energy intake at a 
lunchtime meal to measure the effect of gastrointestinal hormones on appetite (Batterham et al., 
2002; Batterharn et al., 2003a; Wren et al., 2001a; Wynne et al., 2005; Batterharn et al., 2003b). 
As energy intake is habitually less at breakfast in comparison to lunch and dinner, the effect of 
any appetite suppressant may be less apparent at an early morning mealtime. This may 
contribute to the absence of an anorectic effect observed in this pilot study following an 
oxyntomodulin injection on day 2. 
The small pilot study, although not achieving statistically significant weight loss, provided some 
evidence that a larger study may demonstrate a weight-reducing effect of oxyntomodulin. I 
therefore proceeded to perform a larger study using a modified protocol. In this clinical trial I 
altered the protocol to measure energy intake at a lunchtime study meal. In addition, I increased 
the dose of oxyntomodulin administered. A subcutaneous dose of 200 nmol oxyntomodulin 
resulted in plasma OLI levels of 632.9 ± 166.6 pmol/L. Although this was greater than the 
levels achieved by the smaller doses used in the initial study of efficacy, levels remained lower 
than the previously reported intravenous study of normal weight volunteers (907 ± 32 pmol/L) 
(Cohen et al., 2003). Thus, I postulated a further dose increase may more successfully mimic 
these plasma levels. The dose of subcutaneous oxyntomodulin was therefore increased to 400 
nmol following successful administration to two further volunteers. 
Self-administration of 400 nmol oxyntomodulin by subcutaneous injection effectively reduced 
body-weight by 2.4% over a four-week period in the double-blind randomised-controlled study 
of 26 healthy overweight and obese volunteers. The accompanying reduction in leptin and 
increase in adiponectin suggested that this weight loss was at least partly due to a reduction in 
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adipose tissue. Oxyntomodulin also successfully reduced food intake by a significant amount, 
with preservation of sub ective food palatability in the volunteers. j 
The plasma OLI levels achieved by subcutaneous injection were similar to those achieved by an 
intravenous infusion of 3.0 pmol/kg/min in a study which reduced food intake by 19.3% in 
normal weight subjects (Cohen et al., 2003). This anorectic effect is comparable with the effect 
observed in overweight subjects in the current study. This suggests that oxyntomodulin has an 
equipotent anorectic effect in normal weight and overweight subjects, and that obesity does not 
confer resistance to the anorectic effect of oxyntomodulin. 
A recent human intravenous infusion study demonstrated no effect of oxyntomodulin on insulin 
or glucose levels in normal weight humans (Cohen et al., 2003). In the current study, there was 
no evidence of a post-prandial incretin effect. However, there was an increase in pre-prandial 
plasma insulin after oxyntomodulin injection. This pre-prandial increase was considerably 
smaller than that occuff ing post-prandially in response to the study meal and proved insufficient 
to alter plasma glucose levels. GLP-1 has a powerful incretin effect (Kreymann et al., 1987; 
Edwards et al., 1998). Indeed, GLP-1, whilst improving glucose tolerance when given to 
diabetic subjects (Zander et al., 2002), can cause hypoglycaernia in non-diabetic subjects 
(Edwards et al., 1998). To specifically examine the incretin effect of oxyntomodulin, a further 
experiment would be required in which volunteers ingested a study meal of fixed quantities 
prior to measurement of plasma insulin. In the current study, the total area under the curve for 
the incremental insulin level was lower after an injection of oxyntomodulin. However, this 
effect was probably secondary to the anorectic effect of oxyntomodulin at the study meal. Thus, 
any measurement of post-prandial insulin was confounded because of the effect of nutrient 
ingestion on pancreatic insulin secretion. 
There was no evidence of a change in baseline insulin, glucose or lipid levels over the four- 
week study period in this group of healthy obese subjects. Further longer-term studies would 
assess to what degree the weight loss resulting from oxyntomodulin administration may lead to 
an improvement in metabolic parameters in obese subjects. 
The current study did not demonstrate a significant acute effect of oxyntomodulin on the 
circulating level of the orexigenic hormone ghrelin. It has previously been suggested that a 
proportion of the anorectic effect of intravenously administered oxyntomodulin is secondary to 
a suppressant effect on ghrelin (Cohen et al., 2003). However, this does not seem a probable 
mechanism for the dose administered subcutaneously in the current study. Neither does 
167 
oxyntomodulin appear to exert an anorectic effect via an alteration in the levels of circulating 
PYY. 
The decrease in body-weight during oxyntomodulin treatment was secondary to a significant 
reduction in energy intake. This reduction in energy intake was likely to be due to a reduction in 
appetite, as there was preservation of food satisfaction and therefore no evidence of taste 
aversion. Indeed a previous study has demonstrated administration of intravenous 
oxyntomodulin reduces pre-prandial hunger scores in normal weight humans (Cohen et al., 
2003). However, the current study did not demonstrate a change in subjective appetite scores 
prior to the meal following a subcutaneous injection of oxyntomodulin. This may reflect a 
perception of early satiety rather than reduced pre-prandial appetite, or alternatively a failure of 
the visual analogue scores as a sensitive tool of appetite measurement. 
The self-administration of subcutaneous oxyntomodulin was well-tolerated by the subjects and 
good compliance rates were achieved. This was a fixed initial dose study, and perhaps a dose of 
400 nmol oxyntomodulin may not be the optimal dose for all subjects. Indeed, after dose 
reduction, subject EM experienced weight loss with a low incidence of nausea. Subject MB 
demonstrated extremely high plasma OLI levels after a 400 nmol oxyntomodulin injection and 
experienced significant nausea. These subjects may have absorbed oxyntomodulin more rapidly 
or metabolised the peptide more slowly; larger groups studies are needed to assess if this was an 
idiosyncratic response. Studies of the absorption and breakdown kinetics of oxyntomodulin 
could further elucidate inter-individual variations. Conversely, the dose of oxyntomodulin 
administered in the current study may be sub-maximal for many subjects; higher doses of 
peptide may be well-tolerated and result in greater body-weight loss. 
The administration of oxyntomodulin could be an effective long-term treatment for obesity. The 
rate of weight loss achieved by subcutaneous oxyntomodulin is several times that of treatments 
such as orlistat, sibutrarnine and rimonabant. A recent meta-analysis demonstrated that a 
combination of orlistat and calorie-restricted diet resulted in a mean weight loss of 2.75 kg at 
one year, and sibutramine in combination with diet resulted in a mean weight loss of 4.45 kg at 
one year (Li et al., 2005). A recent review suggested that rimonabant (20mg) in combination 
with diet produced an additional 4.9 kg weight loss over one year (Curioni and Andre, 2006). In 
comparison, oxyntomodulin resulted in a mean weight loss of 2.3 ± 0.4 kg over a four-week 
period without dietary intervention. 
The reduction in energy intake observed at the end of the study was statistically no different to 
the reduction on day 2, indicating that the anorectic efficacy of oxyntomodulin was maintained 
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over time. In addition, the rate of weight loss was consistent over the four-week study period. 
Oxyntomodulin levels are increased in patients who have had jejunoileal bypass surgery (Holst 
et al., 1979; Sarson et al., 198 1). This sustained elevation of plasma oxyntomodulin may be one 
of the factors leading to successful permanent weight reduction in these patients. Together, this 
suggests that administration of oxyntomodulin beyond the four-week study period may be 
expected to result in continued weight loss; particularly as there was no evidence of antibody 
formation to the peptide. However, this data is limited by small sample size and the four-week 
duration of the study. 
Longer-term clinical trials involving larger numbers of participants are now required in order to 
investigate the long-term efficacy of oxyntomodulin as an anti-obesity therapy. One factor 
which might limit the use of oxyntomodulin as a treatment for obesity is the amount of peptide 
required per dose. Future work investigating the efficacy of oxyntomodulin analogues, designed 
to be more potent and resistant to breakdown than oxyntomodulin, may be necessary before this 
gut peptide can be exploited as a viable therapy. 
In summary, subcutaneous self-administration of oxyntomodulin three times daily in the 
community reduced energy intake, body-weight and reduced leptin and increased adiponectin 
levels in healthy overweight human subjects. The anorectic effect was well maintained over the 
four-week study period. Available pharmacological agents licensed for weight reduction therapy 
have limited efficacy (Finer, 2002). Several drugs currently in development affect widely 
distributed central neurotransmitter systems and may therefore have a broad spectrum of side- 
effects. Mimicking post-prandial satiety by administration of a natural post-prandial hormone 
such as oxyntomodulin may provide a more specific treatment for obesity. 
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Chapter 4 
The Effect Of Oxyntomodulin On 
Energy Expenditure In Humans 
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4.1 Introduction 
Energy homeostasis is maintained by the balance between energy intake and energy 
expenditure. Endogenous peripheral signals of nutrition act in the hypothalamus to influence 
both food intake and energy usage in order to maintain body-weight. However, a combination of 
over-eating and low physical activity levels contribute to an imbalance which results in weight- 
gain in the current obesigenic environment (Ravussin and Bogardus, 2000; Weinsier et al., 
1998). An anti-obesity treatment which both reduces energy intake and increases activity is 
more likely to be a successful long-term therapy for obesity. 
4.1.1 Components Of Energy Expenditure In Humans 
Energy expenditure can be partitioned into resting energy expenditure, incorporating both basal 
metabolic rate and the thermic effect of food, and activity-related energy expenditure 
(Castaneda et al., 2005). 
Basal metabolic rate is defined as the energy expenditure of a subject lying at physical and 
mental rest, in a thermo-neutral environment, after a 12 hour fast. Measurements of basal 
metabolic rate should be made in the early morning, before any physical activity and without the 
influence of stimulants such as caffeine or nicotine. If these conditions are not met, then a 
resting measurement may be termed resting energy expenditure. Post-prandial thermogenesis 
represents the energy used for digestion, absorption, transport and storage of nutrients, as well 
as any increase in activity or arousal associated with eating. The thermic effect of food results in 
a small increase in energy expenditure over several hours and accounts for approximately ten 
percent of total energy expenditure in man (McNeill, 2000). 
Activity-related energy expenditure comprises of the energy of exercise and non-exercise 
activity thermogenesis (NEAT). For the majority of the world's population volitional exercise is 
negligible and NEAT is the main contributor to activity-related energy expenditure (Levine et 
al., 2006). 
There is a wide inter-individual variation in the energy expended for a given activity due to 
factors such as level of fitness and proficiency. For this reason energy expenditure can also be 
described relative to the baseline levels for each individual. Energy expenditure can be 
expressed as 'metabolic bands' (METS), multiples of the individual's basal metabolic rate or 
resting energy expenditure, which gives an indication of the intensity of activity. Various 
activities have been ascribed WETS ratings', assuming an average resting metabolic rate. For 
example, I MET is expended during quiet sitting, 2 METS on standing, 2.5 METS during light 
household tasks or walking at two miles per hour, 8 METS during cycling and 18 METS 
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running at ten miles per hour (Ainsworth et al., 2000). Activity-related energy expenditure can 
also be expressed as a physical activity level (PAL) which is a ratio relating each individuals 
total energy expenditure to their resting energy expenditure. The expression of energy 
expenditure as PAL provides a convenient was of controlling for age, sex, body-weight and 
body composition. In general, a PAL of 1.2 indicates the lowest level of physical activity, whilst 
1.6-1.7 indicates little or no strenuous activity and a level greater than 2.0 indicates strenuous 
activity or exercise (Black et al., 1996). 
4.1.2 Measurement Of Energy Expenditure In Humans 
4.1.2.1 Physical Activity Questionnaires 
Estimations of activity by completion of a questionnaire are easily administered and have a low 
participant burden, but are poor at estimating energy expenditure on the individual level. This 
inaccuracy is likely due to a combination of recall bias and errors of analysis (Wareham et al., 
2002; Albanes et al., 1990) 
4.1.2.2 Calorimetry 
Direct calorimetry measures energy expenditure using a large chamber designed to measure 
body-heat emission. Although this method is accurate, it is technically difficult as all parts of 
the chamber must be sensitive to heat transfer and there must be no extraneous source of heat. 
As the technique is dependent on the volunteer's body-temperature being constant, 
measurements must be taken over several hours (McNeill, 2000). 
Indirect calorimetry measures energy expenditure using a calculation based on breath-by-breath 
expired gas exchange. In the laboratory, ventilated open-circuit calorimeters are most often 
used. Expired air is collected by means of a face mask, ventilated hood system or whole-body 
ventilated chamber. After the air is mixed, the rate of flow is measured and 02 and/or C02 
concentrations determined. Basal metabolic rate can be measured with effors of < 1%, using a 
high-precision, validated, indirect calorimeter (Donahoo et al., 2004). Calorimetry has a limited 
application for the measurement of normal activity, as subjects must be confined for the 
measurement duration and so cannot perform their usual daily activities (Sun et al., 1994; 
Ravussin et al., 1986). However, this method is a well-established technique for the 
measurement of resting energy expenditure. 
Indirect calorimetry is based on the fact that the oxidation of food consumes oxygen and 
generates carbon dioxide in proportion to the amount of heat generated: 
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C6HI206 + 602 
180g 6x 22.4 L 
6CO2 
6x 22.3 L 
6H20 + Heat 
6x 18g 2.78 MJ 
If Ig of glucose is oxidised, the energy released as heat is 15AU (2780/180) and each litre of 
oxygen consumed is equivalent to the production of 20.7 U (2780/6 x 22.4) of heat. Thus, if the 
amount of oxygen used can be measured, the amount of heat produced or energy expended, can 
be calculated. Similar equations can be written for the oxidation of protein and fat which show 
the amount of energy expended per litre of oxygen used are 19.8 and 19.3 U respectively. The 
respiratory quotient (RQ), defined as the ratio of the volume Of C02 produced to the volume of 
02 consumed, gives an indication of the type of fuel metabolised; the value for carbohydrate is 
approximately 1.0, while that for fat is 0.7 and protein 0.81. Therefore, an equation 
incorporating the volume of oxygen consumed and respiratory quotient can be used to 
accurately derive energy expenditure (Brockway, 1987; Cunningham, 1990; Elia and Livesey, 
1992): 
Energy expenditure = 1.32 X V02 x (1.23xRQ+3.81) 
4.1.2.3 Doubly-labelled Water 
The doubly-labelled water technique (Schoeller and van, 1982; Black et al., 1996; Coward et al., 
1988) provides information on the total energy expended by a free-living individual over a 
period of 10-20 days. The volunteer takes an oral dose of water containing a known amount of 
stable (non-radioactive) isotopes of hydrogen and oxygen. Time is allowed for complete mixing 
of isotopes to occur within the body water space and then samples of urine, saliva or blood are 
collected. These samples are used for measurements of 2H and 0'8 enrichment using mass 
spectroscopy. 
The isotopes 2H (deuterium) and 180, mix with hydrogen and oxygen in body water within 
hours. As energy is expended, C02 and water are produced. The C02 is expired during 
ventilation, whereas water is lost during ventilation, urination, perspiration and evaporation. As 
180 is contained in both C02 and water, it is lost from the body more rapidly than 2 H, which is 
contained only in water. The difference between the rates of loss of 2H and "0 reflects the rates 
at which C02 is produced, which in turn can be used to accurately estimate energy expenditure 
using indirect calorimetry formulae, if a value of RQ is assumed. 
Although the doubly-labelled water technique is currently the gold standard for the 
measurement of total energy expenditure, precision is relatively poor (8-9%) and consequently 
the method is not yet sufficiently refined to provide estimates of individual energy expenditures. 
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Furthermore, only an average value over the time course of the experiment is obtained and the 
relative contribution of resting and activity-related energy expenditure must be estimated. 
Subcomponents of activity-related energy expenditure such as frequency and intensity cannot be 
quantified by this method (Speakman, 1998). 
4.1.2.4 Energy Expenditure Derived From Heart Rate And Movement 
Parameters 
Heart rate and movement sensors are primarily used to measure physical activity intensity and 
can do so with a high time resolution. Individual measurements of either parameter alone are 
compromised: movement has a variable relationship with energy expenditure which is 
dependent on the activity type (Hendelman et al., 2000; Bassett, Jr. et al., 2000), whereas heart 
rate is affected by factors other than activity (for example stroke volume, stress and ambient 
temperature) and is dependent on individual calibration (Strath et al., 2000; Li et al., 1993). 
Methods which combine both heart rate and movement measurement provide a more accurate 
prediction of energy expenditure during free-living activity (Strath et al., 2001; Luke et al., 
1997; Moon and Butte, 1996). 
The 'ActiReg' combined heart rate and movement monitor has been validated by comparison 
with doubly-labelled water techniques (Arvidsson et al., 2006; Hustvedt et al., 2004). However, 
this monitor uses separate devices to detect heart rate and movement, which can be inconvenient 
for the user and presents difficulty in synchronising the two parameters. The 'Actiheart' monitor 
(Cambridge Neurotechnology Ltd, Papworth, UK) has a heart rate monitor and motion sensor 
contained in a single device. This sensor has been validated against both whole-body 
calorimetry using a fixed activity protocol incorporating standard periods of activity and 
inactivity (Rennie et al., 2000) and against a portable indirect calorimeter system at rest and 
during walking and running (Brage et al., 2005). 
The 'Actiheart' monitor consists of a single-piece waterproof sensor attached to two standard 
ECG electrodes placed on the subjects' anterior chest wall. Heart rate measurement is derived 
from electrocardiogram recording and movement is detected by an accelerometer. Analysis of 
these two parameters by branched equation modelling improves the accuracy of calculated 
energy expenditure (Brage et al., 2004). This approach exploits the time synchronisation 
between the two parameters to apply different weighting to heart rate or movement data in order 
to optimise estimates within a 'free-living' environment. At higher heart rates, a greater 
weighting is given to heart rate data as, during periods of higher intensity activity, heart rate is 
highly predictive of energy expenditure. At lower heart rates, a greater weighting is given to 
energy expenditure calculations derived from movement data as this confers greater reliability 
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under these conditions. Individual calibration of data using each participant's resting heart rate, 
heart rate : energy expenditure relationship, and measured resting energy expenditure further 
increases accuracy to within 0.18 ± 4.6 % of directly measured energy expenditure (Brage et al., 
2004). 
4.1.3 Energy Expenditure And Human Obesity 
The National Food Survey's annual measure of household food consumption suggests that the 
UK is becoming progressively more obese despite a lower energy intake than in the 1970's 
(Prentice and Jebb, 1995). This obesity epidemic may be explained by a precipitous reduction in 
energy expenditure (Dietz, Jr. and Gortmaker, 1985; Prentice and Jebb, 1995). Indeed, the 
largest available prospective study, which followed 12000 Finnish adults over a five year period, 
demonstrated that a low level of physical activity was a more important risk factor for excess 
weight gain than any dietary factors (Rissanen et al., 1991). 
There is some evidence that a low resting energy expenditure may contribute to obesity (Astrup 
et al., 1999; Buscemi et al., 2005). However, recent research has indicated resting energy 
expenditure may have minimal impact on weight gain (Weinsier et al., 2000; Wyatt et al., 1999) 
and activity-related energy expenditure may be much more important (Zurlo et al., 1992). One 
prospective study has reported that low physical activity accounts for 77% of weight gain over a 
year (Hunter and Byrne, 2005) and inactivity is a major determinant of increased adiposity 
during overfeeding (Levine et al., 1999). The role of NEAT in obesity was recently highlighted 
by the observation that lean sedentary individuals are standing and ambulatory (as measured by 
postural microsensors and an accelerometer) for 152 minutes longer per day than obese 
participants (Levine et al., 2005). Indeed, the variability of response to an obesigenic 
environment may be explained by inter-individual differences in non-exercise physical activity, 
which vary over 30-fold (Weinsier et al., 1998). Cross-cultural studies of physical activity and 
body-mass index have demonstrated a seven-fold increased risk of being overweight in those 
with a PAL of less than 1.8 (Ferro-Luzzi and Matrino, 1996). Data has suggested a PAL of 
1.75-1.8 is necessary to prevent the transition from normality to overweight and obesity (Saris et 
al., 2003; Erlichman et al., 2002). Furthermore, PAL is also associated with the development of 
obesity-related conditions such as the metabolic cardiovascular syndrome (Wareham et al., 
1998). 
4.2 Hypothesis And Aims 
In Chapter 3,1 demonstrated that self-administration of oxyntomodulin results in a significant 
weight loss of 2.3 ± 0.4 kg in overweight and obese study participants over a four-week period. 
One mechanism of this weight loss was a reduction in food intake. Rodent studies have 
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suggested that administration of oxyntomodulin results in decreased body-weight via an 
increase in energy expenditure, in addition to reducing energy intake ((Dakin et al., 2002; Dakin 
et al., 2004). Rats which received twice-daily intraperitoneal injections of oxyntomodulin (50 
nmol/kg) for seven days had lower adiposity and body-weight than pair-fed animals despite 
identical calorie intake (Dakin et al., 2004). Similarly, rats receiving oxyntomodulin 
intracerebroventricularly over seven days had reduced adiposity and body-weight and an 
increase in core body-temperature, despite decreased food intake (Dakin et al., 2002). It has 
been hypothesised that a positive effect of oxyntomodulin on energy expenditure in rodents may 
occur as a consequence of a change in the thyroid axis: by stimulating TRH release in the 
hypothalamus, preventing the suppression observed in plasma TSH during fasting (Dakin et al., 
2002). 
A coupling of reduced appetite and increased energy expenditure has been observed in humans 
following leptin administration (Ahima et al., 1996). Low-dose leptin replacement reverses the 
adaptive reduction in energy expenditure, sympathetic nervous system tone and circulating T3 
and T4 levels observed after weight loss (Rosenbaum et al., 2002). It has been hypothesised that 
the mechanism of this reversal is a leptin-induced increase in hypothalamic expression of 
POMC and leptin's inhibitory effect on hypothalamic expression of AgRP (Rosenbaum et al., 
2002). Evidence suggests oxyntomodulin may act by stimulating the hypothalamic melanocortin 
system (Dakin et al., 2004), and therefore it is possible that, like leptin, it may have a similar 
dual effect on both appetite and energy expenditure. An increase in a-MSH signalling is able to 
decrease pro-TRH release in the hypothalamus (Kim et al., 2000b), as terminals from 
melanocortin cells in the ARC are closely opposed to TRH-producing cell bodies in the PVN 
(Fekete et al., 2000; Fekete et al., 2002). Logically, it may be considered adaptive for a satiety 
signal to increase energy expenditure, in addition to reducing food intake, in order to reduce or 
maintain body weight. 
Hypothesis: I hypothesise that subcutaneous pre-prandial administration of oxyntomodulin will 
increase energy expenditure, in addition to reducing energy intake, in humans. 
Aims: 
1. To determine the effect of subcutaneous oxyntornodulin on resting energy expenditure 
in healthy overweight and obese volunteers using indirect calorimetry. 
2. To determine the effect of subcutaneous oxyntomodulin on activity-related energy 
expenditure in healthy overweight and obese volunteers within a 'free-living' 
environment using combined heart rate and movement monitoring. 
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4.3 The Effect Of Oxyntomodulin On Energy Homeostasis In Overweight And 
Obese Humans: A Randomised Controlled Trial 
4.3.1 Materials And Methods 
4.3.1.1 Peptide And Chemicals 
Oxyntomodulin was synthesised and prepared as described in Section 3.3.1. Normal saline was 
purchased and prepared as described in Section 3.3.1. Oxyntomodulin and saline were sterile on 
culture and negative for pyrogen. The oxyntomodulin was from the same consignment of 
oxyntomodulin as that used in the study of four-week pre-prandial subcutaneous administration 
of oxyntomodulin to healthy overweight and obese volunteers (Chapter 3). A dose of 400 nmol 
of oxyntomodulin was chosen as it successfully decreased body-weight in this previous study. 
Study participants prepared all injections by the addition of 0.25 millilitres sterile water to 
freeze-dried vials and self-administered the dissolved substance subcutaneously into their 
abdomen using a 27 gauge needle. 
4.3.1.2 Volunteers 
Healthy male and female volunteers, aged 18-55 years, with a stable body-mass index 2540 
k g/M2, were recruited by advertisement and completed the study at the Sir John McMichael 
Centre for research study, Hammersmith Hospital (London, UK). The subjects had stable body- 
weight over the preceding three months and were not on calorie-restricting diets or weight loss 
medications. All subjects were non-smokers with normal physical examination, full blood 
count, urea and electrolytes, liver function tests, glucose and electrocardiograms. Subjects were 
excluded if they demonstrated abnormal eating patterns as measured by questionnaire (Morgan 
et al., 1999; Van Strien et al., 1986). Food preferences were assessed using a nine-point 
hedonistic scale to ensure the study meal was acceptable. Women of child-bearing age were 
advised to use adequate contraception and provided regular urine samples to ensure they were 
not pregnant. 
A power calculation was used in order to estimate the minimum number of subjects required to 
detect a significant effect of oxyntomodulin on participant's energy intake. Based on my 
previous data (Chapter 3), 1 assumed a difference of 170 ± 45 Kcal to be a clinically significant 
reduction in energy intake. Using a power calculator available on-line at 
'http: //calculators. stat. ucla. edu/powercalc/', with a significance level of p<0.05 and 90% power, 
I calculated that a minimum of II subjects were required to complete the protocol. Fifteen 
volunteers were recruited and all participants completed the entire study protocol. 
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Ethical approval was obtained from the Hammersmith, Queen Charlotte's & Chelsea and Acton 
Hospitals' Research Ethics Committee (reference 04/QO401/136). All subjects gave informed 
written consent and the study was performed in accordance with the Declaration of Helsinki. 
4.3.1.3 Protocol 
The study was a randomized controlled double-blinded crossover study designed to investigate 
the effect of oxyntomodulin on energy expenditure and energy intake. Fifteen subjects 
completed three four-day study sessions, separated by at least 72 hours. Each study session 
protocol was identical (Figure 4.0) and was scheduled on the same calendar days of the week. 
During the initial study session, all subjects self-administered saline in order to habituate to the 
procedures. During the second and third study periods subjects self-administered saline or 
oxyntomodulin in random order, as allocated by an independent investigator. All participants 
were advised to continue their usual exercise and dietary regimen throughout the study period. 
Participants self-administered injections subcutaneously, three times daily, 30 minutes prior to 
their meal. Each subject administered nine injections over a study session, commencing at 
lunchtime on day I and terminating at breakfast on day 4. On day 2 and day 3 subjects were 
'free-living' and injections were self-administered in their own environment. Compliance with 
injections was 99.25% during both the saline and oxyntomodulin administration periods, 
estimated by counting returned empty vials and confirmed by checking cutaneous sites of 
injection and inspecting accumulated used needles. 
Energy intake was measured at a study meal in the research unit. For 24 hours prior to 
commencement of each study session, subjects avoided alcohol and strenuous exercise and then 
fasted overnight from 9pm. On day 1, participants attended the research unit and self- 
administered their injection. A meal of known energy content was provided in excess 30 
minutes later and subjects were requested to eat until they felt 'comfortably full'. Each 
individual received an identical study meal on each occasion. Depending on their taste 
preference this was either: chicken curry (171Kcal, 6g protein, 19g carbohydrate, 7.9g fat per 
100g), mushroom stroganoff (123 Kcal, 3. lg protein, 17.9g carbohydrate, 4.3g fat per 100g) or 
chicken tagliatelle (129 Kcal, 6.9g protein, 16.7g carbohydrate, 3.8g fat per 100g). The mass of 
food consumed was measured and used to calculate energy intake. Visual analogue scales were 
completed by the participants before and after the meal in order to evaluate subjective feelings 
of appetite and nausea (Appendix D) and meal palatability. These scales consisted of aI 00mm 
line with text expressing the most positive and most negative ratings anchored at each end. In 
order to assess appetite the volunteers were asked 'How hungry do you feelT, 'How much do 
you think you could eat? ' and 'How full do you feelT with higher values signifying more 
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positive subjective ratings. Blood samples were taken, at baseline and 30,60,90,120 and 150 
minutes post-injection, from an antecubital fossa carmula into lithium/heparin tubes (LIP Ltd., 
Cambridge, UK) containing 2000 kallikrein inhibitor units of aprotinin (Trasylol, Bayer). 
Samples were stored on ice, centrifuged, and the plasma component separated and stored at 
minus 20'C until radioirnmunoassay analysis. Blood pressure and pulse were measured prior to 
each blood sample. 
Resting energy expenditure was measured by indirect calorimetry (Deltatrac II, Datex-Ohmeda 
Limited, Hatfield, UK) on day 4 of each study session. The calorimeter was calibrated 
immediately before each testing session in accordance with manufacturer's guidelines. 
Participants attended the research unit having fasted overnight from midnight. They were placed 
under the ventilated hood of the calorimeter and baseline measurements were taken for 30 
minutes. Subjects then had an injection administered into the subcutaneous tissue of their 
abdomen. A further 60 minutes of data recording was performed. The indirect calorimetry unit 
used breath-by-breath gas exchange to calculate average V02 and VC02 exchange per minute 
whilst the subject was recumbent and resting. Respiratory quotient (RQ) was calculated and 
used to derive energy expenditure: Energy expenditure = 1.32*VO2*(1.23*RQ+3.81). 
Activity-related energy expenditure was measured using the combined movement and heart rate 
sensor 'Actiheart' (Cambridge Neurotechnology Ltd., Papworth, UK). The sensor was set to 
measure movement and heart rate synchronously every 30 seconds over a four-day period. On 
day 1, the monitor was attached to the subjects' anterior chest wall by two ECG electrodes. 
Participants were instructed to replace the ECG electrodes as necessary and advised that the 
monitor would not interfere with their daily activities. The monitor was removed on day 4 of the 
study period; the data was downloaded into a computer, and analyzed using 'Actiheart' 
Software. This software used branched equation modelling to derive 'free-living' daily energy 
expenditure from movement and heart rate parameters (Brage et al., 2004). Each subject had 
individual calibration of the 'Actiheart' monitor data by input of their measured resting energy 
expenditure and mean sleeping heart rate into the model. The subjects also performed a graded 
exercise test on day I of each study session in which they were asked to repeatedly mount a step 
of height 220 millimetres, at a speed of 15 steps per minute increasing to 33 steps per minute, 
over an eight minute period. Using this data, the computer employed linear regression analysis 
to model the relationship between heart rate and activity, which was then used to further 
calibrate the energy expenditure data for each participant. 
Participants' fasting weight was recorded on day I and day 4 of each study session on an 
identical calibrated scale (Marsden, London, UK), accurate to the nearest 100 grams. At each 
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recording, an average of three measurements was taken after the subject had voided urine. 
Participants were requested to record any adverse events which occurred over the study period 
in a diary. 
4.3.1.4 Hormone Measurement 
Plasma oxyntomodulin-like immunoreactivity (OLI), insulin and ghrelin were measured using 
established in-house radioimmunoassays (Appendix B). All samples were assayed in duplicate 
and within one assay to eliminate inter-assay variation. Thyroid stimulating hormone, free 
triiodothyronine (M) and free thyroxine (M) were measured using an Abbott Architect 
analyzer. Glucose was measured using an Olympus AU640 Analyser (Melville, NY). 
4.3.1.5 Statistical Analysis 
Combined data are expressed as mean (± standard error of the mean). The study was a cross- 
over design and therefore statistical analysis was performed comparing paired data sets with 
saline administration as a control. Energy intake and energy expenditure data were normally 
distributed and therefore analysed with paired t tests. Serial measurements of circulating 
oxyntomodulin levels, pulse and blood pressure over time were compared using two-way 
analysis of variance (ANOVA), with a post-hoc Bonferroni test of significance. Energy 
expenditure data from the 'Actiheart' monitor was analysed using 'Actiheart' Software (Version 
2.1, Cambridge Neurotechnology Ltd., Papworth, UK). Prism Version 4.0 was used for 
statistical calculations and p<0.05 was considered significant. Statistical advice was given by 
Mr Joseph Eliahoo at the Statistical Advisory Service, Imperial College London. 
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Figure 4.0: protocol for the investigation of the effect of oxyntomodulin on energy 
expenditure in humans. Participants injected subcutaneous saline or 
oxyntomodulin (400 nmol) pre-prandially, three times daily, over a four day period 
(represented by the nine arrows). The interventions were performed in random 
order, separated by at least 72 hours. Energy intake was measured at a study meal 
on day 1. Energy expenditure was monitored on day 2 and 3 using the 'Actiheart' 
monitor. Indirect calorimetry was performed on day 4. 
DAY F DAY 2 IF-DAY 3 IFDAY 41 
111111111 
Saline or oxyntomodulin injecti 
II 
Study meal 'Free-living' environment 
Kalorimetry 
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4.3.2 Results 
4.3.2.1 Demographics 
Fifteen subjects, four males and II females were recruited, and all completed the protocol 
(Table 4.0). The mean age was 37 ±2 years (range 23 to 49 years) and mean body-mass index 
was 32.3 ± 0.9 kg/m2 (range 25.1 to 39.0 kg/m2). In this cohort of overweight and obese 
subjects, the baseline mean resting metabolic rate was 1286 ± 54 Kcal/day (range 941 to 1672 
Kcal/day, Table 4.0). The volunteers were not taking any prescribed medications. 
4.3.2.2 Energy Intake 
A subcutaneous injection of oxyntomodulin reduced energy intake during the study meal, 
confirming the anorectic effects observed previously (Chapter 3). When subjects self- 
administered saline they ingested 792 ± 94 Kcal, however when the same subjects self- 
administered oxyntomodulin they ingested 663 ± 88 Kcal, a reduction of 128 ± 29 Kcal 
(p=0.0006). When expressed as a percentage of the intake on the saline day for each individual, 
this was equivalent to a reduction of 17.3 ± 5.5 % (p=0.0071, Figure 4.1). Although energy 
intake at the study meal was significantly reduced by oxyntomodulin, water intake remained 
unchanged (saline 0.256 ± 0.038 litres versus oxyntomodulin 0.265 ± 0.035 litres; p=0.7468). 
Immediately before the study meal, there were no differences detected in visual analogue scales 
assessing subjective appetite. After an injection of saline or oxyntomodulin, the change from 
baseline for hunger (5 ±I mm versus 2±4 mm respectively; p=0.5329), prospective food 
intake (3 ±I mm versus 2±6 mm respectively; p=0.7304) and fullness (0 ±4 mm. versus -2 ±2 
respectively; p=0.781 1) were not significantly different. The subjects' ratings of pre-prandial 
nausea were not changed by an injection of oxyntomodulin (saline 4±3 mm versus 
oxyntomodulin 5 12; p=0.6817) and the study meal was rated as equally palatable (saline 64 ± 
6 mm versus oxyntomodulin 57 ±6 mm; p=0.2386). 
Body-weight was reduced over the four-day study period in which the participants self- 
administered oxyntomodulin. During the period over which saline was administered, the 
subjects maintained their body-weight, with a change of 0.0 +_ 0.1 kg or 0.1 ± 0.2 %. After the 
four days of oxyntomodulin injections, the subjects' body-weight decreased by 0.5 ± 0.2 kg 
(p=0.0329) or 0.5 ± 0.2% (p=0.0232, Figure 4.2). 
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Table 4.0: demographic profile of the volunteers, including body mass index (BMI) 
and mean pre-injection resting metabolic rate (RMR). 
SUBJECT SEX AGE 
(Years) 
WEIGHT 
(Kg) 
HEIGHT 
(m) 
BMI 
(Kg/M2) 
RMR 
(Kcal/Day) 
1 Male 46 124.9 1.79 39.0 1672 
2 Male 28 91.2 1.83 27.2 1498 
3 Male 42 105.0 1.76 33.9 1618 
4 Female 40 86.4 1.57 35.1 1092 
5 Female 23 71.8 1.69 25.1 1140 
6 Female 33 88.6 1.75 28.9 1442 
7 Male 40 92.9 1.73 31.0 1394 
8 Female 45 87.2 1.59 34.5 1175 
9 Female 47 80.3 1.55 33.4 941 
10 Female 38 90.2 1.63 33.9 1170 
11 Female 32 86.8 1.65 31.9 1254 
12 Female 25 64.9 1.51 28.5 1032 
13 Female 28 108.3 1.78 34.2 1275 
Female 49 99.8 1.68 35.4 1339 
15 Female 43 87.2 1.64 32.4 1255 
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4.3.2.3 Energy Expenditure 
Indirect calorimetry demonstrated a mean fasting basal respiratory quotient of 0.92 ± 0.02 and a 
fasting basal resting energy expenditure of 1293 d: 53 Kcal/day prior to saline administration. As 
expected, this data was not significantly different from the fasting basal respiratory quotient 
(0.93 ± 0.02; p=0.5803) and resting energy expenditure (1318 ± 64 Kcal/day; p=0.6161) 
measured prior to oxyntomodulin injection. Oxyntomodulin injection did not significantly alter 
respiratory quotient (saline 0.89 ± 0.02 versus oxyntomodulin 0.88± 0.02; p=0.5534) or resting 
energy expenditure (saline 1127 ± 32 Kcal/day versus oxyntomodulin 1242 ± 50 Kcal/day; 
p=0.6987) over a 60 minute post-injection period. Neither was there evidence of an effect of 
oxyntomodulin on resting energy expenditure when adjusted for individual body-weight 
measured at the end of each study period (saline 13.6 ± 0.5 Kcal/kg/day versus oxyritomodulin 
13.7 ± 0.3 Kcal/kg/day; p=0.6555). 
Combined movement and heart rate monitoring was used to measure activity-related energy 
expenditure. In the overweight and obese volunteers, baseline activity-related energy 
expenditure accounted for on average 45 +_ 3% of total energy expenditure (range 31 to 67%). 
Oxyntomodulin treatment resulted in a significant increase in daily activity during the 'free- 
living' period on day 2 and 3. On average, participants expended 1172 ± 110 Kcal/day on 
activity during the period of saline administration. However, during the period of 
oxyntomodulin administration they expended 1301 ± 109 Kcal/day, an increase of 143 ± 109 
Kcal/day. When expressed as a percentage of the activity-related energy expenditure during 
saline administration for each individual, this represented an increase of 26.2 ± 9.9% (p=0.0221; 
Figure 4.3a). When adjusted for individual body-weight at the end of each study period, there 
was a similar increase of 26.8 ± 9.9% (p=0.0197). 
Total energy expenditure was calculated as the sum of resting energy expenditure and activity- 
related energy expenditure. It is therefore not surprising that oxyntomodulin also increased total 
energy expenditure (saline 2443 ± 120 Kcal/day versus 2585 ± III Kcal/day) by a similar 
amount of 143 ± 109 Kcal/day, which represents an increase of 9.4 d: 4.8 % for each individual 
(p=0.0454; Figure 4.3b). When adjusted for individual body-weight at the end of each study 
period, there was a similar increase of 9.8 ± 4.2% (p=0.0357). 
In addition to measurement of mean daily energy expenditure, combined movement and heart 
rate monitoring allows investigation of the intensity of physical activity over time. Intensity can 
be expressed as the time spent by participants in 'metabolic bands', calculated as multiples of 
each individuals' resting energy expenditure. During the oxyntomodulin injection period there 
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was a non-significant trend for the subjects to spend greater time in metabolic bands >2.5 
(approximately equivalent to walking at a slow pace or performing light household tasks) 
compared with controls (52 ± 28% longer, p=0.0861). 
Physical activity level is a way of expressing the amount of energy each individual is expending 
relative to their resting energy expenditure, and is calculated by dividing each individual's total 
energy expenditure by their resting energy expenditure. During saline administration the 
average physical activity level was 1.65 ± 0.06, increasing to 1.74 ± 0.05 during oxyntomodulin 
administration, which represents an increase of 9.5 ± 4.6% for each individual (P=0.0495; 
Figure 4.3c) or 8.1 ± 4.2% (p=0.0438) when adjusted for individual body-weight. 
4.3.2.4 Hormone Assays 
Baseline plasma oxyntomodulin levels were 41 ±7 pmol/L, increasing to 63 ± 16 pmol/L post- 
prandially. However, when participants self-administered oxyntomodulin, levels increased to 
658 ± 85 pmol/L immediately prior to the study meal, and peaked 30 minutes post-prandially at 
7521255 pmol/L (Figure 4.4). 
Thirty minutes after subcutaneous administration of oxyntomodulin there was a statistically 
significant increase in pre-prandial insulin levels of +64 ± 15 pmol/L (p=0.0003, Table 4.1). 
This change in insulin was insufficient to alter plasma glucose levels in this non-diabetic 
population (p=0.3175, Table 4.1). The potential benefits of this insulin-releasing action have not 
yet been explored in subjects with abnormal glucose homeostasis. 
Thirty minutes after an injection of oxyntomodulin, just prior to the study meal, plasma levels of 
ghrelin were not significantly altered compared with control (p=0.2863, Table 4.1). At this time- 
point circulating levels of free T3 (p=0.5203), free T4 (p=0.1626) and thyroid-stimulating 
hormone (p=0.4091) were also unchanged (Table 4.1). Thyroid parameters were also measured 
over the entire 150 minute study period. The TSH remained higher after oxyntomodulin 
administration at all time-points post-injection compared with the group who received saline, 
however, the change from baseline only achieved statistical significance 60 minutes post- 
injection (control: -0.13 ± 0.03 mU/L versus treatment: -0.03 ± 0.06 mU/L; p=0.0402) (Figure 
4.5). There was no change in free T4 or free T3 at the time points measured up to 150 minutes 
(data not shown). 
4.3.2.5 Blood Pressure And Pulse Rate 
Blood pressure and pulse rate were measured manually in the research unit over a 150 minute 
resting period post-injection. Administration of oxyntomodulin did not result in any significant 
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changes in systolic blood pressure (p=0.1388), diastolic blood pressure (p=0.2282) or pulse rate 
(p=0.0840) (data not shown). Pulse rate was also measured by the 'Actiheart' monitor every 30 
seconds during the study period. The pulse rate was not significantly different in the 30 minutes 
following an injection of oxyntomodulin (saline mean 71 ±I bprn versus oxyntomodulin mean 
72 ±I bpm; p=O. 622 1, Figure 4.6). 
4.3.2.6 Adverse Events 
Volunteers recorded any potential adverse events in a diary over the course of the study period. 
The most frequently reported event was a brief discomfort at the site of injection. One subject 
reported discomfort after 14% of saline injections and five out of fifteen subjects reported 
discomfort after, on average, 24 ± 10 % of oxyntomodulin injections (P=0.0357 versus the 
incidence after saline injection). There was no significant increase in the subjects' reporting of 
nausea during the oxyntomodulin administration period when compared to administration of 
saline. However, one participant - subject 11 - reported nausea after 71% of oxyntomodulin 
injections, a level greater than two standard deviations above the mean (Figure 4.7). Subject II 
also demonstrated levels of circulating oxyntomodulin significantly higher than the group mean 
after self-administering oxyntomodulin prior to the study meal (p<0.0001). This subject's 
plasma oxyntomodulin levels increased from a baseline value of 50 pmol/L to 1249 pmol/L 
immediately pre-prandially, and to 3752 pmol/L 60 minutes post-injection. During the 
oxyntomodulin administration period, subject II demonstrated a greater than average reduction 
in energy intake (21.5%, group mean 17.3 ± 5.5%) and greater increase in activity-related 
energy expenditure (47.7%, group mean 26.2 ± 11.9%), although these changes were within the 
normal range. There were no other frequently reported adverse events during the trial. 
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Figure 4.1: the effect of oxyntomodulin on the energy intake of the participants 
during the study meal. Oxyntomodulin (OXM) significantly reduced energy intake 
by 17.3 ± 5.5% (**p=0.0071). 
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Figure 4.2: the effect of oxyntomodulin on the body-weight of the participants over 
the four-day study period. Oxyntomodulin (OXM) significantly decreased body- 
weight by 0.5 ± 0.2% (p=0.0232). 
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Figure 4.3: the effect of oxyntomodulin on energy expenditure of the participants 
over the study period. Oxyntomodulin (OXM) administration resulted in an 
increasein: 
(a) Daily activity- related energy expenditure by 26.2 ± 9.9% (p=0.0221) 
(b) Daily total energy expenditure by 9.4 ± 4.8% (p=0.0454) 
(c) Physical activity level by 9.5 ± 4.6% (p=0.0495). 
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Figure 4.4: the levels of plasma oxyntomodulin-like immunoreactivity (OLI) after 
subcutaneous administration of saline or oxyntomodulin (t--O). 
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Figure 4.5: the levels of plasma thyroid-stimulating hormone (TSH) after 
subcutaneous administration of saline or oxyntomodulin. 
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Figure 4.6: pulse rate measured by the 'Actiheart' monitor every 30 seconds 
following an injection of saline or oxyntomodulin. There were no significant acute 
changes in pulse rate measurements after treatment with oxyntomodulin. 
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Figure 4.7: incidence of nausea reported by subjects during repeated injections of 
saline or oxyntomodulin. There was no significant increase in the subjects' 
reporting of nausea during the oxyntomodulin administration period when 
compared to administration of saline. 
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Table 4.1: the effect of oxyntomodulin on circulating factors 30 minutes after 
injection, prior to a meal. A significant increase in plasma insulin was 
demonstrated after oxyntomodulin injection (***p=0.0003 versus saline). TSH: 
thyroid-stimulating hormone. 
SALINE OXYNTOMODULIN 
Baseline 30 minutes Change Baseline 30 minutes Change 
Insulin 57 ±7 54 ±9 -3 ±9 57 ±6 121 18 +64 ± 15*** 
(pmol/L) 
Glucose 4.71 ± 0.08 4.64 ± 0.09 -0.07 ± 0.06 4.71 ± 0.06 4.77 0.06 +0.06: k 0.06 
(mmol/L) 
Free T3 4.25 ± 0.14 4.20 ± 0.11 -0.05: k 0.06 4.19 ± 0.01 4.20 0.11 +0.01 ± 0.05 
(pmol/L) 
Free T4 12.10 ± 0.32 11.88 ± 0.40 -0.22 ± 0.28 12.06: h 0.46 12.36 ± 0.48 +0.30: k 0.16 
(pmol/L) 
TSH 1.10 J: 0.13 1.10 0.14 0.00: k 0.03 1.14 0.12 1.04 0.10 -0.09 ± 0.10 
(MU) 
Ghrelin 360 ± 53 392 65 +33± 31 399 64 387 63 -12: k 18 
(PMOIAL) I I I I I I 
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4.3.3 Discussion 
Self-administering oxyntomodulin increased energy expenditure, in addition to reducing energy 
intake, in overweight and obese humans over the study period. Energy expenditure can be 
partitioned into resting energy expenditure, incorporating both basal metabolic rate and the 
thermic effect of food, and activity-related energy expenditure (Castaneda et al., 2005). 
Administration of oxyntomodulin resulted in an increase in daily activity-related energy 
expenditure of 26.2 ± 9.9% and an increase in total energy expenditure of 9.4 ± 4.8%.. The 
increase in activity of 143 ± 109 Kcal/day accounted for the increase seen in total energy 
expenditure, indicating that it was an increase in physical activity which resulted in greater total 
energy expenditure. During oxyntomodulin administration, there was a trend for volunteers to 
alter their pattern of activity over time so that they spent slightly longer performing activities of 
higher intensity. Interestingly, oxyntomodulin administration did not alter measurements of 
fasted resting energy expenditure suggesting dissociation between the controls of activity and 
resting energy expenditure. 
The 'Actiheart' combined heart rate and movement monitor has been validated against whole 
body calorimetry and indirect calorimetry using fixed protocols of physical activity and 
inactivity (Rennie et al., 2000; Brage et al., 2005). However, further studies would be useful for 
verification of the expected relationship between heart rate, movement and energy expenditure 
by doubly labelled water methods during 'free-living' periods (Rennie et al., 2000). This is the 
first study assessing the effects of a potential treatment on energy expenditure using combined 
heart-rate and movement measurement. If a treatment had a direct effect on heart rate it could 
alter the expected relationship between heart rate, movement and energy expenditure. In this 
study there was no evidence that the effect of oxyntomodulin on energy expenditure was 
secondary to an alteration in heart rate. Furthermore, oxyntomodulin has not been reported to 
have any effects on the human cardiovascular system and I did not observe any such effects in 
my previous study (Chapter 3). In this study it may be concluded that oxyntomodulin has a 
significant effect on measured energy expenditure secondary to an increase in physical activity. 
The significant increase in daily energy expenditure during oxyntomodulin treatment is of a 
clinically significant magnitude as it approaches the World Health Organization 
recommendation of a 200 Kcal/day increase in low-intensity physical activity (World Health 
Organization, 2000). The baseline physical activity level of these volunteers was within the 
range expected for overweight and obese subjects (PAL=1.65 ± 0.06), but increased to a greater 
level (PAL=1.74 ± 0.05) associated with maintenance of normal weight (Erlichman et al., 2002; 
Saris et al., 2003). Thus, the increase in physical activity after short-term treatment with 
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oxyntomodulin returns energy expenditure back toward 'normal' levels in a 'free-living' 
environment, despite a reduction in energy intake. 
The ability to promote energy usage is an extremely useful property for an anti-obesity therapy. 
The mechanism of this change in energy expenditure in humans in response to oxyntomodulin is 
unclear, but it may occur via a change in the thyroid axis. There was an increase in circulating 
TSH at 60 minutes post-injection in the current study, although this did not produce stimulation 
in free T3 or T4 within the 150 minutes measured post-injection. One other possible mechanism 
is a change in sympathetic activity, although biomarkers of sympathetic activity such as the 
measurement of urinary catecholamines or heart-rate analysis were not performed in this study 
(Rosenbaum et al., 2005). Appetite-suppressant medications such as sibutramine, a combined 
serotonin and noradrenaline reuptake inhibitor, and phentermine, an amphetamine derivative, 
are thought to promote energy expenditure via their sympathomimetic effects in humans (Hirsch 
et al., 2000). In rodents, sibutramine has been reported to cause thermogenesis in rats via 
sympathetic activation of brown adipose tissue (Connoley et al., 1999). However, unfortunate 
side-effects of sympathetic activation by sibutramine include palpitations, tachycardia, 
hypertension, central nervous system and gastrointestinal effects (Li et al., 2005). In contrast, 
the use of an endogenous peripheral signal of energy homeostasis, such as oxyntomodulin, may 
have the advantage of specifically targeting circuits controlling energy homeostasis. This may 
allow treatment of obesity without the side-effects seen with other licensed drugs. Indeed, in the 
current study and in human studies reported to date oxyntomodulin therapy appears well- 
tolerated (Chapter 3 and (Cohen et al., 2003)). 
In accordance with our previous data (Chapter 3), oxyntomodulin significantly reduced energy 
intake at the study meal by 17.3 :: L 5.5% without subjective changes in pre-prandial appetite or 
meal palatability. Reduction in calorie intake after administration of oxyntomodulin suggests an 
alteration of appetite. However, there was no evidence of a decrease in pre-prandial hunger 
measured by visual analogue scale, or alteration in the circulating level of the orexigenic 
hormone ghrelin. This may reflect an alternative mechanism such as an early perception of post- 
prandial satiety, although this hypothesis requires further investigation. 
The anorectic action of oxyntomodulin is thought to be mediated by the glucagon-like peptide I 
receptor as the effect on food intake is not observed in the GLP-1 receptor knock-out mouse 
(Baggio et al., 2004b). It remains controversial whether oxyntomodulin may also exert actions 
via GLP-I receptor-independent mechanisms and indeed whether the effect on energy 
expenditure is mediated via such a mechanism. The effect of the GLP-I receptor ligands, GLP-I 
and Exendin4, on human energy expenditure is unclear. Shalev et aL demonstrated an insulin- 
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dependent increase in energy expenditure during intravenous administration of GLP-I to 
normal-weight volunteers (Shalev et al., 1997). However, Flint et aL found a decrease in resting 
metabolic rate and respiratory quotient during a 'physiological' dose of intravenous GLP-I 
administered to obese men, using a similar indirect calorimetry methodology (Flint et al., 2001). 
One recent study of the long-acting GLP-1 agonist, Liraglutide (NN221 1), failed to demonstrate 
any effect of daily subcutaneous administration on energy expenditure in obese type 2 diabetics 
(Harder et al., 2004). Pannacciulli et aL have suggested that higher fasting endogenous plasma 
GLP-I levels are associated with higher resting energy expenditure and fat oxidation rates in 
humans (Parmacciulli et al., 2006). To date, there have been no reports describing the effects of 
any gut peptide on activity-related energy expenditure in human volunteers for comparison with 
the current study. Therefore, the current literature does not further elucidate whether 
oxyntomodulin and GLP-I receptor ligands have similar or contrasting effects on human energy 
expenditure. 
Understanding the dual effect of oxyntomodulin on energy intake and energy expenditure in 
humans allows an insight into its potential role as a treatment for obesity. Although voluntary 
dietary restriction is a common intervention for obese patients, it is usually accompanied by a 
decrease in energy expenditure (Weinsier et al., 2000). Indeed, maintenance of a ten percent or 
greater reduction in body-weight by obese and non-obese humans is accompanied by a 
reduction in energy expenditure beyond that predicted by loss of body-mass (Rosenbaum et al., 
2002; Leibel et al., 1995). In evolutionary terms, this may be considered an adaptive trait which 
occurs in order to conserve energy and maintain body-weight in times of famine. However, this 
contributes to the difficulty experienced by obese individuals who attempt to diet voluntarily in 
environments which are not physically demanding. In contrast to this effect of voluntary dietary 
restriction, the current study demonstrated that administration of oxyntomodulin increased 
energy expenditure during a period of reduced energy intake. The significant decrease in body- 
weight over the administration period indicates oxyntomodulin administration resulted in 
negative energy balance. However, it is unclear whether weight loss was secondary to a loss of 
body-mass or initial fluid shifts which may be expected during a four-day period of negative 
energy balance (Wynn et al., 1985). Clinical trials of longer duration are required to further 
assess the ability of subcutaneous oxyritomodulin to produce a sustained increase in energy 
expenditure, which could lead to continued weight loss. 
In summary, this study suggested that oxyntomodulin increases energy expenditure and 
decreases energy intake in humans and demonstrates a possible mechanism of weight loss 
during oxyntomodulin administration. Further studies should now be performed in order to 
investigate whether the effect of oxyntomodulin on energy expenditure is maintained over a 
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period of chronic administration. Although the long-term effects and therapeutic potential of 
oxyntomodulin require further study, this data supports the role of oxyntomodulin as a potential 
anti-obesity therapy. 
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Chapter 5 
Discussion 
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The rapidly increasing prevalence of obesity (Hedley et al., 2004) is the result of an interaction 
between environmental factors, such as the availability of highly palatable energy-dense food 
and low requirement for physical activity, and genetic factors which predispose to weight gain 
(Ravussin and Bogardus, 2000; Weinsier et al., 1998). Research groups worldwide are urgently 
searching for an effective anti-obesity treatment. Useful strategies for the development of novel 
anti-obesity therapies could be developed by utilising the physiological systems controlling 
energy homeostasis. 
Oxyntomodulin is a product of proglucagon processing (Tang-Christensen et al., 2001) released 
from intestinal enteroendocrine cells in response to a meal (Ghatei et al., 1983; Le Quellec et al., 
1992). This circulating hormone is considered to be a satiety signal, as it is been found to 
decrease food intake, body-weight and adiposity in rodents when administered centrally or into 
the peritoneum (Dakin et al., 2001; Dakin et al., 2002; Dakin et al., 2004). Rodent studies have 
suggested that the administration of oxyntomodulin results in decreased body-weight via an 
increase in energy expenditure, in addition to reducing energy intake (Dakin et al., 2002; Dakin 
et al., 2004). Rats which received repeated intraperitoneal injections of oxyntomodulin for seven 
days had a lower body-weight than pair-fed animals, despite identical calorie intake (Dakin et 
al., 2004); and ICV administration over seven days resulted in an increase in core temperature, 
despite decreased food intake and body-weight (Dakin et al., 2002). 
I characterised the effect of the peripheral and central administration of oxyntomodulin on food 
intake, energy expenditure and activity in rodents using automated metabolic cages. I 
demonstrated that oxyntomodulin administered into the third cerebral ventricle resulted in a 
short-term reduction in food intake and concurrent increase in total energy expenditure 
measured using indirect calorimetry. In order to investigate which components of energy 
expenditure are increased following oxyntomodulin administration, it would be interesting to 
measure other markers of energy expenditure such as the activity of the autonomic nervous 
system, UCP-I expression in brown adipose tissue or core body temperature. Continuous 
subcutaneous oxyritomodulin infusion to rodents resulted in a significant reduction in body- 
weight over seven days compared with control. The reduction in food intake was transient in 
these studies of continuous administration, perhaps representing the induction of counter- 
regulatory mechanisms which act in order to prevent starvation. There was no evidence of the 
development of resistance to oxyntomodulin when administered at a dose greater than 600 
pmol/kg/min over a seven day period; the effect of oxyntomodulin on body-weight was 
sustained compared to control and after a period of continuous administration these rodents 
retained an anorectic response to an exogenous injection of oxyntomodulin. Thus, 
oxyntomodulin administration by a subcutaneous route is effective in rodents and may reset 
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body-weight at a lower homeostatic point by a dual mechanism of reduced food intake and 
increased energy expenditure. 
I demonstrated a direct stimulatory effect of oxyntomodulin on TRH release in ex vivo 
hypothalamic explants. This supports the hypothesis that a positive effect of oxyritomodulin on 
energy expenditure in rodents may occur by stimulating TRH release in the hypothalamus, 
preventing the suppression observed in plasma TSH during fasting (Dakin et al., 2002). Indeed, 
the effect of oxyntomodulin on both feeding and energy expenditure may be mediated via an 
increase in hypothalamic TRH. TRH has a role in the regulation of energy homeostasis through 
hypophysiotropic neurones in the PVN and also through direct central effects on feeding 
behaviour, thermogenesis, autonomic regulation, and locomotor activity (Lechan and Fekete, 
2006). TRH administered into the central nervous system has been shown to reduce food intake 
in several animal models (Vijayan and McCann, 1977; Suzuki et al., 1982; Steward et al., 
2003). The precise locus of this anorectic TRH effect is unknown, but direct injection of TRH 
into the medial hypothalamus (a region which contains TRH axon terminals) effectively reduces 
food intake (Suzuki et al., 1982). TRH may also have direct effects on thermoregulation, as ICV 
and hypothalamic administration of TRH increase rectal temperature and the temperature of 
brown adipose tissue, without any alteration in circulating T3 levels (Shintani et al., 2005). This 
effect on brown adipose tissue is dependent on sympathetic innervation (Shintani et al., 2005), 
and may be mediated by the effect of TRH on areas such as the DMN and hypothalamic pre- 
optic area which are integrated into the autonomic nervous system (Shintani et al., 2005; Boschi 
and Rips, 1981; Griffiths et al., 1988). TRH has also been shown to have effects on locomotor 
activity, including gross motor movements (forward locomotion, head and body rearing) and 
fine movements (grooming and head swaying), elicited by injection into many brain regions 
including the ventromedial hypothalamus (Lin et al., 1987). Thus, alterations in the levels of 
hypothalamic TRH by oxyntomodulin could affect energy homeostasis through several different 
possible mechanisms. 
I demonstrated a non-significant increase in release of the hypothalamic neuropeptide a-MSH, a 
finding supported by previously published data (Dakin et al., 2004). The feeding effect of 
oxyntomodulin may be partially mediated by an increase in a-MSH. Central administration of 
a-MSH or MTII (both melanocortin-4 receptor agonists) are known to potently reduces food 
intake (Benoit et al., 2000; Rossi et al., 1998; Barsh, 1999). An increase in a-MSH could also 
mediate the effect of oxyntomodulin on energy expenditure. Central administration of a-MSH is 
known to increase oxygen consumption (a marker of energy expenditure) (Pierroz et al., 2002; 
Hwa et al., 2001) and has also been found to stimulate sympathetic nervous activity to brown 
adipose tissue (Yasuda et al., 2004). 
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Hypophysiotropic and non-hypophysiotropic TRH neurones within the PVN (Ishikawa et al., 
1988; Kawano et al., 1991) are integrated with appetite-regulatory neuropeptides within the 
ARC of the hypothalamus. The majority of parvocellular TRH neurones are innervated by 
stimulatory axon terminals containing a-MSH which result in TRH release (Fekete et al., 2000; 
Fekete et al., 2002; Kim et al., 2000b). The central administration of a-MSH induces the 
phosphorylation of c-AMP response element binding (CREB) proteins in the nucleus of anterior 
parvocellular TRH neurones (Sarkar and Lechan, 2003) and in vivo ICV administration of a 
stable a-MSH analogue increases plasma TSH in fasted rats (Kim et al., 2000b). Thus, there is 
functional integration between TRH and a-MSH releasing neurones within the hypothalamus. 
I demonstrated a direct effect of oxyntomodulin on TSH release from the ex vivo pituitary gland. 
This direct effect (and any indirect effect of oxyntomodulin on TSH release via 
hypophysiotropic TRH neurones within the hypothalamus) may stimulate energy expenditure by 
increasing the levels of fT3 and f74. These thyroid hormones increase two components of the 
basal metabolic rate: obligatory thermogenesis and adaptive thermogenesis (Silva, 1995). 
Disease states demonstrate the importance of the thyroid hormones in the control of energy 
expenditure. In the absence of thyroid hormones basal metabolic rate is reduced by up to 30% 
and adaptive thermogenesis in cold-exposed animals is markedly impaired (Silva, 2003), 
whereas hyperthyroidism increases basal metabolic rate (Silva, 2003). 
In Figure 5.0,1 propose a putative schematic model for the mechanism of the dual action of 
oxyntomodulin administration on energy homeostasis, in which an increase in hypothalamic 
TRH and a-MSH mediate a reduction in food intake and increase in energy expenditure. The 
intra-hypothalamic interaction between a-MSH and TRH neurones and the direct stimulatory 
effect of oxyntomodulin on pituitary TSH are included in this model. In order to further 
investigate the mechanism of action of oxyntomodulin, it would be useful to determine the 
effect of oxyntomodulin administration on mRNA and protein levels of hypothalamic cc-MSH, 
CART, NPY, AgRP and TRH. It would also be instructive to investigate the in vivo effects on 
peripheral oxyntomodulin administration on circulating TSH and thyroid hormone levels in 
rodents. Dakin et aL have investigated the effect of repeated ICV administration of 
oxyntomodulin on the thyroid axis, demonstrating that oxyntomodulin prevented fasting- 
induced suppression of TSH, but there were no significant differences in the levels of M or M. 
The effect of peripheral administration of oxyntomodulin on these parameters in rodents is 
unknown. 
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Figure 5.0: Schaematic diagram of the proposed mechanism of action of 
oxyntomodulin. Oxyntomodulin increases the release of TRH and a-MSH within 
the hypothalamus. The alteration in signalling within these neuropeptide pathways 
reduces food intake and increases energy expenditure. Oxyntomodulin also induces 
TSH release directly from the pituitary, which may contribute to its action on 
energy homeostasis. A decrease in food intake and increase in energy expenditure 
results in negative energy balance and subsequent weight loss. TRH: thyrotropin- 
releasing hormone; ct-MSH: alpha-melanocyte stimulating hormone; TSH: 
thyroid-stimulating hormone; fIF3: triiodothyronine; f'F4: thyroxine. 
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A preliminary human study performed in our laboratory found that intravenous administration 
of oxyntomodulin reduced short-term food intake in normal weight human volunteers (Cohen et 
al., 2003). The feasibility of using oxyntomodulin for the treatment of human obesity depends 
on oxyntomodulin producing a sustained reduction in food intake in overweight volunteers. In 
addition, an appropriate route of administration must be available for the treatment to be 
clinically relevant. In Chapter 3,1 investigated the effect of repeated subcutaneous 
oxyntomodulin administration on food intake and body-weight in healthy overweight and obese 
volunteers. Four weeks of self-administered subcutaneous oxyntomodulin reduced body-weight 
by 2.4%, a magnitude of weight loss which is extremely favourable when compared to the 
available anti-obesity therapies, orlistat, sibutramine and rimonabant (Li et al., 2005; Pi-Sunyer 
et al., 2006). The accompanying reduction in leptin and increase in adiponectin in response to 
oxyntomodulin treatment suggested that the weight loss was at least partly due to a reduction in 
adipose tissue. 
I demonstrated that subcutaneous self-administration of oxyntomodulin significantly reduced 
food intake, with preservation of subjective food palatability, in overweight and obese 
volunteers. The anorectic effect of oxyntomodulin was maintained throughout the course of the 
four-week study period. This contrasted to the effect of oxyntomodulin on food intake observed 
in the rodent experiments (Chapter 2), in which continuous administration of oxyntomodulin 
resulted in a transient effect on food intake which was only present during the first few days. 
This interesting comparison between the rodent and human data may reflect a species 
difference, or it may be due to the different dosing regimens applied in the rodent and human 
experiments (continuous versus bolus). Alternatively, the much slower rate of percentage 
weight loss observed in the human subjects may not induce compensatory mechanisms to the 
same extent as the greater percentage weight loss observed in the rodent models. 
The overweight and obese human volunteers had a sustained reduction in food intake and a 
consistent rate of weight loss (on average 0.45 kg per week) in response to oxyntomodulin 
treatment over the four-week study period. This suggests that continued administration of 
oxyntomodulin beyond this study period may be expected to result in further weight loss. 
Elevated oxyntomodulin levels are thought to contribute to the permanent reduction in weight 
and appetite observed in obese patients following gastrointestinal bypass surgery (Sarson et al., 
1981). The effective weight loss observed after surgically induced modulation of gut hormones 
suggests that the exogenous administration of oxyntomodulin may be an effective long-term 
therapy for obese individuals without the complications that restrict the use of surgery. Longer 
studies of oxyntomodulin administration of at least six months duration, involving much larger 
patient numbers are required to prove the efficacy of oxyntomodulin as a long-term anti-obesity 
204 
therapy. Particularly as some studies have shown that other weight-reducing agents, such as 
dexfenfluramine (a serotonin agonist), lose efficacy over a six-month treatment period (Bever 
and Perry, 1997). 
I proceeded to investigate the effect of subcutaneous oxyntomodulin administration on energy 
expenditure in overweight and obese volunteers. Self-administration of oxyntomodulin 
increased total energy expenditure by 9.4%, despite a reduction in food intake during the study 
period. This increase in total energy expenditure during oxyntomodulin administration was due 
to an increase in activity-related energy expenditure of on average 143 Kcal/day. There was no 
measurable acute change in resting energy expenditure in response to an injection of 
oxyntomodulin. Oxyntomodulin administration resulted in an increase in total energy usage of a 
magnitude which approaches the recommended increase in low-intensity physical activity of 
200 kcal/day for overweight people (World Health Organization, 2000). At baseline, our group 
of overweight and obese volunteers had a reduced physical activity level, as expected in this 
population. However, during oxyntomodulin treatment, activity increased to a level associated 
with maintenance of a normal body-weight (Erlichman et al., 2002; Saris et al., 2003). Thus, 
short-term oxyntomodulin treatment increases physical activity back toward 'normal' levels in 
overweight and obese volunteers. 
The alteration in the level of physical activity observed during oxyntomodulin administration 
was secondary to a trend for volunteers to alter their pattern of activity. Volunteers spent 
slightly less time performing activities of lower physical intensity and longer performing 
activities of higher intensity. This seemed to be a subtle change in non-exercise activity 
thermogenesis, rather than a significant increase in the highest metabolic bands which represent 
exercises such as jogging or running. However, these small changes resulted in a significant 
change in total energy expenditure, supporting the proposal that low intensity activity (such as 
standing, fidgeting and maintenance of posture) can have a significant effect on total energy 
expenditure in humans (Levine et al., 1999; Levine et al., 2000; Fruhbeck, 2005). 
Voluntary dietary restriction in order to lose weight results in a compensatory decrease in 
energy expenditure (Rosenbaum et al., 2002; Leibel et al., 1995; Weinsier et al., 2000). This 
contributes to the difficulty experienced by sedentary obese individuals who attempt to reduce 
their body-weight by dieting. In contrast, short-term oxyntomodulin administration resulted in 
an increase in energy expenditure during a period of reduced energy intake. This effect on 
energy expenditure is of great benefit for any potential anti-obesity therapy. Longer-term 
clinical trials are required to investigate whether oxyntomodulin treatment can lead to a 
sustained increase in energy usage in overweight and obese humans. 
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One factor that may limit the use of oxyntomodulin as a weight loss therapy is the amount of 
peptide required per dose. The dose given in Chapter 3 and 4, four hundred nmol of peptide 
(2mg) three times a day, is a significant amount given the cost of synthesis. Analogues of 
oxyntomodulin with a greater resistance to breakdown could perhaps be administered at lower 
doses or less frequently. Exendin-4 is a reptilian peptide (Raufman et al., 1992), which has a 
long-lasting agonist effect at the GLP-I receptor (Goke et al., 1993; Thorens et al., 1993; 
Schepp et al., 1994) due to its resistance to breakdown by the enzyme DPP4 (Thum et al., 
2002). A study of the administration of exendin4 at a much lower dose than oxyntomodulin (10 
mcg) demonstrated a small weight loss of 2.3 kg over 26 weeks in type 2 diabetics (Heine et al., 
2005). Analogues of oxyntomodulin with resistance to enzymatic degradation could perhaps 
prove more economical and acceptable weight loss agents, whilst retaining the significant 
weight-reduction properties of the naturally-occurring sequence. Breakdown-resistant analogues 
of other gut hormones are already in development. For example, modification of the PYY3-36 
molecule using reversible PEGylation (the reversible attachment of polyethylene glycol to PYY 
via a spontaneously cleavable linker) has been found to increase the functional half-life in 
circulation from 3 to 24 hours in rodents (Shechter et al., 2005). An alternative strategy for 
prolonging the life of a peptide in circulation is to couple it to albumin, a technique which may 
prove effective for GLP-I (Baggio et al., 2004a). The relevance of these techniques to the 
oxyntomodulin molecule and the efficacy of these innovations in human volunteers require 
further investigation. 
Despite the intense research into appetite regulation and the emerging abundance of potential 
pharmacological targets, few new drugs reach human trials and even fewer enter clinical 
practice. Unwanted side-effects can occur with drugs that target the central signalling pathways, 
as they also affect extra-hypothalamic regions not involved in energy homeostasis. For example, 
sibutramine (a combined serotonin and noradrenaline reuptake inhibitor) has been found to 
cause an increase in heart rate and blood pressure, secondary to its effects on the sympathetic 
nervous system (Li et al., 2005). Rimonabant (a newly-licensed cannabinoid receptor I 
antagonist) has been reported to cause psychiatric symptoms including anxiety and depression 
(Pi-Sunyer et al., 2006). In contrast, the use of endogenous peripheral signals, such as 
oxyntomodulin, may have the advantage of specifically targeting the appetite circuits. Indeed, in 
human studies reported to date oxyntomodulin therapy appear well- tolerated (Chapter 3, 
Chapter 4, (Cohen et al., 2003)). 
Elucidating the hypothalamic mechanism of action of oxyntomodulin is largely dependent on 
evidence from animal studies. However, data from the two human studies I performed provides 
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some suggestion of the possible mechanism by which oxyntomodulin modulates energy 
homeostasis in humans. The reduction in food intake in response to the administration of 
oxyntomodulin was not accompanied by a change in pre-prandial appetite scores in the studies 
described in Chapter 3 and 4, although this was not the case during intravenous administration 
of oxyntomodulin to normal weight humans (Cohen et al., 2003). The effect of subcutaneous 
oxyntomodulin on appetite in overweight and obese humans may be primarily a perception of 
early post-prandial satiety, rather than reduced pre-prandial appetite. A visual analogue score 
assessment of early satiety would be best investigated by administering oxyntomodulin prior to 
providing a meal of fixed calorie content, as in my studies the anorectic effect of oxyntomodulin 
confounded any post-prandial recording of appetite scores. Another possible mechanism by 
which oxyntomodulin may reduce food intake in humans is via a delay in gastric emptying. 
Oxyntomodulin, GLP-l and exendin-4 have been found to delay gastric emptying in humans 
(Schjoldager et al., 1988; Verdich et al., 2001a; Edwards et al., 2001). However, oxyntomodulin 
is likely to have anorectic effects independent of gastric emptying as a reduction in appetite has 
been demonstrated in fasted volunteers (Cohen et al., 2003) and in rodents, food intake has been 
inhibited without any demonstrable effect on gastric emptying (Dakin et al., 2004). 
Oxyntomodulin administered intravenously has been found to suppress circulating ghrelin levels 
in humans (Cohen et al., 2003), however this does not seem a probable mechanism for the 
anorectic effect observed after subcutaneous infusion as there was no significant suppression of 
ghrelin levels in the studies described in Chapter 3 and 4. 
There is some evidence that the mechanism of increased energy expenditure in humans may be 
partly mediated by the thyroid axis. An increased level of circulating TSH was observed after 
administration of oxyntomodulin compared with saline (Chapter 4). This did not produce an 
increase in free T3 or T4 within the 150 minutes measured post-injection, but this may not 
perhaps be expected within this sampling period, particularly as the levels of oxyntomodulin do 
not peak until on average 30 minutes after subcutaneous injection. For comparison, in healthy 
individuals a bolus dose of intravenous TRH is followed by a rise in serum TSH concentration 
peaking after 20 to 30 minutes and a subsequent increase in circulating T3 and T4 after 120 to 
180 minutes (Faglia, 1998; Braverman and Utiger, 2005). However, it remains a possibility that 
oxyntomodulin does not alter circulating T3 and T4 in humans and this warrants further 
investigation. 
A coupling of reduced food intake and increased energy expenditure has been previously 
observed in humans following leptin administration (Ahima et al., 1996). Low-dose leptin 
replacement has been found to reverse the adaptive reduction in energy expenditure, 
sympathetic activity and circulating thyroid levels observed after weight loss (Rosenbaum et al., 
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2002) and it has been postulated from animal studies that this reversal is secondary to alterations 
in hypothalamic appetite-regulatory neuropeptides including POMC expression (Rosenbaum et 
al., 2002). It is possible that the effect of oxyntomodulin administration on energy homeostasis 
in humans is mediated via similar integrative mechanisms as represented in Figure 5.0. The 
central mechanism by which oxyntomodulin administration suppresses food intake and 
increases energy expenditure in humans could be further investigated by sophisticated methods 
of brain imaging. The hypothalamic functional magnetic resonance imaging (MRI) response has 
been successfully studied in rodents following the administration of glucose (Mahankali et al., 
2000), positron emission tomography has been used to generated functional brain maps of the 
neuroanatomical correlates of hunger and satiety in human volunteers (Del et al., 2002) and 
functional MRI has been used to investigate the temporal response of the brain after eating in 
humans (Liu et al., 2000). A recent study using manganese-enhanced MRI in rodents has 
demonstrated a reduction in neuronal activity in the ARC, PVN and supraoptic nuclei of the 
hypothalamus in response to intraperitoneal oxyntomodulin administration (Chaudhri et al., 
2006). It may soon be possible to visualise the hypothalamic regions involved in energy 
homeostasis and investigate how these areas are modulated by the administration of peripheral 
signals, such as oxyntomodulin, in humans. 
In summary, oxyntomodulin administration decreases food intake and increases energy 
expenditure, resulting in a reduction in body-weight in both rodents and humans. The effect is 
preserved in obese humans, making this peptide an attractive target in the development of anti- 
obesity agents. As for many chronic illnesses, it is possible that the homeostatic mechanisms 
which regulate energy homeostasis may results in compensatory responses to the administration 
of a single therapeutic agent. It has already been demonstrated that hormonal combination 
therapies may be more efficacious in the reduction of energy intake than the administration of a 
single hormone (Neary et al., 2005). However, it remains to be seen whether repeated co- 
administration of gastrointestinal hormones or the use of oxyntomodulin in combination with 
other anti-obesity interventions will prove to have a more robust effect on weight loss in 
humans. Large-scale clinical trials are essential in order to establish whether oxyntomodulin can 
realise its therapeutic potential. In the future, oxyntomodulin may prove to be an effective 
weapon in the treatment of obesity. 
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6.1 Appendix A: Amino Acids 
Ala (A) Alanine 
Cys (C) Cystine 
Asp (D) Aspartic acid 
Glu (E) Glutamic acid 
Phe (F) Phenylalanine 
Gly (G) Glycine 
His (H) Histidine 
Ile (1) Isoleucine 
Lys (K) Lysine 
Leu (L) Leucine 
Met (M) Methionine 
Asn (N) Asparagine 
Pro (P) Proline 
Gln (Q) Glutamine 
Arg (R) Arginine 
Ser (S) Serine 
Thr (T) Threonine 
Val (V) Valine 
Trp (W) Tryptophan 
Tyr (Y) Tyrosine 
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6.2 Appendix B: Radioirnmunoassay Methods And Solutions 
6.2.1 Radioimmunoassay Methods 
Radioimmunoassays (RIAs) were used to measure circulating plasma hormones and peptides 
released from hypothalamic explants and pituitary quadrants. The RIAs were performed under 
the guidance and supervision of Professor M. Ghatei (Professor of Regulatory Peptides, 
Department of Metabolic Medicine, Imperial College London), who monitored the specificity 
and sensitivity of all the 'in-house' RIAs. 
6.2.2 General Principle of a Radioimmunoassay 
RIA is a technique for measuring biological substances present at low levels in tissue and 
plasma samples. The measurement of peptides by RIA relies on competition between 
radiolabelled and non-radiolabelled antigen for a fixed number of specific antibody binding 
sites. Adding increasing amounts of unlabelled antigen, either from samples or standards, to a 
constant quantity of labelled antigen and a constant and limited quantity of antibody results in a 
decrease in the labelled antigen bound to antibody at equilibrium. The antibody-bound antigen 
is separated from the free antigen either by addition of dextran-coated charcoal (which binds 
free antigen in ihe charcoal pellet) or by complexing the primary antibody with a secondary 
antibody (free antigen remains in the supernatant). Following centrifugation and separation, the 
activity in the bound and free components is measured in a y-counter and the data used to 
construct a standard curve. By reference to the standard curve, the concentration of unknown 
samples can be calculated. 
*Ag + Ab + Ag +-+ *AgAb + Ag Ab 
Where *Ag = radiolabelled antigen, Ag = unlabelled antigen and Ab = antibody. 
Inter-assay variation can be calculated by assaying aliquots of the same sample in each assay 
performed and comparing the concentrations obtained in each. To measure and correct for intra- 
assay baseline drift, tubes with no sample ('zero' tubes) are placed at regular intervals 
throughout the assay and a standard curves are performed at the beginning and end of each 
assay. The general structure of the RIA is outlined in the table below which shows the content 
of the tubes according to their designation. 
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The following tubes are important for the assessment and performance of the assay: 
Non-specific binding: low binding indicates adequate label integrity 
V2X: assesses if greater sensitivity could be achieved by adding half the volume of label. 
2 X: assesses if greater sensitivity could be achieved by adding double the volume of label. 
Zero tubes: allows assessment of assay drift. 
Excess antibody: assesses the immunological integrity of the labelled peptide. 
Quality Controls: includes previously aliquoted samples containing high and low levels of the 
antigen. These tubes allow the assays to be standardised. 
Tube number Designation 
1-2 Non-specific binding 
3-4 V2 X 
5-6 2X 
7-8 Zero 
9-10 Zero 
11-12 Standard 1 
13-14 Standard 2 
15-16 Standard 3 
17-18 Standard 4 
19-20 Standard 5 
21-22 Standard 6 
23-24 Standard 7 
25-26 Standard 8 
27-28 Standard 9 
29-30 Standard 10 
31-34 Zero 
35-... Samples 
Zeros Duplicate zeros every 50 samples 
Second standard curve Standards 
Final two tubes Excess 
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6.2.3 Hypothalamic Neuropeptide RlAs 
The peptides used were purchased from Phoenix Pharmaceuticals (Belmont, CA, USA). All 
other reagents and materials were supplied by Sigma (Poole, Dorset, UK), or BDH (Poole, 
Dorset, UK). Professor M. Ghatei iodinated the peptides and purified them by HPLC using a 
C18 column (Waters, Milford, CT, USA) (Wood et al., 1981). The solvents were acetonitrile 
and water and all solutions for IIPLC contained 0.05% (v/v) trifluoroacetic acid (TFA). 
Solvents were passed through 0.2 tim disc filters under vacuum prior to use. The flow rate was 
maintained at Iml/min. The column was equilibrated with 15% (v/v) acetonitrile before addition 
of the iodinated reaction mixture. The acetonitrile concentration was maintained at 20% for the 
first 10 minutes before being gradually increased to 20-45% acetonitrile over the following 90 
minutes. 1.5 ml ftactions were collected into aI ml solution of 20mM Hepes (pH 11) and 0.3% 
Bovine Serum Albumen (BSA, ICN Biochemicals). The fractions were tested by RIA and used 
at 1500 cpni/tube. Antisera were raised in rabbits immunised with each peptide conjugated to 
Freund's adjuvant. All assays were performed in 0.06M phosphate buffer (0.05M 
Na2HP04.21120,0.006M KH2P04.0.01M disodium-EDTA. 21120,0.008M NaN3), at pH 7.4 with 
0.3% BSA, unless otherwise stated. 
All samples were assayed in duplicate. Standard curves prepared for each assay used synthetic 
peptide made up to varying concentrations in assay buffer and added in duplicate at volume of 
1,2,3,5,10,15,20,30,50 and 100pl. The assays were incubated for 72 hours at 4'C. Free and 
bound peptides were separated using secondary antibody or charcoal adsorption. For secondary 
antibody separation, samples were pre-incubated for at least 30 minutes with 100 pl of goat 
anti-rabbit solid-phase secondary antibody (Pharmacia Diagnostics, Uppsala, Sweden). 
Immediately prior to centrifugation, 500 ItL of 0.01% Triton-X-100 solution was added to each 
tube. For charcoal adsorption, the free fraction was separated using 4 mg of charcoal per tube 
suspended in 0.06M phosphate buffer with gelatine, added immediately prior to centrifugation. 
The samples were then centrifuged at 1500g, 4'C, for 20 minutes. Bound and free label were 
separated and both the pellet and supernatant counted for 180 seconds in a 7-counter (model 
NEI 600, Thermo Electron Corporation). Peptide concentrations in the samples were calculated 
using a non-linear plot (RIA Software, Thermo Electron Corporation) and results calculated in 
terms of the standard. 
6.2.3.1 a-MSH RIA 
A sample volume of 200 pI from hypothalamic slice media was used and all tubes were 
buffered to a total volume of 400 ýtl in 0.06M phosphate buffer with 0.3% BSA. A standard 
concentration of 0.25 pmol/ml was used and the antiserum was used at a final dilution of 
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1: 20000. The antiserum showed full cross-reactivity to synthetic a-MSH, but no cross-reactivity 
to any other POMC product. Separation was performed by charcoal adsorption of the free 
fraction. 
6.2.3.2 CART RIA 
A sample volume of 10 ill from hypothalamic slice media was used and all tubes were buffered 
to a total volume of 700 pI in 0.06M phosphate buffer with 0.3% BSA and 0.02% Tween-20. A 
standard concentration of I pmol/ml was used and the antiserurn was used at a final dilution of 
1: 80000. The assay was separated by charcoal adsorption. 
6.2.3.3 NPY RIA 
A sample volume of 150 gI from hypothalamic slice media was used and all tubes were 
buffered to a total volume of 350 pl in 0.06M phosphate buffer with 0.1% BSA A standard 
concentration of 0.5 pmol/ml was used and the antiserurn was used at a final dilution of 
1: 120000. The assay was separated using a secondary antibody technique. 
6.2.3.4 TRH RIA 
A sample volume of 200 pI from hypothalamic slice media was used and all tubes were 
buffered to a total volume of 350 pI in 0.06M phosphate buffer with 0.3% BSA. A standard 
concentration of 1.25 pmol/mI was used and the antibody used at a final dilution of 1: 25000. 
Antiserum. for the TRH RIA was kindly given by H. M. Fraser (Medical Research Centre 
Reproductive Biology Unit, Edinburgh, UK). The assay was separated using charcoal 
adsorption. 
6.2.3.5 AgRP RIA 
AgRP was measured using reagents and methods from Phoenix Pharmaceuticals (Kalsruhe, 
Germany). The AgRP (82-121)-NH2 assay utilises 12'I-labeled AgRP and AgRP antiserum to 
determine the level of AgRP in samples. Reagents were supplied and reconstituted according to 
the protocol. Assay buffer (200 1d) was added to the non-specific binding (NSB) tubes. 
Standards, quality controls and pituitary quadrant media (100 [d) were added in duplicate. 
Primary antibody (rabbit anti-peptide serum, 100 pl) was added to all tubes except those 
measuring NSB. The assay was incubated for 24 hours at 4*C. Following this incubation period, 
100 1,1 of 1251-AgRP (10000 cpm/100 pl) was added to all tubes. The assay was incubated for a 
further 24 hours at 4'C. Goat anti-rabbit secondary antibody (100 gl) and normal rabbit serum 
(100 pl) were added to all tubes. The assay was incubated at room temperature for 90 minutes 
prior to adding buffer (500 gl). The tubes were centrifuged at 1500g, 40C, for 20 minutes. The 
pellet and supernatant were separated and counted using a y-counter. The AgRP concentration 
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in the samples was calculated using a non-linear plot and results calculated in terms of the 
standard. 
6.2.4 TSH RIA 
Plasma levels of TSH were measured by radioimmunoassay using the reagents and methods 
generously provided by the NIDDK and National Hormone and Pituitary Program (Dr A 
Parlow, Habor University of California, Los Angeles Medical Centre). 
Purified TSH (2 [tg) was aliquoted in 0.5M phosphate buffer (pH 7.6) and stored at -70 *C until 
use. A2 [tg aliquot of TSH in 20 ttl of 0.5 M phosphate buffer was iodinated with 0.5 mCi of 
Na 1251 (IMS30 Amersham Biosciences) using Chloramine T (1.4 gg / 10 [d) and the reaction 
stopped 15 seconds later with sodium metabisulphate (4.8 [tg / 10 gl) (BDH) (Wood et al., 
1981). The iodinated peptide was separated from the free iodine and unlabelled peptide by size 
exclusion chromatography using a 12 cm Sephadex G50 column (Amersham Biosciences). The 
column was equilibrated with 0.5 M phosphate buffer containing 0.5% BSA. Fractions of 0.5 ml 
were collected and activity measured. The first three fractions containing the highest counts 
were tested in the RIA. 
The TSH assay was carried out in Kemteck buffer (pH 7.4). Samples were assayed in a total 
volume of 400 pl with 1500 cpm/tube of iodinated hormone. Standards were serially diluted 
with the concentration of the highest standard at I OOng/ml and the antibody was used at a final 
dilution of 1: 2400000. A sample volume of 10 pI from pituitary quadrant media was used and 
the assay separated using secondary antibody. The samples were pre-incubated for 30 minutes 
with 100 Itl of goat anti-rabbit secondary antibody (Pharmacia Diagnositics). Immediately prior 
to centrifugation, 500 pl of 0.01% Triton-X-100 solution was added to each tube. The samples 
were then immediately centrifuged at 1500g, 4*C, for twenty minutes. Bound and free label 
were separated and both the pellet and supernatant counted for 180 seconds in a T-counter 
(model NE1600, Thermo Electron Corporation). Peptide concentrations in the samples were 
calculated using a non-linear plot (RIA Software, Thermo Electron Corporation) and results 
calculated in terms of the NIDDK standard preparation (NIDDK rat TSH RP-3). 
6.2.5 Plasma Hormone RIM 
6.2.5.1 Oxyntomodulin-like immunoreactivity (OLI) RIA 
There is no specific assay for oxyntomodulin and assays detect both glicentin and OXM, 
collectively known as oxyntomodulin-like immunoreactivity (OLI). Oxyntomodulin and 
glicentin both contain the sequence of glucagon, and therefore can be detected by antibodies 
against the non-terminal epitopes of glucagon (side-viewing antisera). Assays based on side- 
viewing antisera, to glucagon will also cross-react with pancreatic glucagon (total glucagon (TG) 
assay). However the concentration of pancreatic glucagon can be specifically determined using 
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antisera directed against the exposed C-terminal of glucagon (pancreatic glucagon (PG) assay). 
Hence by subtracting the PG from the TG, the concentration of oxyntomodulin and glicentin 
(OLI) can be estimated (Ghatei et al., 1983) (Figure 131). The assay is thus based on the 
subtraction of RIA values obtained with the C-terminal-directed PG antiserum RCS5 from the 
TG immunoreactivity determined with the side-viewing glucagon antiserum R59 (Figure B I). 
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Figure 131: the principle of the oxyntomodulin-like immunoreactivity (OLI) assay. 
The side-viewing total glucagon antibody (T(; ), which is directed at the middle of 
the glucagon sequence, will detect pancreatic glucagon, glicentin and 
oxyntomodulin. The C-terminal directed glucagon antibody will detect only 
pancreatic glucagon. Measurement of OLI: glicentin + oxyntomodulin (OXM) is 
made by the subtraction of PG from the TG assay. The numbers refer to the amino 
acid position starting at the N-terminal amino acid. GRPP: glicentin-related 
pancreatic polypeptide. 
Antisera to pure porcine pancreatic glucagon (Novo Industry A/S, Copenhagen, Denmark) were 
raised in rabbits. One of the antibodies generated (RCS5), which was raised against glucagon 
conjugated to BSA with bis-diazo-benzidene (pH 5), was directed against the C-terminal of 
pancreatic glucagon and showed less than 0.01% cross-reactivity with porcine glicentin. The 
other antiserum (R59), which was raised against glucagon conjugated to BSA with 
carbodiimide, was directed against the N-terminal to mid-region of the glucagon molecule and 
cross-reacted 94% with porcine glicentin. Pancreatic glucagon assay standards were prepared 
from a standard vial supplied by the WHO International Laboratory for Biological Standards 
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(Holly Hill, London, UK). Stability of the aliquoted peptide was maintained by making up 
standard vials in a solution of O. IM formic acid containing 0.1 mol/L lactose, 0.4 mmol/L BSA 
and 1,600 KIU/ml aprotinin, lyophilised and stored in vacuo at -20'C. 
For the total glucagon assay a sample volume of 100 jil of the volunteers' plasma samples was 
used and all tubes were buffered to a total volume of 700 RI in 0.06M phosphate buffer with 
0.3% BSA. The standard was used at a concentration of I pmol/ml and the R59 antibody was 
used at a final dilution of 1: 1600. The pancreatic glucagon assay used a sample volume of 200 
RI and all tubes were buffered to a total volume of 800 [d in 0.05 M sodium barbitone buffer 
(pH 8.0), containing 30 [tmol/L BSA and 200 KIU/ml aprotinin. All standard and assay control 
tubes contained 200 [d of Haemacel (Beacon, Tunbridge Wells, UK). The standard was used at 
a concentration of 0.5 pmol/ml and the RCS5 antibody was used at a final dilution of 1: 320000. 
After five days incubation at 4'C, the assay was separated using charcoal adsorption and 
centrifuged at 1500g, 4C, for twenty minutes Bound and free label were separated and both the 
pellet and supernatant counted for 100 seconds in a y-counter (model NEI 600, Thermo Electron 
Corporation). Peptide concentrations in the samples were calculated using a non-linear plot 
(RIA Software, Thermo Electron Corporation). The concentration of OLI in plasma was taken 
as the difference between the total (non-specific) glucagon cross-reactivity determined by the 
R59 assay and the pancreatic glucagon immunoreactivity determined by the RCS5 assay. The 
OLI assay could detect changes of 10 pmol/L (95% confidence limit) with an intra-assay 
variation of 5.7%. All tubes were assayed in duplicate and within one assay to avoid inter-assay 
variation. 
6.2.5.2 PYY RIA 
Plasma PYY was measured using a specific and sensitive radioimmunoassay (Adrian et al., 
1985a). The antiserurn (Y21) was raised in rabbits against synthetic porcine PYY (Bachem Ltd. 
UK), coupled to BSA by gluteraldehyde, and used at a final dilution of 1: 50,000. The Y21 
antibody to PYY did not cross-react with pancreatic polypeptide, neuropeptide Y or other 
known gastrointestinal hormones. The 12'lodine labelled PYY was prepared by the iodogen 
method and purified by HPLC (Wood et al., 1981). The assay was performed in a total volume 
of 700 gl of 0.06M phosphate buffer with 0.3% BSA, using a 200 til sample volume. The assay 
was incubated for 3 days at 4C before separation of free and antibody-bound label by 
secondary antibody (sheep anti-rabbit antibody). The assay detected changes of 2 pmol/L (95% 
confidence limits), with an intra-assay coefficient of variation of 5.8%. All samples were 
assayed in duplicate and within one assay to avoid inter-assay variation. 
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6.2.5.3 Insulin RIA 
The insulin RIA was developed using "in house" methods and reagents (Kreymann et al., 1987). 
Natural porcine insulin was iodinated using the iodogen method and purified by HPLC (Wood 
et al., 1981). The insulin antibody was raised in guinea pigs against human insulin conjugated to 
BSA by glutaraldehyde. The antibody cross-reacts with all mammalian forms of insulin and in 
this assay antibody was used at a dilution of 1: 250000. A sample volume of 100 [il of the 
volunteers' plasma was used and all tubes were buffered to a total volume of 700 til in 0.06M 
phosphate buffer with 0.3% BSA. A standard concentration of 2 pmol/ml was used and the 
assay was separated by charcoal adsorption. 
6.2.5.4 Ghrefin RIA 
Plasma ghrelin was measured with a specific and sensitive radioimmunoassay (Patterson et al., 
2005). This assay measures both octanoyl and des-octanoyl ghrelin and does not cross-react 
with any other known gastrointestinal or pancreatic hormone. 125 I-ghrelin was prepared with 
Bolton & Hunter reagent (Amersham International, UK) and purified by HPLC using a linear 
gradient from 10 to 40% acetonitrile, 0.05% TFA over 90 minutes. The antiserum, SC-10368 
(Santa Cruz Biotechnology) was used at a final dilution of 1: 50000 and a standard concentration 
of 2 pmol/mI was used. A sample volume of 50 [d of the volunteers' plasma was used and all 
tubes were buffered to a total volume of 700 [il in 0.06M phosphate buffer with 0.3% BSA. The 
assay was separated using charcoal absorption. The assay detected changes of 20 pmol/L of 
plasma ghrelin with a 95% confidence limit and the intra-assay coefficient of variation was 
5.5%. 
6.2.5.5 Leptin RIA 
Leptin was measured using reagents and methods from Linco Research Inc. (St Charles, MO, 
USA). The human leptin assay utilises 125 I-labeled human leptin and human leptin antiserum to 
determine the level of leptin in plasma by the double antibody/PEG technique. Assay buffer was 
added to the non-specific binding (NSB) tubes (300 RI), reference tubes (200 RI) and to the 
remaining tubes (100 RI). Standards, quality controls and plasma samples (100 [d) were added 
in duplicate. 125I-human leptin (100 Id) was added to all tubes and primary antibody (rabbit anti- 
human leptin antibody, 100 [d) was added to all tubes except those measuring NSB and total 
counts. The assay was incubated for 24 hours at 4*C. Following this incubation period, Iml of 
cold (4'C) precipitating reagent was added to all tubes except those measuring total counts. The 
assay was incubated for a further 20 minutes at 4'C. The tubes were centrifuged at 2000g, 4'C, 
for 20 minutes. The pellet and supernatant were separated and counted using a T-counter (model 
NEI 600, Thermo Electron Corporation). The human leptin concentration in the samples was 
calculated using a non-linear plot (RIA Software, Thermo Electron Corporation) and results 
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calculated in terms of the standard. For a sample concentration of 10.4 ng/ml, intra-assay 
coefficient of variance was 3.9%, and inter-assay coefficient of variance was 4.7%. 
6.2.5.6 Adiponectin RIA 
Adiponectin was measured using reagents and methods from Linco Research Inc. (St Charles, 
MO, USA). The human adiponectin assay utilises 1251-labeled murine adiponectin and a multi- 
species adiponectin rabbit antiserum to determine the level of adiponectin in plasma by the 
double antibody/PEG technique. The adiponectin standard is prepared using recombinant 
human adiponectin and can be used to determine the circulating levels of adiponectin in human 
serum/plasma samples. Circulating concentrations of adiponectin in human plasma are at pg1rnI 
levels, whereas the assay range is I- 200 ng/ml. The plasma samples were therefore diluted 
1: 500 prior to use in this RIA. 
Assay buffer was added to the non-specific binding (NSB) tubes (300 pl), reference tubes (200 
pl) and to the remaining tubes (100 [d). Standards, quality controls and plasma samples (100 pl) 
were added in duplicate. 125 I-human adiponectin (100 pl) was added to all tubes and primary 
antibody (rabbit anti-adiponectin antibody, 100 ýtl) was added to all tubes except those 
measuring NSB and total counts. The assay was incubated for 24 hours at room temperature 
(20-25"C). Following this incubation period, 10 [d of rabbit carrier (30% normal rabbit serum) 
and 1.0 ml of cold (4'C) precipitating reagent was added to all tubes except those measuring 
total counts. The assay was incubated for a further 20 minutes at 4'C. The tubes were 
centrifuged at 2000g, 4'C, for 20 minutes. The pellet and supernatant were separated and 
counted using a y-counter (model NE1600, Thermo Electron Corporation). The human 
adiponectin concentration in the samples was calculated using a non-linear plot (RIA Software, 
Thermo Electron Corporation) and results calculated in terms of the standard. For a sample 
concentration of 3 pg/ml, intra-assay coefficient of variance was 6.21%, and inter-assay 
coefficient of variance was 6.9%. 
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6.2.6 Solutions Used In This Thesis 
2M calcium chloride: Dissolve 5.88g of CaC12.21-120 in 20 ml water and sterilise by 
passing through a 0.22 micron filter and store in I ml aliquots at -20'C. 
Dextran coated charcoal: Add 2.4 g of charcoal and 0.24 g of dextran to 100 ml of 
phosphate buffer with gelatine and mixed for twenty minutes at 200C 
2xHEPES-buffered saline: Dissolve 1.6gNaCl, 75mgKCI, 21mgNa2HP04,0.22 
glucose and Ig HEPES in a total volume of 90ml water. Adjust to pH 7.05 with 0.5M 
NaOH and volume to I 00ml with water. Sterilise by passing through a 0.22 micron 
filter and store in 5ml aliquots at -201C. 
Kemtek buffer: Dissolve in 4L of cool, pre-boiled distilled water, 22.40 g NaH2P04. 
9.96 g Na2IF04,14.80 g EDTA, 1.00 g Thimersal and pH adjusted to 7.4 with 
hydrochloric acid. Add 1.00 ml BSA (30%). 
m 1M Magnesium chloride: Dissolve 203.3 9 M9CI2 in IL water. 
Phosphate buffer (RIA buffer): Dissolve 48 g of Na2HP04.21-120,4.13 g KH2P04ý 
18.61 g CjOH14H208Na2.2H20,2.5 g NaN3 in 5L of boiled cooled water. Confirm pH as 
7.4 ± 0.1 and store at 4*C. 
Phosphate buffer with gelatin: Prepare the buffer as for phosphate buffer, with 12.5 g 
of gelatin dissolved in the boiling water. Allow to cool before the addition of the other 
ingredients. Confirm pH as 7.4 ± 0.1 and store at 4*C. 
Sephadex G50 superfine: Add 8g fine grade Sephadex G-50 beads (diameter: 20-80 
lim, Sigma), 2 ml 100 x TE and 0.1 ml 20% SDS to 200 ml water and autoclave to 
expand beads. 
a 5M sodium chloride: Dissolve 292.2 g NaCl in IL water. 
10M sodium hydroxide: Dissolve 400 g of NaOH in 500 ml water and top up to IL by 
adding additional water. 
100x TE: Dissolve 121. lg Trizma base and 3.7g COH14H2O8Na2.2H20 in 800ml water 
and adjust pH with hydrochloric acid. Make up to IL with additional water. 
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6.3 Appendix C: Supplementary Data 
Figure Cl: the effect of continuous administration of oxyntomodulin (1000 or 2000 
pmol/kg/min) on cumulative food intake. Statistical values in the legend are 
analysed using a GEE and are given for the 1000 pmol/kg/min group (n=8) and 
2000 pmol/kg/min group (n=8) respectively. (A) Day I (p=0.5052 and p=0.3236), 
(B) Day 2 (p=0.2177 and p=0.0601), (C) Day 3 (p=0.4800 and p=0.7964), (D) Day 4 
(p=0.1145 and p=0.4792), (E) Day 5 (p=0.0121 and p=0.3274) and (F) Day 6 
(p=0.9166 and p=0.9101). The solid bar below the x axis represents the dark-phase 
and the open bar represents the light-phase. The dotted lines represent standard 
error of the mean. Statistical significance shown graphically refers to p<0.05 
(Mann-Whitney test). 
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Figure C2: the effect of continuous administration of oxyntomodulin (1000 or 2000 
pmol/kg/min) on energy expenditure. Statistical values in the legend are analysed 
using a GEE and are given for the 1000 pmol/kg/min group (n=8) and 2000 
pmol/kg/min group (n=8) respectively. (A) Day 1 (p=0.2667 and p=0.1998), (B) Day 
2 (p=0.1703 and p=0.2598), (C) Day 3 (p=0.0760 and p=0.3247), (D) Day 4 
(p=0.0054 and p=0.6638), (E) Day 5 (p=0.0020 and p=0.3064) and (F) Day 6 
(p=0.0054 and p=0.6536). The solid bar below the x axis represents the dark-phase 
and the open bar represents the light-phase. The dotted lines represent standard 
error of the mean. Statistical significance shown graphically refers to p<0.05 
(Mann-Whitney test). 
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Figure C3: the effect of continuous administration of oxyntomodulin (1000 or 2000 
pmol/kg/min) on horizontal activity (XAMB). Statistical values in the legend are 
analysed using a GEE and are given for the 1000 pmol/kg/min group (n=8) and 
2000 pmol/kg/min group (n=8) respectively. (A) Day 1 (p=0.7019 and p=0.0174), 
(B) Day 2 (p=0.8963 and p=0.0015), (C) Day 3 (p=0.2721 and p=0.2148), (D) Day 4 
(p=0.3671 and p=0.1470), (E) Day 5 (p=0.5222 and p=0.4299) and (F) Day 6 
(p=0.0308 and p=0.3214). The solid bar below the x axis represents the dark-phase 
and the open bar represents the light-phase. The dotted lines represent standard 
error of the mean. Statistical significance shown graphically refers to p<0.05 
(Mann-Whitney test). 
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Figure C4: the effect of continuous administration of oxyntomodulin (1000 or 2000 
pmol/kg/min) on vertical activity (ZTOT). Statistical values in the legend are 
analysed using a GEE and are given for the 1000 pmol/kg/min group (n=8) and 
2000 pmol/kg/min group (n=8) respectively. (A) Day I (p=0.3190 and p=0.1417), 
(B) Day 2 (p=0.6619 and p=0.0384), (C) Day 3 (p=0.0499 and p=0.2270), (D) Day 4 
(p=0.0842 and p=0.5775), (E) Day 5 (p=0.6504 and p=0.6445) and (F) Day 6 
(p=0.1232 and p=0.0395). The solid bar below the x axis represents the dark-phase 
and the open bar represents the light-phase. The dotted lines represent standard 
error of the mean. Statistical significance shown graphically refers to p<0.05 
(Mann-Whitney test). 
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Figure C5: the effect of continuous administration of oxyntomodulin (300 or 600 
pmol/kg/min) on cumulative food intake. Statistical values in the legend are 
analysed using a GEE and are given for the 300 pmol/kg/min group (n=8) and 600 
pmol/kg/min group (n=8) respectively. (A) Day 1 (p=0.0166 and p=0.0002), (B) Day 
2 (p=0.0612 and p=0.0618), (C) Day 3 (p=0.3132 and p=0.0169), (D) Day 4 
(p=0.9324 and p=0.4835), (E) Day 5 (p=0.1707 and p=0.9537), (F) Day 6 (p=0.5363 
and p=0.9048) and (G) Day 7 (p=0.7572 and p=0.1452). The solid bar below the x 
axis represents the dark-phase and the open bar represents the light-phase. The 
dotted lines represent standard error of the mean. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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Figure C6: the effect of continuous administration of oxyntomodulin (300 or 600 
pmol/kg/min) on horizontal activity (XAMB). Statistical values in the legend are 
analysed using a GEE and are given for the 300 pmol/kg/min group (n=8) and 600 
pmol/kg/min group (n=8) respectively. (A) Day 1 (p=0.0844 and p<0.0001), (B) Day 
2 (p=0.3372 and p=0.0091), (C) Day 3 (p=0.0387 and p=0.0516), (D) Day 4 
(p=0.0017 and p=0.0378), (E) Day 5 (p=0.0025 and p=0.0005), (F) Day 6 (p=0.0002 
and p=0.0002) and (G) Day 7 (p=0.0912 and p=0.0102). The solid bar below the x 
axis represents the dark-phase and the open bar represents the light-phase. The 
dotted lines represent standard error of the mean. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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Figure C7: the effect of continuous administration of oxyntomodulin (300 or 600 
pmol/kg/min) on vertical activity (ZTOT). Statistical values in the legend are 
analysed using a GEE and are given for the 300 pmol/kg/min group (n=8) and 600 
pmol/kg/min group (n=8) respectively. (A) Day 1 (p=0.2990 and p=0.3673), (B) Day 
2 (p=0.1179 and p=0.7637), (C) Day 3 (p=0.0387 and p=0.2208), (D) Day 4 
(p=0.0906 and p=0.0430), (E) Day 5 (p=0.3401 and p=0.2209), (F) Day 6 (p=0.2178 
and p=0.4642) and (G) Day 7 (p=0.0724 and p=0.2006). The solid bar below the x 
axis represents the dark-phase and the open bar represents the light-phase. The 
dotted lines represent standard error of the mean. Statistical significance shown 
graphically refers to p<0.05 (Mann-Whitney test). 
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Figure C8: the effect of an overnight fast on (A) interval and (B) cumulative 
vertical activity (ZTOT) in mice receiving 600 pmol/kg/min oxyntomodulin by 
continuous subcutaneous infusion (n=12 per group). The solid bar below the x axis 
represents the dark-phase and the open bar represents the light-phase. Statistical 
significance shown graphically refers to p<0.05 (Mann-Whitney test). 
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6.4 Appendix D: Healthy Volunteer Information, Eating Questionnaires And 
Visual Analogue Forms 
6.4.1 Example Of Information Sheet 
Information Sheet for Research Participants 
You will be given a copy of this Information Sheet and a signed copy of your 
consent form to keep, should you decide to participate in the study. 
Study title: Effect of chronic administration of oxyntomodulin on body weit! ht 
You are being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following Information carefully and discuss it with friends, relatives and your GII if you 
wish. Ask Lis it' there is anything that is not clear or ifyou Would like more information. Take 
time to decide whether or not you wish to take part. 
We will be happy to let you have a copy of the leaflet entitled 'Medical Research and You' 
published by Consumers for Ethics in Research (CFRES). This leaflet gives more information 
about medical research and looks at some questions you may want to ask. 
If you do decide to take part, please let Lis know beforehand If You have been involved In ally 
other study during the last year. You are free to withdraw at any tune without explanation. 
'['hank you l'or reading this. 
What is the purpose of the study? 
OXY1110111odulin Is a naturally Occurring substance found in tile blood of' healthy people. It is 
made in the put and released after a meal. Oxyntoniodulin is known to affect the rate at NN111ch L- 
food passes through the gut and decreases appetite in healthy individuals. This study anns to see 
whether these effects on appetite lead to weight loss, by giving regular small injections of 
oxyritoniodulin tinder the skin. This is the first step in seeing whether oxyritornodulin may be a 
satisfactory treatment for obesity. 
Whv have I been chosen? 
Healthy individuals are being recruited to take part in this study. We are looking for people who 
fall into the overweight category, as defined by Body Mass Index of'25 to 40 kg/m2 (calculated 
by dividing Your weight in kilograms by your height in metres squared). 
You should not take part in this study if you 
have any illness or if you take any regular medication likely to ai*f'ect the study (the doctor will 
discuss this With You) 
If You are pregnant or breast feeding 
if you have given blood in the last three months 
It is important that you should not become pregnant dUring the Course of the Study or for one 
month following the study, as the effect of oxyritornodUlin in pregnancy is not known. It is 
therefore important that you have adequate and reliable contraception during this period. 
Do I have to take part? 
It IS LIP to You to decide whether or not to take part. If you do decide to take part you will be 
given this information shect to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and Without giVin_g a reason. 
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What will happen to me if I take part? 
If you agree to take part in this study, you will first be examined by one of the doctors and have 
a number of blood tests and a heart recording (ECG) to ensure you are fit and healthy. You will 
also be asked to complete a questionnaire about your eating habits and be given a small 
injection of saline. (Saline is water with a small concentration of salt dissolved in it, and is 
commonly used. ) This is to see if you can tolerate regular injections needed for the study. 
During the study you will receive small injections of either oxyntomodulin or saline (salt water). 
The study is a randomised, double-blind trial. This means that neither yourself, nor your 
research doctors know what treatment you are being given, although, if your doctor needs to 
find out he/she can do so. 
You will be asked to attend the Department of Medicine (Ward 5 West Charing Cross Hospital) 
for several days out of a period of 6 weeks. 
For the first week that you are asked to attend, you will be given education on making up and 
giving yourself injections. With all injections given under the skin, there is a risk of local 
infection or possibly allergy or irritation from the injection itself. This risk can be minimised by 
using a different part of the stomach on every occasion that you inject yourself (known as 
'rotating the injection sites') 
In the second week, you will be started on a4 week course of injections. The first 3 injections 
will be supervised in the hospital, to ensure that you make-up and give yourself the injection 
correctly, and that no untoward effects occur. The three injections will be given on the same day 
during which time we will monitor your heart rate and blood pressure. After that, you will be 
given dietary advice and also the treatment to administer to yourself at home. 
Every week, we will ask you to return to the hospital for a quick check up to make sure that the 
treatment is not having any side effects. This will involve some routine blood tests. You will 
only be given enough treatment to last I week at a time. 
On days 1,2, and 29 of the study, you will be asked to eat nothing from 9pm the evening before 
and to drink only water from midnight. You will be asked to attend ward 5 West at Charing 
Cross Hospital between 8.00am and approximately 6.30pm. You will be asked to give your 
morning injection on the ward, and you will then be given a meal 30 minutes after the injection, 
to see how your appetite has been affected by the treatment. On these days, a plastic cannula 
will be placed into a vein in one of your arms, in order to collect blood samples. You may feel a 
little discomfort when the cannula is inserted. During the morning you will be seated, or lying 
on a couch, and may read or watch television. On days 2 and 29 you will also be requested to 
keep a record of all food and drink consumed on the day before and day after attending the 
hospital. 
On day 28 you will attend Charing Cross Hospital for an 'oral glucose tolerance test'. You will 
be asked to eat nothing from 9pm the evening before and to drink only water from midnight. 
The next morning on the ward you will be asked to consume a sugary drink. Blood will be taken 
at the start of the test and at half hourly intervals for 90 minutes. This test will assess how well 
your body responds to sugar. 
The amount taken in each blood sample is approximately equivalent to one and a half 
teaspoonfuls. The total amount of blood taken during the entire study will be approximately 350 
mls, which is less than amount taken during a blood donation session. 
The blood samples will be analysed for oxyntomodulin and related hormones. The blood 
samples will also be analysed for blood sugar and similar substances that are found in the blood 
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and are related to metabolism. All blood samples will be destroyed once the study has been 
completed. No blood samples will be used for any form of genetic analysis. 
After the study finishes you will be reviewed by the team and offered further dietary follow-up. 
What do I have to do? 
You will need to be trained to inject your oxyntomodulin or saline by experienced staff at 
Charing Cross Hospital. 
The only restrictions on your lifestyle are that, on days 1,2,28 and 29, you will be asked to eat 
nothing from 9pm the evening before and to drink only water from midnight. For twenty-four 
hours before each treatment, on days 1,2,28 and 29, you will be asked to refrain from taking 
strenuous exercise and drinking alcohol. You will need to keep a record of all food and drinks 
consumed in the day before, and for the twenty-four hours after, day 2 and day 29. Throughout 
the study we will ask you to keep a diary of possible side-effects of the treatment that you are 
receiving. You will be asked to keep to a healthy diet between days 3 and 28. 
Pregnancy will be excluded in female volunteers at the start of the study by questioning and also 
a pregnancy test. You should have adequate contraception for the period of the study and for I 
month afterwards as the effects of oxyntomodulin in pregnancy are not known 
What is the druLy or Procedure that is beint! tested? 
Oxyntomodulin is a naturally occurring hormone found in the circulation of healthy people. 
Oxyntomodulin has been used many times over the past 10 years both in our department and 
others worldwide in healthy men and women without harmful effects. We know from previous 
work that the amount of oxyntomodulin in the blood increases after a meal. We have shown that 
in healthy volunteers oxyntomodulin given into a vein reduces appetite and food intake from a 
buffet consumed during the treatment. We know the dose we need to give as an injection under 
the skin to mimic the levels of oxyntomodulin that caused this effect. This dose of 
oxyntomodulin is less than doses previously given in volunteers without any harmful effects. 
Hence the dose of oxyntomodulin that you will be given is small and designed to increase the 
levels of oxyntomodulin in your body to a level previously shown to reduce appetite and food 
intake without causing any harmful effects. 
What are the side effects of takint! part? 
From our previous studies described above we do not expect any side effects, but the 
unexpected can occur. As oxyntomodulin has not previously been given as an injection under 
the skin over a period of weeks there may be potential hazards relating to oxyntomodulin that 
we are unaware of. During the study experienced doctors will be available at any time should 
you have any concerns. If you suffer from any ill effects during the study you should report 
them to these doctors immediately. You may ask for the study to stop at any time without 
prejudice and if there are any side effects, the study will be stopped. 
What are the possible disadvantages and risks of taking part? 
It is possible that if the treatment is given to a pregnant woman it will harm the unborn child. 
Pregnant women or women planning pregnancy must not, therefore, take part in this study. 
Women who are at risk of pregnancy will be asked to have a pregnancy test before taking part to 
exclude the possibility of pregnancy. Women who could become pregnant must use an effective 
contraceptive during the course of this study. Any woman who finds that she has become 
pregnant while taking part in the study should immediately tell her research doctor. 
What are the possible benerits of taking part? 
The information that we get from this study may help us to better treat future patients who 
suffer from being overweight. You must be aware that you may not lose weight as a result of 
participating in this study. Firstly you have an equal chance of receiving placebo as receiving 
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the active treatment. Secondly it is not yet established whether oxyritornodulin is effective in 
promoting weight loss - the airn of this study Is to establish whether or not this is the case. If 
YOU WOUld like fOllOW-LIp dietary advice after the study has finished this will be provided. 
What if new information becomes available? 
Sometimes during the course of a research pro ject, new information becomes available about 
the treatment that is being studied. 11' this happens, your research doctor will tell you about it 
and discuss with you whether you want to continue in the study. If you decide to Continue In the 
study you will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you frorn the study. 
What happens when the research study stops? 
Once the study has finished, the results of tile StUdy can be made available to you and/or your 
GP should YOU wish. It' you have any problems immediately following the StUdy. then YOU 
should contact one of the research doctors on the numbers provided below. 
What if something Voes wron2? 
In the event of' any adverse events occurring as a consequence of your participation in this 
study, you will be compensated through the Imperial College School of Medicine's 'No-fault' 
Compensation scheme. 
Will my taking part in this study be kept confidential? 
All Hiformation that is collected about you during the course ofthe research will be kept strictly 
confidential. Any information abO11t YOU that lemes the hospital will have your name and 
address removed so that you cannot be recognised from it. It is a requirement that your Gl) is 
informed, with your consent, of your participation in this study, at the start ofthe study. 
What will happen to the results of the research study? 
The results are likeiv to be J)Ubllslied in the six niontlis following the study. Your confidentiality 
will be ensured at all tinies and you will not be identified in any publication. At the end ofthe 
study, the results of the study can be made available to you and/or your GP should you ýklsli. 
Who is orp_anisinp, and fundinjI the research? 
This study is being orgamsed by the department ot'l-ndocrinology at I lanimersinith and CharinO L- Cross Hospitals and ftinded by the medical charities, the Wellcome Trust and the Medical 
Research Council. 
Who has reviewed the study? 
This study has been revieNved by the Riverside Research Ethics Co"I'llittee. 
Contact for Further Information 
If you experience any problems during the study, you may withdraw at any stage. The doctors 
involved in the study, Drs Park and Wynne will be available by telephone at any tinie and call 
be contacted through Professor Bloom's secretary (020 8383 3242). The hospital switchboard 
(020 8383 1000) has horne and mobile phone numbers for all the doctors involved in the study 
and can contact thern at any time outside normal working hours. We will pay your travel 
expenses to and frorn the hospital, whenever you attend for this study. 
The local Research E'thics Committee has approved the above statement: 
Signed. (Chair) Date: 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL: 2006 
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6.4.2 Dutch Eating Questionnaire (DEBQ) 
Volunteer Name: Date: 
Volunteer No. 
Please place an (, /) in the box which applies best to each of the numbered statements. All of the results 
will be strictly confidential. Most of the questions directly relate to food or eating, although other types of 
questions have been included. Please answer each question carefully. Thank you. 
1. If you have put on weight, do you eat less than you usually do? 
E3 Never U Seldom 1: 1 Sometimes E3 Often U Very Often Not Relevant 
2. Do you try to cat less at mealtimes than you would like to eat? 
EI Never El Seldom El Sometimes El Often E3 Very Often 
3. How often do you refuse food or drink offered because you are concerned about your weight? 
El Never El Seldom 1: 1 Sometimes 1: 1 Often El Very Often 
4. Do you watch exactly what you eat? 
El Never 13 Seldom El Sometimes E3 Often El Very Often 
5. Do you deliberately eat foods that are slimming? 
El Never El Seldom U Sometimes El Often Very Often 
6. When you have eaten too much, do you eat less than usual the following days? 
El Never El Seldom El Sometimes LI Often 1: 1 Very Often El Not Relevant 
7. Do you deliberately cat less in order not to become heavier? 
El Never 1: 1 Seldom El Sometimes El Often El Very Often 
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8. How often do you try not to eat between meals because you are watching your weight? 
El Never 1: 1 Seldom El Sometimes El Often E3 Very Often 
9. How often in the evening do you try not to eat because you are watching your weight? 
El Never 1: 1 Seldom U Sometimes El Often 1: 1 Very Often 
10. Do you take into account your weight with what you eat? 
1: 1 Never El Seldom U Sometimes El Often Very Often 
11. Do you have the desire to eat when you are irritated? 
El Never 1: 1 Seldom 1: 1 Sometimes LI Often Very Often El Not Relevant 
12. Do you have a desire to eat when you have nothing to do? 
El Never El Seldom 1: 1 Sometimes L] often El Very Often El Not Relevant 
13. Do you have a desire to eat when you are depressed or discouraged? 
El Never El Seldom El Sometimes El Often El Very Often El Not Relevant 
14. Do you have a desire to eat when you are feeling lonely? 
1: 1 Never 1: 1 Seldom El Sometimes El Often El Very Often El Not Relevant 
15. Do you have a desire to eat when somebody lets you down? 
El Never El Seldom 1: 1 Sometimes El Often 
16. Do you have a desire to eat when you are cross? 
1: 1 Never El Seldom El Sometimes 1: 1 Often 
El Very Often El Not Relevant 
El Very Often U Not Relevant 
17. Do you have a desire to eat when you are approaching something unpleasant to happen? 
U Never El Seldom El Sometimes 1: 1 Often 1: 1 Very Often 
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18. Do you get the desire to eat when you are anxious, worried or tense? 
El Never 1: 1 Seldom 1: 1 Sometimes El Often El Very Often 
19. Do you have a desire to eat when things are going against you or when things have gone wrong? 
El Never El Seldom 1: 1 Sometimes El Often El Very Often 
20. Do you have a desire to eat when you are frightened? 
LI Never El Seldom 1: 1 Sometimes E3 Often Very Often EJ Not Relevant 
21. Do you have a desire to eat when you are disappointed? 
El Never 1: 1 Seldom U Sometimes 1: 1 Often 0 Very Often L3 Not Relevant 
22. Do you have a desire to cat when you are bored or restless? 
E3 Never E3 Seldom El Sometimes El Often El Very Often E3 Not Relevant 
23. Do you have a desire to eat when you are emotionally upset? 
1: 1 Never El Seldom El Sometimes LI Often LJ Very Often El Not Relevant 
24. If food tastes good to you, do you cat more than usual? 
1: 1 Never El Seldom El Sometimes El Often El Very Often 
25. If food smells and looks good do you eat more than usual? 
1: 1 Never El Seldom El Sometimes Q Often Ll Very Often 
26. If you see or smell something delicious, do you have the desire to eat it? 
1: 1 Never El Seldom L1 Sometimes U Often El Very Often 
27. If you have something delicious to eat, do you eat it straight away? 
El Never 1: 1 Seldom El Sometimes El Often El Very Often 
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28. If you walk past the baker do you have the desire to buy something delicious? 
El Never El Seldom E3 Sometimes E3 Often E3 Very Often 
29. If you walk past a snackbar or a caM, do you have the desire to buy something delicious? 
El Never 1: 1 Seldom L) Sometimes El Often El Very Often 
30. If you see others eating, do you also have the desire to cat? 
El Never El Seldom El Sometimes El Often El Very Often 
31. Can you resist eating delicious foods? 
1: 1 Never U Seldom L) Sometimes El Often El Very Often 
32. Do you eat more than usual, when you see others eating? 
El Never El SeIdom El Sometimes El Often Very Often 
33. When preparing a meal are you inclined to eat something? 
1: 1 Never El Seldom 1: 1 Sometimes E3 Often E3 Very Often 
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6.4.3 SCOFF Questionnaire 
1. Do you ever make yourself sick because you feel uncomfortably full? 
2. Do you worry you have lost control over how much you eat? 
3. Have you recently lost more than one stone in a3 month period? 
4. Do you believe yourself to be fat when others say you are too thin? 
5. Would you say that food dominates your life? 
One point is given for every 'yes' answer. 
A score of ý! 2 indicates a likely case of anorexia nervosa or bulimia nervosa. 
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6.4.4 Example Of Visual Analogue Scale 
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
NOT AT ALL EXTREMELY 
HOW PLEASANT WOULD IT BE TO EAT RIGHT NOW? 
NOT AT ALL EXTREMELY 
HOW FULL DO YOU FEEL RIGHT NOW? 
NOT AT ALL EXTREMELY 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
NOTHING A LARGE AMOUNT 
HOW SICK DO YOU FEEL RIGHT NOW? 
NOT AT ALL EXTREMELY 
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Original Article 
Subcutaneous Oxyntontodulin Reduces Body Weight in 
Overweight and Obese Subjects 
A Double-Blind, Randomized, Controlled Trial 
Katie Wynne, " Adrian J: Park, ' Caroline J. Small, ' Michael Patterson, ' Sandra M. Ellis, 2 
Kevin G. Murphy, ' Alison M. Wren, ' Gary S. Frost, 2 Karim Meeran, ' Mohammad A. Ghatei, 1 
and Stephen R. Bloom' 
This study investigated the effect of subcutaneously 
administered oxyntomodulin on body weight in healthy 
overweight and obese volunteers. Participants self-ad- 
ministered saline or oxyntomodulin subcutaneously in a 
randomized, double-blind, parallel-group protocol. In- 
jeetions were self-administered for 4 weeks, three times 
daily, 30 min before each meal. The volunteers were 
asked to maintain their regular diet and level of physical 
exercise during the study period. Subjeets'body weight, 
energy intake, and levels of adipose hormones were 
assessed at the start and end of the study. Body weight 
was reduced by 2.3 :t0.4 kg in the treatment group over 
the study period compared with 0.5 ± 0.5 kg in the 
control group (P = 0.0106). On average, the treatment 
group had an additional 0.45-kg weight loss per week. 
The treatment group demonstrated a reduction in leptin 
and an increase in adiponectin. Energy intake by the 
treatment group was significantly reduced by 170 ± 37 
kcal (25 ± 5%) at the initial study meal (P = 0.0007) 
and by 250 ± 63 kcal (35 ± 9%) at the final study meal 
(P = 0.0023), with no change in subjective food palat- 
ability. Oxyntomodulin treatment resulted in weight 
loss and a change in the levels of adipose hormones 
consistent with a loss of adipose tissue. The anorectic 
effect was maintained over the 4-week period. Oxynto- 
modulin represents a potential therapy for obesity. 
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T he prevalence of obesity is rapidly increasing 
worldwide; currently >65% of adults in the U. S. 
are overweight (1). Although even a modest 
weight loss can improve the health of obese 
individuals, efforts to treat the obesity pandemic have 
been unsuccessful. Novel therapeutic targets are urgently 
required. 
Several gut hormones have been found to modulate 
appetite (2-4). Oxyntomodulin is a peptide product of the 
proglucagon gene released from the Icells of the small 
intestine in response to food ingestion (5). Oxyntomodulin 
has been reported to reduce food intake by 19.3% during 
an intravenous infusion administered to normal-weight 
humans, an efrect that continues for >12 h after infusion 
(6). Furthermore, in rodents, repeated intraperitoneal ad- 
ministration over 7 days has been associated with reduced 
white adipose tissue and a highly significant reduction in 
weight compared with controls (7). Thus, oxyntomodulin 
may offer a novel treatment for human obesity. 
We hypothesized that self-administered subcutaneous 
oxyntomodulin would induce weight loss, reduce appetite, 
and alter the levels of adipose hormones in overweight and 
obese volunteers investigated in a 4-week community- 
based study. 
RESEARCH DESIGN AND METHODS 
Healthy male and female volunteers, ages 18-55 years, with a stable BMI of 
25-40 kg/m' were recruited by advertisement and followed between January 
and August 2004. All potential subjects were nonsmokers with normal 
physical examination, routine blood tests, and electrocardiograms. Subjects 
were screened using the standard Dutch Eating Behavior Questionnaire (8) 
and SCOFF Questionnaire (9) and were excluded if they demonstrated 
abnormal eating behavior. Food preferences were assessed using a nine-point 
hedonistic scale to ensure that the study meal was acceptable. Subjects were 
given a subcutaneous injection of saline to assess whether they would And 
regular injections acceptable. A power calculation was used to estimate the 
number of subjects required to detect a significant effect of oxyntomoduHn on 
a participant's body weight. Assuming a difference of I :t0.2 kg to be clinically 
significant and using a significance level of P<0.05 and 9096 power, it was 
calculated that 12 subjects were required in each group; the final treatment 
group consisted of 14 subjecu, and the final control group consisted of 12 
subjects. Women of child-bearing age were advised to avoid pregnancy by 
using adequate contraception and were asked to provide regular urine tests to 
ensure they were not pregnant. The participants completed the study protocol 
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I K. WYNNE AND ASSOCIATES 
TABLE I 
Baseline parameters of the participants 
Control 
group 
Treatment 
group p 
n 12 14 
BW (kgtm2) 32.8 ± 0.9 33.7 ± 0.9 0.467 
Age (years) 35.0 ± 2.0 32.5 ± 1.8 0.3573 
Height (m) 1.64 ± 0.03 1.67 t 0.02 0.3453 
Weight (kg) 89.0 ± 4.7 94.6 ± 3.4 0.3300 
Femaletmale 11/1 IM - 
Leptin (ng/ml) 283 ± 24 325 ± 60 0.4561 
Adiponectin (ýLg/ml) 111.4 ± 11.3 83.6 ± 9.5 0.0707 
Insulin (pmoIA) 26.7 ± 8.5 34.5 ± 4.7 0.4151 
Glucose (mmol/1) 4.61 ± 0.09 4.76 ± 0.11 0.3430 
Cholesterol (mmol/1) 4.71 t 0.26 4.66 ± 0.19 0.8820 
HDL (nuno]A) 1.07 ± 0.06 1.12 ± 0.09 0.6747 
Ghrelin (pmol/1) 493 ± 87 371 ± 65 0.2627 
Peptide YY (pmol/1) 11.8 ± 1.6 12.2 ± 2.1 0.8881 
Data are means :t SE. An unpaired 9 test was used to compare values 
between the two groups. 
in the community and also attended the Charing Cross Hospital clinical trials 
unit at the start and end of the study for assessment of energy intake. 
Ethical approval was obtained from the Riverside Medical Ethics Commitý 
tee (reference no. 3397). Ali subjects gave informed written consent, and the 
study was performed in accordance with the Declaration of Helsinki. 
The study followed a double-blind, placebo-controlled, parallel-group 
protocol designed to investigate the effect of oxyntomodulin on body weight, 
food intake, and adipose hormones. Oxyntomodulin was synthesized by 
Bachem UX, sterile for culture and negative for pyrogen, as previously 
described (10). A subcutaneous dose of 400 nmol was chosen, which allowed 
us to achieve the same blood concentration as a previous human intravenous 
infusion study that demonstrated a reduction in calorie Intake (6). 
From recrultment, subjects were instructed to continue their current level 
of exercise and usual diet in a regimen of three meals per day. For I week 
before the study, all subjects self-administered saline Injections three times 
daily, 30 min preprandial[ly, Into their abdominal subcutaneous tissue. All 
subjects prepared their Injections by adding 0.25 nd sterile water to vials 
containing freeze-dried sodium chloride and self-administered injections using 
a 27-gauge needle. Subjects who failed to comply with the protocol during this 
week were removed from the study. 
Subjects were randomly allocated to the control or treatment group by an 
independent investigator. Randomization was performed by stratification 
using the parameters BMI and age; subsequent randomization into the control 
or treatment group was performed by coin toss. The control and treatment 
groups were therefore matched for BMI and age and had similar mean height 
and weight measurements (Table 1). The estimated energy requirements for 
the control and treatment groups were not significantly different. 
During the 4-week study period, subjects self-administered normal saline 
or oxyntomodulin (400 nmol), three times dauy, 30 min preprandially. An 
identical protocol for injection preparation was used as In the previous week, 
and the saline and oxyntomoduUn vials were indistinguishable. The subjects 
were reviewed weekly by blinded Investigators to measure body weight, 
check injection technique, and monitor subjects for side effects and compli- 
ance. Adverse events during the iWection period were recorded by diary. 
Protocol compliance was 94.4 ± 1.1% in the control group and 95.3 :t1.2% In 
the treatment group, estimated by counting the number of returned empty 
vials. Compliance was also confirmed by checking for cutaneous sites of 
injection and inspecting the number of subjects' accumulated used needles. 
Subjects were weighed on each visitý and three fasting weights were recorded 
on three separate days at both the start and end of the study using a calibrated 
electronic scale (Marsden, London, U. K) accurate to the nearest 100 8. 
Subjects wore the same light clothing and voided urine before each measure- 
ment. PreiWection blood samples were taken at the start and end of the study 
to measure leptin and adiponectin levels. 
Energy intake was measured during three lunchtime study meals on days 
1,2, and 29. The day before each study meal, subjects refrained from alcohol 
and strenuous exercise and fasted overnight. Subjects first ingested a fixed 
200-kcal breakfast and 210 min later self-administered their injection (desig. 
nated as 9- 0). A meal of known energy content was provided in excess 
quantity 30 min later, and subjects were requested to eat until they felt 
comfortably full. On day 1. all subjects administered a saline injection. On 
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days 2 and 29, the control group administered Wine and the treatment group 
administered oxyntomodulin. Visual analog scales, 100 min in length, were 
completed throughout the study meal day to evaluate subjective feelings of 
hunger, nausea, and meal palatability. 
Blood samples were taken at 9- -30,0,15,30,60,90,150,210, and 240 min 
to screen for any effect of oxyntomodulin on other analytes Crable 3). Ali 
blood samples were collected from an antecubital fossa cannula into lithhun/ 
heparin tubes (LIP, Cambridge, U. K. ) containing 2,000 k&Wkrein inhibitor 
units of aprotinin CIhsylol; Bayer) and stored on ice. After centrifugation, 
plasma was immediately separated and stored at -20T until being analyzed. 
Blood pressure and pulse were measured before each blood sample on each 
of the study meal days. 
Hormone measurements. Commercially available assays were used to 
measure plasma leptin and adiponectin (IAnco Research, St. Charles, MO). 
Plasma oxyntomoduHn-like activity (01.1) was measured using an established 
in-house radioimmunoassay (5). Plasma taken 30 and 90 min after injection 
was analyzed by gel permeation chromatography to assess oxyntomodulin 
degradation (6). Insulin, peptide YY, and ghrelin-like immunoreactivity were 
measured using in-house radloinimunoassays (11-13). Ali samples were 
assayed In duplicate and within one assay to eliminate Interassay variation. 
Glucose and total and RDL cholesterol were measured by an Olympus 
Analyzer. 
Statistical analyses. Combined data are expressed as means ± SF_ Data 
were compared using paired 9 tests for within-group analyses and unpaired I 
tests for between-group anallyses. The changes in body weight, food date, and 
adipose hormones were normally distributed and therefore analyzed using 
parametric analyses. Serial measurements of pulse and blood pressum over 
time were compared using two-way ANOVA. The integrated area under the 
curve for incremental plasma insulin was calculated using the trapezoid rule. 
Prism Version 3.0 was used for statistical calculations, and P<0.05 was 
considered significant 
RESULTS 
Participant flow. Eligibility for the study was assessed in 
89 subjects; 33 healthy subjects were eligible according to 
study criteria, and 56 were excluded because of either 
abnormal eating behavior or coexisting health problems. 
Of the 33 eligible subjects, 31 agreed to enter the study. 
After 2 subjects were excluded in the week before ran- 
dornization because of noncompliance with saline injec- 
tions, 29 were randomized into the study phase: 16 into the 
treatment group and 13 into the control group. One female 
subject, randomized to the treatment group, withdrew at 2 
weeks. Another female subject, randomized to the control 
group, withdrew at 3 weeks. Both subjects cited a dislike 
of self-administering injections as their reason for with- 
drawal. A male volunteer, subject X was removed from 
the treatment group after day 2 due to nausea. Intention- 
to-treat analysis was not possible as these subjects were 
lost to follow-up. Thus 26 subjects completed the entire 
4-week injection period, 14 within the treatment group and 
12 within the control group. 
Effect of oxyntomodulin on body weight. Repeated 
preprandial subcutaneous injection of oxyntomodulin re- 
sulted in a 2.4 ± 0.4% reduction in body weight, compared 
with a 0.5 ± 0.6% reduction in the control group (P = 
0.0129) over the 4-week study period. This represented a 
significant weight loss of 2.3 ± 0.4 kg in the treatment 
group and 0.5 ± 0.5 kg weight loss in the control group 
(P = 0.0106) (Fig. 1). After 2 weeks, interim data demon- 
strated a significant weight loss of 1.1 ± 0.3 kg in the 
treatment group (P = 0.0343), which increased to 1.4 ± 0.4 
kg after 3 weeks (P = 0.0331). Thus, on average, there was 
an additional 0.45-kg weight loss per week in the oxynto- 
modulin group. 
Over the study period, there was a change in adipose 
hormones in the treatment group consistent with a reduc- 
tion in adipose tissue. At the start of the study, the plasma 
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FIG. 1. Change in body weight after self-administration of subcutane. 
ous saline (n - 12) or oxyntomoduHn (OXM; n- 14). In the treatment 
group, a signiticant weight loss of 1.1 :b0.3 kg was observed after 2 
weeks (*P - 0.0343). This loss increased to 1.4 * 0.4 kg after 3 weeks 
of injections (*P - 0.0331). A total weight loss of 2.3 :k0.4 kg was 
observed by the end ofthe 4-week study period (**P - 0.0106). SE bars 
are shown. 
leptin and adiponectin levels in the control and treatment 
groups were not significantly different. In the treatment 
group, the plasma leptin levels were reduced from base- 
line (325 ± 50 ng/ml) by 79 ± 35 ng/ml (19.5 ± 6.2%); this 
change was significant when compared with the control 
group (P = 0.0185) (Table 2). The plasma adiponectin 
levels were increased from baseline (83.6 ± 9.5 ýLghnl) by 
8.3 ± 4.3 ILgIml (9.4 ± 4.9%) in the treatment group; this 
change was also signifIcant when compared with the 
control group (P = 0.0068) (Table 2). 
Effect of oxyntomodulin on food intake and appetite. 
A subcutaneous injection of oxyntomodulin reduced en- 
ergy intake during the study meal. The energy intake of the 
control group was not significantly different on day 1 
(716 ± 108 kcal), 2 (660 ± 99 kcal), or 29 (711 ± 87 kcal). 
On day 1, when the treatment group self-administered a 
saline Wection, energy intake (678 ± 45 kcal) was not 
statistically different from that of the control group. How- 
ever, subjects who self-administered oxyntomodulin had 
significantly lower energy intake on days 2 (508 ± 46 kcal; 
P=0.0007) and 29 (428 ± 61 kcal; P=0.0023) when 
compared with their energy intake on day I (FIg. 2). 
There were no significant differences in the preprandial 
visual analog scales for hunger and nausea in the control 
and treatment groups 30 min after injection (data not 
shown). There also was no difference in the postprandial 
TABLE 2 
Changes in screened analytes over the 4-week study period 
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FIG. 2. Energy Intake at the study meal, 30 min after self-administra. 
tion ofsubcutaneous saline (n = 10) or oxyntomoduUn (OXM; x= 12). 
The data are expressed as the percent of each subject's energy intake 
on day 1, when all subjects self-administered a saline Injection. On day 
2 the control group consumed 92.6 * 3.9% of its energy intake on day 
1: whereas the treatment group consumed only 75.3 ± 5.3% (P - 
0.0194). On day 29, the control group consumed 107.0 :t7.7% of its day 
I intake and the treatment group consumed 65.3 * 9.2% (P - 0.0030). 
11cre was no significant difference between the amount consumed on 
day 2 and day 29 in the treatment group (P = 0.0938) or the amount 
consumed on day 2 and day 29 in the control group (P - 0.1480). SE 
bars are shown. 
assessment of subjective palatability of the food between 
the control (day 2,44 t6 nun; day 29,48 18 mm) and 
treatment (day 2,43 ±5 nun; day 29,44 ±7 nun) groups. 
Only two subjects in each group failed to complete the 
study meal protocol These subjects did not consume the 
same food type at each study meal. In the interest of 
accuracy, these subjects were excluded from food intake 
and appetite analysis before unblinding. Thus, study meal 
data were analyzed with n= 10 for the control group and 
n= 12 for the treatment group. 
Plasma levels of oxyntomodulin. After an injection of 
oxyntomodulin, plasma OU increased to a peak of 972 t 
165 pmol/l at 30 min (FIg. 3). In comparison, on the days 
that subjects administered saline, the mean baseline level 
of 011 was 97.4 t 5.5 pmol/I and the peak postprandial 
level of OU was 116.5 ± 10.4 pmol/I at 150 min. 
Gel permeation analysis (14) of plasma samples from 
the treatment group demonstrated a single immunoreac- 
tive peak eluting at the same position as synthetic oxyn- 
tomodulin, with no indication of any degradative 
fragments. There was also no antibody formation at the 
end of the study, as assessed by plasma binding of the 
oxyntornodulin label. 
Hormone, lipid, and glucose levels. There was a statis- 
Control 
Initial value 
group 
Change in value 
at 4 weeks 
Treatment 
Initial value 
group 
Change in value 
at 4 weeks p 
n 12 12 14 14 
Leptin (ng/ml) 283 t 24 31 ± 25 325 ± 50 -79 ±35 0.0185* 
Adiponectin (ýtg/ml) 111.4 t 11.3 -7.6 ± 3.0 83.6 t 9.5 8.3 ± 4.3 0.0068* 
Insulin (pmol/1) 26.7 ± 8.5 -1.1 ± 5.4 34.6 ± 4.7 -7.8 ± 4.4 0.3394 
Glucose (mmol/1) 4.61 ± 0.09 0.21 ± 0.09 4.76 ± 0.11 0.12 ± 0.08 0.4111 
Cholesterol (mmoLl) 4.71 ± 0.26 -0.26 ± 0.15 4.66 ± 0.19 -0.15 ± 0.11 0.5154 HDL (mmol/1) 1.07 ± 0.06 -0.01 ± 0.03 1.12 ± 0.09 -0.02 ± 0.03 0.8459 
Ghrelin (pmoV1 493 ± 87 47 ± 68 371 ± 65 35 ± 44 0.8586 
Peptide YY (pmol/1) 11.8 ± 1.6 -2.6 ± 1.5 12.2 ± 2.1 -0.6 ± 1.6 0.3651 
Data are means t SF- An unpaired t test was used to compare changes in the control vs. the treatment group. *Significant difference. 
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FIG. S. OxyntomoduUn-Uke immunoreactivity levels for the subjects 
within the treatment group (n = 14) after self-administration of 
subcutaneous saline or oxyntomodulin (OXM). The time of injection 
was designated as t=0 min, and the study meal was consumed at 30 
min. SE bars are shown. 
tically significant increase in preprandial insulin levels 30 
min after subcutaneous administration of oxyntomodulin, 
but the increase was small compared with the effect of 
meal ingestion and not sufficient to affect plasma glucose 
levels (Table 3). This effect on insulin was present on both 
day 2 and day 29 (FIg. 4). The area under the curve for the 
incremental insulin level was nonsignificantly lower on 
day 2 (18.0 t 0.9 nmol - min-' - 1-1; P=0.1378) and 
significantly lower on day 29 (14.9 t 0.7 nmol - min-' - 1- 1; 
P=0.0398) over the 4-h postiWection period compared 
with the day saline was administered (day 1: 21.6 t 1.1 
nmol - min-' - 1-1). 
The injection of oxyntomodulin did not acutely affect 
plasma levels of peptide YY or ghrelin 30 min after 
injection (Table 3). There were no other significant 
chronic preinjection changes observed over the 4-week 
study period in the analytes screened (e. g., in lipid param- 
eters or insulin levels) Crable 2). 
Adverse events. Short-lived minor discomfort at the 
injection site was reported by 8 of 14 of the subjects in the 
treatment group and 5 of 12 of the control group. In total, 
6.9% of all oxyntomodulin injections and 6.6% of all saline 
injections were reported to cause minor discomfort; thus 
discomfort did not appear related to the substance irjected. 
Transient m. Ud nausea was reported with 3% of oxynto- 
modulin irJections compared with 0.2% of all saline Wec- 
tions (P = 0.0389). These data included subject Y, who 
experienced nausea associated with 13 of the first 47 
injections. The dose subject Y administered was halved, 
and the incidence of nausea decreased to 2 out of the 
remaining 37 Wections. On day 29, subject Y had a peak 
011 level of 868 pmol/l, compared with the mean peak for 
the group of 972 t 619 pmoL4, despite taking only half the 
meal 
-Day I 
-Day 2 
-Day 29 
-30 0 30 60 90 150 
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FIG. 4. Insulin levels for the treatment group (n = 14) after self- 
administration of saline (day 1) and oxyntomodulin (days 2 and 29). 
The time of injection was designated as t=0 min, and the study meal 
was consumed at t- 30 min. After oxyntomodulin injection, there was 
a small but significant rise in preprandial insulin (***day 2, P=0.0004; 
day 29, P=0.0008). On day 1, the integrated area under the curve for 
the Incremental insulin level after the injection was 21.6 * 1.1) umol - 
min-' - I-'. The area under the curve was nonsignificantly lower on day 
2 (18.0 * 0.9 umol - min-' - I`; P-0.1378) and significantly lower on 
day 29 (14.9 :t0.7 umol - min-' - I`; P=0.0398). SE bars are shown. 
dose of oxyntomodWin. A second participant, subject Y, 
was removed from the treatment group after day 2 be- 
cause of adverse effects and was not included in the 
analysis; after each of the initial three oxyntomodulin 
irjections, subject X had significant nausea that interfered 
with daily activities. This subject's plasma OU levels 
peaked at 2,140 pmo]A 15 niin postinjection and were 
significantly higher than the rest of the treatment group 
over the entire 4-h study period (P < 0.0001 by two-way 
ANOVA). Another subject regularly experienced nausea 
for 2 days during her midmenstrual cycle and was included 
in the treatment group data in the interest of stringency. 
The incidence of all other reported adverse events was 
<2% and not significantly different between the treatment 
and control groups. There were no effects of oxyntomodu- 
lin self-administration on pulse rate or systolic or diastolic 
blood pressure as measured during the study meal days. 
Follow-up data. The treatment group regained 1.1 ± 0.4 
kg 2 weeks after terminating the oxyntomodulin iWec- 
tions. The control group gained 0.5 ± 0.2 kg and were 
0.0 ± 0.6 kg different from their initial weight The 
difference in weight loss between the control and treat- 
ment group was no longer significant 2 weeks after the end 
of the study period (P = 0.134). One subject in the control 
group and one in the treatment group were lost to fol- 
low-up after the end of the study-, therefore, the follow-up 
data were analyzed with n- 11 in the control group and 
n= 13 in the treatment group. 
TABLE 3 
Acute response of analytes to iNection of saline or oxyntomodulin In the treatment group 
Day 1 (saline) Day 2 (oxyntomodulin) Day 29 (oxyntomodulin) 
Change at Change at Change at 
Initial value 30 min Initial value 30 min p Initial value 30 min p 
hisulin (pmol4) 34.6 ± 4.7 -6.1 ± 3.2 27.4 ± 3.6 32.6 ± 7.7 0.0004* 26.7 ± 4.3 40.5 ± 10.1 0.0008* 
Glucose (mmol/1) 4.79 ± 0.09 -0.04 ± 0.06 4.73 ± 0.10 0.07 ± 0.08 0.300 4.88 ± 0.09 0.02 ± 0.07 0.6629 
Ghrelin (pmol/1) 370 ± 65 -5 :t 23 375 t 74 -42 ± 35 0.3429 405 ± 86 -49 ± 22 0.2327 
Peptide YY (pmol/1) 12.2 ± 2.1 1.1 ± 2.2 15.2 ± 4.4 -3.5 ± 4.1 0.3377 12.1 ± 1.6 -2.6 ± 1.3 0.1637 
Data are means ± SE. A paired t test was used to compare the change from baseline 30 min after an injection of oxyntomodulin with the 
change on day I when the treatment group injected saline. *Significant difference. 
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DISCUSSION 
Self-administering oxyntomodulin subcutaneously effec- 
tively reduced body weight by 2.496 over a 4-week period in 
healthy overweight and obese volunteers. This effect was 
substantial considering that all subjects were asked to 
continue their usual diet and level of exercise. The accom- 
panying reduction in leptin and increase in adiponectin 
suggest that the weight loss demonstrated was at least 
partly due to a reduction in adipose tissue. A significant 
reduction in energy intake with preservation of subjective 
food pala tability was also observed. The magnitude of t1iis 
anorectic effect was sufficient to account for the weight 
loss in the treatment group (15). 
The plasma OLI levels achieved by subcutaneous Wec- 
tion were similar to those achieved by an intravenous 
infusion of 3.0 pmol - kg- i. min-' in a study that reduced 
food intake by 19.3% in normal weight subjects (6). This 
anorectic effect was comparable with the effect observed 
in overweight subjects in the current study. This suggests 
that oxyntomodulin has an equipotent anorectic effect in 
normal weight and overweight subjects and that obesity 
does not confer resistance to the anorectic effect of 
oxyntomodulin. 
A recent human intravenous infusion study demon- 
strated no effect of oxyntomodulin on insulin or glucose 
levels in normal-weight humans (6). In the current study, 
there was no evidence of a postprandial incretin effect. 
There was a small increase in preprandial plasma insulin 
after oxyntomodulin injection. However, this increase was 
not sufficient to alter plasma glucose levels. Other gut 
hormones, such as glucagon-like peptide, are known to 
have a powerful incretin effect (12). Indeed, glucagon-like 
peptide 1, while improving glucose tolerance when given 
to type 2 diabetic subjects (16), can cause hypoglycernia in 
nondiabetic subjects (17). There was no evidence of a 
change in baseline insulin, glucose, or lipid levels over the 
4-week study period in this group of healthy obese sub- 
jects. Further studies are needed to assess to what degree 
long-term oxyntomodulin administration leads to an im- 
provement in metabolic parameters in obese subjects with 
abnormal glucose and lipid metabolisrn. 
The current study did not demonstrate an effect of 
oxyntomodulin on the circulating level of the orexigenic 
hormone ghrelin. It has been suggested that a proportion 
of the anorectic effect of intravenously administered oxyn- 
tomodulin is secondary to its suppressant effect on ghrelin 
(6). However, this does not seem a likely mechanism for 
the dose administered subcutaneously in the current 
study. The decrease in body weight was secondary to a 
significant reduction in energy intake. This reduction in 
energy intake was likely due to a reduction in appetite, as 
there was preservation of food satisfaction and therefore 
no evidence of taste aversion. Indeed, a previous study 
demonstrated that administration of intravenous oxynto- 
modulin reduces preprandial hunger scores in normal- 
weight humans (6). However, the current study did not 
demonstrate a change in subjective appetite scores before 
the meal after a subcutaneous injection of oxyntomodulin. 
This may have reflected a perception of early satiety rather 
than a reduced preprandial appetite or a failure of the 
visual analog scores as a tool of appetite measurement. 
The self-administration of subcutaneous oxyntomodulin 
2394 
was welt-tolerated by the subjects, and good compliance 
rates were achieved. This was a fixed initial dose study-, a 
dose of 400 runol oxyntomodulin may not be appropriate 
for all subjects. Indeed, subject Y experienced a much 
lower incidence of nausea after the dose was reduced. 
Subject X demonstrated extremely high plasma OIJ levels 
after oxyntornodulin irJection and experienced significant 
nausea. These subjects may have absorbed oxyritomodulin 
more rapidly or metabolized the peptide more slowly. 
Larger groups studies are needed to assess if this was an 
idiosyncratic response. 
These preliminary data suggest that the administration 
of oxyntomodulin could be an effective treatment for 
obesity. The reduction in food intake seen at the end of the 
study was statistically no different to the reduction on day 
2, indicating that the efficacy of oxyntomodulin was main- 
tained. In addition, the rate of weight loss was consistent 
over the 4-week study period. Oxyntomodulin levels are 
increased in patients who have had jejunoileal bypass 
surgery (18,19). This sustained elevation of plasma oxyn- 
tomodulin may be one of the factors leading to successful 
weight reduction in these patients. There was no evidence 
of oxyntomodulin antibody formation from the assay data. 
Together, this suggests that administration of oxynto- 
modulin beyond the 4-week study period may be expected 
to result in continued weight loss. However, these data are 
limited by our small sample size and the 4-week duration 
of the study. Longer-terrn clinical trials involving larger 
numbers of participants are required to demonstrate the 
long-term efficacy of oxyntomodulin as an antiobesity 
therapy. 
In summary, subcutaneous self-administration of oxyn- 
tomodulin three times daily in the community reduced 
body weight, decreased food intake, and altered the levels 
of adipose hormones in overweight and obese nondiabetic 
human subjects. The anorectic effect was well maintained 
over the 4-week study period, and the weight loss com- 
pared favorably with that achieved through other drug 
therapies. Currently available pharmacological agents li- 
censed for weight reduction therapy have limited efficacy 
(20). Several drugs now in development affect widely 
distributed central neurotransmitter systems and may 
therefore have a broad spectrum of side effects. Mimicking 
postprandial satiety by administering a natural postpran- 
dial hormone such as oxyntomodulin may provide a more 
specific treatment for obesity. 
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ORIGINAL ARTICLE 
Oxyntomodulin increases energy expenditure in 
addition to decreasing energy intake in overweight 
and obese humans: a randomised controlled trial 
K Wynne 1,3, Aj Park 1,3, Q Small', K Meeran', MA Ghateil, GS FroSt2 and SR Bloom' 
'Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital, London, UK and 2Department of 
Dietetics, Imperial College London, Hammersmith Hospital, London, UK 
Background: Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti- 
obesity therapy. 
Objective: To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free- 
living' overweight and obese volunteers. 
Design: Randomized double-blind controlled cross-over trial. 
Setting: Community and hospital-based. 
Participants: Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m2). All volunteers 
completed the study protocol. 
Interventions: Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were 
advised to maintain their normal dietary and exercise regimen. 
Measurements: (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; 
(2) energy intake, measured during a study meal. 
Results: Oxyntomodulin administration reduced energy intake at the study meal by 128±29kcal (P=0.0006) or 17.3±5.5% 
(P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure, but Increased 
activity-related energy expenditure by 143±109kcal/day or 26.2±9.9% (P=0.0221); total energy expenditure by 9.4±4.8% 
(P=0.0454) and physical activity level by 9.5±4.6% (P=0.0495). A reduction in body weight of 0.5±0.2% was observed 
during the oxyntomodulin administration period (P = 0.0232). 
Conclusion: Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. 
This data supports the role of oxyntomodulin as a potential anti-obesity therapy. 
Internationallournol of Obesity advance online publication, 18 April 2006; doi: 10.1038/sj. ijo. 0803344 
Keywords: energy expenditure; activity, appetite; oxyntomodulin; proglucagon 
Introduction 
The rapidly increasing prevalence of obesityl is the result of 
an interaction between environmental factors such as highly 
palatable energy-dense food and little requirement for 
physical activity, and genetic factors which pre-dispose to 
weight gain. Z3 Current interventions and therapies have not 
abated the mounting obesity criSiS. 4 However, manipulation 
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of the gut-brain axis offers potential strategies for the 
development of novel anti-obesity therapies. 
The 37 amino-acid peptide, oxyntomodulin, Is a product 
of the proglucagon gene released post-prandially from the 
L-cells of the small intestine In proportion to calorie intake. 5 
It is a satiety signal, which has been shown to reduce energy 
intake when administered to rodents and humans. " 
We have recently demonstrated that repeated pre-prandial 
self-administration of oxyntomodulin results in significant 
weight loss of 2.3 ± 0.4 kg (2.4 ± 0.4% body-weight) in over- 
weight and obese study participants over a 4-week period. 9 
One mechanism of this weight loss In humans is a decrease 
in energy intake; it has been observed that oxyntomoduIin 
significantly suppresses energy intake by 19±6% when 
administered Intravenously at a dose of 3. Opmol/kgminG 
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and by 25±5 to 35±9% when administered subcutaneously 
at a dose of 400nmols. 9 However, rodent studies have 
suggested that Increased energy expenditure, as well as 
reduced energy Intake, is responsible for the decrease In body 
weight observed after administration of oxyntomodulin . 
7, a 
Rats, which received twice-daily intraperitoneal injections of 
oxyntomodulin (50nmol/kg) for seven days demonstrated 
lower adiposity and body weight than pair-fed animals, 
despite Identical calorie intake. $ It has been hypothesised 
that a positive effect of oxyntomodulin on energy expendi- 
ture in rodents may occur as a consequence of a change In 
the thyroid axis. 7 
Increased sedentary behaviour is an important factor in 
the development of human obesity. 10 Whilst low-resting 
energy expenditure may contribute to obesity, 11,12 recent 
research has indicated it has minimal Impact on weight 
gain 13,14 and activity-related energy expenditure may be 
much more Important. 15 It has been reported that low 
physical activity accounted for 77% of weight gain over a 
year In one prospective study 16 and inactivity is a major 
determinant of increased adiposity during overfeeding. " 
Indeed, the variability of response to an obesigenic environ- 
ment may be explained by inter-individual differences in 
non-exercise physical activity, which vary over 30-fold. 3 An 
anti-obesity treatment which both increases activity and 
reduces energy intake is more likely to be a. successful long- 
term therapy for obesity. 
The effect of oxyntomodulln on energy expenditure in 
humans has not been investigated. We hypothesised that 
subcutaneous oxyntomodulin self-administered before 
meals would increase energy -expenditure in addition to 
reducing energy Intake in overweight and obese volunteers. 
Methods (experimental) 
Volunteers 
Healthy male and female volunteers, aged 18-55 years, with 
a stable body-mass index (BMI) 25-40kg/m2, were recruited 
by advertisement and completed the study between February 
and May 2005 at the Sir John McMichael Centre for research 
study, Hammersmith Hospital (London, UK). The subjects 
had stable body weight over the preceding 3 months and 
were not on calorie-restricting diets or weight-loss medica- 
tions. Ali subjects were non-smokers with normal physical 
examination, routine blood tests and electrocardiograms. 
Subjects were excluded if they demonstrated abnormal 
eating patterns as measured by questionnaire. 18,19 Food 
preferences were assessed using a nine-point hedonistic scale 
to ensure the study meal was acceptable. Women of child- 
bearing age were advised to use adequate contraception and 
provided regular urine samples to ensure they were not 
pregnant. 
A power calculation was used in order to estimate the 
minimum number of subjects required to detect a significant 
effect of oxyntomodulin on participant's energy intake. 
Intemabonal joumal of Obeslty 
Based on our previous data, 9 assuming a difference of 
170±45kcal to be clinically significant, using a significance 
level of P<0.05 and 90% power, it was calculated that a 
minimum of 11 subjects were required to complete the 
protocol. Fifteen volunteers were recruited and all partici- 
pants completed the entire study protocol. 
Ethical approval was obtained from the Medical Ethics 
Committee (04/QO401/136). Ali subjects gave informed 
written consent and the study was performed In accordance 
with the Declaration of Helsinki. 
Matefials 
Human sequence oxyntomodulln peptide was synthesized 
(Bachem, UK), and confirmed as sterile on culture and 
pyrogen free (Cape Cod Ltd, Liverpool, UK). Individual doses 
of freeze-dried oxyntomodulln and sodium chloride were 
prepared in vials indistinguishable from each other, A dose of 
400 nmol of oxyntomodulin was chosen as it successfully 
decreased body weight In our previous study. 9 Study 
participants prepared all injections by the addition of 
0.25 ml sterile water to the vials and self-administered the 
dissolved substance subcutaneously into their abdomen 
using a 27 gauge needle. 
Protocol 
The study was a randomised controlled double-blind cross- 
over study designed to investigate the effect of oxyntomo- 
dulin on energy expenditure and energy intake. Fifteen 
subjects completed three 4-day study sessions, separated by 
at least 72h. Each study session protocol was Identical 
(Figure 1) and was scheduled on the same calendar days of 
the week. During the initial study session, all subjects self- 
administered saline in order to habituate to the procedures. 
During the second and third study periods subjects self- 
administered saline and oxyntomodulin in random order, as 
allocated by an independent Investigator. All participants 
were advised to continue their usual exercise and dietary 
regimen throughout the study period. 
.fIIIIIIII 
Saline oroxyntomodulin Injecdons 
Istudyntem I Tree-uving- environment 
IlCalorime 
Figure I Participants injected saline and 400nmol oxyntomodulln pre. 
prandially, three times claily, ever a four day period. The Interventions were 
performed In random order, separated by at least 72h. Energy expenditure 
was monitored over the study period. A study mial to measure energy Intake 
was completed on day I and Indirect calorimetry was performed on day 4. 
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Participants self-administered injections subcutaneously, 
three times daily, 30min before their meal. Each subject 
administered nine injections over a study session, commen- 
cing at lunchtime on day I and terminating at breakfast on 
day 4. On days 2 and 3 subjects were 'free-living' and 
Injections were self-administered in their own environment. 
Compliance with injections was 99.25% during both the 
saline and oxyntomoduilin administration periods, estimated 
by counting returned empty vials and confirmed by check- 
ing cutaneous sites of injection and inspecting accumulated 
used needles. 
Energy intake was measured at a study meal in the research 
unit. For 24 h before commencement of each study session, 
subjects avoided alcohol and strenuous exercise and then 
fasted overnight from 2100. On day 1, participants attended 
the research unit and self-administered their injection. A 
meal of known energy content was provided in excess 30 min 
later and subjects were requested to eat until they felt 
'comfortably full'. Each individual received an Identical study 
meal on each occasion. Depending on their taste preference 
this was either: chicken curry (171 kcal, 6g protein, 19 g 
carbohydrate, 7.9g fat per 100g), mushroom stroganoff 
(123kcal, Mg protein, 17.9g carbohydrate, 4.3g fat per 
100g) or chicken tagliatelle (129kcal, 6.9g protein, 16.7g 
carbohydrate, 3.8 g fat per 100g). The mass of food consumed 
was measured and used to calculate energy Intake. Visual 
analogue scales (previously described in Batterham et An 
were completed by the participants before and after the meal 
In order to evaluate subjective feelings of appetite, nausea 
and meal palatability. These scales consisted of a 100 mm line 
with text expressing the most positive and most negative 
ratings anchored at each end. In order to assess appetite the 
volunteers were asked 'How hungry do you feel? ', 'How much 
do you think you could eat? 'and'How full do you feel? 'with 
higher values signifying more positive subjective ratings. 
Blood samples were taken, at baseline and 30,60,90,120 and 
150min post-injection, from an antecubital fossa cannula 
into lithium/heparin tubes (LIP Ltd., Cambridge, UK) con- 
taining 2000 kallikrein inhibitor units of aprotinin (Trasylol, 
Bayer). Samples were stored on Ice, centrifuged, and the 
plasma component separated and stored at minus 20'C until 
radioimmunoassay analysis. Blood pressure and pulse were 
measured before each blood sample. 
Resting energy expenditure was measured by indirect 
calorimetry (Deltatrac II (Datex-Ohmeda Limited, Hatfield, 
UK)) on day 4 of each study session. The calorimeter was 
calibrated immediately before each testing session in 
accordance with manufacturer's guidelines. Participants 
attended the research unit having fasted overnight from 
midnight. They were placed under the hood of the 
calorimeter and baseline measurements were taken for 
30min. Subjects then had an injection administered 
into the subcutaneous tissue of their abdomen. A further 
30min of data recording was performed. The Indirect 
calorimetry unit used breath-by-breath expired gases to 
calculate average V02 and VC02 per hour while the subject 
was recumbent and resting. Respiratory quotient (RQ) was 
calculated and used to derive energy expenditure: Energy 
expenditure= 1.32 x V02 x (1.23 x RQ+3.81). 
Activity-related energy expenditure was measured using 
the combined movement and heart rate sensor Actiheart2' 
(Cambridge Neurotechnology Ltd., Papworth, UK). This 
sensor has recently been developed in order to allow 
measurement of human energy expenditure in a 'free-living' 
environment and has been validated against whole-body 
calorimetry using a fixed activity protocol. 22 It consists of a 
single-piece waterproof monitor attached to two standard 
ECG electrodes placed on the subjects' chest. For the current 
study, the sensor was set to measure movement and heart 
rate every 30s over the 4-day-period. Participants were 
instructed to replace the ECG electrodes if necessary and 
advised that the monitor would not interfere with their daily 
activities. The monitor was removed on day 4 of the study 
period; the data was downloaded into a computer, and 
analysed using Actiheart Software. This software used 
branched equation modelling to derive 'free-living' daily 
energy expenditure from movement and heart rate para- 
meters. 23 Each subject had individual calibration of the 
Actiheart monitor data by input of their measured resting 
energy expenditure into the model. The subjects also 
performed a graded exercise test on day I of each study 
session In which they were asked to repeatedly mount a 
step of height 220mm, at a speed of 15 steps per minute 
increasing to 33 steps per minute, over an 8 min period. 
Using this data, the computer employed linear regression 
analysis to model the relationship between heart rate and 
work rate, which was then used to further calibrate the 
energy expenditure data for each participant. 
Participants' fasting weight was recorded on days I and 4 
of each study session on the same calibrated scale (Marsden, 
London, UK), accurate to the nearest 100g. At each 
recording, an average of three measurements was taken after 
the subject had voided urine. Participants were requested to 
record any adverse events which occuff ed over the study 
period in a diary. 
Honnone analysis 
Plasma oxyntomodulin-like activity (OLD was measured using 
an established in-house radioimmunoassay. s The OLI assay 
could detect changes. of I0pmoVI (95% confidence limit) 
with an intra-assay variation of 5.8%. Insulin and ghrelin-like 
immunoreactivity were measured using in-house radio- 
immunoassays. 24,25 The insulin assay could detect changes 
of 6pmol/I (95% confidence limit) with an Intra-assay 
variation of 5.4%, whereas the &elin assay could detect 
changes of 8 pmoVI (95% confidence limit) with an intra-assay 
variation of 9.5%. All samples were assayed in duplicate and 
within one assay to eliminate inter-assay variation. Thyroid 
stimulating hormone, free T3 and free T4 were measured using 
an Abbott Architect analyzer. Glucose was measured using an 
Olympus AU640 clinical chemistry analyzer. 
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Statistical analysis 
Combined data are expressed as mean (± s. e. ). The study was 
a cross-over design and therefore statistical analysis was 
performed comparing paired data sets with saline adminis- 
tration as a control. Energy Intake and energy expenditure 
data were normally distributed and therefore analysed with 
paired t-tests. Serial measurements of circulating oxynto- 
modulin levels, pulse and blood pressure over time were 
compared using two-way analysis of variance (ANOVA). 
Energy expenditure data from the Actiheart monitor was 
analysed using Actiheart Software (Version 2.1, Cambridge 
Neurotechnology Ltd., Papworth, UK). Prism Version 4.0 was 
used for statistical calculations and P<0.05 was considered 
significant. 
Results 
Demographics 
Fifteen' subjects, four males and 11 females were recruited, 
and all completed the protocol (Table 1). The mean age was 
37±2 years (range 23-49 years) and mean body-mass index 
was 32.3±0.9 kg/m2 (range 25.1-39.0 kg/m2). These subjects 
were not taking prescribed medications. 
Energy intake 
A subcutaneous injection of oxyntomodulin reduced energy 
intake during the study meal. When subjects self-adminis- 
tered saline they ingested 792±94kcal, however, when 
the same subjects self-administered oxyntomodulin 
they Ingested 663±88kcal, a reduction of 128±29kcal 
(P=0.0006). When expressed as a percentage of the intake 
on the saline day for each individual, this was equivalent to a 
reduction of 17.3±S. 5% (P=0.0071, Figure 2). Although 
energy intake at the study meal was significantly reduced by 
oxyntomodulin, water intake remained unchanged (saline 
Table I Demographic: profile of the volunteers, Including body mass Index 
(BMI) and mean pre-injection resting metabolic rate (RMR) 
Subject Sex Age (years) Weight (kg) Height (m) SMI (kglff? ) RMR (kcallday) 
I Male 46 124.9 1.79 39.0 1672 
2 Male 28 91.2 1.83 27.2 1498 
3 Male 42 105.0 1.76 33.9 1618 
4 Female 40 86.4 1.57 33.1 1092 
5 Female 23 71.8 1.69 25.1 1140 
6 Female 33 88.6 1.75 28.9 1442 
7 Male 40 92.9 1.73 31.0 1394 
a Female 45 87.2 1.59 34.5 1175 
9 Female 47 80.3 135 33.4 941 
10 Female 38 90.2 1.63 33.9 1170 
11 Female 32 86.8 1.65 31.9 1254 
12 Female 25 64.9 I. S1 28.5 1032 
13 Female 28 108.3 1.78 34.2 1275 
14 Female 49 99.8 1.68 35.4 1339 
15 Female 43 87.2 1.64 32.4 12SS 
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0.256±0.0381 versus oxyntomodulin 0.265±0.035L 
P=0.7468). 
Immediately before the study meal, there were no 
differences detected in visual analogue scales assessing 
subjective appetite. After an injection of saline or oxynto. 
modulin, the change from baseline for hunger (5 ±1 versus 
2±4mm, respectively, P-0.5329), prospective food intake 
(3 ±1 versus 2±6 mm, respectively, P=0.7304) and fullness 
(0±4mm versus -2±2, respectively, P=0.7811) were not 
significantly different. The subjects' ratings of pre-prandial 
nausea were not changed by an injection of oxyntomodulin 
(saline 4±3mm versus oxyntomodulin 5±2; P=0.6817) 
and the study meal was rated as equally palatable (saline 
64 ±6 mm versus oxyntomodulin 57±6 mm; P=0.2386). 
Body-weight was reduced over the 4-day study period in 
which the participants self-administered oxyntomodulin. 
During the period over which saline was administered, the 
subjects maintained their body-weight, with a change of 
0.0 ± 0.1 kg or 0.1 ± 0.2%. After 4 days of oxyntornodulin 
injections, the subjects' body-weight decreased by 
0.5 ± 0.2 kg (P = 0.0329) or O. S ± 0.2% (P - 0.0232). 
Energy expenditure 
Indirect calorimetry demonstrated a mean fasting basal 
respiratory quotient of 0.92±0.02 and a fasting basal resting 
energy expenditure of 1293±53kcal/day before saline 
administration. As expected, this data was not significantly 
different from the fasting basal respiratory quotient 
(0.93±0.02; P=0.5803) and resting energy expenditure 
(1318±64kcal/day; P=0.6161) measured before oxyntomo- 
dulin injection. Oxyntomodulin injection did not signifi- 
cantly alter respiratory quotient (saline 0.89±0.02 versus 
oxyntomodulin 0.88±0.02; P=0.5534) or resting energy 
expenditure (saline 1127±32kcaVday versus oxyntomodu- 
lin 1242±50kcal/day, P=0.6987) over a 30min post-injec- 
tion period. Neither was there evidence of an effect of 
oxyntomoduHn on resting energy expenditure when ad- 
justed for individual body-weight measured at the end of 
each studyperiod (saline 13.6±0.5 kcal/kg/day versus oxynto. 
modulin 13.7±0.3 kcal/kg/day, P- 0.6555). 
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Figure 2 The effect of oxyntomodulin (OXM) on the energy Intake of the 
participants duflng the study meal. Energy Intake was significantly reduced by 
17.3 ± 5.5% (P- 0.0071). 
249 
Oxyntomodulin and energy balance 
K Wynne et of 
Combined movement and heart rate monitoring measured 
activity-related energy expenditure. Oxyntomodulln re- 
sulted in an increase in daily activity during the 'free-living' 
period on days 2 and 3. On average participants expended 
1172±110kcal/day during the period of saline administra- 
tion. However, during the period of oxyntornodulin admin- 
Istration they expended 1301±109kcal/day, an Increase of 
143±109kcal/day. When expressed as a percentage of the 
activity-related energy expenditure during saline adminis- 
tration for each individual, this represented an increase of 
26.2±9.9% (P=O. OZ21; Figure 3a). When adjusted for 
Individual body-weight at the end of each study period, 
there was a similar increase of 26.8±9.9% (P=0.0197). Total 
energy expenditure was calculated as the sum of resting 
energy expenditure and activity-related energy expenditure. 
It is therefore not surprising that oxyntomodulin also 
Increased total energy expenditure (saline 2443 ± 120 versus 
2585 ± 111 kcal/day) by a similar amount of 143 ± 109 kcal/ 
day, which represents an increase of 9.4±4.8% for each 
individual (P=0.0454; Figure 3b). When adjusted for 
individual body-weight at the end of each study period, 
there was a similar increase of 9.8±4.2% (P=0.0357). 
Physical activity level is a way of expressing the amount of 
energy each individual is expending relative to their resting 
energy expenditure, and is calculated by dividing each 
individual's total energy expenditure by their resting energy 
expenditure. During saline administration the average 
physical activity level was 1.65±0.06, increasing to 
1.74±0.05 during oxyntomodulin administration, which 
represents an Increase of 9.5±4.6% for each individual 
(P=0.0495; Figure 3c) or . 
8.1±4.2% (P=0.0438) when 
adjusted for Individual body-weight. 
In addition to measurement of mean daily energy 
expenditure, combined movement and heart rate monitor- 
Ing allows investigation of the intensity of physical activity 
over time. Intensity can be expressed as the time spent by 
participants in 'metabolic bands', calculated as multiples of 
each individuals' resting energy expenditure. During the 
oxyntomodulin Injection period there was a non-significant 
trend for the subjects to spend greater time in metabolic 
bands >2.5, compared with controls (52±28% longer, 
P=0.0861). 
Hormone assays 
Baseline plasma oxyntomodulin levels were 41±7pmol/l, 
increasing to 63 ± 16 pmol/I post-prandially. However, when 
participants self-administered oxyntomodulin, levels In- 
creased to 658±85pmol/I immediately before the study 
meal (Figure 4). 
At 30min after subcutaneous administration of oxynto- 
modulin there- was a statistically significant Increase in pre- 
prandlat Insulin levels of +64±15pmol/I (P=0.0003, 
Table 2). This change in insulin was Insufficient to alter 
plasma glucose levels in this non-diabetic population 
(P = 0.3175, Table 2). The potential benefits of this insulin- 
releasing action have not yet been explored in subjects with 
abnormal glucose homeostasis. 
The injection of oxyntomodulin did not change circulat- 
ing levels of free T3 (P=0.5203), free T4 (P=0.1626) or 
thyroid-stimulating hormone (P=0.4091) (Table 2). Neither 
did the injection of oxyntomodulin acutely affect plasma 
levels of ghrelln, 30 min after injection (P - 0.2863, Table 2). 
Blood pressure and pulse rate 
Blood pressure and pulse rate were measured manually in 
the research unit over a 150 min rest period post-injection. 
Administration of oxyntomodulin did not result in any 
significant changes in systolic blood pressure (P=0.1388, 
two-way ANOVA), diastolic blood pressure (P = 0.2282, two- 
way ANOVA) or pulse rate (P=0.0840, two-way ANOVA) 
(data not shown). Pulse rate was also measured by the 
Actibeart monitor every 30s over the same resting period. 
The pulse rate was not significantly different following an 
injection of oxyntomodulin (saline mean 71±1 b. p. m. 
versus oxyi6omodulln mean 72±1b. p. m.; P=0.6221,2- 
way ANOVA). 
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Figure 3 The effect of oxyntomodulin (OXM) on energy expenditure of the 
participants during the study period. (a) Daily activity-related energy 
expenditure was increased by 26.2±9.9% (P-0.02211ý (b) Daily total 
energy expenditure was Increased by 9.4±4.8% (P-0.0454). (c) Physical 
activity level was Increased by 9.5 ± 4.6% (P - 0.0495). 
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Figure 4 The levels of oxyntomodulin-like activity (Oij) were measured by 
radioimmunoassay. Baseline levels were 41: t 7pmol/l, rising to 63 ±16 pmolA 
post-prandially. After subcutaneous administration of 400nmol oxyntomo- 
dulin (OXM), levels Increased to 658± 85 pmol/I immediately pre-prandially, 
and peaked at 752±255 pmol/I 30min after the meal. 
Intemational loumal of Obesity 
250 
Oxyntomodulin and energy balance 
K Wynne et al 
6 
Table2 The effect of oxyntomodulin on circulating factors 30 min after Injection, prior to a meai 
AnoVe Sarthe Oxyntomodulin 
Baseline 30 min Change Baseline 30min Change 
Insulin (pmol/1) 57± 7 54±9 -3±9 57±6 121 ±18 +64±15- 
Glucose (mmol/D 4.71±0.08 4.64±0.09 -0.07±0.06 4.71 ±0.06 4.77±0.06 +0.06±0.06 
Free T3 (prnol/1) 4.25±0.14 4.20±0.11 -0.05±0.06 4.19±0.01 4.20±0.11 +0.01 ±0.05 
Free T4 (pmol/1) 12.10±0.32 11.88±0.40 -0.22±0.28 12.06±0.46 12.36±0.48 +0.30±0.16 
TSH (mU) 1.10±0.13 1.10±0.14 0.00±0.03 1.14±0.12 1.04±0.10 -0.09±0.10 
Ghrelin (pmol/1) 360±53 392±65 +33 ± 31 399±64 387±63 -12±18 
A significant Increase In plasma Insulin was demonstrated after oxyntomodulin Injection (*-P - 0.0003). Thyroid-stimulating hormone is abbreviated to TSH. 
Adverse events 
Volunteers recorded any adverse events in a diary over the 
course of the study period. There was no significant increase 
in the subjects' reporting of nausea during the oxynto- 
modulin administration period when compared to adminis- 
tration of saline. However, one participant - subject 11 - 
reported nausea after 71% of oxyntomodulin injections, a 
level>2 s. d. above the mean. Subject 11 also demonstrated 
levels of circulating oxyntomodulin significantly higher 
than the group mean after self-administering oxynto- 
modulin before the study meal (2-way ANOVA, f= 17.6 1, 
P<0.0001). This subject's plasma oxyntomoduIin levels 
increased from a baseline value of SOpmol/I upto 1249 
pmol/I immediately pre-prandially, and to 3752pmol/l 
60 min post-injection. During the oxyntornodulin adminis- 
tration period, subject 11 demonstrated a greater than 
average reduction in energy intake (21.5%, group mean 
17.3±5.5%) and greater increase In activity-related energy 
expenditure (47.7%, group mean 26.2±11.9%), although 
these changes were within the normal range. There were no 
other frequently reported adverse events during the trial. 
Discussion 
Self-administering oxyntomodulin increased energy expen- 
diture back toward normal levels, in addition to reducing 
energy intake in overweight and obese humans over the 
study period. Energy expenditure can be partitioned into 
resting energy expenditure, incorporating both basal meta- 
boliC rate and the thermic: effect of food, and activity-related 
energy expenditure. 26 Oxyntomodulin administration did 
not alter resting energy expenditure, pulse rate or the 
thyroid axis. However, it did increase daily activity-related 
energy expenditure by 26.2±9.9%; total energy expenditure 
by 9.4±4.8% and physical activity level by 9.5±4.6% during 
the 'free-living' period, despite a reduction in energy intake. 
The increase in activity of 143 ± 109 kcal/day accounted for 
the increase seen In total energy expenditure, indicating that 
it was an increase in physical activity which resulted in 
increased total energy expenditure. The magnitude of this 
Increase in energy expenditure Is significant and comparable 
to the World Health Organization recommendation of a 
200kcal/day increase in low-intensity physical aCtiVity. 27 
Although the mechanisms which control energy expendi- 
ture are not well-defined, it could be speculated that 
oxyntomodulin, a signal of positive energy balance, may 
act to both Increase energy expenditure and reduce energy 
intake, allowing activity during a period of adequate 
nutrition. The anorectic action of oxyntomodulin is thought 
to be mediated by the glucagon-Iike peptide-1 receptoL 28 
However, the effect of the endogenous ligand glucagon-like 
peptide-1 on energy expenditure is unclear. Several studies in 
rodents and humans have provided contradictory evidence 
as to whether glucagon-like peptide-I has a stimulatory or 
inhibitory effect on energy expenditure. 28-31 To date this is 
the first study investigating the effect of a gut peptide on 
'free-living' energy expenditure in human volunteers. 
In accordance with our previous data, 9 oxyntomodulin 
significantly reduced energy intake at the study meal by 
17.3±5.5% without subjective changes in pre-prandial 
appetite or meal palatability, Reduction in calorie intake 
after administration of oxyntomodulin suggests an altera- 
tion of appetite. However, there was no evidence of a 
decrease in pre-prandial hunger measured by visual analogue 
scale, or alteration In the circulating level of the orexigenic 
hormone ghrelin. This may reflect an alternative mechanism 
such as an early perception of post-prandial satiety; although 
this hypothesis requires further investigation. Rodent data 
has demonstrated that circulating oxyntomodulin activates 
regions of the brain involved in energy homeostasis within 
the hypothalamus and brainstem, such as the arcuate 
nucleus, 5 paraventricular nucleus, area postrema and nu- 
cleus of the solitary tract. 28 Within the hypothalamus, 
the anorectic effect may be mediated by an increase in 
a-melanocortin-stimulating hormone. 8 
Understanding the effects of oxyntomodulin on energy 
homeostasis in humans allows an insight into its potential 
role as a treatment for obesity. Although voluntary dietary 
restriction is a common Intervention for obese patients, It Is 
usually accompanied by a decrease in energy expenditure, at 
least in the short-term . 
13 In evolutionary terms, this can 
be considered an adaptive trait which occurs in order to 
conserve energy. However, this contributes to the difficulty 
experienced by obese individuals who attempt to diet 
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voluntarily in environments which are not physically 
demanding. In contrast to this effect of voluntary dietary 
restriction, the current study demonstrated that administra- 
tion of oxyntomodulin increased energy expenditure during 
a period of reduced energy intake. The significant decrease 
In body-weight over the administration period indicates 
oxyntomodulin administration resulted in negative energy 
balance; although It Is unclear whether weight loss was 
secondary to a loss of body-mass or initial fluid shifts during 
this 4-day study period . 
32 
This study suggests that energy expenditure and energy 
intake may be coupled in humans and demonstrates a 
possible mechanism of weight-loss during oxyntomodulin 
administration. Further studies should now be performed in 
order to investigate whether the effect of oxyntomodulin on 
energy expenditure Is maintained over a period of chronic 
administration. Although the therapeutic potential of oxynto- 
modulin requires further investigation, this data supports 
the role of oxyntomodulin as a potential anti-obesity 
therapy. 
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Subcutaneous Ghrelin Enhances Acute Food Intake in 
Malnourished Patients Who Receive Maintenance Peritoneal 
Dialysis: A Randomized, Placebo-Controlled Trial 
Katie Wynne, * KaHi Giannitsopoulou, * Caroline J. Small, * Michael Patterson, * Gary Frost, * 
Mohammad A. Ghatei, * Edwina A. Brownt Stephen R. Bloom, * and Peter Choit 
' *Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital, and 
tDirectorate of Renal and Transplant Medicine, Hammersmith Hospitals NHS Trust, Charing Cross Hospital, London, 
United Kingdom 
Anorexia and malnutrition confer significant morbidity and mortality to patients with end-stage kidney disease but are 
resistant to therapy. The aim of this study was to determine whether subcutaneous administration of ghrelin, an appetite- 
stimulating gut hormone, could enhance food intake in patients who are receiving maintenance peritoneal dialysis and have 
evidence of malnutrition. The principal outcome measure was energy intake during a measured study meal. Secondary 
outcome measures were BP and heart rate and 3-d food intake after intervention. Nine peritoneal dialysis patients with mild 
to moderate malnutrition (mean serum albumin 28.6 :h5.0 g/L, total cholesterol 4.4 :t0.6 mmoM subjective global assessment 
score of 5.7 :t1.7) were given subcutaneous ghrelin (3.6 nmol/kg) and saline placebo in a randomized, double-blind, crossover 
protocol. Administration of subcutaneous ghrelin significantly increased the group mean absolute energy intake, compared 
with placebo, during the study meal (690 : t: 190 versus 440 t 250 kcal; P=0.0062). When expressed as proportional energy 
increase for each individual, ghreIin administration resulted in immediate doubling of energy intake (204 : t: 120 versus 100%; 
P=0.0319). Administration of ghrelin maintained a nonsignificant increase in energy intake over 24 h after intervention 
(2009 :t 669 versus 1579 : t: 330 kcal) and was not followed by subsequent underswing (1790 ± 370 versus 1670 :t 530 and 1880 t 
390 versus 1830 : t: 530 kcal on days 2 and 3, respectively). Chrelin administration resulted in a significant fall in mean arterial 
BP (P = 0.0030 by ANOVA). There were no significant adverse events during the study. Subcutaneous ghrelin administration 
enhances short-term food intake in dialysis patients with mild to moderate malnutrition. 
I Am Soc Nephrol 16: ??? -???, 2005. doi: 10.1681/ASN. 2005010039 
E nd-stage kidney disease is a chronic condition associ- 
ated with a high prevalence of nutritional dysfunction 
(1). This malnutrition is resistant to intervention (2) and 
is a major predictor of morbidity and mortality in patients who 
receive both peritoneal dialysis (PD) and hemodialysis (3,4). 
There is a linear correlation between body mass index (BMI) 
and survival in dialysis patients (5), to the extent that the usual 
association of increased mortality with obesity is reversed in 
patients who receive renal replacement therapy (6). Nutritional 
parameters that have been correlated independently with in- 
creased mortality and morbidity include low senun albumin 
(4,7,8), low serum cholesterol (7,9), and a low measured sub- 
jective global assessment score of nutrition (4,10). 
Malnutrition in chronic kidney disease is multifactorial, but 
reduced protein and energy intake play an important role (1). 
Patients with kidney failure experience a complex anorexic 
syndrome that is evident early in the course of the disease, 
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before the requirement for dialysis (11), including patients with 
a GFR >50 n-d/min per 1.73 M2 (12). Reduced dietary energy 
and protein intake is common in patients who are on mainte- 
nance PD and hemodialysis (1), and inadequate dietary intake 
correlates with poor nutritional outcomes (13). The effects of 
diminished dietary energy intake in some PID patients may be 
offset by increased glucose absorption from peritoneal dialy- 
sate (14). Proposed mechanisms for anorexia include derange- 
ment of gut hormones, reduced gastric emptying, and the an- 
orectic effects of cytokines and uremic toxins (1). 
The hormone ghrelin, principally secreted from the stomach 
(15), is thought to function as an appetite enhancer (16). Ghrelin 
is also important in long-term body weight regulation, as cir- 
culating ghrelin levels are inversely correlated with energy 
balance (17) and chronic ghrelin administration results in 
weight gain in animal models (18). Ghrelin mediates its orexi- 
genic action via the type la growth hormone secretagogue 
receptor (15). Ligation of this receptor also results in release of 
growth hormone, although the appetite-enhancing effect of ghre.: 
lin is independent of growth hormone (19). The activity of ghrelin 
is dependent on acylation of the third serine residue (20). Secreted 
acylated ghrelin exerts orexigenic effect but is rapidly converted in 
the circulation to cleacylated ghrelin, which does not activate the 
Copyright 0 2005 by the American Society of Nephrology ISSN: 1046-6673/1607-0001 
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type la growth hormone secretagogue receptor and is not known 
to exhibit orexigenic effect or endocrine activity (15,20). 
Intravenous infusion of ghrelin stimulates appetite in healthy 
volunteers (21) and cancer patients (22). Therefore, we hypoth- 
esized that subcutaneously administered ghrelin could enhance 
acute food intake among I'D patients with evidence of malnu- 
trition and provide the potential for practical therapeutic inter- 
vention. j 
Materials and Methods 
Patients 
Malnourished patients, between the ages of 18 and 55 yr, were 
recruited from the Pl) unit of Hammersmith Hospitals NHS Trust, 
which forms part of the West London Renal Centre. Thirty-eight eligi- 
ble patients were invited to participate; 11 were interviewed, and nine 
patients consented to trial participation. The trial was performed be- 
tween January and July 2004. Patients were defined as malnourished 
when they demonstrated two of three qualifying criteria: Serum albu- 
min <35 g/L by Bromcresol Purple (normal range 35 to 48) with 
normal C-reactive protein, serum cholesterol <45 mmol/L, or subjec- 
tive global assessment (SCA) score : 56/7 (23). A modified seven-point 
SGA score (severe malnutrition I to Z- mild to moderate malnutrition 3 
to 5; mild malnutrition to well nourished 6 to 7) was used (4). Patients 
with a history of diabetes or coronary or cerebrovascular disease were 
excluded to minimize risk for intercurrent events. Factors that could 
confound food intake analysis, such as psychologic food &version, 
abdominal discomfort during PD exchanges, dialysis fills <1 L, and 
recent initiation of PD (<6 mo), were also exclusion criteria. The Riv- 
erside Medical Ethics Committee approved the protocol (reference 
number 3721). Participants gave written consent, and the study was 
performed in accordance with the Declaration of Helsinki. 
Protocol 
The study was performed as a randomized, double-blind, placebo- 
controlled, crossover protocol in a dedicated clinical trials unit at Char- 
ing Cross Hospital. Before initiation, patients attended a sham study 
Am Soc Nephrol 16: ??? -???, 2005 
session to acclimatize to study conditions and to ensure palatability of 
the study meal, which was assessed using a nine-point hedonistic scale. 
On subsequent study visits, patients received an injection of 3.6 
nmol/kg subcutaneous ghrelin or saline in random order, separated by 
at least 7 d. A subcutaneous dose of 3.6 nmol/kg ghrelin was chosen as 
the smallest effective dose from a dose-response pilot study performed 
in healthy volunteers (Dr. N. Neary and Dr. M. Druce, Department of 
Metabolic Medicine, Imperial College London, UK, personal commu- 
nication, November 2003). An independent physician performed the 
randomization of injection sequence. 
On the day before each study meal, patients refrained from alcohol 
and strenuous exercise, consumed a standard-calorie prefast meal, and 
then fasted overnight from 9 p. m. On each study day, patients received 
their injection at 11.30 a. m. and were provided with their selected meal 
in excess at 12: 00 pm. The patients were placed in isolation and 
requested to eat until they felt comfortably full. The study meal, of 
known caloric content, was weighed before and after ad libitum feeding 
to measure energy intake. Each individual received an identical meal at 
each study visit. The average calorie density of meals was 620 kcal/100 
g. Water intake was also measured during this period. Throughout the 
study, participants were encouraged to relax by reading or watching 
films. Clocks were removed from the study room to limit the effect of 
meal anticipation on appetite sensation. Visual analogue scales, 100 
mm in length, were recorded at baseline and subsequently every 30 min 
to evaluate subjective feelings of hunger, nausea, and meal palatability. 
B? and heart rate were measured and serial blood samples were taken 
for hormone assays at baseline and at 15,30,60,75, and 90 min after 
injection. All blood samples were collected from an antecubital fossa 
cannula into lithium/heparin tubes (LIP Ltd., Cambridge, UK) that 
contained 2000 kaIlikrein inhibitor units of aprotinin (Trasylol; Bayer, 
Newbury, UK) and stored on ice. After centrifugation, plasma was 
separated immediately and stored at -20*C until analysis. Diaries of 
food consumption were recorded by each participant for 72 h after each 
study visit. Study participants received careful guidance regarding 
completion of their food diaries, and caloric intake was estimated by 
decoding diaries with Dietplan-5 (Forestfield Software, Horsham, West 
Sussex, UK) nutritional analysis software. 
Table 1. Study participants' demographic and nutritional parameterso 
Patient Gender Age Diagnosis PD Duration Albumin Cholesterol SGA Estimated Dry BMI - First (yr) Type (MO) (g/L) (mmol/L) Score Weight (kg) (kg/m2) Injection 
1 m 48 Chronic APD 120 34 4.1 6 . 90.6 30.1 saline 
glornerulonephritis 
2 m 52 Hypertensive CAPD 12 25 4.0 6 73 25.0 ghrelin 
nephropathy 
3 F 53 IgA nephropathy CAPD 42 33 3.6 6 67 26.5 ghrelin 
4 F 39 . Tubulointerstitial C-APD 30 33 4.1 6 73.4 25.9 ghrelin 
nephritis 
5 F 49 Adult polycystic APD 23 29 5.3 5 55.6 19.7 saline 
kidney disease 
6 m 45 Hereditary nephritis APD 36 20 4.1 5 47.3 17.6 saline 
7 F 55 Adult polycystic APD 30 26 4.8 5 48.2 21.1 saline 
kidney disease 
8 F 55 Adult polycystic CAPD 7 33 5.3 6 75.6 30.1 saline 
kidney disease 
9 m 52 IgA nephropathy APD 84 24 4.1 6 76.4 26.1 ghrelin 
TD, peritoneal dialysis; SGA, subjective global assessment; BMI, body mass index; APD, automated peritoneal dialysis; 
CAPD, continuous ambulatory peritoneal dialysis. 
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Materials 
The synthesized human ghrelin (GSSFLSPEliQRVQQRMKKPPA- 
KLQPR, Bachem St. Helens, UK) was sterile on culture after 7 d, and the 
limulus amoebocyte assay for pyrogen was negative (Associates of 
Cape Cod, Liverpool, UK). A 10-fold dose (36 nmol/kg) of ghrelin was 
administered to C57BL/6 mice for toxicity testing; behavioral observa- 
tion and blinded histologic exan-dnation revealed no abnormalities. The 
orexigenic bioactivity of synthesized human ghrelin was confirmed by 
administration to a cohort of male Wistar rats. On each study day, a 
blinded physician prepared the injections by the addition of sterile 
water to freeze-dried vials of ghrehn or saline. The participants re- 
ceived 0.2 ml of the dissolved substance into their abdominal subcuta- 
neous tissue with the use of a 27-gauge needle. 
Hormone Measurements 
Total ghrelin, insulin, and pepticle YY were measured using estab- 
lished in-house RIA (24-26). All samples were assayed in duplicate and 
within one assay to eliminate interassay variation. The ghrelin assay 
cross-reacted fully with acylated and deacylated human ghrelin but did 
not cross-react with any other gastrointestinal or pancreatic peptide 
hormones. Briefly, antisenun (SC-10368) was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA) and used at a final dilution of 1: 50,000. 
The 'I ghrelin was prepared with Bolton & Hunter reagent (Amer- 
sham International, Little Chalfont, UK) and purified by RP-HPLC 
using a linear gradient from 10 to 40% acetonitrile and 0.05% TFA over 
90 min. The specific activity of ghrelin label was 48 Bq/finoL The assay 
was performed in total volume of 0.7 in] of 0.06 M phosphate buffer 
(pH 7.2) that contained 0.3% BSA and was incubated for 3d at VC 
before separation of free and bound antibody by charcoal absorption. 
The ghrelin assay was able to detect changes of 8 pmol/L (95% confi- 
dence interval ICII) with an intra-assay variation of 9.5%. The insulin 
assay was able to detect changes of 6 pmol/L (95% CI) with an intra- 
assay variation of 5.4%. The pepticle YY assay was able to detect 
changes of 2 pmol/L (95% CI) with an intra-assay variation of 5.8%. A 
commercially available assay was used to measure plasma leptin (Linco 
Research, St. Charles, MO). Growth hormone was analyzed using an 
Advantage automated chemiluminescent immunoassay (Nichols Insti- 
tute Diagnostics, San Juan Capistrano, CA), and glucose levels were 
measured by an Olympus AU640 clinical chemistry analyzer (Melville, 
NY). 
Statistical Analyses 
Blinded analysis of food diary data was performed using Dietplan-5 
nutritional analysis software. Statistical comparisons between treat- 
ments for food intake, preprandial visual analogue scores, and hor- 
mone levels were made using nonparametric paired t test. Comparison 
of repeated measurements of BP and subjective measures of nausea and 
fatigue were performed by two-way ANOVA. Statistical analysis was 
performed with Prism software (version 3.0; GraphPad Software, San 
Diego, CA). All values are expressed as mean ± SE. 
Results 
Five female and four male patients, mean age 49.8 ± 1.7 yr, 
agreed to participate in the study, and all nine completed the 
protocol. Demographic and nutritional parameters are dis- 
played in Table 1. All patients were in a clinically stable con- 
dition. Mean serum albumin for the group was 28.6 ± 1.7 g/L, 
with mean total cholesterol of 4.4 ± 0.2 mmol/L and mean SCA 
score of 5.7 ± 1.7. Six participants fulfilled all qualiý4ng criteria 
for malnutrition, and three individuals fulfilled two of three 
Chrelin and Food Intake in Malnourished Patients on rD 
criteria. No patient had a serum albumin within the normal 
range, although all patients had a C-reactive protein level 
within the normal range. The mean BMI was 24.7 t 1.5 kg /M2. 
The National Kidney Foundation's Dialysis Outcomes Qual- 
ity Initiative (27) and the LJK Renal Association's target creati- 
nine clearance of 2-60 L/wk per 1.73 ml (28) was achieved by 
all patients. Mean duration of PD was 42.7 t 12.2 mo, and no 
patient had experienced peritonitis within 6 mo of the trial. 
Throughout the study period, there were no changes in dialysis 
delivery between the study interventions for any patient. Spe- 
cifically, each patient presented for his or her study meals with 
identical dialysate volume and glucose concentrations. There 
IE 
-------2; -- 
Saline Ghrolln 
ii 
C 
Q 
Ghrolln 
Figure 1. Energy intake after administration of subcutaneous 
saline or 3.6 nmol/kg ghrelin. (A) Absolute energy intake for 
individual participants during study meals, with mean abso- 
lute energy intake represented by the bold line. Data were 
analyzed by nonparametric paired t test. (B) Proportional in- 
crease in energy intake for each participant during study meals, 
with mean absolute energy intake represented by the bold line. 
Energy intake after saline injection was ascribed a value of 
100%. Data were analyzed by nonparametric paired t test. 
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Figure 2. Subjective measures of appetite, nausea, and fatigue after administration of subcutaneous saline (dotted line) or 3.6 
runol/kg ghrelin (solid line). (A through F) Change from baseline values of visual analogue scores. Patients recorded their 
subjective assessment in response to a questionnaire asking (A) 'How hungry do you feel? " (B) "How pleasant would it be to eat? " 
(C) 'How full do you feel? ' (D) How much do you think you can eat? " (E) 'How nauseated do you feel? " (F) 'How sleepy do 
you feel? ' The injection was administered at 0 min, and the study meal was provided at 30 min. 
was no deviation from study timings, and each study partici- intake during the study meal in eight of nine patients (Figure 
pant received his or her meals at identical intervals after his or IA). Significant differences in group mean absolute energy 
her last instillation of dialysis fluid. intake were observed between administration of subcutaneous 
Administration of subcutaneous ghrelin increased energy saline and ghrelin (440 ± 250 versus 690 ± 190 kcal, respec- 
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Figure 3, Energy intake calculated from diaries of food con- 
sumption, up to 72 h after administration of subcutaneous 
saline or 3.6 nmol/kg ghrelin. 
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Figure 4. Plasma ghrelin immunoreactivity (solid line) and 
growth hormone levels (dotted line) after ghrelin administra- 
tion. The injection was administered at 0 min, and the study 
meal was provided at 30 min. 
tively; P=0.0062; Figure IA). When expressed as proportional 
energy increase for each individual, ghrelin administration re- 
sulted in doubling of energy intake (100 versus 204 1- 120%; P= 
0.0319; Figure 113). There were no significant differences in 
water intake after saline or ghrelin administration (132 -- 26 
versits 165 :!: 46 ml; Pý0,4573). 
Visual analogue scores of subjective parameters of appetite 
were recorded before and after administration of the study 
injection (Figure 2). Administration of ghrelin was associated 
with changes in visual analogue scores, which were consistent 
Ghrelin and Food Intake in MaInounshed Patients on I'D 
with a subjective increase in preprandial appetite (Figure 2, A 
through D). However, in comparison with changes observed 
after saline administration, the observed differences in appetite 
scores after ghrelin administration did not achieve statistical 
significance for the subjective scores of hunger (saline 9 _-t 
3 min 
versus ghrelin 14 -- 4 mm; P=0.2668; Figure 2A), desire to eat 
(saline 6 ý: 5 mm versus ghrelin 11 _-ý 
4 mm; P=0.4905; Figure 
2B), fullness (saline 414 min versus ghrelin -10 t5 mm; P 
0.0972; Figure 2C), and expected food consumption (saline 4 
3 min versus ghrelin 12 -3 min; 
P=0.2014, Figure 2D). 
There was a nonsignificant trend for enhanced meal enjoy- 
ment after ghrelin administration when assessed by postpran- 
dial food palatability score (saline 57 1- 8 min versus ghrelin 
65 
-- 
7 min; P=0.0921). Throughout the study period, there 
were no significant differences in nausea (P = 0.2171 by 
ANOVA; Figure 2E) or fatigue (P = 0.9294 by ANOVA; Figure 
2F) between saline and ghrelin administration. 
Blinded analysis of food diaries, completed by the patients 
over the 3d after injection, suggested that increased energy 
intake after ghrelin administration was maintained over 24 h, 
although this was nonsignificant (saline 1579 !: 130 kcal versus 
ghrelin 2009--250 kcal; P=0.0645, Figure 3). Importantly, the 
increase in energy intake after ghrelin administration was not 
followed by an underswing (saline 1670 * 210 kcal versus 
ghrelin 1790 -- 140 
kcal; saline 1830 -1 
220 kcal versus ghrelin 
1880 - 150 kcal on days 2 and 3, respectively; Figure 3). 
Patients with end-stage kidney disease demonstrated signif- 
icantly higher circulating leptin levels (214.3 -1 
4.6 pmol/L) 
than 16 BMI-matched healthy subjects (80.0 1- 2.0; P<0.0001). 
Baseline hormonal analysis also revealed that study partici- 
pants had significantly higher enclogenous total plasma ghrelin 
immunoreactivity (1076 -1 
92 pmol/L) than BMI-matched 
healthy control subjects (738 -- 104 pmol/L; P=0.0330). After 
administration of subcutaneous ghrelin, the patients' total 
plasma ghrelin immunoreactivity increased, reached a plateau 
at 30 min (mean 12737 -- 3300 pmol/L; range 1421-25787 
pmol/L), and started to fall after 75 min (Figure 4). As ex- 
pected, growth hormone concentrations also increased from 
baseline (2.6 -- 0.6 IU/I. ) and peaked at 30 min (70.3 -- 13.0 
IU/L), indicating that the administered exogenous ghrelin was 
bioactive (Figure 4). 
Administration of glirelin was not associated with changes in 
preprandial insulin levels (salin 
,e 
86.2 ± 25.5 pmol/L versus 
ghrelin 82.3 ± 14.7 pmol/L; P -- 0.7957), preprandial glucose 
concentration (saline 4.33 -- 0.09 mmol/L versus ghrelin 4.56 
0.12 mmol/L; Pý0.2209), or pepticle YY levels (saline 54.4 
8.4 pmoI/L versus ghrelin 51.3 -1 
8.4 pmol/L; P=0.6571) 30 
min after injection, Administration of ghrelin was associated 
with a significant decline in mean arterial pressure from a 
baseline 110.4 
-- 
6.5 mmHg (P = 0.0030 by ANOVA; Figure 
5A), diastolic BP from mean baseline 88.6 _- 4.2 mmHg 
(P = 
0.0039 by ANOVA; Figure 5D), and a nonsignificant trend 
toward fall in systolic BP from mean baseline 132.1 ± 9.4 
mmfig (P = 0.0747 by ANOVA; Figure 5C) The change in BP 
was evident within 15 min of ghrelin administration and was 
maintained for the 90-min observation period. No symptomatic 
hypotension occurred during the study. Administration of 
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Figure 5. BP during the study meal, after administration of saline (dotted line) or 3.6 nmol/kg subcutaneous ghrelin (solid line). 
The change from participants' baseline mean arterial BP, pulse rate, and systolic and diastolic BP is shown in A, B, C, and D, 
respectively. All data were analyzed by a two-way ANOVA. 
ghrelin was not associated with a change in pulse rate (P - 
0.2358 by ANOVA; Figure 5B). There were no adverse events 
during the study period. 
Discussion 
Subcutaneous ghrelin administration resulted in a two-fold 
increase in short-term energy intake for each individual in a 
cohort of mildly to moderately malnourished I'D patients. The 
mean absolute energy intake for the group increased from 
440 ± 80 to 690 :t 60 kcal after a 10-fold increase in circulating 
ghrefin levels. The immediate increase in energy intake at the 
study meal was followed by a trend toward increased energy 
intake over the following 24 h (Figure 3). Importantly, there 
was no subsequent compensatory reduction in energy intake 
over the following 72 h, which would negate any potential 
therapeutic benefit of chronic administration. 
We demonstrated elevated endogenous total ghrelin levels in 
this cohort of PD patients, compared with BNU-matched healthy 
individuals, in agreement with observations by Perez-Fontan et al. 
(29) and Ayala et aL (30). Although there are high endogenous 
levels of total ghrelin, dietary energy intake is paradoxically re- 
duced in PD patients. There are a number of possible explana- 
tions. First, this may reflect other abnormalities of appetite signal- 
in& which are present in patients with kidney disease. For 
example, the current study also demonstrated elevated circulating 
leptin levels in PD patients, in keeping with previous observations 
(31,32), and inappropriately elevated leptin concentrations are 
associated with weight loss (33). Dialysis patients also display 
abnormafly high concentrations of other anorectic gut peptides 
that may contribute to appetite loss and gastrointestinal dysfunc- 
tion, including motilin, somatostatin, peptide YY, vasoactive in- 
testinal peptide, pancreatic polypeptide (34), and cholecystokinin 
(35). Second, recent evidence suggests that the ratio of deacylated 
to acylated ghrelin is disordered in kidney disease and is a more 
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potent driver of renal anorexia than total ghrelin immunoreactiv- 
ity (36). 
Despite the disordered endocrine system demonstrated in 
patients with kidney disease, this study demonstrates that the 
orexigenic effect of exogenous ghrelin administration is re- 
tained in patients with kidney disease and that there is no 
apparent ghrelin resistance associated with elevated total en- 
dogenous ghrelin levels. Indeed, we demonstrated a greater 
increase in food intake than previous trials of intravenously 
administered ghrelin to healthy individuals and anorexic can- 
cer patients (21,22). This may reflect the high circulating total 
ghrelin levels achieved and subsequent correction of a disor- 
dered deacylated to acylated ghrelin ratio. 
A significant fall in mean and diastolic BP was observed 
during study sessions, without symptomatic hypotension or 
reflex tachycardia. This effect seemed additive to the patients' 
ongoing antibypertensive therapy, which was not altered dur- 
ing the study, eight of nine patients were regularly taking 
antihypertensive medication, five of these requiring multiple 
therapy. A reduction in BP was seen throughout the study meal 
period and is in accordance with previous observations con- 
ceming the beneficial effects of intravenous ghrehn on BP and 
cardiac output in healthy volunteers and patients with heart 
failure (37,38). There is a close association between malnutrition 
and cardiovascular death in patients with end-stage kidney 
disease (39). In addition, emerging data also suggest an anti- 
inflammatory role for ghrelin (40). Chrelin receptor ligation on 
T cells and monocytes inhibits the expression of proinflamma- 
tory anorectic cytokines such as IL-I, IL-6, and TNF-a and is 
hypothesized to provide a link between the metabolic axis and 
immune system (41). Epidemiologic data reveal an intimate 
relationship among inflammation, malnutrition, and cardiovas- 
cular outcomes (42,43). Thus, a therapy that is able to improve 
energy intake, reduce inflammation, and enhance cardiovascu- 
lar function would be of great value to patients with kidney 
disease. 
This study was designed as a short-term, single-dose analysis 
of the effects of ghrelin administration to establish efficacy. 
Patients with established cardiovascular disease were excluded 
to minimize adverse events; thus, few patients with severe 
wasting nutritional deficiency were eligible. However, it is 
these patients who are most likely to derive the greatest clinical 
benefit from treatment, and further investigation is needed to 
establish the efficacy of exogenous ghrelin within this high-risk 
group. Nonetheless, we have shown clearly that subcutaneous 
ghrelin administration is able to increase substantially acute 
spontaneous energy intake in mildly to moderately malnour- 
ished patients who receive maintenance PD. Long-term ghrelin 
administration may have the potential to improve nutritional 
parameters and patient outcomes. Longer term studies are now 
required. 
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